D000001 kalcimycin[Calcimycin] 1974 11 19 2013 07 08 1984 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 91(75); was A 23187 1975-90 (see under ANTIBIOTICS 1975-83) use CALCIMYCIN to search A 23187 1975-90 91; was A 23187 1975-90 (see under ANTIBIOTICS 1975-83) Antibiotics (1973-1974) Carboxylic Acids (1973-1974) D000900 Anti-Bacterial Agents D061207 Calcium Ionophores D03.438.221.173 M0000001 kalcimycin[Calcimycin] 4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-((3,9,11-trimethyl-8-(1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl)-1,7-dioxaspiro(5.5)undec-2-yl)methyl)-, (6S-(6alpha(2S*,3S*),8beta(R*),9beta,11alpha))- 37H9VM9WZL An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems. 52665-69-7 (Calcimycin) M0000001 M0353609 T000002 Calcimycin 1999 01 01 FDA SRS (2014) NLM (1975) cze0000001 kalcimycin 2006 03 22 M0353609 A-23187 0 M0000001 M0353609 T000001 A-23187 1990 03 08 NLM (1991) T000001 A 23187 T000003 Antibiotic A23187 1990 03 08 NLM (1991) T000003 A23187, Antibiotic T000004 A23187 1974 11 11 UNK (19XX) D000002 abat[Temefos] 1999 01 01 2013 07 08 1991 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD for use to kill or control insects, use no qualifiers on the insecticide or the insect; appropriate qualifiers may be used when other aspects of the insecticide are discussed such as the effect on a physiologic process or behavioral aspect of the insect; for poisoning, coordinate with ORGANOPHOSPHATE POISONING 96; was ABATE 1972-95 (see under INSECTICIDES, ORGANOTHIOPHOSPHATE 1972-90) 96; was ABATE 1972-95 (see under INSECTICIDES, ORGANOTHIOPHOSPHATE 1972-90) Insecticides (1966-1971) D007306 Insecticides D02.705.400.625.800 D02.705.539.345.800 D02.886.300.692.800 M0000002 abat[Temefos] Phosphorothioic acid, O,O'-(thiodi-4,1-phenylene) O,O,O',O'-tetramethyl ester ONP3ME32DL An organothiophosphate insecticide. 3383-96-8 (Temefos) M0000002 M0352201 M0000002 M0352200 T000008 Temefos 1999 01 01 FDA SRS (2014) INN (19XX) USAN (1974) T000007 Temephos 1994 12 01 NLM (1996) cze0000002 abat 2006 03 22 M0352201 Abate 0 M0000002 M0352201 T000005 Abate 1994 11 14 NLM (1996) M0352200 Difos 0 M0000002 M0352200 T000006 Difos 1986 10 07 UNK (19XX) D000003 jatka[Abattoirs] 1999 01 01 1997 06 20 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000592 standards ST WA 707 J01.576.423.200.700.100 M0000003 jatka[Abattoirs] Places where animals are slaughtered and dressed for market. T000009 Abattoirs 1999 01 01 NLM (1966) T000009 Abattoir T000010 Slaughterhouses 1974 03 29 UNK (19XX) T000010 Slaughterhouse cze0032993 jatka 2007 02 26 cze Thesaurus D000004 zkratky jako téma[Abbreviations as Topic] 1999 01 01 2007 07 09 includes acronyms; do not confuse with Publication Type ABBREVIATIONS 2008(1963) 2008; see ABBREVIATIONS 1963-2007 L01.143.506.598.400.556.131 M0000004 zkratky jako téma[Abbreviations as Topic] Shortened forms of written words or phrases used for brevity. M0000004 M0511063 T698652 Abbreviations as Topic 2007 05 31 NLM (2008) cze0000003 zkratky jako téma 2006 03 22 M0511063 akronyma jako téma[Acronyms as Topic] M0000004 M0511063 T701041 Acronyms as Topic 2007 06 29 NLM (2008) cze0035800 akronyma jako téma 2008 05 22 cze Thesaurus D000005 břicho[Abdomen] 1999 01 01 2011 06 24 Q000469 parasitology PS Q000002 abnormalities AB Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000531 radionuclide imaging RI Q000294 innervation IR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000473 pathology PA Q000601 surgery SU GEN: prefer specifics; abdom muscles = ABDOMINAL MUSCLES but RECTUS ABDOMINIS is available; abdominal pain = ABDOMINAL PAIN; abrupt dis requiring emerg surg = ABDOMEN, ACUTE D000005 Abdomen Q000293 injuries D000007 Abdominal Injuries D000005 Abdomen Q000530 radiography D011860 Radiography, Abdominal A01.923.047 M0000005 břicho[Abdomen] That portion of the body that lies between the THORAX and the PELVIS. Část těla, která leží mezi hrudníkem a pánví. T000012 Abdomen 1999 01 01 NLM (1966) T000012 Abdomens cze0000004 břicho 2006 03 22 cze0045383 abdomen 2011 10 06 cze Thesaurus D000006 akutní bolest břicha[Abdomen, Acute] 1999 01 01 2015 07 08 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH WI 900 C10.597.617.044.200 C23.888.592.612.054.200 C23.888.821.030.249 M0000006 akutní bolest břicha[Abdomen, Acute] A clinical syndrome with acute abdominal pain that is severe, localized, and rapid in onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases. Klinickým syndromem náhlé příhody břišní je kritický stav a rychlý nástup. Příčinou jsou různé poruchy, zranění nebo nemoci. T000013 Abdomen, Acute 1999 01 01 NLM (1966) T000013 Abdomens, Acute T000013 Acute Abdomen T000013 Acute Abdomens cze0044712 akutní bolest břicha 2011 08 30 cze Thesaurus cze0044713 akutní břišní bolest 2011 08 30 cze Thesaurus cze0000005 břicho - náhlé příhody 2006 03 22 cze0035098 náhlá příhoda břišní 2008 01 11 cze Thesaurus cze0037669 náhlé příhody břišní 2009 03 05 cze Thesaurus D000007 poranění břicha[Abdominal Injuries] 1999 01 01 2010 06 25 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH general term for inj of organs in the abdom cavity; prefer specific organs /inj WI 900 C26.017 M0000007 poranění břicha[Abdominal Injuries] General or unspecified injuries involving organs in the abdominal cavity. Obecné nebo nespecifikované zranění orgánů v dutině břišní. T000015 Abdominal Injuries 1999 01 01 ABDOMINAL INJ NLM (1966) T000014 Injuries, Abdominal 1986 01 01 INJ ABDOMINAL UNK (19XX) T000014 Abdominal Injury T000014 Injury, Abdominal cze0057818 poranění břicha 2014 08 01 cze Thesaurus cze0000006 břicho - poranění 2006 03 22 D000008 nádory břicha[Abdominal Neoplasms] 1999 01 01 1995 06 08 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000648 ultrastructure UL Q000737 chemistry CH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000098 blood supply BS Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH general term for neopl of organs in the abdom cavity; prefer specific organ/neopl terms; /blood supply /chem /second /secret /ultrastruct permitted; coord IM with histol type of neopl if given (IM) C04.588.033 M0000008 nádory břicha[Abdominal Neoplasms] T000016 Abdominal Neoplasms 1999 01 01 ABDOMINAL NEOPL NLM (1966) T000016 Abdominal Neoplasm T000016 Neoplasm, Abdominal T000016 Neoplasms, Abdominal cze0047569 nádory břicha 2012 04 14 cze Thesaurus cze0047571 abdominální nádory 2012 04 14 cze Thesaurus cze0000007 břicho - nádory 2006 03 22 cze0047570 břišní nádory 2012 04 14 cze Thesaurus cze0047572 nádory v oblasti břicha 2012 04 14 cze Thesaurus D000009 břišní svaly[Abdominal Muscles] 1999 01 01 2002 07 02 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU RECTUS ABDOMINIS is available; hernia = HERNIA, VENTRAL; /growth: coord with MUSCLE DEVELOPMENT; /embryol: coord with MUSCLE DEVELOPMENT if pertinent 93; was ABDOMINAL WALL 1966-92 WI 900 use ABDOMINAL MUSCLES to search ABDOMINAL WALL 1966-92 93; was ABDOMINAL WALL 1963-92 D034861 Abdominal Wall A02.633.567.050 M0000009 břišní svaly[Abdominal Muscles] Muscles forming the ABDOMINAL WALL including RECTUS ABDOMINIS, external and internal oblique muscles, transversus abdominis, and quadratus abdominis. (from Stedman, 25th ed) Jedná se o svaly formující BŘIŠNÍ STĚNU včetně přímého svalu břišního (MUSCULUS RECTUS ABDOMINIS), zevních a vnitřních šikmých svalů břišních, příčného svalu břišního a čtyřhranného svalu bederního. T000018 Abdominal Muscles 1999 01 01 NLM (1966) T000018 Abdominal Muscle T000018 Muscle, Abdominal T000018 Muscles, Abdominal cze0000008 břišní svaly 2006 03 22 D000010 nervus abducens[Abducens Nerve] 1999 01 01 2014 06 20 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU neoplasms = ABDUCENS NERVE DISEASES (IM) + CRANIAL NERVE NEOPLASMS (IM) + histological type of neoplasm (IM) 77; was ABDUCENT NERVE 1963-76 WL 330 use ABDUCENS NERVE to search ABDUCENT NERVE 1966-76 77; was ABDUCENT NERVE 1963-76 D000010 Abducens Nerve Q000293 injuries D020222 Abducens Nerve Injury D065827 Abducens Nucleus A08.800.800.120.030 M0000010 nervus abducens[Abducens Nerve] The 6th cranial nerve which originates in the ABDUCENS NUCLEUS of the PONS and sends motor fibers to the lateral rectus muscles of the EYE. Damage to the nerve or its nucleus disrupts horizontal eye movement control. T000019 Abducens Nerve 1999 01 01 NLM (1966) T000019 Nerve, Abducens T000020 Sixth Cranial Nerve 1996 07 31 NLM (1998) T000020 Cranial Nerve, Sixth T000020 Nerve, Sixth Cranial T000020 Nerves, Sixth Cranial T000020 Sixth Cranial Nerves T856510 Nerve VI 2014 03 14 NLM (2015) T856510 Nerve VIs T856511 Nervus Abducens 2014 03 14 NLM (2015) T856511 Abducen, Nervus T856511 Abducens, Nervus T856511 Nervus Abducen T000021 Abducent Nerve 1976 05 26 UNK (19XX) T000021 Abducent Nerves T000021 Nerve, Abducent T000022 Cranial Nerve VI 1996 07 31 NLM (1998) T000022 Cranial Nerve VIs T000022 Nerve VI, Cranial T000022 Nerve VIs, Cranial cze0000009 nervus abducens 2006 03 22 cze0043854 VI. hlavový nerv 2011 05 27 cze Thesaurus cze0043853 odtahovací nerv 2011 05 27 cze Thesaurus D000011 virus Abelsonovy myší leukemie[Abelson murine leukemia virus] 1979 04 16 2015 06 22 1991 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY infection: coord IM with RETROVIRIDAE INFECTIONS (IM) + TUMOR VIRUS INFECTIONS (IM) + LEUKEMIA, EXPERIMENTAL (IM) 2002 (1980) 2002; see ABELSON LEUKEMIA VIRUS 1991-2001, see MOUSE LEUKEMIA VIRUSES 1980-1990 Mouse Leukemia Viruses (1966-1979) B04.613.807.375.525.020 B04.820.650.375.525.020 M0000011 virus Abelsonovy myší leukemie[Abelson murine leukemia virus] A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS. T445670 Abelson murine leukemia virus 2001 05 04 NLM (2002) T000023 Abelson Leukemia Virus 1999 01 01 NLM (1980) T000023 Leukemia Virus, Abelson T000023 Virus, Abelson Leukemia cze0063657 virus Abelsonovy myší leukemie 2015 09 29 cze Thesaurus cze0000010 virus Abelsonovy myší leukémie 2006 03 22 D000012 abetalipoproteinémie[Abetalipoproteinemia] 1999 01 01 2013 07 08 1966 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 1966(1964) 1966 C16.320.565.398.500.440.500 C18.452.584.500.875.440.500 C18.452.648.398.500.440.500 M0000012 abetalipoproteinémie[Abetalipoproteinemia] An autosomal recessive disorder of lipid metabolism. It is caused by mutation of the microsomal triglyceride transfer protein that catalyzes the transport of lipids (TRIGLYCERIDES; CHOLESTEROL ESTERS; PHOSPHOLIPIDS) and is required in the secretion of BETA-LIPOPROTEINS (low density lipoproteins or LDL). Features include defective intestinal lipid absorption, very low serum cholesterol level, and near absent LDL. T000024 Abetalipoproteinemia 1999 01 01 GHR (2014) NLM (1964) OMIM (2013) ORD (2010) T365904 Bassen-Kornzweig Disease 1999 11 04 BASSEN KORNZWEIG DIS NLM (2000) T365904 Bassen Kornzweig Disease T365903 Microsomal Triglyceride Transfer Protein Deficiency Disease 1999 11 04 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFIC DIS GHR (2014) NLM (2000) ORD (2010) T751239 Betalipoprotein Deficiency Disease 2009 05 14 GHR (2014) NLM (2010) ORD (2010) T751239 Betalipoprotein Deficiency Diseases T751239 Deficiency Disease, Betalipoprotein T751239 Deficiency Diseases, Betalipoprotein T751239 Disease, Betalipoprotein Deficiency T751239 Diseases, Betalipoprotein Deficiency T646365 Microsomal Triglyceride Transfer Protein Deficiency 2005 07 20 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFIC NLM (2007) OMIM (2013) T811395 Acanthocytosis 2011 11 15 GHR (2014) OMIM (2013) T811395 Acanthocytoses T000025 Bassen-Kornzweig Syndrome 1974 03 29 GHR (2014) OMIM (2013) ORD (2010) UNK (19XX) T000025 Bassen Kornzweig Syndrome cze0000011 abetalipoproteinémie 2006 03 22 cze0039748 Bassenův-Kornzweigův syndrom 2010 04 20 cze Thesaurus D000013 vrozené vady[Congenital Abnormalities] 1999 01 01 2007 07 09 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH general only: prefer /abnorm with specific anatomical term or specific animal: Manual 19.7+, 19.8.1; policy: Manual 23.20+ 2008 (1963) 2008; see ABNORMALITIES 1963-2007 D000013 Congenital Abnormalities Q000139 chemically induced D000014 Abnormalities, Drug-Induced C16.131 M0000013 vrozené vady[Congenital Abnormalities] Malformations of organs or body parts during development in utero. T000029 Congenital Abnormalities 1978 12 18 CONGEN ABNORM NLM (1980) T000029 Abnormality, Congenital T000029 Congenital Abnormality T000032 Deformities 1974 03 29 UNK (19XX) T000032 Deformity T000031 Congenital Defects 1977 03 22 CONGEN DEFECTS UNK (19XX) T000031 Congenital Defect T000031 Defect, Congenital T000030 Defects, Congenital 1977 03 22 DEFECTS CONGEN UNK (19XX) T000028 Abnormalities, Congenital 1978 12 18 ABNORM CONGEN UNK (19XX) T000027 Birth Defects 1976 05 08 UNK (19XX) T000027 Birth Defect T000027 Defect, Birth T000027 Defects, Birth cze0000015 vrozené vady 2006 03 22 Previous Czech Indexing: abnormality (1990-2007) The preferred Czech term is equivalent to the non-preferred English term "Congenital Defects" cze0000014 deformity 2006 03 22 cze0000013 kongenitální defekty 2006 03 22 cze0000012 vrozené abnormality 2006 03 22 D000014 abnormality vyvolané léky[Abnormalities, Drug-Induced] 1999 01 01 2013 07 08 1964 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH IM; do not use /chem ind /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific chem /adv eff-pois-tox (IM) + specific organ /abnorm or specific abnorm /chem ind (IM); Manual 23.20.3 64 QS 679 64 D013723 Teratogens D064793 Teratogenesis C16.131.042 M0000014 abnormality vyvolané léky[Abnormalities, Drug-Induced] Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. T000034 Abnormalities, Drug-Induced 1999 01 01 ABNORM DRUG IND NLM (1964) T000034 Abnormalities, Drug Induced T000033 Drug-Induced Abnormalities 1977 12 07 DRUG IND ABNORM UNK (19XX) T000033 Abnormality, Drug-Induced T000033 Drug Induced Abnormalities T000033 Drug-Induced Abnormality cze0000016 abnormality vyvolané léky 2006 03 22 D000015 abnormality mnohočetné[Abnormalities, Multiple] 1999 01 01 2011 07 05 1968 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH IM; do not use /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific abnorm (IM); Manual 23.20.2 68 QS 675 68 Abnormalities (1966-1967) D008607 Intellectual Disability C16.131.077 M0000015 abnormality mnohočetné[Abnormalities, Multiple] T000036 Abnormalities, Multiple 1999 01 01 ABNORM MULTIPLE NLM (1968) T000035 Multiple Abnormalities 1986 01 01 MULTIPLE ABNORM UNK (19XX) cze0000017 abnormality mnohočetné 2006 03 22 D000016 abnormality vyvolané zářením[Abnormalities, Radiation-Induced] 1978 03 20 2015 06 22 1979 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH IM; do not use /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific abnorm (IM) 79 QS 681 79 Abnormalities (1966-1978) Radiation Injuries (1966-1978) D064793 Teratogenesis C16.131.080 C26.733.031 G01.750.748.500.031 N06.850.460.350.850.500.031 N06.850.810.300.360.031 M0000016 abnormality vyvolané zářením[Abnormalities, Radiation-Induced] Congenital changes in the morphology of organs produced by exposure to ionizing or non-ionizing radiation. Vrozené změny v morfologii orgánů vzniklé po expozici ionizujícímu nebo neionizujícímu záření. T000038 Abnormalities, Radiation-Induced 1999 01 01 ABNORM RAD IND NLM (1979) T000038 Abnormalities, Radiation Induced T000037 Radiation-Induced Abnormalities 1978 03 20 RAD IND ABNORM UNK (19XX) T000037 Abnormality, Radiation-Induced T000037 Radiation Induced Abnormalities T000037 Radiation-Induced Abnormality cze0000018 abnormality vyvolané zářením 2006 03 22 cze0062770 vrozené vady vyvolané zářením 2015 07 09 cze Thesaurus D000017 krevní skupiny - systém ABO[ABO Blood-Group System] 1975 07 25 2005 06 30 1976 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000652 urine UR Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD IM; coord with disease /blood (IM), not /immunol nor /genet; TN 230 76; was ABO FACTORS 1963-75 WH 420 use ABO BLOOD-GROUP SYSTEM to search ABO FACTORS 1966-75 76; was ABO FACTORS 1963-75 D23.050.301.290.031 D23.050.705.230.031 M0000017 krevní skupiny - systém ABO[ABO Blood-Group System] 0 The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. M0000017 M0000019 M0000017 M0000018 T000040 ABO Blood-Group System 1999 01 01 NLM (1976) T000040 ABO Blood Group System T000040 ABO Blood-Group Systems T000040 Blood-Group System, ABO T000040 Blood-Group Systems, ABO T000040 System, ABO Blood-Group T000040 Systems, ABO Blood-Group T000042 H Blood Group System 1984 09 20 UNK (19XX) T000041 H Blood Group 1980 08 04 UNK (19XX) T000041 Blood Group, H T000041 Blood Groups, H T000041 H Blood Groups T000039 ABH Blood Group 1988 06 07 UNK (19XX) T000039 ABH Blood Groups T000039 Blood Group, ABH T000039 Blood Groups, ABH cze0000019 krevní skupiny - systém ABO 2006 03 22 M0000019 Blood Group H Type 1 Antigen 0 M0000017 M0000019 T000044 Blood Group H Type 1 Antigen 1984 03 05 UNK (19XX) M0000018 faktory AB0[ABO Factors] 0 M0000017 M0000018 T000043 ABO Factors 1975 07 22 UNK (19XX) T000043 ABO Factor T000043 Factor, ABO T000043 Factors, ABO cze0039118 faktory AB0 2010 02 10 cze Thesaurus D000018 slez[Abomasum] 1999 01 01 1995 05 18 1968 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU a ruminant's 4th stomach; dis: coord IM with STOMACH DISEASES /vet (IM); neopl: coord IM with STOMACH NEOPLASMS /vet (IM) + histol type /vet (IM); ulcer: coord IM with STOMACH ULCER /vet (IM) 68 QL 862 68 Stomach (1966-1967) A13.869.106 M0000020 slez[Abomasum] The fourth stomach of ruminating animals. It is also called the "true" stomach. It is an elongated pear-shaped sac lying on the floor of the abdomen, on the right-hand side, and roughly between the seventh and twelfth ribs. It leads to the beginning of the small intestine. (From Black's Veterinary Dictionary, 17th ed) T000045 Abomasum 1999 01 01 NLM (1968) T000045 Abomasums cze0000020 slez 2006 03 22 cze0000021 žaludek přežvýkavců čtvrtý 2006 03 22 D000019 abortiva[Abortifacient Agents] 1999 01 01 2014 06 25 1975 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD use no qualifiers for abortifacients when used to interrupt pregnancy; note entry term ABORTIFACIENT EFFECT: use only for the abortifacient effect of a chemical substance 75 QV 175 75 Abortion, Induced (1970-1974) D010120 Oxytocics D27.505.696.875.131 D27.505.954.705.131 M0000021 abortiva[Abortifacient Agents] 0 Chemical substances that interrupt pregnancy after implantation. M0000021 M0556260 T000046 Abortifacient Agents 1999 01 01 POPLINE (1978) T000046 Agents, Abortifacient T000047 Contraceptive Agents, Postconception 1978 12 18 POPLINE (1978) T000047 Agents, Postconception Contraceptive T000047 Postconception Contraceptive Agents T000048 Abortifacients 1991 10 09 NLM (1993) cze0000022 abortiva 2006 03 22 M0556260 Abortifacient Effect 0 M0000021 M0556260 T788179 Abortifacient Effect 2011 03 31 NLM (2012) T788179 Effect, Abortifacient T788180 Abortifacient Effects 2011 03 31 NLM (2012) T788180 Effects, Abortifacient D000020 abortiva nesteroidní[Abortifacient Agents, Nonsteroidal] 1974 11 11 2014 06 25 1991 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD do not use /ther use for use of the abortifacients as abortifacients 91(75); was see under ABORTIFACIENT AGENTS 1975-90 QV 175 91; was see under ABORTIFACIENT AGENTS 1975-90 Abortion, Induced (1970-1974) specific chemical (1971-1974) D27.505.696.875.131.100 D27.505.954.705.131.100 M0000022 abortiva nesteroidní[Abortifacient Agents, Nonsteroidal] 0 Non-steroidal chemical compounds with abortifacient activity. T000050 Abortifacient Agents, Nonsteroidal 1999 01 01 NLM (1975) T000050 Agents, Nonsteroidal Abortifacient T000050 Nonsteroidal Abortifacient Agents T000049 Abortifacient Agents, Non-Steroidal 1977 12 07 UNK (19XX) T000049 Abortifacient Agents, Non Steroidal T000049 Agents, Non-Steroidal Abortifacient T000049 Non-Steroidal Abortifacient Agents cze0000023 abortiva nesteroidní 2006 03 22 D000021 abortiva steroidní[Abortifacient Agents, Steroidal] 1974 11 11 2005 06 30 1991 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD do not use /ther use for use of the abortifacients as abortifacients 91(75); was see under ABORTIFACIENT AGENTS 1975-90 QV 175 91; was see under ABORTIFACIENT AGENTS 1975-90 Abortion, Induced (1970-1974) specific chemical (1970-1974) D27.505.696.875.131.200 D27.505.954.705.131.200 M0000023 abortiva steroidní[Abortifacient Agents, Steroidal] 0 Steroidal compounds with abortifacient activity. T000051 Abortifacient Agents, Steroidal 1999 01 01 NLM (1975) T000051 Agents, Steroidal Abortifacient T000051 Steroidal Abortifacient Agents T000052 Steroid Abortifacients 1978 12 18 POPLINE (1978) T000052 Abortifacients, Steroid cze0000024 abortiva steroidní 2006 03 22 D000022 potrat spontánní[Abortion, Spontaneous] 1999 01 01 2005 06 30 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH /chem ind permitted but do not confuse with ABORTION, INDUCED; check the tags HUMANS & FEMALE & PREGNANCY 99(63) 99; see ABORTION 1966-98; for ABORTION, SPONTANEOUS see ABORTION 1992-98 D000022 Abortion, Spontaneous Q000662 veterinary D000034 Abortion, Veterinary D000019 Abortifacient Agents D037881 Aborted Fetus C13.703.039 M0000024 potrat spontánní[Abortion, Spontaneous] Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference. M0000024 M0000025 T000053 Abortion, Spontaneous 1999 01 01 NLM (1999) T000053 Abortions, Spontaneous T000053 Spontaneous Abortions T000054 Miscarriage 1974 03 29 UNK (19XX) T000054 Miscarriages T484312 Spontaneous Abortion 2002 03 04 NLM (2003) cze0000025 potrat spontánní 2006 03 22 M0000025 Abortion, Tubal M0000024 M0000025 T000055 Abortion, Tubal 1978 12 18 NLM (1980) T000055 Abortions, Tubal T000055 Tubal Abortion T000055 Tubal Abortions D000023 žadatelky o potrat[Abortion Applicants] 1974 11 19 2015 06 23 1976 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN don't forget also check tags HUMANS & FEMALE & PREGNANCY 76(75); was see under ABORTION 1975 76; was see under ABORTION 1975 Abortion, Induced (1970-1974) Abortion, Therapeutic (1966-1974) M01.050 M0000026 žadatelky o potrat[Abortion Applicants] Individuals requesting induced abortions. M0000026 M0000028 M0000026 M0000027 T000056 Abortion Applicants 1999 01 01 NLM (1975) T000056 Abortion Applicant T000056 Applicant, Abortion T000056 Applicants, Abortion T000057 Abortion Seekers 1974 11 11 POPLINE (1978) T000057 Abortion Seeker T000057 Seeker, Abortion T000057 Seekers, Abortion cze0000026 žadatelky o potrat 2006 03 22 M0000028 žadatelky o potrat - opakovaný[Abortion Seekers, Repeated] M0000026 M0000028 T000059 Abortion Seekers, Repeated 1978 12 18 POPLINE (1978) T000059 Abortion Seeker, Repeated T000059 Repeated Abortion Seeker T000059 Repeated Abortion Seekers T000059 Seeker, Repeated Abortion T000059 Seekers, Repeated Abortion cze0046688 žadatelky o potrat - opakovaný 2012 02 20 cze Thesaurus M0000027 žadatelky o potrat odmítnuté[Abortion Seekers, Refused] M0000026 M0000027 T000058 Abortion Seekers, Refused 1978 12 18 POPLINE (1978) T000058 Abortion Seeker, Refused T000058 Refused Abortion Seeker T000058 Refused Abortion Seekers T000058 Seeker, Refused Abortion T000058 Seekers, Refused Abortion cze0046687 žadatelky o potrat odmítnuté 2012 02 20 cze Thesaurus D000024 potrat nezákonný[Abortion, Criminal] 1999 01 01 2015 06 23 Q000009 adverse effects AE Q000401 mortality MO Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH don't forget also check tags HUMANS & FEMALE & PREGNANCY; for abortifacients in crim abort see note on ABORTION, INDUCED W 867 I01.198.240.089 M0000029 potrat nezákonný[Abortion, Criminal] Illegal termination of pregnancy. T000060 Abortion, Criminal 1999 01 01 NLM (1966) T000060 Abortions, Criminal T000060 Criminal Abortion T000060 Criminal Abortions T000062 Abortion, Illegal 1977 03 17 POPLINE (1978) T000061 Illegal Abortion 1977 03 17 BIOETHICS (1989) T000061 Abortions, Illegal T000061 Illegal Abortions cze0000027 potrat nezákonný 2006 03 22 D000025 potrat eugenický[Abortion, Eugenic] 1974 11 19 2015 06 23 1991 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST do not use /util except by MeSH definition; don't forget also check tags HUMANS or ANIMALS & FEMALE & PREGNANCY 91(75); was see under ABORTION, INDUCED 1975-90 91; was see under ABORTION, INDUCED 1975-90 E04.520.050.050 M0000030 potrat eugenický[Abortion, Eugenic] Abortion performed because of possible fetal defects. M0000030 M0000031 T000064 Abortion, Eugenic 1999 01 01 NLM (1975) T000064 Abortions, Eugenic T000064 Eugenic Abortions T000063 Eugenic Abortion 1974 11 11 UNK (19XX) cze0000028 potrat eugenický 2006 03 22 M0000031 Abortion, Selective M0000030 M0000031 T000065 Abortion, Selective 1995 03 22 POPLINE (1994) T000065 Abortions, Selective T000065 Selective Abortions T000066 Selective Abortion 1977 03 17 BIOETHICS (1974) D000026 habituální potrat[Abortion, Habitual] 1999 01 01 2005 06 30 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH WQ 225 D005313 Fetal Death D020964 Embryo Loss C13.703.039.089 M0000032 habituální potrat[Abortion, Habitual] Three or more consecutive spontaneous abortions. T000067 Abortion, Habitual 1999 01 01 NLM (1963) T000067 Abortions, Habitual T000067 Habitual Abortion T000067 Habitual Abortions T000069 Miscarriage, Recurrent 1997 10 08 NLM (1999) T000069 Miscarriages, Recurrent T000069 Recurrent Miscarriage T000069 Recurrent Miscarriages T000068 Abortion, Recurrent 1996 07 25 NLM (1998) T000068 Abortions, Recurrent T000068 Recurrent Abortion T000068 Recurrent Abortions cze0053461 habituální potrat 2013 06 24 cze Thesaurus cze0053459 opakovaný potrat 2013 06 24 cze Thesaurus cze0000029 potrat habituální 2006 03 22 cze0053460 potrat opakovaný 2013 06 24 cze Thesaurus D000027 potrat neúplný[Abortion, Incomplete] 1974 11 11 2005 06 30 1975 09 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH restrict to spontaneous, not induced abortions; check the tags FEMALE & PREGNANCY 75 WQ 225 75 Abortion, Spontaneous (1966-1974) C13.703.039.093 M0000033 potrat neúplný[Abortion, Incomplete] Premature loss of PREGNANCY in which not all the products of CONCEPTION have been expelled. T000070 Abortion, Incomplete 1999 01 01 NLM (1975) T000070 Abortions, Incomplete T000070 Incomplete Abortion T000070 Incomplete Abortions cze0000030 potrat neúplný 2006 03 22 D000028 indukovaný potrat[Abortion, Induced] 1999 01 01 2002 07 02 1971 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST do not use /util except by MeSH definition; for use of an abortifacient here or in ABORTION, CRIMINAL, coord IM with abortifacient agent (IM with no qualif, not /adv eff unless text specifically discusses adverse eff); don't forget also check tags FEMALE & PREGNANCY 71; was see under ABORTION, CRIMINAL & ABORTION, THERAPEUTIC 1963-70, was see under ABORTION, LEGAL 1964-70; EMBRYOTOMY was heading 1963-85 use ABORTION, INDUCED to search EMBRYOTOMY 1966-85; search ABORTION, CRIMINAL & ABORTION, LEGAL & ABORTION, THERAPEUTIC 1966-70 71; was see under ABORTION, CRIMINAL & ABORTION, THERAPEUTIC 1963-70, was see under ABORTION, LEGAL 1964-70; EMBRYOTOMY was heading 1963-85 Abortion, Criminal (1966-1970) Abortion, Legal (1966-1970) Abortion, Therapeutic (1966-1970) D037881 Aborted Fetus E04.520.050 M0000037 indukovaný potrat[Abortion, Induced] Intentional removal of a fetus from the uterus by any of a number of techniques. (POPLINE, 1978) M0000037 M0000035 M0000037 M0000043 M0000037 M0000036 M0000037 M0000034 M0000037 M0000039 M0000037 M0000044 M0000037 M0000040 M0000037 M0000041 M0000037 M0000042 M0000037 M0000045 M0000037 M0000038 T000076 Abortion, Induced 1999 01 01 ABORTION IND BIOETHICS (1999) POPLINE (1978) T000075 Induced Abortion 1981 08 26 IND ABORTION UNK (19XX) T000075 Abortions, Induced T000075 Induced Abortions T373837 Abortion (Induced) 1999 11 09 NLM (2000) T373837 Abortions (Induced) cze0047443 indukovaný potrat 2012 04 01 cze Thesaurus cze0047451 abortus arteficialis 2012 04 01 cze Thesaurus cze0061378 abortus inductus 2015 02 19 cze Thesaurus cze0034867 interrupce 2007 12 03 cze Thesaurus cze0000031 potrat indukovaný 2006 03 22 cze0047442 umělé přerušení těhotenství 2012 04 01 cze Thesaurus cze0047446 umělé ukončení těhotenství 2012 04 01 cze Thesaurus cze0047445 umělý potrat 2012 04 01 cze Thesaurus M0000035 potratovost[Abortion Rate] M0000037 M0000035 T000073 Abortion Rate 1978 12 18 POPLINE (1978) T000073 Abortion Rates T000073 Rate, Abortion T000073 Rates, Abortion cze0047444 potratovost 2012 04 01 cze Thesaurus M0000043 techniky provádění potratů[Abortion Techniques] M0000037 M0000043 T000083 Abortion Techniques 1990 01 10 NLM (1991) T000083 Abortion Technique T000083 Technique, Abortion T000083 Techniques, Abortion T000082 Abortion Technics 1978 12 18 NLM (1979) T000082 Abortion Technic T000082 Technic, Abortion T000082 Technics, Abortion cze0047447 techniky provádění potratů 2012 04 01 cze Thesaurus cze0064340 techniky umělého ukončení těchotenství 2015 11 09 cze Thesaurus M0000036 potrat indukovaný léky[Abortion, Drug-Induced] M0000037 M0000036 T000074 Abortion, Drug-Induced 1978 12 18 ABORTION DRUG IND POPLINE (1978) T000074 Abortion, Drug Induced T000074 Abortions, Drug-Induced T000074 Drug-Induced Abortion T000074 Drug-Induced Abortions cze0061379 potrat indukovaný léky 2015 02 19 cze Thesaurus cze0061383 potrat vyvolaný chemickými látkami 2015 02 19 cze Thesaurus M0000034 předchozí potrat[Previous Abortion] M0000037 M0000034 T000072 Previous Abortion 1978 12 18 POPLINE (1978) T000072 Abortion, Previous T000072 Abortions, Previous T000072 Previous Abortions T000071 Abortion History 1978 12 18 ABORTION HIST POPLINE (1978) T000071 Abortion Histories T000071 Histories, Abortion T000071 History, Abortion cze0047448 předchozí potrat 2012 04 01 cze Thesaurus M0000039 potrat solným roztokem[Abortion, Saline-Solution] M0000037 M0000039 T000078 Abortion, Saline-Solution 1978 12 18 ABORTION SALINE SOL POPLINE (1978) T000078 Abortion, Saline Solution T000078 Abortions, Saline-Solution T000078 Saline-Solution Abortion T000078 Saline-Solution Abortions cze0047452 potrat solným roztokem 2012 04 01 cze Thesaurus M0000044 potrat mýdlovým roztokem[Abortion, Soap-Solution] M0000037 M0000044 T000084 Abortion, Soap-Solution 1978 12 18 ABORTION SOAP SOL POPLINE (1978) T000084 Abortion, Soap Solution T000084 Abortions, Soap-Solution T000084 Soap-Solution Abortion T000084 Soap-Solution Abortions cze0047453 potrat mýdlovým roztokem 2012 04 01 cze Thesaurus M0000040 protipotratové skupiny[Anti-Abortion Groups] M0000037 M0000040 T000079 Anti-Abortion Groups 1985 08 08 POPLINE (1986) T000079 Anti Abortion Groups T000079 Anti-Abortion Group T000079 Group, Anti-Abortion T000079 Groups, Anti-Abortion cze0047450 protipotratové skupiny 2012 04 01 cze Thesaurus M0000041 embryotomie[Embryotomy] M0000037 M0000041 T000080 Embryotomy 1985 06 06 UNK (19XX) T000080 Embryotomies cze0000032 embryotomie 2006 03 22 M0000042 potrat místo antikoncepce[Fertility Control, Postconception] M0000037 M0000042 T000081 Fertility Control, Postconception 1978 12 18 POPLINE (1978) T000081 Postconception Fertility Control cze0061381 potrat místo antikoncepce 2015 02 19 cze Thesaurus cze0061380 kontrola porodnosti pomocí potratu 2015 02 19 cze Thesaurus M0000045 nepovedený potrat[Abortion Failure] M0000037 M0000045 T000085 Abortion Failure 1995 03 22 POPLINE (1994) T000085 Abortion Failures T000085 Failure, Abortion T000085 Failures, Abortion cze0047449 nepovedený potrat 2012 04 01 cze Thesaurus M0000038 potrat roztokem rivanolu[Abortion, Rivanol] M0000037 M0000038 T000077 Abortion, Rivanol 1979 09 27 POPLINE (1978) T000077 Abortions, Rivanol T000077 Rivanol Abortion T000077 Rivanol Abortions cze0061376 potrat roztokem rivanolu 2015 02 19 cze Thesaurus D000029 potrat legální[Abortion, Legal] 1999 01 01 2015 06 23 1964 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST /adv eff permitted; do not use /util (except by MeSH definition) /vet; don't forget also HUMANS & FEMALE & PREGNANCY 64 64 E04.520.050.055 M0000047 potrat legální[Abortion, Legal] Termination of pregnancy under conditions allowed under local laws. (POPLINE Thesaurus, 1991) M0000047 M0000046 T000087 Abortion, Legal 1999 01 01 POPLINE (1978) T000087 Abortions, Legal T000087 Legal Abortion T000087 Legal Abortions cze0000033 potrat legální 2006 03 22 M0000046 potrat na požádání[Abortion on Demand] M0000047 M0000046 T000086 Abortion on Demand 1977 03 17 BIOETHICS (1989) cze0041406 potrat na požádání 2010 08 19 cze Thesaurus D000030 potrat zamlklý[Abortion, Missed] 1999 01 01 2005 06 30 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH check the tags FEMALE & PREGNANCY WQ 225 C13.703.039.173 M0000048 potrat zamlklý[Abortion, Missed] The retention in the UTERUS of a dead FETUS two months or more after its DEATH. T000088 Abortion, Missed 1999 01 01 NLM (1966) T000088 Abortions, Missed T000088 Missed Abortion T000088 Missed Abortions cze0000034 potrat zamlklý 2006 03 22 D000031 potrat septický[Abortion, Septic] 1999 01 01 2005 06 30 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH /vet permitted only if discussed as "septic" abortion: do not use automatically for animal abortion in brucellosis, vibriosis, trichomoniasis, etc; check the tags FEMALE & PREGNANCY C01.539.674.173 C13.703.039.256 C13.703.700.173 M0000050 potrat septický[Abortion, Septic] Any type of abortion, induced or spontaneous, that is associated with infection of the UTERUS and its appendages. It is characterized by FEVER, uterine tenderness, and foul discharge. Jakýkoliv typ potratu (vyvolaný nebo spontánní), který je spojený s infekcí dělohy a jejího okolí. Je charakterizován horečkou, citlivostí dělohy a páchnoucím výtokem. T000090 Abortion, Septic 1999 01 01 NLM (1963) T000090 Abortions, Septic T000090 Septic Abortions T637142 Septic Abortion 2005 04 20 NLM (2006) cze0000035 potrat septický 2006 03 22 D000032 potrat léčebný[Abortion, Therapeutic] 1999 01 01 1997 06 20 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST do not use /util except by MeSH definition; don't forget also check tags FEMALE & PREGNANCY E04.520.050.060 M0000051 potrat léčebný[Abortion, Therapeutic] Abortion induced to save the life or health of a pregnant woman. (From Dorland, 28th ed) T000092 Abortion, Therapeutic 1999 01 01 ABORTION THER POPLINE (1978) T000091 Therapeutic Abortion 1977 03 17 THER ABORTION BIOETHICS (1974) T000091 Abortions, Therapeutic T000091 Therapeutic Abortions cze0000036 potrat léčebný 2006 03 22 D000033 hrozící potrat[Abortion, Threatened] 1999 01 01 2005 07 12 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH check the tags FEMALE & PREGNANCY WQ 225 C13.703.039.339 M0000052 hrozící potrat[Abortion, Threatened] UTERINE BLEEDING from a GESTATION of less than 20 weeks without any CERVICAL DILATATION. It is characterized by vaginal bleeding, lower back discomfort, or midline pelvic cramping and a risk factor for MISCARRIAGE. T000093 Abortion, Threatened 1999 01 01 NLM (1966) T000093 Abortions, Threatened T000093 Threatened Abortion T000093 Threatened Abortions cze0047373 hrozící potrat 2012 03 26 cze Thesaurus cze0000037 potrat hrozící 2006 03 22 D000034 potrat veterinární[Abortion, Veterinary] 1999 01 01 2007 07 09 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH coordinate IM with specific type of abortion /vet (IM); check the tags ANIMALS & FEMALE & PREGNANCY SF 887 C13.703.039.422 C22.021 M0000053 potrat veterinární[Abortion, Veterinary] Premature expulsion of the FETUS in animals. T000095 Abortion, Veterinary 1999 01 01 ABORTION VET NLM (1966) T000094 Veterinary Abortion 1986 01 01 VET ABORTION UNK (19XX) T000094 Abortions, Veterinary T000094 Veterinary Abortions cze0000038 potrat veterinární 2006 03 22 D000035 odreagování[Abreaction] 1999 01 01 1997 06 20 1968 01 01 no qualif 68 WM 420.5.A2 68 F04.754.720.107 M0000054 odreagování[Abreaction] A process in psychotherapy in which the patient is "desensitized" to emotionally painful, often forgotten (repressed) memories by recalling and reacting to them in the "safety" of the treatment setting. Postup v psychoterapii, v němž pacient prochází procesem desenzibilizace a uvolnění potlačených emocí, nevědomých komplexů. Znovuprožívá původní zážitek a reaguje na něj v bezpečném prostředí. Uplatňuje se v psychoanalýze a psychoterapii. T000096 Abreaction 1999 01 01 NLM (1968) T000096 Abreactions cze0000039 odreagování 2006 03 22 D000036 abrin[Abrin] 1974 11 19 2007 07 09 1991 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 91(75); was see under PLANT PROTEINS 1975-90 91; was see under PLANT PROTEINS 1975-90 Disulfides (1973-1974) Plant Proteins (1971-1975) D08.811.277.450.430.700.750.111 D12.776.503.499.249 D12.776.765.678.906.111 M0000055 abrin[Abrin] Abrins 1393-62-0 A toxic lectin from the seeds of jequirity, Abrus precatorius L. Very active poison. Five different proteins have so far been isolated: Abrus agglutinin, the component responsible for: hemagglutinating activity, & abrins a-d, the toxic principals each consisting of two peptide chains are held together by disulfide bonds. M0000055 M0000057 M0000055 M0000056 T000097 Abrin 1999 01 01 NLM (1975) cze0000040 abrin 2006 03 22 M0000057 Abrin C 0 M0000055 M0000057 T000099 Abrin C 1981 06 08 UNK (19XX) M0000056 Abrin A 0 M0000055 M0000056 T000098 Abrin A 1981 06 08 UNK (19XX) D000037 předčasné odlučování placenty[Abruptio Placentae] 1999 01 01 2005 06 30 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH WQ 212 C13.703.420.078 C13.703.590.132 M0000058 předčasné odlučování placenty[Abruptio Placentae] Premature separation of the normally implanted PLACENTA from the UTERUS. Signs of varying degree of severity include UTERINE BLEEDING, uterine MUSCLE HYPERTONIA, and FETAL DISTRESS or FETAL DEATH. T000100 Abruptio Placentae 1999 01 01 NLM (1966) T632336 Placental Abruption 2005 03 03 NLM (2006) T632336 Abruption, Placental T632336 Abruptions, Placental T632336 Placental Abruptions cze0000041 předčasné odlučování placenty 2006 03 22 cze0000042 abrupce placenty 2006 03 22 cze0049485 předčasné odlučování lůžka 2012 09 18 cze Thesaurus D000038 absces[Abscess] 1999 01 01 2005 08 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000635 transmission TM Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH IM; coord IM with site (organ/dis term) (IM) + precoord organism/infect term (IM); if unspecified bacterial abscess do not coord with BACTERIAL INFECTIONS (since most abscesses are bact) but coord with specific bact infect term if given (as ABSCESS + STAPHYLOCOCCAL INFECTIONS) D004653 Empyema C01.539.830.025 C23.550.470.756.100 M0000059 absces[Abscess] Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. Chorobná dutina vzniklá zánětem a vyplněná hnisem. Může vzniknout v jakémkoliv orgánu, způsobuje jeho poškození a vyvolává i celkové příznaky (horečku, hubnutí, nechutenství aj.). V léčbě se uplatňují antibiotika. Často je nutný i chirurgický zákrok (odstranění hnisu). (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz) T000101 Abscess 1999 01 01 NLM (1966) T000101 Abscesses cze0000043 absces 2006 03 22 D000039 peritonzilární absces[Peritonsillar Abscess] 1999 01 01 2008 07 08 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000635 transmission TM Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH coordinate IM with infection term (IM) but not BACTERIAL INFECTIONS (since most abscesses are bacterial) 89; was ABSCESS, PERITONSILLAR 1963-88 use PERITONSILLAR ABSCESS to search ABSCESS, PERITONSILLAR 1966-88 89; was ABSCESS, PERITONSILLAR 1963-88 C01.539.830.025.675 C07.550.781.750.500 C08.730.561.750.500 C09.775.649.750.500 M0000060 peritonzilární absces[Peritonsillar Abscess] An accumulation of purulent material in the area between the PALATINE TONSIL and its capsule. Paratonzilární absces, flegmona – absces, resp. flegmona v přilehlých tkáních kolem patrové tonzily. Podle lokalizace abscesu se rozlišuje supratonzilární horní absces (maximum zánětu je ve stejnostranné polovině měkkého patra), zevní laterální absces (prosáknutí předního patrového oblouku a vysunutí tonzily mediálně), a dolní infratonzilární absces (zánět se šíří na dolní část patrového oblouku, na laterální stěnu hypofaryngu a do vchodu hrtanu, srov. parafaryngeální absces). P. a. se rozvíjí nejč. ve druhém týdnu průběhu angíny nebo po akutní exacerbaci chronické tonzilitidy. Jednostranná bolestivá dysfagie může být doprovázena zvýšenou salivací, regurgitací tekutin nosem, trismem a huhňavou řečí spolu s bolestivým zduřením regionálních uzlin. Léčba je chirurgická (incize, tonzilektomie) a antibiotická. (cit. Velký lékařský slovník online, 2013 http://lekarske.slovniky.cz/ ) T000103 Peritonsillar Abscess 1999 01 01 NLM (1966) T000103 Abscesses, Peritonsillar T000103 Peritonsillar Abscesses T000102 Abscess, Peritonsillar 1988 05 23 UNK (19XX) cze0000044 peritonzilární absces 2006 03 22 cze0053222 paratonzilární absces 2013 04 24 cze Thesaurus D000040 kyselina abscisová[Abscisic Acid] 1974 11 19 2013 07 08 1991 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 93(75) 93; see ABSCISSINS 1991-92, see CYCLOHEXANECARBOXYLIC ACID 1975-90 Cyclohexanecarboxylic Acids (1974) D010937 Plant Growth Regulators D02.241.223.268.034 D02.455.326.271.665.202.061 D02.455.426.392.368.367.379.249.024 D02.455.849.131.061 D02.455.849.765.033 M0000061 kyselina abscisová[Abscisic Acid] 2,4-Pentadienoic acid, 5-(1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl)-3-methyl-, (S-(Z,E))- 72S9A8J5GW Abscission-accelerating plant growth substance isolated from young cotton fruit, leaves of sycamore, birch, and other plants, and from potatoes, lemons, avocados, and other fruits. 113349-29-4 ((Z,E)-isomer) 14375-45-2 ((+-)-isomer) 14398-53-9 ((R)-isomer) 14674-85-2 ((E,Z)-(+-)-isomer) 21293-29-8 (Abscisic Acid) 2228-72-0 ((E,E)-(+-)-isomer) 41621-76-5 ((R)-isomer, monoammonium salt) 52392-36-6 ((E,E)-isomer) 6755-41-5 ((E,E)-isomer) 7773-56-0 (cpd w/o isomeric designation) M0000061 M0330738 M0000061 M0330737 M0000061 M0330678 M0000061 M0330677 M0000061 M0330680 M0000061 M0330679 T000104 Abscisic Acid 1999 01 01 NLM (1975) T000105 Abscissins 1992 04 15 NLM (1993) T000106 Abscissic Acid 1992 03 25 NLM (1993) cze0000045 kyselina abscisová 2006 03 22 cze0000046 abscisiny 2006 03 22 M0330738 Abscisic Acid, (+,-)-Isomer 14375-45-2 M0000061 M0330738 T360932 Abscisic Acid, (+,-)-Isomer 1999 09 13 NLM (1999) M0330737 Abscisic Acid, (Z,E)-Isomer 113349-29-4 M0000061 M0330737 T360931 Abscisic Acid, (Z,E)-Isomer 1999 09 13 NLM (1999) M0330678 Abscisic Acid, (E,Z)-(+,-)-Isomer 14674-85-2 M0000061 M0330678 T360872 Abscisic Acid, (E,Z)-(+,-)-Isomer 1999 09 13 NLM (1999) M0330677 Abscisic Acid, (R)-Isomer 14398-53-9 M0000061 M0330677 T360871 Abscisic Acid, (R)-Isomer 1999 09 13 NLM (1999) M0330680 Abscisic Acid Monoammonium Salt, (R)-Isomer 41621-76-5 M0000061 M0330680 T360874 Abscisic Acid Monoammonium Salt, (R)-Isomer 1999 09 13 NLM (1999) M0330679 Abscisic Acid, (E,E)-(+-)-Isomer 2228-72-0 M0000061 M0330679 T360873 Abscisic Acid, (E,E)-(+-)-Isomer 1999 09 13 NLM (1999) D000041 absentérství[Absenteeism] 1999 01 01 1994 05 27 IM; no qualif was in Cat F & J 1967-82, was in Cat F & I 1963-66 F02.784.692.107 M0000062 absentérství[Absenteeism] Chronic absence from work or other duty. Chronická nepřítomnost v zaměstnání nebo u jiné povinnosti. T000107 Absenteeism 1999 01 01 NLM (1966) cze0000047 absentérství 2006 03 22 D000042 absorpce[Absorption] 1999 01 01 2015 06 15 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE beginning in 2015: used for searching; INDEXER: Do not use; CATALOGER: Do not use D007408 Intestinal Absorption D012869 Skin Absorption G01.595.014 G02.149.767.019 G02.842.750.019 G03.495.023 G03.787.024 G07.690.725.015 M0000063 absorpce[Absorption] The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy. T000108 Absorption 1999 01 01 NLM (1966) cze0000048 absorpce 2006 03 22 D000043 referování a indexace jako téma[Abstracting and Indexing as Topic] 1999 01 01 2007 10 30 Q000379 methods MT Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST IM; medical abstracting & indexing: do not coordinate with MEDICINE; do not confuse with Publication Types ABSTRACTS or MEETING ABSTRACTS 2008(1963); for INDEXES as topic use REFERENCE BOOKS 1996-1998 2008; see ABSTRACTING AND INDEXING 1963-2007; for INDEXES as topic see REFERENCE BOOKS 1996-98 L01.453.245.100 M0000065 referování a indexace jako téma[Abstracting and Indexing as Topic] Activities performed to identify concepts and aspects of published information and research reports. M0000065 M0000066 M0000065 M0372380 M0000065 M0000064 T700404 Abstracting and Indexing as Topic 2007 06 21 NLM (2008) T000110 Indexing and Abstracting 1979 03 29 INDEXING ABSTRACTING UNK (19XX) T708842 Indexing and Abstracting as Topic 2007 10 30 NLM (2008) T000111 Abstracting and Indexing 1999 01 01 ABSTRACTING INDEXING NLM (1966) cze0000049 referování a indexace jako téma 2006 03 22 cze0035808 referování a indexování jako téma 2008 05 22 cze Thesaurus M0000066 rejstříky jako téma[Indexes as Topic] M0000065 M0000066 T700406 Indexes as Topic 2007 06 21 NLM (2008) cze0035805 rejstříky jako téma 2008 05 22 cze Thesaurus M0372380 indexace[Indexing] M0000065 M0372380 T000114 Indexing 1974 03 29 UNK (19XX) T700407 Indexing as Topic 2007 06 21 NLM (2008) cze0035804 indexace 2008 05 22 cze Thesaurus cze0035806 indexace jako téma 2008 05 22 cze Thesaurus cze0035807 indexování 2008 05 22 cze Thesaurus M0000064 referování[Abstracting] M0000065 M0000064 T000109 Abstracting 1979 03 29 UNK (19XX) T700405 Abstracting as Topic 2007 06 21 NLM (2008) cze0035802 referování 2008 05 22 cze Thesaurus cze0035803 referování jako téma 2008 05 22 cze Thesaurus D000044 podpěry zubní[Dental Abutments] 1999 01 01 2015 06 22 1970 01 01 Q000523 psychology PX Q000469 parasitology PS Q000382 microbiology MI Q000941 ethics ES Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD tooth or root used as anchor for denture or implant, etc.; DF: DENT ABUTMENTS 91; was ABUTMENTS, DENTAL 1970-90 use DENTAL ABUTMENTS to search ABUTMENTS, DENTAL 1970-90 91; was ABUTMENTS, DENTAL 1970-90 Dental Cavity Preparation (1966-1969) Denture, Partial (1966-1969) E06.780.346.500 E07.695.190.175 M0000067 podpěry zubní[Dental Abutments] Natural teeth or teeth roots used as anchorage for a fixed or removable denture or other prosthesis (such as an implant) serving the same purpose. T000118 Dental Abutments 1999 01 01 DENT ABUTMENTS NLM (1970) T000117 Abutments, Dental 1990 04 09 ABUTMENTS DENT NLM (1991) T000115 Abutment, Dental 1990 01 25 ABUTMENT DENT NLM (1991) T000116 Dental Abutment 1990 04 09 DENT ABUTMENT NLM (1991) cze0000050 podpěry zubní 2006 03 22 D000045 akácie[Acacia] 1999 01 01 2015 06 23 1991 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME acacia pharmaceut agents are probably GUM ARABIC 91(86)63; was see under TREES 1986-90; was heading 1963-85 91,63-85; was see under TREES 1986-90; was heading 1963-85 B01.650.940.800.575.100.401.025 M0000068 akácie[Acacia] A plant genus of the family FABACEAE. The gums and tanning agents obtained from Acacia are called GUM ARABIC. The common name of catechu is more often used for Areca catechu (ARECA). M0000068 M0397059 T000119 Acacia 1999 01 01 NLM (1986) T000119 Acacias T000121 Wattle Tree 1985 05 14 UNK (19XX) T000121 Tree, Wattle T000121 Trees, Wattle T000121 Wattle Trees T000120 Locust Tree 1985 05 14 UNK (19XX) T000120 Locust Trees T000120 Tree, Locust T000120 Trees, Locust cze0000051 akácie 2006 03 22 M0397059 Acacia catechu M0000068 M0397059 T459714 Acacia catechu 2001 08 30 NLM (2003) T459714 Acacia catechus T459714 catechu, Acacia T459714 catechus, Acacia D000046 vysokoškolská lékařská centra[Academic Medical Centers] 1979 06 01 2012 07 03 1980 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD specify geog; DF: ACAD MED CENTERS 80; was see HOSPITALS, UNIVERSITY 1979 search HOSPITALS, UNIVERSITY 1979 80; was see HOSPITALS, UNIVERSITY 1979 Hospitals, Teaching (1968-1974) Hospitals, University (1975-1979) D062606 Tertiary Care Centers N02.278.020 M0000069 vysokoškolská lékařská centra[Academic Medical Centers] Medical complexes consisting of medical school, hospitals, clinics, libraries, administrative facilities, etc. T000127 Academic Medical Centers 1999 01 01 ACAD MED CENTERS NLM (1980) T000129 Centers, University Medical 1989 11 29 CENTERS UNIV MED NLM (1991) T000125 Medical Center, Academic 1989 11 29 MED CENTER ACAD NLM (1991) T000130 Medical Center, University 1989 11 29 MED CENTER UNIV NLM (1991) T000133 University Medical Centers 1979 06 01 UNIV MED CENTERS UNK (19XX) T000132 Medical Centers, University 1979 06 15 MED CENTERS UNIV UNK (19XX) T000131 University Medical Center 1989 11 29 UNIV MED CENTER NLM (1991) T000122 Academic Medical Center 1989 11 29 ACAD MED CENTER NLM (1991) T000123 Center, Academic Medical 1989 11 29 CENTER ACAD MED NLM (1991) T000128 Center, University Medical 1989 11 29 CENTER UNIV MED NLM (1991) T000124 Centers, Academic Medical 1989 11 29 CENTERS ACAD MED NLM (1991) T000126 Medical Centers, Academic 1979 06 15 MED CENTERS ACAD UNK (19XX) cze0000052 vysokoškolská lékařská centra 2006 03 22 D000047 akademie a ústavy[Academies and Institutes] 1999 01 01 1999 11 03 1970 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST not for educ acad & institutes ( = SCHOOLS or its indentions); Acad of Med: do not index also under MEDICINE; NY Acad of Med: when geog coord needed use NEW YORK CITY; DF: ACADEMIES 70(65) 70 N03.540.052 M0000071 akademie a ústavy[Academies and Institutes] Organizations representing specialized fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., National Academy of Sciences, Brookings Institution, etc. M0000071 M0000072 M0000071 M0000073 M0000071 M0000070 T000137 Academies and Institutes 1999 01 01 ACADEMIES INSTITUTES NLM (1965) T000136 Institutes and Academies 1979 03 29 INSTITUTES ACAD UNK (19XX) T000135 Academy and Institute 1989 11 30 ACAD INSTITUTE NLM (1991) T000135 Institute and Academy cze0000053 akademie a ústavy 2006 03 22 M0000072 ústavy[Institutes] M0000071 M0000072 T000138 Institutes 1974 03 29 UNK (19XX) cze0046668 ústavy 2012 02 10 cze Thesaurus M0000073 výzkumné ústavy[Research Institutes] M0000071 M0000073 T000139 Research Institutes 1977 03 17 BIOETHICS (1974) T000139 Institute, Research T000139 Institutes, Research T000139 Research Institute cze0046667 výzkumné ústavy 2012 02 10 cze Thesaurus cze0046666 výzkumné instituce 2012 02 10 cze Thesaurus M0000070 akademie[Academies] M0000071 M0000070 T000134 Academies 1979 03 29 ACAD UNK (19XX) T000134 Academy cze0046665 akademie 2012 02 10 cze Thesaurus D000048 Acanthamoeba[Acanthamoeba] 1987 04 30 2009 07 06 1988 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY infection: coordinate IM with AMEBIASIS (IM); coordinate with specific protozoan terms (ANTIGENS, PROTOZOAN, etc) if pertinent 88 88 Amoeba (1966-1987) B01.046.500.100.075.080 M0000074 Acanthamoeba[Acanthamoeba] A genus of free-living soil amoebae that produces no flagellate stage. Its organisms are pathogens for several infections in humans and have been found in the eye, bone, brain, and respiratory tract. Volně žijící jednobuněčný organismus (améba) vytvářející cysty. Žije ve vodě a v půdě, zahrnuje několik druhů. Způsobuje infekce CNS (encefalitidu, srov. GAE, akantamébóza) a amébovou keratitidu. U infekcí CNS jsou postiženi obv. oslabení jedinci. Diagnostika může být přímá (mikroskopie, kultivace) i nepřímá (sérologická). (cit. Velký lékařský slovník online, 2013 http://lekarske.slovniky.cz/ ) T000140 Acanthamoeba 1999 01 01 NLM (1988) T000140 Acanthamoebas cze0000054 Acanthamoeba 2006 03 22 D000049 Acanthocephala[Acanthocephala] 1999 01 01 2009 07 06 1974 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY infection: coord IM with HELMINTHIASIS (IM); for antigens, coord with ANTIGENS, HELMINTH, for antibodies, coord with ANTIBODIES, HELMINTH 74; was see under HELMINTHS 1963-73 QX 200 search HELMINTHS 1966-73 74; was see under HELMINTHS 1963-73 B01.050.500.500.132 M0000075 Acanthocephala[Acanthocephala] A phylum of parasitic worms, closely related to tapeworms and containing two genera: Moniliformis, which sometimes infects man, and Macracanthorhynchus, which infects swine. T000141 Acanthocephala 1999 01 01 NLM (1974) T000141 Acanthocephalas T000142 Thorny-Headed Worms 1975 01 01 UNK (19XX) T000142 Thorny Headed Worms T000142 Thorny-Headed Worm T000142 Worm, Thorny-Headed T000142 Worms, Thorny-Headed cze0000055 Acanthocephala 2006 03 22 cze0042490 vrtejši 2011 01 28 cze Thesaurus D000050 akantocyty[Acanthocytes] 1974 11 11 2003 07 09 1991 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA A 11 qualif 91(75); was see under ERYTHROCYTES, ABNORMAL 1975-90 91; was see under ERYTHROCYTES, ABNORMAL 1975-90 A11.118.290.330.100 A11.443.240.330.100 A15.145.229.334.330.100 M0000076 akantocyty[Acanthocytes] Erythrocytes with protoplasmic projections giving the cell a thorny appearance. T000143 Acanthocytes 1999 01 01 NLM (1975) T000143 Acanthocyte cze0000056 akantocyty 2006 03 22 D000051 akantolýza[Acantholysis] 1999 01 01 2008 07 10 1991 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH ACANTHOLYSIS BULLOSA see EPIDERMOLYSIS BULLOSA is also available 91(69); was see under SKIN DISEASES 1969-90 91; was see under SKIN DISEASES 1969-90 Skin/pathology (1966-1968) specific skin disease/pathology (1966-1968) C17.800.865.070 C23.550.035 M0000077 akantolýza[Acantholysis] Separation of the prickle cells of the stratum spinosum of the epidermis, resulting in atrophy of the prickle cell layer. It is seen in diseases such as pemphigus vulgaris (see PEMPHIGUS) and DARIER DISEASE. T000144 Acantholysis 1999 01 01 NLM (1969) T000144 Acantholyses cze0000057 akantolýza 2006 03 22 D000052 Acanthosis nigricans[Acanthosis Nigricans] 1999 01 01 2012 07 03 Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA a type of melanosis WR 265 C17.800.621.430.530.100 M0000078 Acanthosis nigricans[Acanthosis Nigricans] A circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. It occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder. T000145 Acanthosis Nigricans 1999 01 01 NLM (1966) OMIM (2013) ORD (2010) T000145 Acanthosis Nigrican T000145 Nigrican, Acanthosis T000145 Nigricans, Acanthosis cze0000058 Acanthosis nigricans 2006 03 22 D000053 Acaridea[Acari] 1999 01 01 2009 07 06 1975 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME Q000472 pathogenicity PY 75 QX 473 75 Arachnida (1966-1974) B01.050.500.131.166.132 M0000079 Acaridea[Acari] A large, subclass of arachnids comprising the MITES and TICKS, including parasites of plants, animals, and humans, as well as several important disease vectors. T000146 Acari 1999 01 01 NLM (1975) cze0000059 Acaridea 2006 03 22 D000054 zrychlení[Acceleration] 1999 01 01 2009 07 06 Q000009 adverse effects AE IM WD 720 G01.595.560.107 M0000080 zrychlení[Acceleration] An increase in the rate of speed. T000147 Acceleration 1999 01 01 NLM (1966) T000147 Accelerations cze0000060 zrychlení 2006 03 22 D000055 nervus accessorius[Accessory Nerve] 1999 01 01 2014 06 13 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU neoplasm = ACCESSORY NERVE DISEASES (IM) + CRANIAL NERVE NEOPLASMS (IM) + histological type of neoplasm (IM) WL 330 D000055 Accessory Nerve Q000293 injuries D061227 Accessory Nerve Injuries A08.800.800.120.060 M0000081 nervus accessorius[Accessory Nerve] The 11th cranial nerve which originates from NEURONS in the MEDULLA and in the CERVICAL SPINAL CORD. It has a cranial root, which joins the VAGUS NERVE (10th cranial) and sends motor fibers to the muscles of the LARYNX, and a spinal root, which sends motor fibers to the TRAPEZIUS and the sternocleidomastoid muscles. T000148 Accessory Nerve 1999 01 01 NLM (1966) T000148 Accessory Nerves T000148 Nerve, Accessory T000148 Nerves, Accessory T000151 Spinal Accessory Nerve 1974 03 29 UNK (19XX) T000151 Accessory Nerve, Spinal T000151 Accessory Nerves, Spinal T000151 Nerve, Spinal Accessory T000151 Nerves, Spinal Accessory T000151 Spinal Accessory Nerves T856514 Nerve XI 2014 03 14 NLM (2015) T856514 Nerve XIs T856515 Nervus Accessorius 2014 03 14 NLM (2015) T856515 Accessorius, Nervus T000150 Cranial Nerve XI 1996 07 31 NLM (1998) T000149 Eleventh Cranial Nerve 1996 07 31 NLM (1998) T000149 Cranial Nerve, Eleventh T000149 Cranial Nerves, Eleventh T000149 Eleventh Cranial Nerves T000149 Nerve, Eleventh Cranial T000149 Nerves, Eleventh Cranial cze0000061 nervus accessorius 2006 03 22 cze0046265 XI. hlavový nerv 2012 01 17 cze Thesaurus cze0046266 nerv přídatný 2012 01 17 cze Thesaurus cze0046267 přídatný nerv 2012 01 17 cze Thesaurus D000056 prevence úrazů[Accident Prevention] 1999 01 01 2008 07 08 Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000706 statistics & numerical data SN Q000592 standards ST Q000639 trends TD D011482 Protective Devices N06.850.135.060 M0000083 prevence úrazů[Accident Prevention] Efforts and designs to reduce the incidence of unexpected undesirable events in various environments and situations. T000153 Accident Prevention 1999 01 01 ACCIDENT PREV NLM (1966) T000152 Prevention, Accident 1986 01 01 PREV ACCIDENT UNK (19XX) T000152 Accident Preventions T000152 Preventions, Accident cze0056513 prevence úrazů 2014 04 18 cze Thesaurus cze0059167 prevence úrazu 2014 10 16 cze Thesaurus cze0056514 předcházení úrazům 2014 04 18 cze Thesaurus cze0000062 úrazy - prevence 2006 03 22 D000057 sklon k úrazům[Accident Proneness] 1974 11 11 2002 07 02 1975 09 01 no qualif 75 75 Accidents (1966-1974) F01.145.015 M0000084 sklon k úrazům[Accident Proneness] Tendency toward involvement in accidents. Implies certain personality characteristics which predispose to accidents. Jedná se o sklony k účasti při nehodách. Zahrnuje určité osobnostní charakteristiky, které vedou k častějším úrazům. T000154 Accident Proneness 1999 01 01 NLM (1975) T000154 Accident Pronenesses T000154 Proneness, Accident T000154 Pronenesses, Accident cze0055028 sklon k úrazům 2013 12 10 cze Thesaurus cze0058822 dispozice k úrazům 2014 09 25 cze Thesaurus cze0000064 nehody - dispozice 2006 03 22 cze0000063 úrazy - dispozice 2006 03 22 D000058 úrazy pádem[Accidental Falls] 1986 06 24 2015 06 16 1991 01 01 Q000191 economics EC Q000266 history HI Q000401 mortality MO Q000517 prevention & control PC Q000706 statistics & numerical data SN 91(87); was see under ACCIDENTS 1987-90 91; was see under ACCIDENTS 1987-90 Accidents (1966-1986) N06.850.135.122 M0000085 úrazy pádem[Accidental Falls] Falls due to slipping or tripping which may result in injury. M0000085 M000597654 T000156 Accidental Falls 1999 01 01 NLM (1987) T000866038 Falls 2014 09 04 NLM (2016) T000866036 Falling 2014 09 04 NLM (2016) T000155 Falls, Accidental 1986 06 24 UNK (19XX) T000155 Accidental Fall T000155 Fall, Accidental cze0000065 úrazy pádem 2006 03 22 M000597654 Slip and Fall M0000085 M000597654 T000866037 Slip and Fall 2014 09 04 NLM (2016) T000866037 Fall and Slip D000059 úrazy a nehody[Accidents] 1999 01 01 2009 07 28 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD GEN or unspecified; prefer specifics D000059 Accidents Q000517 prevention & control D000056 Accident Prevention N06.850.135 M0000086 úrazy a nehody[Accidents] T000157 Accidents 1999 01 01 POPLINE (1986) T000157 Accident cze0000066 úrazy a nehody 2006 03 22 D000060 nehody letecké[Accidents, Aviation] 1999 01 01 2009 07 28 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD IM; coord with specific inj (IM) WD 740 N06.850.135.185 M0000087 nehody letecké[Accidents, Aviation] T000158 Accidents, Aviation 1999 01 01 NLM (1966) T000158 Accident, Aviation T000158 Aviation Accident T000158 Aviation Accidents cze0000067 nehody letecké 2006 03 22 D000061 úrazy v domácnosti[Accidents, Home] 1999 01 01 2009 07 28 1970 01 01 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD IM; coord with specific inj (IM) 70(69) WA 288 70 Accidents (1966-1968) N06.850.135.217 M0000088 úrazy v domácnosti[Accidents, Home] T000160 Accidents, Home 1999 01 01 NLM (1969) T000159 Home Accidents 1974 03 29 UNK (19XX) T000159 Accident, Home T000159 Home Accident cze0000068 úrazy v domácnosti 2006 03 22 D000062 pracovní nehody[Accidents, Occupational] 1999 01 01 2011 06 24 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD coordinate IM with specific occupation (IM) 79; was in Cat G & J 1979-82, was ACCIDENTS, INDUSTRIAL in Cat G & J 1967-78 & Cat G & I 1963-66 use ACCIDENTS, OCCUPATIONAL to search ACCIDENTS, INDUSTRIAL 1966-78 79; was ACCIDENTS, INDUSTRIAL 1963-78 D009784 Occupational Diseases D060051 Occupational Injuries N06.850.135.240 M0000090 pracovní nehody[Accidents, Occupational] Unforeseen occurrences, especially injuries in the course of work-related activities. M0000090 M0000089 T000164 Accidents, Occupational 1999 01 01 ACCIDENTS OCCUP NLM (1966) T000163 Occupational Accidents 1995 03 08 OCCUP ACCIDENTS NLM (1996) T000163 Accident, Occupational T000163 Occupational Accident cze0047603 pracovní nehody 2012 04 15 cze Thesaurus M0000089 průmyslové nehody[Accidents, Industrial] M0000090 M0000089 T000162 Accidents, Industrial 1978 05 08 ACCIDENTS INDUST UNK (19XX) T000161 Industrial Accidents 1995 03 15 INDUST ACCIDENTS NLM (1996) T000161 Accident, Industrial T000161 Industrial Accident cze0047604 průmyslové nehody 2012 04 15 cze Thesaurus cze0047601 průmyslové úrazy 2012 04 15 cze Thesaurus D000063 dopravní nehody[Accidents, Traffic] 1999 01 01 2009 07 28 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD implies automobile accid so do not coord with AUTOMOBILES unless the auto is especially discussed; coord IM with BICYCLING (IM) or MOTORCYCLES (IM) if pertinent; not for railroad accidents ( = RAILROADS + ACCIDENTS) or all-terrain vehicles, motorbikes or snowmobiles ( = OFF-ROAD MOTOR VEHICLES + ACCIDENTS) WA 275 D012622 Seat Belts D017278 Air Bags N06.850.135.392 M0000091 dopravní nehody[Accidents, Traffic] Accidents on streets, roads, and highways involving drivers, passengers, pedestrians, or vehicles. Traffic accidents refer to AUTOMOBILES (passenger cars, buses, and trucks), BICYCLING, and MOTORCYCLES but not OFF-ROAD MOTOR VEHICLES; RAILROADS nor snowmobiles. T000166 Accidents, Traffic 1999 01 01 NLM (1966) T000165 Traffic Accidents 1993 05 24 BIOETHICS (1982) T000165 Accident, Traffic T000165 Traffic Accident cze0053126 dopravní nehody 2013 04 15 cze Thesaurus cze0000070 nehody dopravní 2006 03 22 D000064 aklimatizace[Acclimatization] 1999 01 01 2008 07 08 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES includes to climate, altitude, weather but not to gravity ( = ADAPTATION, PHYSIOLOGICAL) G07.700.062.133 G16.100.057.500.133 M0000092 aklimatizace[Acclimatization] Adaptation to a new environment or to a change in the old. T000168 Acclimatization 1999 01 01 NLM (1966) T000167 Acclimation 1994 10 31 NLM (1996) cze0000071 aklimatizace 2006 03 22 D000065 akomodace oční[Accommodation, Ocular] 1999 01 01 2008 07 10 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES do not confuse with ADAPTATION, OCULAR, adjustment of eye to light WW 109 G14.640.079 M0000093 akomodace oční[Accommodation, Ocular] The dioptric adjustment of the EYE (to attain maximal sharpness of retinal imagery for an object of regard) referring to the ability, to the mechanism, or to the process. Ocular accommodation is the effecting of refractive changes by changes in the shape of the CRYSTALLINE LENS. Loosely, it refers to ocular adjustments for VISION, OCULAR at various distances. (Cline et al., Dictionary of Visual Science, 4th ed) M0000093 M0471007 T000169 Accommodation, Ocular 1999 01 01 NLM (1966) T620583 Ocular Distance Accommodation 2004 11 30 NLM (2006) T620583 Accommodation, Ocular Distance T620583 Distance Accommodation, Ocular T620583 Ocular Distance Accommodations T613339 Ocular Accommodation 2004 10 14 NLM (2006) cze0000072 akomodace oční 2006 03 22 M0471007 Accommodation, Lens Adjustment of lens to distance. M0000093 M0471007 T604100 Accommodation, Lens 2004 08 17 NLM (2006) T604100 Lens Accommodation D000066 účetnictví[Accounting] 1999 01 01 1996 06 10 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST IM; coord with SPEC (IM) or specific financial endeavor (IM) N03.219.463.030 M0000094 účetnictví[Accounting] System of recording financial transactions. T000170 Accounting 1999 01 01 NLM (1966) T000170 Accountings cze0000073 účetnictví 2006 03 22 D000066388 průmysl ropy a zemního plynu[Oil and Gas Industry] 2015 07 01 2014 10 23 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2015 2015 D005579 Fossil Fuels D010578 Petroleum D059206 Natural Gas J01.576.655.875.750 M000594798 průmysl ropy a zemního plynu[Oil and Gas Industry] INDUSTRY concerned with the extraction, processing, distribution, marketing and storage of PETROLEUM and NATURAL GAS. M000594798 M000594936 M000594798 M000594935 T000860464 Oil and Gas Industry 2014 06 10 NLM (2015) T000860626 Gas and Oil Industry 2014 06 12 NLM (2015) cze0061186 průmysl ropy a zemního plynu 2015 02 05 cze Thesaurus cze0061185 průmysl těžby ropy a zemního plynu 2015 02 05 cze Thesaurus cze0061187 průmysl zpracování ropy a zemního plynu 2015 02 05 cze Thesaurus M000594936 naftový průmysl[Petroleum Industry] M000594798 M000594936 T000860468 Petroleum Industry 2014 06 10 NLM (2015) T000860468 Industries, Petroleum T000860468 Industry, Petroleum T000860468 Petroleum Industries T000860465 Crude Oil Industry 2014 06 10 NLM (2015) T000860465 Crude Oil Industries T000860465 Industries, Crude Oil T000860465 Industry, Crude Oil T000860465 Oil Industries, Crude T000860465 Oil Industry, Crude cze0061188 naftový průmysl 2015 02 05 cze Thesaurus cze0061189 petrolejový průmysl 2015 02 05 cze Thesaurus M000594935 plynárenský průmysl[Natural Gas Industry] M000594798 M000594935 T000860628 Natural Gas Industry 2014 06 12 NLM (2015) T000860628 Gas Industries, Natural T000860628 Gas Industry, Natural T000860628 Industries, Natural Gas T000860628 Natural Gas Industries T000860629 Industry, Natural Gas 2014 06 12 NLM (2015) cze0061190 plynárenský průmysl 2015 02 05 cze Thesaurus D000066428 uhelný průmysl[Coal Industry] 2015 07 01 2015 10 05 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2015 Coal Mining (1965-2014) D005579 Fossil Fuels J01.576.655.875.200 M000594937 uhelný průmysl[Coal Industry] Enterprise associated with the mining, processing, marketing and distribution of COAL. T000860740 Coal Industry 2014 06 16 NLM (2015) T000860740 Coal Industries T000860740 Industries, Coal T000860740 Industry, Coal cze0060660 uhelný průmysl 2014 12 01 cze Thesaurus D000066448 řízení pod vlivem návykové látky[Driving Under the Influence] 2015 07 02 2014 10 15 2016 01 01 Q000706 statistics & numerical data SN Q000639 trends TD Q000208 ethnology EH Q000331 legislation & jurisprudence LJ Q000517 prevention & control PC Q000523 psychology PX 2016 2016 Automobile Driving (1967-2015) F01.145.250.250 F01.145.263.500 I01.880.735.223.250 I03.125.649 M000595368 řízení pod vlivem návykové látky[Driving Under the Influence] Operating a motor vehicle while impaired by alcohol or other drugs including those prescribed by physicians. T000868330 Driving Under the Influence 2014 10 10 NLM (2016) OBSSR (2016) T000867175 Drinking and Driving 2014 09 24 NLM (2016) OBSSR (2016) T000867175 Driving and Drinking T000867174 Drunken Driving 2014 09 24 NLM (2016) OBSSR (2016) T000867174 Driving, Drunken T000868331 Driving While Intoxicated 2014 10 10 NLM (2016) OBSSR (2016) T000868331 While Intoxicated, Driving T000861577 Drunk Driving 2014 07 07 NLM (2016) OBSSR (2016) T000861577 Driving, Drunk cze0060680 řízení pod vlivem návykové látky 2014 12 03 cze Thesaurus cze0060681 řízení pod vlivem alkoholu 2014 12 03 cze Thesaurus cze0060683 řízení pod vlivem léku 2014 12 03 cze Thesaurus cze0060682 řízení v opilosti 2014 12 03 cze Thesaurus D000066449 lidské embryonální kmenové buňky[Human Embryonic Stem Cells] 2015 07 01 2014 12 03 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016 2016 Embryonic Stem Cells (2006-2015) A11.872.700.250.750 M000595369 lidské embryonální kmenové buňky[Human Embryonic Stem Cells] A type of PLURIPOTENT STEM CELLS derived from early stage human embryos, up to and including the BLASTOCYST stage. T000861578 Human Embryonic Stem Cells 2014 07 07 NLM (2016) T000861584 hESCs 2014 07 07 NLM (2016) T000861583 Stem Cells, Human Embryonic 2014 07 07 NLM (2016) T000861580 Human Embryonic Stem Cell 2014 07 07 NLM (2016) T000861581 Cells, Human Embryonic Stem 2014 07 07 NLM (2016) cze0060859 lidské embryonální kmenové buňky 2014 12 22 cze Thesaurus cze0060860 embryonální kmenové buňky člověka 2014 12 22 cze Thesaurus D000066450 myší embryonální kmenové buňky[Mouse Embryonic Stem Cells] 2015 07 01 2014 12 03 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016 2016 Embryonic Stem Cells (2006-2015) A11.872.700.250.875 M000595370 myší embryonální kmenové buňky[Mouse Embryonic Stem Cells] PLURIPOTENT STEM CELLS derived from the BLASTOCYST INNER CELL MASS of day 3.5 mouse embryos. T000861585 Mouse Embryonic Stem Cells 2014 07 07 NLM (2016) T000861596 mESCs 2014 07 07 NLM (2016) T000861594 Stem Cells, Mouse Embryonic 2014 07 07 NLM (2016) T000861590 Cells, Mouse Embryonic Stem 2014 07 07 NLM (2016) T000861591 Mouse Embryonic Stem Cell 2014 07 07 NLM (2016) cze0061049 myší embryonální kmenové buňky 2015 01 12 cze Thesaurus cze0061050 embryonální kmenové buňky myší 2015 01 12 cze Thesaurus D000066473 embryonální zárodečné buňky[Embryonic Germ Cells] 2015 07 10 2015 07 10 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016 2016 Germ Cells (1974-2015) A11.497.124 A11.872.700.250.625 M000595433 embryonální zárodečné buňky[Embryonic Germ Cells] PLURIPOTENT STEM CELLS that are derived from early GERM CELLS. T000861736 Embryonic Germ Cells 2014 07 08 NLM (2016) T000861736 Cell, Embryonic Germ T000861736 Cells, Embryonic Germ T000861736 Embryonic Germ Cell T000861736 Germ Cell, Embryonic T000861738 EG Cells 2014 07 08 NLM (2016) T000861738 Cell, EG T000861738 Cells, EG T000861738 EG Cell T000861737 Germ Cells, Embryonic 2014 07 08 NLM (2016) cze0060752 embryonální zárodečné buňky 2014 12 11 cze Thesaurus D000066477 pracovní výkon[Work Performance] 2015 07 01 2015 06 16 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Employee Performance Appraisal (1963-2015) D017132 Workplace I03.946.675 M000595463 pracovní výkon[Work Performance] Measure of how well someone performs given tasks at their place of work. M000595463 M000602080 T000861806 Work Performance 2014 07 09 NLM (2016) OBSSR (2016) T000861806 Performance, Work T000861806 Performances, Work T000861806 Work Performances T000861820 Performance at Work 2014 07 09 NLM (2016) OBSSR (2016) cze0061833 pracovní výkon 2015 04 10 cze Thesaurus cze0061834 výkonnost v práci 2015 04 10 cze Thesaurus M000602080 vykonaná práce[Job Performance] Measure of how well an individual performs tasks in a work-related environment. M000595463 M000602080 T000874694 Job Performance 2015 02 04 NLM (2016) OBSSR (2016) T000874694 Job Performances T000874694 Performance, Job T000874694 Performances, Job cze0061835 vykonaná práce 2015 04 10 cze Thesaurus D000066479 kriminální chování[Criminal Behavior] 2015 07 01 2014 10 15 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000941 ethics ES Q000208 ethnology EH Q000266 history HI 2016 2016 Criminal Psychology (1963-2015) D003415 Crime D003417 Criminal Psychology D057237 Criminals F01.145.250 M000595471 kriminální chování[Criminal Behavior] Conduct leading to commission of unlawful acts. T000861864 Criminal Behavior 2014 07 09 NLM (2016) OBSSR (2016) T000861864 Behavior, Criminal T000861864 Behaviors, Criminal T000861864 Criminal Behaviors T000866968 Criminal Conduct 2014 09 22 NLM (2016) T000866968 Conduct, Criminal T000866931 Criminal Intent 2014 09 22 NLM (2016) OBSSR (2016) T000866931 Criminal Intents T000866931 Intent, Criminal T000866931 Intents, Criminal T000866932 Illicit Behavior 2014 09 22 NLM (2016) OBSSR (2016) T000866932 Behavior, Illicit T000866932 Behaviors, Illicit T000866932 Illicit Behaviors T000868328 Unlawful Behavior 2014 10 10 NLM (2016) OBSSR (2016) T000868328 Behavior, Unlawful T000868328 Behaviors, Unlawful T000868328 Unlawful Behaviors T000868329 Illegal Behavior 2014 10 10 NLM (2016) OBSSR (2016) T000868329 Behavior, Illegal T000868329 Behaviors, Illegal T000868329 Illegal Behaviors cze0060727 kriminální chování 2014 12 04 cze Thesaurus cze0060729 nezákonné chování 2014 12 04 cze Thesaurus cze0060728 zločinné chování 2014 12 04 cze Thesaurus cze0060730 zločinné úmysly 2014 12 04 cze Thesaurus D000066491 klinické rozhodování[Clinical Decision-Making] 2015 07 02 2015 07 01 2016 01 01 Q000941 ethics ES Q000379 methods MT use DECISION MAKING for decision making by the patient 2016 2016 Decision Making (1972-2015) D003661 Decision Support Techniques D020000 Decision Support Systems, Clinical E01.055 M000595509 klinické rozhodování[Clinical Decision-Making] Process of formulating a diagnosis based on medical history and physical or mental examinations, and/or choosing an appropriate intervention. T000861932 Clinical Decision-Making 2014 07 10 NLM (2016) OBSSR (2016) T000861932 Clinical Decision Making T000861932 Decision-Making, Clinical T000868327 Medical Decision-Making 2014 10 10 NLM (2016) OBSSR (2016) T000868327 Decision-Making, Medical T000868327 Medical Decision Making cze0061485 klinické rozhodování 2015 02 26 cze Thesaurus cze0061486 rozhodování v klinické praxi 2015 02 26 cze Thesaurus cze0061487 rozhodování v medicíně 2015 02 26 cze Thesaurus D000066492 kognitivní stárnutí[Cognitive Aging] 2015 07 07 2015 07 06 2016 01 01 Q000502 physiology PH Q000523 psychology PX 2016 2016 Aging (1984-2015) D003072 Cognition Disorders G07.700.320.124.260 M000595510 kognitivní stárnutí[Cognitive Aging] Phenomenon that occurs when learning and memory abilities decrease naturally due to age. T000861934 Cognitive Aging 2014 07 10 NLM (2016) OBSSR (2016) T000861934 Aging, Cognitive cze0061488 kognitivní stárnutí 2015 02 26 cze Thesaurus cze0061489 vliv stárnutí na kognitivní funkce 2015 02 26 cze Thesaurus D000066494 kognitivní neurověda[Cognitive Neuroscience] 2015 07 07 2015 07 06 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST use for the discipline only (education, history, etc) 2016 2016 F04.096.628.255.500 H01.158.610.030 M000595512 kognitivní neurověda[Cognitive Neuroscience] Field of study concerning MENTAL PROCESSES, LEARNING, and the brain regions associated with them. T000861940 Cognitive Neuroscience 2014 07 10 NLM (2016) OBSSR (2016) T000861940 Neuroscience, Cognitive cze0061071 kognitivní neurověda 2015 01 16 cze Thesaurus D000066498 emoční nastavení[Emotional Adjustment] 2015 07 10 2015 07 09 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016; for PSYCHOLOGICAL ADJUSTMENT use ADAPTATION, PSYCHOLOGICAL 2000-2015 2016; for PSYCHOLOGICAL ADJUSTMENT see ADAPTATION, PSYCHOLOGICAL 2000-2015 D000275 Adjustment Disorders D012917 Social Adjustment F01.058.144 F01.752.543.500.250 M000595534 emoční nastavení[Emotional Adjustment] Psychological process that occurs when an individual adapts to a significant emotional event or stimulus. T000861976 Emotional Adjustment 2014 07 11 NLM (2016) OBSSR (2016) T000861976 Adjustment, Emotional T000861976 Adjustments, Emotional T000861976 Emotional Adjustments T000878012 Psychological Adjustment 2015 04 09 NLM (2016) OBSSR (2016) T000878012 Adjustment, Psychological T000878012 Adjustments, Psychological T000878012 Psychological Adjustments T000874707 Emotional Adaptation 2015 02 04 NLM (2016) OBSSR (2016) T000874707 Adaptation, Emotional T000874707 Adaptations, Emotional T000874707 Emotional Adaptations cze0061831 emoční nastavení 2015 04 10 cze Thesaurus cze0061832 emocionální adaptace 2015 04 10 cze Thesaurus D000066499 rozpoznání obličeje[Facial Recognition] 2015 07 07 2015 07 06 2016 01 01 Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016 2016 Pattern Recognition, Visual (1977-2015) F02.463.593.524.500.500 F02.463.593.932.622.500 M000595535 rozpoznání obličeje[Facial Recognition] Ability to identify an individual and interpret their feelings and emotions based on their facial expressions. M000595535 M000602087 T000877950 Facial Recognition 2015 04 08 NLM (2016) OBSSR (2016) T000877950 Recognition, Facial T000861979 Face Perception 2014 07 11 NLM (2016) OBSSR (2016) T000861979 Perception, Face cze0061840 rozpoznání obličeje 2015 04 10 cze Thesaurus cze0061842 vnímání obličejů 2015 04 10 cze Thesaurus cze0061843 vnímání výrazu obličeje 2015 04 10 cze Thesaurus M000602087 rozpoznání identity[Identity Recognition] Identification of another individual by their facial and other bodily features. M000595535 M000602087 T000874705 Identity Recognition 2015 02 04 NLM (2016) OBSSR (2016) T000874705 Recognition, Identity cze0061841 rozpoznání identity 2015 04 10 cze Thesaurus D000066502 prarodiče[Grandparents] 2015 07 01 2015 04 09 2016 01 01 Q000193 education ED Q000523 psychology PX 2016 2016 Intergenerational Relations (1963-2015) D005190 Family F01.829.263.403 I01.880.853.150.452 M01.264 M000595544 prarodiče[Grandparents] Member of a family who has children and grandchildren. M000595544 M000602084 M000595544 M000602085 T000877952 Grandparents 2015 04 08 NLM (2016) OBSSR (2016) T000862000 Grandparent 2014 07 11 NLM (2016) OBSSR (2016) cze0061836 prarodiče 2015 04 10 cze Thesaurus cze0061839 prarodič 2015 04 10 cze Thesaurus M000602084 babička[Grandmother] M000595544 M000602084 T000874702 Grandmother 2015 02 04 NLM (2016) OBSSR (2016) T000874702 Grandmothers cze0061838 babička 2015 04 10 cze Thesaurus M000602085 dědeček[Grandfather] M000595544 M000602085 T000874703 Grandfather 2015 02 04 NLM (2016) OBSSR (2016) T000874703 Grandfathers cze0061837 dědeček 2015 04 10 cze Thesaurus D000066505 chování při vyhledávání pomoci[Help-Seeking Behavior] 2015 07 01 2014 10 15 2016 01 01 2016 2016 F01.145.813.217 M000595549 chování při vyhledávání pomoci[Help-Seeking Behavior] Form of social behavior in which assistance is sought from others. T000862010 Help-Seeking Behavior 2014 07 11 NLM (2016) OBSSR (2016) T000862010 Behavior, Help-Seeking T000862010 Behaviors, Help-Seeking T000862010 Help Seeking Behavior T000862010 Help-Seeking Behaviors cze0061083 chování při vyhledávání pomoci 2015 01 16 cze Thesaurus cze0061082 vyhledání pomoci 2015 01 16 cze Thesaurus D000066506 heuristika[Heuristics] 2015 07 06 2015 06 15 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016 2016 D000067508 Computer Heuristics D001185 Artificial Intelligence F02.463.425.725.500 F02.463.785.810.500 M000595550 heuristika[Heuristics] Experience-based techniques for problem-solving, learning, and discovery that find a solution which is not guaranteed to be optimal, but sufficient for a given set of goals. T000862013 Heuristics 2014 07 11 NLM (2016) OBSSR (2016) T000862013 Heuristic T000870522 Rule of Thumb 2014 11 05 NLM (2016) OBSSR (2016) cze0060713 heuristika 2014 12 04 cze Thesaurus cze0060714 metoda přibližného výpočtu 2014 12 04 cze Thesaurus cze0060715 odhad "od oka" 2014 12 04 cze Thesaurus D000066511 násilí mezi partnery[Intimate Partner Violence] 2015 07 01 2015 04 09 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 Spouse Abuse (1997-2015) D012742 Sex Offenses I01.198.240.856.575 I01.880.735.900.688 M000595633 násilí mezi partnery[Intimate Partner Violence] A pattern of assaultive and coercive behavior by an individual against their partner or spouse that may include physical injury, psychological abuse, sexual assault, progressive isolation, stalking, deprivation, intimidation, and reproductive coercion. M000595633 M000602082 T000862156 Intimate Partner Violence 2014 07 14 NLM (2016) OBSSR (2016) T000862156 Partner Violence, Intimate T000862156 Violence, Intimate Partner T000877954 Intimate Partner Abuse 2015 04 08 NLM (2016) OBSSR (2016) T000877954 Abuse, Intimate Partner T000877954 Partner Abuse, Intimate cze0061855 násilí mezi partnery 2015 04 10 cze Thesaurus cze0061859 hrubé zacházení s partnerem 2015 04 10 cze Thesaurus cze0061858 násilí ze strany intimního partnera 2015 04 10 cze Thesaurus M000602082 dating violence[Dating Violence] M000595633 M000602082 T000874698 Dating Violence 2015 02 04 NLM (2016) OBSSR (2016) T000874698 Violence, Dating cze0061856 dating violence 2015 04 10 cze Thesaurus cze0061857 násilnické chování ve vztahu 2015 04 10 cze Thesaurus D000066530 neurorehabilitace[Neurological Rehabilitation] 2015 07 01 2015 06 26 2016 01 01 Q000523 psychology PX Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 Rehabilitation (1963-2015) E02.831.477 H02.403.680.600.750 N02.421.784.511 M000595649 neurorehabilitace[Neurological Rehabilitation] Physician-supervised programs designed to rehabilitate people with diseases, trauma, or disorders of the NERVOUS SYSTEM. T000862197 Neurological Rehabilitation 2014 07 14 NLM (2016) OBSSR (2016) T000862197 Rehabilitation, Neurological T000862202 Neurologic Rehabilitation 2014 07 14 NLM (2016) OBSSR (2016) T000862202 Rehabilitation, Neurologic T000865830 Neurorehabilitation 2014 09 02 NLM (2016) OBSSR (2016) cze0061181 neurorehabilitace 2015 02 05 cze Thesaurus cze0061180 neurologická rehabilitace 2015 02 05 cze Thesaurus D000066550 fyzické násilí[Physical Abuse] 2015 07 01 2015 04 09 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 Child Abuse (1963-2016) I01.198.240.856.688 I01.880.735.900.744 M000595685 fyzické násilí[Physical Abuse] Violence inflicted on an individual through physical contact. T000862254 Physical Abuse 2014 07 15 NLM (2016) OBSSR (2016) T000862254 Abuse, Physical T000877960 Physical Violence 2015 04 08 NLM (2016) OBSSR (2016) T000877960 Violence, Physical T000862255 Physical Maltreatment 2014 07 15 NLM (2016) OBSSR (2016) T000862255 Maltreatment, Physical cze0061844 fyzické násilí 2015 04 10 cze Thesaurus cze0061845 tělesné týrání 2015 04 10 cze Thesaurus D000066553 problémové chování[Problem Behavior] 2015 07 06 2015 01 09 2016 01 01 Q000523 psychology PX 2016 2016 Child Behavior Disorders (1963-2016) D019958 Attention Deficit and Disruptive Behavior Disorders F01.145.126.972 F01.145.179.750 M000595694 problémové chování[Problem Behavior] Troublesome or disruptive behavioral displays. M000595694 M000599813 T000862301 Problem Behavior 2014 07 15 NLM (2016) OBSSR (2016) T000862301 Behavior, Problem T000862301 Behaviors, Problem T000862301 Problem Behaviors T000862304 Behavioral Problem 2014 07 15 NLM (2016) OBSSR (2016) T000862304 Behavioral Problems T000862304 Problem, Behavioral T000862304 Problems, Behavioral cze0061191 problémové chování 2015 02 05 cze Thesaurus M000599813 rušivé chování[Disruptive Behavior] M000595694 M000599813 T000872095 Disruptive Behavior 2014 12 15 NLM (2016) T000872095 Behavior, Disruptive T000872095 Behaviors, Disruptive T000872095 Disruptive Behaviors cze0061192 rušivé chování 2015 02 05 cze Thesaurus cze0061193 disruptivní porucha chování 2015 02 05 cze Thesaurus cze0061194 rozvratnická porucha chování 2015 02 05 cze Thesaurus D000066608 pití nezletilých[Underage Drinking] 2015 07 06 2014 12 03 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 D000067292 Alcohol Drinking in College F01.145.022.750 F01.145.317.269.875 I01.880.735.878 M000595823 pití nezletilých[Underage Drinking] Consumption of ALCOHOLIC BEVERAGES by persons under the legal drinking age. M000595823 M000598918 T000862469 Underage Drinking 2014 07 18 NLM (2016) OBSSR (2016) T000862469 Drinking, Underage T000862477 Underage Alcohol Use 2014 07 18 NLM (2016) OBSSR (2016) T000862477 Alcohol Use, Underage T000862479 Youth Drinking 2014 07 18 NLM (2016) OBSSR (2016) T000862479 Drinking, Youth T000862476 Underage Alcohol Consumption 2014 07 18 NLM (2016) OBSSR (2016) T000862476 Alcohol Consumption, Underage T000862474 Teen Drinking 2014 07 18 NLM (2016) OBSSR (2016) T000862474 Drinking, Teen T000862475 Teenage Drinking 2014 07 18 NLM (2016) OBSSR (2016) T000862475 Drinking, Teenage T000862472 Adolescent Alcohol Use 2014 07 18 NLM (2016) OBSSR (2016) T000862472 Alcohol Use, Adolescent T000862471 Adolescent Alcohol Consumption 2014 07 18 NLM (2016) OBSSR (2016) T000862471 Alcohol Consumption, Adolescent T000862478 Youth Alcohol Consumption 2014 07 18 NLM (2016) OBSSR (2016) T000862478 Alcohol Consumption, Youth T000862473 Adolescent Drinking 2014 07 18 NLM (2016) OBSSR (2016) T000862473 Drinking, Adolescent cze0060693 pití nezletilých 2014 12 04 cze Thesaurus cze0060694 pití alkoholu u nezletilých 2014 12 04 cze Thesaurus M000598918 věková hranice pro konzumaci alkoholu[Legal Drinking Age] The age at which an individual can lawfully consume alcohol M000595823 M000598918 T000868332 Legal Drinking Age 2014 10 10 NLM (2016) OBSSR (2016) T000868332 Drinking Age, Legal T000868332 Drinking Ages, Legal T000868332 Legal Drinking Ages T000868334 Minimum Legal Drinking Age 2014 10 10 NLM (2016) OBSSR (2016) T000868333 Minimum Drinking Age 2014 10 10 NLM (2016) OBSSR (2016) T000868333 Drinking Age, Minimum T000868333 Drinking Ages, Minimum T000868333 Minimum Drinking Ages cze0060695 věková hranice pro konzumaci alkoholu 2014 12 04 cze Thesaurus cze0060696 legální věk pro konzumaci alkoholu 2014 12 04 cze Thesaurus cze0060697 minimální věk pro konzumaci alkoholických nápojů 2014 12 04 cze Thesaurus D000066630 ektopická exprese[Ectopic Gene Expression] 2015 07 07 2015 07 06 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Gene Expression Regulation (1981-2015) G05.355.315.202 M000595942 ektopická exprese[Ectopic Gene Expression] The expression of a gene in an abnormal place, or at an abnormal time in an organism. Ectopic Gene Expression is often induced artificially by genetic techniques. T000862730 Ectopic Gene Expression 2014 07 22 NLM (2016) T000862730 Ectopic Gene Expressions T000862730 Expression, Ectopic Gene T000862730 Expressions, Ectopic Gene T000862730 Gene Expression, Ectopic T000862730 Gene Expressions, Ectopic T000862731 Ectopic Expression 2014 07 22 NLM (2016) T000862731 Ectopic Expressions T000862731 Expression, Ectopic T000862731 Expressions, Ectopic cze0060731 ektopická exprese 2014 12 04 cze Thesaurus cze0060732 ektopická exprese genů 2014 12 04 cze Thesaurus D000066670 plasticita buňky[Cell Plasticity] 2015 07 09 2015 07 07 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Cell Differentiation (1966-2015) D009473 Neuronal Plasticity G04.299.335.250 M000595981 plasticita buňky[Cell Plasticity] The ability of a cell to change its PHENOTYPE in response to changes in the environment. T000862767 Cell Plasticity 2014 07 23 NLM (2016) T000862767 Cell Plasticities T000862767 Plasticities, Cell T000862767 Plasticity, Cell T000867169 Cellular Plasticity 2014 09 24 NLM (2016) T000867169 Cellular Plasticities T000867169 Plasticities, Cellular T000867169 Plasticity, Cellular cze0060699 plasticita buňky 2014 12 04 cze Thesaurus cze0060700 buněčná plasticita 2014 12 04 cze Thesaurus D000066673 buněčná sebeobnova[Cell Self Renewal] 2015 07 09 2015 07 07 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Cell Differentiation (1966-2015) D013234 Stem Cells G04.299.134.220.235 G04.299.233.750.500.375 G05.355.105.415 G07.700.320.249.410.750.500.625 M000595987 buněčná sebeobnova[Cell Self Renewal] The ability of certain cell types, such as progenitor cells or tumor cells, to go through numerous cycles of CELL DIVISION while still maintaining an undifferentiated or partially differentiated state. M000595987 M000600198 T000862773 Cell Self Renewal 2014 07 23 NLM (2016) T000862773 Cell Self Renewals T000862773 Renewal, Cell Self T000862773 Renewals, Cell Self T000862773 Self Renewal, Cell T000862773 Self Renewals, Cell cze0060719 buněčná sebeobnova 2014 12 04 cze Thesaurus cze0060721 sebeobnova buněk 2014 12 04 cze Thesaurus cze0060722 sebeobnova buňky 2014 12 04 cze Thesaurus M000600198 sebeobnova kmenových buněk[Stem Cell Self-Renewal] The ability of STEM CELLS to divide while maintaining an undifferentiated state. This process perpetuates the stem cell pool throughout the life of an organism. M000595987 M000600198 T000871599 Stem Cell Self-Renewal 2014 12 03 NLM (2016) T000871599 Cell Self-Renewal, Stem T000871599 Cell Self-Renewals, Stem T000871599 Self-Renewal, Stem Cell T000871599 Self-Renewals, Stem Cell T000871599 Stem Cell Self Renewal T000871599 Stem Cell Self-Renewals T000871600 Stem Cell Renewal 2014 12 03 NLM (2016) T000871600 Cell Renewal, Stem T000871600 Cell Renewals, Stem T000871600 Renewal, Stem Cell T000871600 Renewals, Stem Cell T000871600 Stem Cell Renewals cze0060720 sebeobnova kmenových buněk 2014 12 04 cze Thesaurus D000066768 výzkum v rehabilitaci[Rehabilitation Research] 2015 07 01 2014 10 15 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 Rehabilitation (2004-2015) D006233 Disabled Persons H01.770.644.145.472 M000596264 výzkum v rehabilitaci[Rehabilitation Research] Studies and research concerning the psychological, educational, social, vocational, industrial, and economic aspects of REHABILITATION. T000863419 Rehabilitation Research 2014 07 31 NLM (2016) OBSSR (2016) T000863419 Research, Rehabilitation cze0061991 výzkum v rehabilitaci 2015 04 30 cze Thesaurus cze0062270 studie aspektů rehabilitace 2015 06 11 cze Thesaurus D000066792 ortodontisté[Orthodontists] 2015 07 01 2014 10 15 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000523 psychology PX 2016 2016 M01.526.485.330.655 N02.360.330.655 M000596291 ortodontisté[Orthodontists] Dentists who specialize in the treatment of misaligned TEETH and MALOCCLUSION. M000596291 M000596293 T000863539 Orthodontists 2014 08 01 NLM (2016) T000863539 Orthodontist cze0060691 ortodontisté 2014 12 04 cze Thesaurus M000596293 Dentofacial Orthopedists Dentists who specialize in the diagnosis and treatment of neuromuscular and skeletal abnormalities of the developing or mature orofacial structures. M000596291 M000596293 T000863542 Dentofacial Orthopedists 2014 08 01 NLM (2016) T000863542 Dentofacial Orthopedist T000863542 Orthopedist, Dentofacial T000863542 Orthopedists, Dentofacial D000066794 ústní a čelistní chirurgové[Oral and Maxillofacial Surgeons] 2015 07 01 2014 12 03 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000523 psychology PX 2016 2016 M01.526.485.330.483 N02.360.330.483 M000596294 ústní a čelistní chirurgové[Oral and Maxillofacial Surgeons] Dentists who specialize in the surgical treatment of injuries, diseases, and abnormalities of the oral and maxillofacial regions. M000596294 M000596544 T000863543 Oral and Maxillofacial Surgeons 2014 08 01 NLM (2016) T000863544 Oral Surgeons 2014 08 01 NLM (2016) T000863544 Oral Surgeon T000863544 Surgeon, Oral T000863544 Surgeons, Oral T000863545 Maxillofacial Surgeons 2014 08 01 NLM (2016) T000863545 Maxillofacial Surgeon T000863545 Surgeon, Maxillofacial T000863545 Surgeons, Maxillofacial cze0064407 ústní a čelistní chirurgové 2015 11 11 cze Thesaurus cze0061195 orální a maxilofaciální chirurgové 2015 02 05 cze Thesaurus M000596544 Exodontists Dentists specializing in TOOTH EXTRACTION. M000596294 M000596544 T000863947 Exodontists 2014 08 07 NLM (2016) T000863947 Exodontist D000066829 neuroprotekce[Neuroprotection] 2015 07 07 2015 07 06 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 G11.561.600.638 M000596409 neuroprotekce[Neuroprotection] The physiological processes and techniques used by the body to prevent neuronal injury and degeneration in the central nervous system following acute disorders or as a result of chronic neurodegenerative diseases. T000863754 Neuroprotection 2014 08 05 NLM (2016) OBSSR (2016) T000877958 Neuronal Protection 2015 04 08 NLM (2016) OBSSR (2016) T000877958 Protection, Neuronal T000877959 Neural Protection 2015 04 08 NLM (2016) OBSSR (2016) T000877959 Protection, Neural T000877957 Neuron Protection 2015 04 08 NLM (2016) OBSSR (2016) T000877957 Protection, Neuron cze0061860 neuroprotekce 2015 04 10 cze Thesaurus cze0061861 ochrana neuronů 2015 04 10 cze Thesaurus D000066888 strava, jídlo, výživa[Diet, Food, and Nutrition] 2015 07 01 2015 06 17 2016 01 01 used for searching; INDEXER: Do not use; CATALOGER: Do not use 2016 2016 G07.203 M000596765 strava, jídlo, výživa[Diet, Food, and Nutrition] Concepts involved with nutritional physiology, including categories of substances eaten for sustenance, nutritional phenomena and processes, eating patterns and habits, and measurable nutritional parameters. T000864255 Diet, Food, and Nutrition 2014 08 12 NLM (2016) cze0061072 strava, jídlo, výživa 2015 01 16 cze Thesaurus cze0061073 dieta, potraviny, výživa 2015 01 16 cze Thesaurus D000066889 tritikále[Triticale] 2015 07 01 2014 10 14 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; use EDIBLE GRAIN 1998-2015 2016; see CEREALS 1998-2015 Cereals (1970-2015) Poaceae (1970-2015) B01.650.940.800.575.100.822.906 M0003855 tritikále[Triticale] A CEREAL GRAIN plant resulting from a cross between TRITICUM and SECALE CEREALE. T007371 Triticale 1996 07 12 NLM (1998) T000864288 Triticosecale 2014 08 12 NLM (2016) T000864289 Triticum x Secale 2014 08 12 NLM (2016) cze0047127 tritikále 2012 03 15 cze Thesaurus cze0047129 triticale 2012 03 15 cze Thesaurus cze0047128 žitovec 2012 03 15 cze Thesaurus D000066891 výsledky intenzivní péče[Critical Care Outcomes] 2015 07 01 2014 10 15 2016 01 01 2016 2016 N04.761.559.590.399.250 N05.715.360.575.575.200 M000596781 výsledky intenzivní péče[Critical Care Outcomes] A measure of the mortality and morbidity rates among patients who receive CRITICAL CARE and INTENSIVE CARE as determined from the date of hospital discharge or release. T000864332 Critical Care Outcomes 2014 08 12 NLM (2016) T000864332 Care Outcome, Critical T000864332 Care Outcomes, Critical T000864332 Critical Care Outcome T000864332 Outcome, Critical Care T000864332 Outcomes, Critical Care cze0061092 výsledky intenzivní péče 2015 01 16 cze Thesaurus D000066908 tréninková simulace[Simulation Training] 2015 07 01 2014 10 15 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 I02.903.847 M000596822 tréninková simulace[Simulation Training] A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment. M000596822 M000598229 T000864418 Simulation Training 2014 08 13 NLM (2016) T000864418 Training, Simulation cze0061233 tréninková simulace 2015 02 09 cze Thesaurus cze0061235 cvičná simulace 2015 02 09 cze Thesaurus M000598229 interaktivní výuka[Interactive Learning] M000596822 M000598229 T000864420 Interactive Learning 2014 08 13 NLM (2016) T000864420 Learning, Interactive cze0061234 interaktivní výuka 2015 02 09 cze Thesaurus D000066928 proso[Millets] 2015 07 01 2015 06 17 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME general or unspecified; note several specific millet terms are available 2016 2016 Panicum (1981-2015) B01.650.940.800.575.100.822.587 M000596863 proso[Millets] An agronomic group especially of small-seeded grasses, mainly grown for human and animal consumption. T000864488 Millets 2014 08 14 NLM (2016) T000864488 Millet cze0060665 proso 2014 12 01 cze Thesaurus cze0060666 jáhly 2014 12 01 cze Thesaurus D000066949 biobehaviorální přístup[Biobehavioral Sciences] 2015 07 09 2015 07 07 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 D058025 Interdisciplinary Studies H01.770.644.108.687 M000597265 biobehaviorální přístup[Biobehavioral Sciences] An interdisciplinary scientific approach to the study of complex interactions among biological, social, behavioral, environmental factors, and their effects on health outcomes. T000868692 Biobehavioral Sciences 2014 10 15 NLM (2016) T000868692 Biobehavioral Science T000868692 Science, Biobehavioral T000868692 Sciences, Biobehavioral T000865524 Biobehavioral Approach 2014 08 27 NLM (2016) T000865524 Approach, Biobehavioral T000865527 Biobehavioral Model 2014 08 27 NLM (2016) T000865527 Biobehavioral Models T000865527 Model, Biobehavioral T000865527 Models, Biobehavioral cze0060701 biobehaviorální přístup 2014 12 04 cze Thesaurus cze0060702 biobehaviorální model nemoci 2014 12 04 cze Thesaurus D000066970 proteinová korona[Protein Corona] 2015 07 01 2014 10 15 2016 01 01 Q000032 analysis AN Q000737 chemistry CH Q000276 immunology IM Q000378 metabolism ME Q000379 methods MT 2016 2016 D12.776.642 M000597344 proteinová korona[Protein Corona] 0 A layer of protein coating adsorbed by NANOPARTICLES upon entry into PLASMA or other protein-containing biological fluids, which affects how nanoparticles are internalized by cells and cleared from the body. T000865574 Protein Corona 2014 08 27 NLM (2016) T000865574 Corona, Protein cze0061480 proteinová korona 2015 02 26 cze Thesaurus D000066988 vegetariáni[Vegetarians] 2015 07 06 2014 10 15 2016 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016 2016 Diet, Vegetarian (1963-2015) D014676 Diet, Vegetarian M01.928 M000597380 vegetariáni[Vegetarians] Persons who do not eat MEAT. M000597380 M000597831 T000865615 Vegetarians 2014 08 28 NLM (2016) T000865615 Vegetarian cze0060662 vegetariáni 2014 12 01 cze Thesaurus M000597831 lakto-ovo vegetariáni[Lacto-Ovo Vegetarians] Persons who adopt a VEGETARIAN DIET that includes both EGGS and DAIRY PRODUCTS, but no MEAT. M000597380 M000597831 T000866293 Lacto-Ovo Vegetarians 2014 09 09 NLM (2016) T000866293 Lacto Ovo Vegetarians T000866293 Lacto-Ovo Vegetarian T000866293 Vegetarian, Lacto-Ovo T000866293 Vegetarians, Lacto-Ovo T000866290 Ovo-Lacto Vegetarians 2014 09 09 NLM (2016) T000866290 Ovo Lacto Vegetarians T000866290 Ovo-Lacto Vegetarian T000866290 Vegetarian, Ovo-Lacto T000866290 Vegetarians, Ovo-Lacto cze0060663 lakto-ovo vegetariáni 2014 12 01 cze Thesaurus cze0060664 laktoovo vegetariáni 2014 12 01 cze Thesaurus D000066989 vegani[Vegans] 2015 07 06 2014 10 15 2016 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016 2016 Diet, Vegetarian (1967-2015) D000067269 Diet, Vegan M01.928.500 M000597400 vegani[Vegans] Persons who avoid consuming animal products or animal-derived substances, such as MEAT; EGGS; or HONEY. Some vegans also refrain from using animals or animal products in any form or for any purpose, such as in CLOTHING or household goods. T000865622 Vegans 2014 08 28 NLM (2016) T000865622 Vegan cze0060661 vegani 2014 12 01 cze Thesaurus D000067 účty splatné a pohledávky[Accounts Payable and Receivable] 1977 05 05 1990 05 30 1991 01 01 no qualif; DF: ACCOUNTS PAYABLE 91(78); was see under ACCOUNTING 1978-90 91; was see under ACCOUNTING 1978-90 Accounting (1966-1977) N03.219.463.030.080 M0000096 účty splatné a pohledávky[Accounts Payable and Receivable] Short-term debt obligations and assets occurring in the regular course of operational transactions. M0000096 M0000095 T000172 Accounts Payable and Receivable 1999 01 01 ACCOUNTS PAYABLE RECEIVABLE NLM (1978) cze0000074 účty splatné a pohledávky 2006 03 22 M0000095 Accounts Payable M0000096 M0000095 T000171 Accounts Payable 1990 03 08 NLM (1991) D000067009 sport pro děti a mládež[Youth Sports] 2015 07 01 2014 10 15 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000293 injuries IN Q000592 standards ST Q000502 physiology PH 2016 2016 Sports (1970-2014) I03.450.642.845.987 M000597564 sport pro děti a mládež[Youth Sports] SPORTS activities designed and/or organized for CHILDREN or YOUTH. M000597564 M000597565 T000865857 Youth Sports 2014 09 02 NLM (2016) T000865857 Sport, Youth T000865857 Sports, Youth T000865857 Youth Sport T000868657 Adolescent Sports 2014 10 14 NLM (2016) T000868657 Adolescent Sport T000868657 Sport, Adolescent T000868657 Sports, Adolescent T000867025 Children's Sports 2014 09 22 NLM (2016) T000867025 Children Sports T000867025 Children's Sport T000867025 Childrens Sports T000867025 Sport, Children's T000867025 Sports, Children's cze0060698 sport pro děti a mládež 2014 12 04 cze Thesaurus M000597565 Organized Youth Sports M000597564 M000597565 T000865864 Organized Youth Sports 2014 09 02 NLM (2016) T000865864 Organized Youth Sport T000865864 Sport, Organized Youth T000865864 Sports, Organized Youth T000865864 Youth Sport, Organized T000865864 Youth Sports, Organized D000067010 gramotnost[Literacy] 2015 07 10 2015 07 10 2016 01 01 Q000208 ethnology EH Q000266 history HI Q000523 psychology PX Q000706 statistics & numerical data SN Q000592 standards ST Q000639 trends TD 2016; for ILLITERACY use EDUCATIONAL STATUS 2016; for ILLITERACY see EDUCATIONAL STATUS D006236 Handwriting D011932 Reading D014956 Writing D057220 Health Literacy F01.145.209.429 L01.143.563 N01.824.196.500 M000597566 gramotnost[Literacy] Ability to read and write. M000597566 M0007114 T000865866 Literacy 2014 09 02 NLM (2016) OBSSR (2016) cze0060748 gramotnost 2014 12 11 cze Thesaurus M0007114 negramotnost[Illiteracy] M000597566 M0007114 T013849 Illiteracy 1975 01 01 NLM (1988) cze0045682 negramotnost 2011 12 04 cze Thesaurus D000067011 vážná akutní podvýživa[Severe Acute Malnutrition] 2015 07 01 2014 10 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Nutrition Disorders (1980-2014) C18.654.521.719 M000597567 vážná akutní podvýživa[Severe Acute Malnutrition] Acute form of MALNUTRITION which usually affects children, characterized by a very low weight for height (below -3z scores of the median World Health Organization standards), visible severe wasting, or occurrence of nutritional EDEMA. It can be a direct or indirect cause of fatality in children suffering from DIARRHEA and PNEUMONIA. Do not confuse with starvation, a condition in which the body is not getting enough food, usually for extended periods of time. T000865867 Severe Acute Malnutrition 2014 09 02 NLM (2016) T000865867 Acute Malnutrition, Severe T000865867 Malnutrition, Severe Acute cze0060755 vážná akutní podvýživa 2014 12 11 cze Thesaurus D000067012 osobní bankovnictví[Banking, Personal] 2015 07 01 2014 10 23 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000379 methods MT 2016 2016 Economics (1975-2014) D020402 Medical Savings Accounts N03.219.463.030.100 M000597568 osobní bankovnictví[Banking, Personal] A financial account set up between a financial institution (such as a commercial bank) and a customer (individual, group, or business), whereby the latter may deposit and withdraw money, and where applicable, be paid interest. M000597568 M000598223 M000597568 M000598993 T000868601 Banking, Personal 2014 10 14 NLM (2016) T000868601 Personal Banking T000866401 Banking, Commercial 2014 09 10 NLM (2016) T000866401 Commercial Banking T000865883 Bank Accounts 2014 09 02 NLM (2016) T000865883 Account, Bank T000865883 Accounts, Bank T000865883 Bank Account T000866399 Banking, Financial 2014 09 10 NLM (2016) T000866399 Financial Banking cze0060706 osobní bankovnictví 2014 12 04 cze Thesaurus cze0060707 bankovní účty 2014 12 04 cze Thesaurus M000598223 spořicí účty[Savings Accounts] M000597568 M000598223 T000865888 Savings Accounts 2014 09 02 NLM (2016) T000865888 Account, Savings T000865888 Accounts, Savings T000865888 Savings Account cze0060710 spořicí účty 2014 12 04 cze Thesaurus M000598993 běžný účet[Checking Accounts] M000597568 M000598993 T000868599 Checking Accounts 2014 10 14 NLM (2016) T000868599 Account, Checking T000868599 Accounts, Checking T000868599 Checking Account cze0060708 běžný účet 2014 12 04 cze Thesaurus D000067013 design zařízení založený na znalostech[Evidence-Based Facility Design] 2015 07 01 2014 10 15 2016 01 01 Q000639 trends TD Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST 2016 2016 N02.278.200.252 M000597569 design zařízení založený na znalostech[Evidence-Based Facility Design] An approach, process, or methodology which emphasizes credible evidence and the best available scientific knowledge, judiciously integrated to achieve the best possible outcomes in structural design. For example, the design of a new OUTPATIENT CLINIC might incorporate a review of published research on outpatient clinic design, decisions on similar past projects, along with interviews with staff and consumers. T000868653 Evidence-Based Facility Design 2014 10 14 NLM (2016) T000868653 Design, Evidence-Based Facility T000868653 Designs, Evidence-Based Facility T000868653 Evidence Based Facility Design T000868653 Evidence-Based Facility Designs T000868653 Facility Design, Evidence-Based T000868653 Facility Designs, Evidence-Based cze0064143 design zařízení založený na znalostech 2015 10 22 cze Thesaurus D000067029 fyzický vzhled těla[Body, Physical Appearance] 2015 07 01 2014 10 15 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000208 ethnology EH 2016 2016 D001828 Body Image E01.370.600.115.450 G07.100.175 M000597655 fyzický vzhled těla[Body, Physical Appearance] The superficial physical looks, characteristics, or qualities of an individual as distinguished from the underlying unseen nature or attributes. T000866040 Body, Physical Appearance 2014 09 04 NLM (2016) T000866040 Appearance Body, Physical T000866040 Physical Appearance Body T000866042 Physical Appearance 2014 09 04 NLM (2016) T000866042 Appearance, Physical T000866039 Physical Appearance, Body 2014 09 04 NLM (2016) T000866039 Appearance, Body Physical T000866039 Body Physical Appearance T000866043 Outward Appearance 2014 09 04 NLM (2016) T000866043 Appearance, Outward cze0060753 fyzický vzhled těla 2014 12 11 cze Thesaurus cze0060754 tělesný zjev 2014 12 11 cze Thesaurus D000067030 ovocné a zeleninové šťávy[Fruit and Vegetable Juices] 2015 07 01 2014 12 18 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD coordinate with specific fruit or vegetable 2016 2016 Beverages (1963-2015) G07.203.100.606 J02.200.606 M000597658 ovocné a zeleninové šťávy[Fruit and Vegetable Juices] The liquids extracted from plants. M000597658 M000598121 M000597658 M000598120 T000866787 Fruit and Vegetable Juices 2014 09 18 NLM (2016) cze0060853 ovocné a zeleninové šťávy 2014 12 22 cze Thesaurus cze0060854 ovocné a zeleninové džusy 2014 12 22 cze Thesaurus M000598121 zeleninové šťávy[Vegetable Juices] M000597658 M000598121 T000866789 Vegetable Juices 2014 09 18 NLM (2016) T000866789 Juice, Vegetable T000866789 Juices, Vegetable T000866789 Vegetable Juice cze0060856 zeleninové šťávy 2014 12 22 cze Thesaurus cze0060858 zeleninové džusy 2014 12 22 cze Thesaurus M000598120 ovocné šťávy[Fruit Juices] M000597658 M000598120 T000866788 Fruit Juices 2014 09 18 NLM (2016) T000866788 Fruit Juice T000866788 Juice, Fruit T000866788 Juices, Fruit cze0060855 ovocné šťávy 2014 12 22 cze Thesaurus cze0060857 ovocné džusy 2014 12 22 cze Thesaurus D000067048 ghí[Ghee] 2015 07 01 2015 01 12 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use DIETARY FATS 1982-2015 2016; see DIETARY FATS 1982-2015 Dietary Fats (1969-2015) D10.212.302.199.500 G07.203.300.350.100.500 G07.203.300.375.200.500 J02.500.350.100.500 J02.500.375.200.500 M0006336 ghí[Ghee] 0 The clarified portion of milk, cream, or butter obtained by the removal of the nonfat constituents. (from Dictionary of Food Ingredients, 4th ed., 2001) T012265 Ghee 1981 03 18 UNK (19XX) T012265 Ghees T000872921 Anhydrous Butterfat 2014 12 31 NLM (2016) T000872921 Anhydrous Butterfats T000872921 Butterfat, Anhydrous T000872921 Butterfats, Anhydrous T000872922 Butter Oil 2014 12 31 NLM (2016) T000872922 Butter Oils T000872922 Oil, Butter T000872922 Oils, Butter T000866126 Clarified Butter 2014 09 05 NLM (2016) T000866126 Butter, Clarified T000866126 Butters, Clarified T000866126 Clarified Butters cze0060667 ghí 2014 12 01 cze Thesaurus cze0060668 přepuštěné máslo 2014 12 01 cze Thesaurus cze0060692 přečištěné máslo 2014 12 04 cze Thesaurus D000067071 hydraulické štěpení[Hydraulic Fracking] 2015 07 01 2014 10 15 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 J01.576.655.875.750.500 M000597774 hydraulické štěpení[Hydraulic Fracking] A drilling technology in which NATURAL GAS is extracted from large deposits of impermeable rock formations known as shale, deep within the earth’s crust. This drilling technique involves injecting large volumes of high-pressure fracturing fluid (a mixture of water, sand, and chemicals) several thousand feet underground, thereby creating cracks or fissures in the shale formation, and releasing trapped gas. T000866225 Hydraulic Fracking 2014 09 08 NLM (2016) T000866225 Fracking, Hydraulic T000866229 Hydraulic Fracturing 2014 09 08 NLM (2016) T000866229 Fracturing, Hydraulic T000866228 Fraccing 2014 09 08 NLM (2016) T000868627 Hydrofracturing 2014 10 14 NLM (2016) T000868627 Hydrofracturings T000867023 Hydrofracking 2014 09 22 NLM (2016) T000866224 Fracking 2014 09 08 NLM (2016) cze0060749 hydraulické štěpení 2014 12 11 cze Thesaurus cze0060751 frakování 2014 12 11 cze Thesaurus cze0060750 hydraulické frakování 2014 12 11 cze Thesaurus D000067073 psychické trauma[Psychological Trauma] 2015 07 06 2015 02 05 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 Depression (1965-2014) D013313 Stress Disorders, Post-Traumatic F03.950.750.375 M000597776 psychické trauma[Psychological Trauma] Overwhelming emotional damage caused by a distressful event or series of events. T000866236 Psychological Trauma 2014 09 08 NLM (2016) T000866236 Trauma, Psychological cze0060733 psychické trauma 2014 12 04 cze Thesaurus cze0060734 duševní trauma 2014 12 04 cze Thesaurus D000067074 vliv vrstevnické skupiny[Peer Influence] 2015 07 01 2015 07 01 2016 01 01 2016 2016 Peer Group (1968-2015) F01.829.316.483.750 M000597777 vliv vrstevnické skupiny[Peer Influence] The effect or sway that a PEER GROUP exerts on the beliefs, value systems and behavior of each member of a group. The social expectations for individuals to conform to peer group influence is known as peer pressure. M000597777 M000597778 T000866237 Peer Influence 2014 09 08 NLM (2016) T000866237 Influence, Peer cze0061994 vliv vrstevnické skupiny 2015 04 30 cze Thesaurus cze0061601 vliv skupiny na své členy 2015 03 12 cze Thesaurus cze0061602 vliv vrstevníků 2015 03 12 cze Thesaurus M000597778 skupinový nátlak[Peer Pressure] M000597777 M000597778 T000866238 Peer Pressure 2014 09 08 NLM (2016) T000866238 Pressure, Peer cze0061598 skupinový nátlak 2015 03 12 cze Thesaurus cze0061993 vliv party 2015 04 30 cze Thesaurus cze0061599 vnější tlak vrstevníků 2015 03 12 cze Thesaurus cze0061600 vzájemný tlak mezi členy skupiny 2015 03 12 cze Thesaurus D000067075 výrobky ze zeleniny[Vegetable Products] 2015 07 01 2014 10 14 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Vegetables (1966-2015) G07.203.300.850.450 J02.500.850.800 M000597800 výrobky ze zeleniny[Vegetable Products] Food that is manufactured from various parts of vegetables. T000866269 Vegetable Products 2014 09 08 NLM (2016) T000866269 Product, Vegetable T000866269 Products, Vegetable T000866269 Vegetable Product cze0061097 výrobky ze zeleniny 2015 01 16 cze Thesaurus cze0061099 rostlinné produkty 2015 01 16 cze Thesaurus cze0061098 zeleninové produkty 2015 01 16 cze Thesaurus D000067088 reklama zaměřená na spotřebitele[Direct-to-Consumer Advertising] 2015 07 01 2014 10 15 2016 01 01 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST 2016 2016 Advertising as Topic (1983-2014) J01.219.687.274.500 M000597832 reklama zaměřená na spotřebitele[Direct-to-Consumer Advertising] Advertising that directly targets consumers of certain products such as pharmaceuticals. T000866306 Direct-to-Consumer Advertising 2014 09 09 NLM (2016) T000866306 Advertising, Direct-to-Consumer T000866306 Direct to Consumer Advertising T000868651 Direct-to-Consumer Marketing 2014 10 14 NLM (2016) T000868651 Direct to Consumer Marketing T000868651 Marketing, Direct-to-Consumer cze0060756 reklama zaměřená na spotřebitele 2014 12 11 cze Thesaurus cze0063794 DTC reklama 2015 10 07 cze Thesaurus cze0060757 marketing zaměřený na spotřebitele 2014 12 11 cze Thesaurus cze0063795 reklama zaměřená přímo na pacienta 2015 10 07 cze Thesaurus D000067108 DTC screening a testování[Direct-To-Consumer Screening and Testing] 2015 07 06 2015 06 26 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000523 psychology PX 2016 2016 D059026 Diagnostic Self Evaluation E01.370.398 N02.421.726.233.166 M000597879 DTC screening a testování[Direct-To-Consumer Screening and Testing] Laboratory testing and diagnostic imaging services offered to consumers outside of the patient-physician relationship. T000866388 Direct-To-Consumer Screening and Testing 2014 09 10 NLM (2016) T000866388 Direct To Consumer Screening and Testing T000866396 Direct-To-Consumer Screening 2014 09 10 NLM (2016) T000866396 Direct To Consumer Screening T000866396 Direct-To-Consumer Screenings T000866396 Screening, Direct-To-Consumer T000866396 Screenings, Direct-To-Consumer T000866395 Direct-To-Consumer Testing 2014 09 10 NLM (2016) T000866395 Direct To Consumer Testing T000866395 Direct-To-Consumer Testings T000866395 Testing, Direct-To-Consumer T000866395 Testings, Direct-To-Consumer cze0063791 DTC screening a testování 2015 10 07 cze Thesaurus cze0063788 DTC screening 2015 10 07 cze Thesaurus cze0063786 DTC testování 2015 10 07 cze Thesaurus cze0063787 přímé testování a screening pacientů 2015 10 07 cze Thesaurus cze0063790 přímé testování pacientů 2015 10 07 cze Thesaurus cze0063789 přímý screening pacientů 2015 10 07 cze Thesaurus cze0063793 testy přímo ke spotřebiteli 2015 10 07 cze Thesaurus cze0063792 testy přímo pro zákazníka 2015 10 07 cze Thesaurus D000067128 extracelulární vezikuly[Extracellular Vesicles] 2015 07 10 2015 07 10 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA Q000235 genetics GE 2016 2016 A11.284.295.588 M000597885 extracelulární vezikuly[Extracellular Vesicles] Membrane limited structures derived from cell membranes and cytoplasmic material, and released into EXTRACELLULAR SPACE. They circulate through the EXTRACELLULAR FLUID and through the peripheral blood in the MICROVASCULATURE where cells, much larger, cannot, thereby affecting a variety of intercellular communication processes. M000597885 M000597887 M000597885 M000597888 T000866403 Extracellular Vesicles 2014 09 10 NLM (2016) T000866403 Extracellular Vesicle T000866403 Vesicle, Extracellular T000866403 Vesicles, Extracellular cze0061080 extracelulární vezikuly 2015 01 16 cze Thesaurus cze0061081 extracelulární váčky 2015 01 16 cze Thesaurus M000597887 Exovesicles M000597885 M000597887 T000866406 Exovesicles 2014 09 10 NLM (2016) T000866406 Exovesicle M000597888 apoptotická tělíska[Apoptotic Bodies] Extracellular vesicles released from fragmenting apoptotic cells. Apoptotické tělísko – morfologický obraz typický pro apoptózu. Svraštělá buňka, která je posléze fagocytována, aniž dojde k úniku proteolytických enzymů a vzniku zánětlivé reakce. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) M000597885 M000597888 T000866407 Apoptotic Bodies 2014 09 10 NLM (2016) T000866407 Apoptotic Body T000866407 Bodies, Apoptotic T000866407 Body, Apoptotic cze0061079 apoptotická tělíska 2015 01 16 cze Thesaurus D000067148 mykoviry[Fungal Viruses] 2015 07 01 2014 12 18 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY coordinate with specific fungus/ virol 2016 2016 Fungi or specific/virology (1994-2015) B04.352 M000597932 mykoviry[Fungal Viruses] Viruses infecting species of FUNGI. T000866450 Fungal Viruses 2014 09 11 NLM (2016) T000866450 Fungal Virus T000866450 Virus, Fungal T000866450 Viruses, Fungal T000866451 Mycoviruses 2014 09 11 NLM (2016) T000866451 Mycovirus cze0061506 mykoviry 2015 02 27 cze Thesaurus cze0061507 houbové viry 2015 02 27 cze Thesaurus D000067170 buňky podobné intersticiálním Cajalovým buňkám[Telocytes] 2015 07 06 2015 01 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016; for INTERSTITIAL CELL OF CAJAL-LIKE CELLS use INTERSTITIAL CELLS OF CAJAL 2010-2015 2016; for INTERSTITIAL CELL OF CAJAL-LIKE CELLS see INTERSTITIAL CELLS OF CAJAL 2010-2015 D056885 Interstitial Cells of Cajal A11.329.830.750 M0533148 buňky podobné intersticiálním Cajalovým buňkám[Telocytes] A type of interstitial cells that have very long and thin CELL SURFACE EXTENSIONS called TELOPODES. T000870458 Telocytes 2014 11 03 NLM (2016) T000870458 Telocyte T746485 Interstitial Cell of Cajal-Like Cells 2009 02 24 NLM (2010) T746485 Interstitial Cell of Cajal Like Cells T000873253 Interstitial Cajal-Like Cells 2015 01 07 NLM (2016) T000873253 Cajal-Like Cells, Interstitial T000873253 Cells, Interstitial Cajal-Like T000873253 Interstitial Cajal Like Cells cze0038690 buňky podobné intersticiálním Cajalovým buňkám 2009 07 28 cze Thesaurus D000067190 exoskeleton[Exoskeleton Device] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000941 ethics ES Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Orthotic Devices (2006-2015) Robotics (1999-2015) D012371 Robotics E07.341 M000598118 exoskeleton[Exoskeleton Device] Device designed to wear externally to support muscular skeletal system in various movements such as RANGE OF MOTIONS; WEIGHT-BEARING; GAIT; and LOCOMOTION. M000598118 M000598119 T000866782 Exoskeleton Device 2014 09 18 NLM (2016) T000866782 Device, Exoskeleton T000866782 Devices, Exoskeleton T000866782 Exoskeleton Devices cze0060737 exoskeleton 2014 12 04 cze Thesaurus cze0060736 bionický exoskeleton 2014 12 04 cze Thesaurus M000598119 robotický exoskeleton[Robotic Exoskeleton] Robotic Exoskeleton M000598118 M000598119 T000866783 Robotic Exoskeleton 2014 09 18 NLM (2016) T000866783 Exoskeleton, Robotic T000866783 Exoskeletons, Robotic T000866783 Robotic Exoskeletons cze0060735 robotický exoskeleton 2014 12 04 cze Thesaurus D000067208 alergie na korýše[Shellfish Hypersensitivity] 2015 07 06 2014 11 21 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Food Hypersensitivity (1964-2015) Shellfish (1964-2015) D057096 Shellfish Poisoning C20.543.480.370.763 M000598204 alergie na korýše[Shellfish Hypersensitivity] Allergic reaction to SHELLFISH or shellfish products. T000866948 Shellfish Hypersensitivity 2014 09 22 NLM (2016) T000866948 Hypersensitivities, Shellfish T000866948 Hypersensitivity, Shellfish T000866948 Shellfish Hypersensitivities T000866949 Shellfish Allergy 2014 09 22 NLM (2016) T000866949 Allergies, Shellfish T000866949 Allergy, Shellfish T000866949 Shellfish Allergies cze0060669 alergie na korýše 2014 12 01 cze Thesaurus cze0060670 alergie na měkýše 2014 12 01 cze Thesaurus D000067248 selhání při léčbě, zdravotní péči[Failure to Rescue, Health Care] 2015 07 09 2015 07 09 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC 2016 2016 Resuscitation (1992-2015) Treatment Failure (2005-2015) E01.789.800.760.500 H01.770.644.145.431.500 N04.761.559.590.200 N04.761.559.590.800.760.500 N05.715.360.575.575.300 N05.715.360.575.575.800.760.500 M000599441 selhání při léčbě, zdravotní péči[Failure to Rescue, Health Care] Inability to prevent a clinical deterioration resulting from a complication of an underlying medical condition or a complication of medical care. It implies that common risk factors for such a complication were not recognized in a timely manner or treated appropriately. Neschopnost zabránit klinickému zhoršení vyplývajícímu z komplikace základního zdravotního stavu, nebo komplikace zdravotní péče. To znamená, že běžný rizikový faktor pro vznik takové komplikace nebyl rozpoznán včas nebo vhodně léčen. T000871085 Failure to Rescue, Health Care 2014 11 20 NLM (2016) T000871102 Health Care, Failures to Rescue 2014 11 21 NLM (2016) T000871101 Health Care, Failure to Rescue 2014 11 21 NLM (2016) T000867106 Failure to Rescue (Health Care) 2014 09 23 NLM (2016) T000867106 Failure to Rescues (Health Care) T000867106 Rescue, Failure to (Health Care) T000867106 Rescues, Failure to (Health Care) cze0061664 selhání při léčbě, zdravotní péči 2015 03 13 cze Thesaurus cze0061666 neschopnost zabránit zhoršení stavu pacienta 2015 03 13 cze Thesaurus cze0061665 neschopnost zachránit pacienta 2015 03 13 cze Thesaurus D000067250 psychiatrická rehabilitace[Psychiatric Rehabilitation] 2015 07 01 2015 06 26 2016 01 01 Q000523 psychology PX Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 H02.403.680.600.875 N02.421.784.578 M000598273 psychiatrická rehabilitace[Psychiatric Rehabilitation] Specialty field that promotes recovery, community functioning, and increased well-being of individuals diagnosed with mental disorders that impair their ability to live meaningful lives. T000867112 Psychiatric Rehabilitation 2014 09 23 NLM (2016) OBSSR (2016) T000867112 Rehabilitation, Psychiatric T000881819 Mental Health Rehabilitation 2015 06 15 NLM (2016) OBSSR (2016) T000881819 Health Rehabilitation, Mental T000881819 Rehabilitation, Mental Health T000867114 Psychosocial Rehabilitation 2014 09 23 NLM (2016) OBSSR (2016) T000867114 Rehabilitation, Psychosocial cze0061198 psychiatrická rehabilitace 2015 02 05 cze Thesaurus cze0061199 psychosociální rehabilitace 2015 02 05 cze Thesaurus D000067251 syndrom vzplanutí nemoci[Symptom Flare Up] 2015 07 01 2015 06 22 2016 01 01 2016 2016 Incidence (1990-2015) Recurrence (1972-2015) C23.550.291.937.500 M000598274 syndrom vzplanutí nemoci[Symptom Flare Up] A transient exacerbation of symptoms of an existing disease or condition. T000871086 Symptom Flare Up 2014 11 20 NLM (2016) T000871086 Flare Up, Symptom T000871086 Flare Ups, Symptom T000871086 Symptom Flare Ups T000871105 Symptom Flaring Up 2014 11 21 NLM (2016) T000871105 Flaring Up, Symptom T000871105 Flaring Ups, Symptom T000871105 Symptom Flaring Ups T000871089 Acute Symptom Flare 2014 11 20 NLM (2016) T000871089 Acute Symptom Flares T000871089 Flare, Acute Symptom T000871089 Flares, Acute Symptom T000871089 Symptom Flare, Acute T000871089 Symptom Flares, Acute T000871087 Symptom Flareup 2014 11 20 NLM (2016) T000871087 Flareup, Symptom T000871087 Flareups, Symptom T000871087 Symptom Flareups T000871088 Symptom Flare-up 2014 11 20 NLM (2016) T000871088 Flare-up, Symptom T000871088 Flare-ups, Symptom T000871088 Symptom Flare-ups cze0060724 syndrom vzplanutí nemoci 2014 12 04 cze Thesaurus cze0060725 flare up fenomén 2014 12 04 cze Thesaurus cze0060726 flare-up efekt 2014 12 04 cze Thesaurus D000067268 preparace izolovaného srdce[Isolated Heart Preparation] 2015 07 06 2015 06 22 2016 01 01 Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST 2016 2016 Heart (1963-2015) Perfusion (1963-2015) D015428 Myocardial Reperfusion Injury E05.519 E05.598.750 M000598304 preparace izolovaného srdce[Isolated Heart Preparation] Method of isolation and maintenance of a working heart for various cardiac measurements. The model allows for the separation of cardiac and systemic variables in the denervated heart. M000598304 M000598306 M000598304 M000599514 M000598304 M000598305 M000598304 M000599513 T000867186 Isolated Heart Preparation 2014 09 24 NLM (2016) T000867186 Isolated Heart Preparations T000867186 Preparation, Isolated Heart T000867186 Preparations, Isolated Heart T000867188 Isolated Perfused Heart Model 2014 09 24 NLM (2016) cze0061091 preparace izolovaného srdce 2015 01 16 cze Thesaurus M000598306 izolované srdce podle Langendorffa[Langendorff Perfused Heart] M000598304 M000598306 T000867191 Langendorff Perfused Heart 2014 09 24 NLM (2016) T000867191 Heart, Langendorff Perfused T000867191 Perfused Heart, Langendorff T000867190 Langendorff Perfused Isolated Heart Preparation 2014 09 24 NLM (2016) cze0061089 izolované srdce podle Langendorffa 2015 01 16 cze Thesaurus M000599514 Working Heart Preparation Technique M000598304 M000599514 T000867194 Working Heart Preparation Technique 2014 09 24 NLM (2016) M000598305 Working Heart Preparation M000598304 M000598305 T000867192 Working Heart Preparation 2014 09 24 NLM (2016) T000867192 Preparation, Working Heart T000867192 Preparations, Working Heart T000867192 Working Heart Preparations T000867193 Working Heart Technique 2014 09 24 NLM (2016) T000867193 Technique, Working Heart T000867193 Techniques, Working Heart T000867193 Working Heart Techniques M000599513 technika preparace izolovaného srdce[Isolated Heart Preparation Technique] M000598304 M000599513 T000867187 Isolated Heart Preparation Technique 2014 09 24 NLM (2016) cze0061090 technika preparace izolovaného srdce 2015 01 16 cze Thesaurus D000067269 dieta veganská[Diet, Vegan] 2015 07 09 2015 07 07 2016 01 01 Q000009 adverse effects AE Q000191 economics EC Q000208 ethnology EH Q000266 history HI Q000523 psychology PX Q000706 statistics & numerical data SN 2016; use DIET, VEGETARIAN 2003-2015 2016; see DIET, VEGETARIAN 2003-2015 Diet, Vegetarian (1967-2015) D000066989 Vegans E02.642.249.300.750 G07.203.650.240.300.750 M0416012 dieta veganská[Diet, Vegan] Dietary practice of avoiding animal products in any form. T483886 Diet, Vegan 2002 02 28 NLM (2003) T483886 Diets, Vegan T483886 Vegan Diets T489882 Vegan Diet 2002 04 17 NLM (2003) T000865601 Veganism 2014 08 28 NLM (2016) cze0016707 dieta veganská 2006 03 22 cze0064406 veganská strava 2015 11 11 cze Thesaurus cze0060630 veganství 2014 12 01 cze Thesaurus D000067289 techniky výzkumu chování[Behavior Observation Techniques] 2015 07 09 2015 07 07 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 E05.796.112 F04.669.112 M000598346 techniky výzkumu chování[Behavior Observation Techniques] A wide range of formal and informal techniques used to document behavior. T000869172 Behavior Observation Techniques 2014 10 21 NLM (2016) OBSSR (2016) T000869172 Behavior Observation Technique T000869172 Observation Technique, Behavior T000869172 Observation Techniques, Behavior T000869173 Behavioral Observation Techniques 2014 10 21 NLM (2016) OBSSR (2016) T000869173 Behavioral Observation Technique T000869173 Observation Technique, Behavioral T000869173 Observation Techniques, Behavioral T000867286 Behavior Observation 2014 09 25 NLM (2016) OBSSR (2016) T000867286 Behavior Observations T000867286 Observation, Behavior T000867286 Observations, Behavior T000867287 Behavioral Observation 2014 09 25 NLM (2016) OBSSR (2016) T000867287 Behavioral Observations T000867287 Observation, Behavioral T000867287 Observations, Behavioral cze0061481 techniky výzkumu chování 2015 02 26 cze Thesaurus cze0061482 pozorování chování 2015 02 26 cze Thesaurus cze0061484 techniky pozorování chování 2015 02 26 cze Thesaurus cze0061483 výzkum chování 2015 02 26 cze Thesaurus D000067290 škály posuzující chování[Behavior Rating Scale] 2015 07 09 2015 07 07 2016 01 01 Q000266 history HI Q000706 statistics & numerical data SN Q000592 standards ST 2016 2016 F04.711.271 M000598347 škály posuzující chování[Behavior Rating Scale] Instrument designed to assess human or animal behavior, using a standardized format. M000598347 M000598349 T000867288 Behavior Rating Scale 2014 09 25 NLM (2016) OBSSR (2016) T000867288 Behavior Rating Scales T000867288 Rating Scale, Behavior T000867288 Rating Scales, Behavior T000867289 Behavioral Rating Scale 2014 09 25 NLM (2016) OBSSR (2016) T000867289 Behavioral Rating Scales T000867289 Rating Scale, Behavioral T000867289 Rating Scales, Behavioral T000867289 Scale, Behavioral Rating cze0061236 škály posuzující chování 2015 02 09 cze Thesaurus cze0061237 škálový dotazník chování 2015 02 09 cze Thesaurus M000598349 Behavior Test Written, visual, or verbal evaluation administered to assess the cognitive and emotional functioning of both humans and animals. M000598347 M000598349 T000867291 Behavior Test 2014 09 25 NLM (2016) OBSSR (2016) T000867291 Behavior Tests T000867291 Test, Behavior T000867291 Tests, Behavior T000867292 Behavioral Test 2014 09 25 NLM (2016) OBSSR (2016) T000867292 Behavioral Tests T000867292 Test, Behavioral T000867292 Tests, Behavioral D000067292 pití alkoholu na vysoké škole[Alcohol Drinking in College] 2015 07 09 2015 07 07 2016 01 01 Q000208 ethnology EH Q000523 psychology PX 2016 2016 Alcohol Drinking (1963-2015) D000066608 Underage Drinking F01.145.317.269.625 M000598358 pití alkoholu na vysoké škole[Alcohol Drinking in College] Alcohol consumption among college students. T000871165 Alcohol Drinking in College 2014 11 24 NLM (2016) OBSSR (2016) T000870990 College Student Drinking 2014 11 19 NLM (2016) OBSSR (2016) T000870990 Student Drinking, College T000870992 Alcohol Drinking, College Students 2014 11 19 NLM (2016) OBSSR (2016) T000867306 College Drinking 2014 09 25 NLM (2016) OBSSR (2016) T000867306 Drinking, College T000870991 University Student Drinking 2014 11 19 NLM (2016) OBSSR (2016) T000870991 Student Drinking, University cze0060704 pití alkoholu na vysoké škole 2014 12 04 cze Thesaurus cze0060705 pití alkoholu u vysokoškoláků 2014 12 04 cze Thesaurus D000067329 metabolicky benigní obezita[Obesity, Metabolically Benign] 2015 07 01 2015 01 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Obesity (2005-2015) C18.654.726.500.698 C23.888.144.699.500.250 E01.370.600.115.100.160.120.699.500.375 G07.100.100.160.120.699.500.375 M000598563 metabolicky benigní obezita[Obesity, Metabolically Benign] A sub-PHENOTYPE of obese individuals who have a risk for CARDIOVASCULAR DISEASES between that of healthy individuals with normal weight and unhealthy individuals with obesity. T000867594 Obesity, Metabolically Benign 2014 10 01 NLM (2016) T000867594 Benign Obesity, Metabolically T000867593 Metabolically Healthy Obesity 2014 10 01 NLM (2016) T000867593 Healthy Obesity, Metabolically T000867593 Obesity, Metabolically Healthy T000867592 Metabolically Benign Obesity 2014 10 01 NLM (2016) cze0062078 metabolicky benigní obezita 2015 05 22 cze Thesaurus cze0062079 metabolicky zdravá obezita 2015 05 22 cze Thesaurus D000067348 celozrnné výrobky[Whole Grains] 2015 07 01 2015 02 26 2016 01 01 Q000191 economics EC Q000266 history HI Q000600 supply & distribution SD Q000592 standards ST Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 2016 Cereals (1973-2015) G07.203.300.300.550.500 G07.203.300.775.500.500 J02.500.300.550.500 J02.500.775.500.500 M000598785 celozrnné výrobky[Whole Grains] Edible seeds which contain all components of the seed - germ, bran, and ENDOSPERM. M000598785 M000600566 T000867950 Whole Grains 2014 10 06 NLM (2016) T000867950 Grain, Whole T000867950 Grains, Whole T000867950 Whole Grain cze0061230 celozrnné výrobky 2015 02 09 cze Thesaurus cze0061232 produkty z celozrnné mouky 2015 02 09 cze Thesaurus M000600566 celozrnné obiloviny[Whole Grain Cereals] M000598785 M000600566 T000872170 Whole Grain Cereals 2014 12 15 NLM (2016) T000872170 Cereal, Whole Grain T000872170 Cereals, Whole Grain T000872170 Grain Cereal, Whole T000872170 Grain Cereals, Whole T000872170 Whole Grain Cereal cze0061229 celozrnné obiloviny 2015 02 09 cze Thesaurus cze0061231 výrobky z celozrnné mouky 2015 02 09 cze Thesaurus D000067368 transanální endoskopická chirurgie[Transanal Endoscopic Surgery] 2015 07 01 2015 01 12 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 E01.370.388.250.630.500 E04.210.240.250.680.500 E04.502.250.250.250.680.500 E04.502.250.630.500 M000599080 transanální endoskopická chirurgie[Transanal Endoscopic Surgery] Surgical procedures performed through the anus using a PROCTOSCOPE. T000868945 Transanal Endoscopic Surgery 2014 10 17 NLM (2016) T000868945 Endoscopic Surgeries, Transanal T000868945 Endoscopic Surgery, Transanal T000868945 Surgeries, Transanal Endoscopic T000868945 Surgery, Transanal Endoscopic T000868945 Transanal Endoscopic Surgeries T000868949 Transanal Endoscopic Surgical Procedures 2014 10 17 NLM (2016) cze0061075 transanální endoskopická chirurgie 2015 01 16 cze Thesaurus cze0061077 endoskopická chirurgie transanální 2015 01 16 cze Thesaurus cze0061076 endoskopické operace transanální 2015 01 16 cze Thesaurus cze0061078 endoskopické transanální operační výkony 2015 01 16 cze Thesaurus D000067369 transanální mikroskopická chirurgie[Transanal Endoscopic Microsurgery] 2015 07 01 2015 01 12 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 microsurgery (1985-2015) E01.370.388.250.630.500.500 E04.210.240.250.680.500.500 E04.494.787 E04.502.250.250.250.680.500.500 E04.502.250.630.500.500 M000599083 transanální mikroskopická chirurgie[Transanal Endoscopic Microsurgery] A specialized form of transanal endoscopic surgery for microscopically controlled operations in the RECTUM. T000868953 Transanal Endoscopic Microsurgery 2014 10 17 NLM (2016) T000868953 Endoscopic Microsurgeries, Transanal T000868953 Endoscopic Microsurgery, Transanal T000868953 Microsurgeries, Transanal Endoscopic T000868953 Microsurgery, Transanal Endoscopic T000868953 Transanal Endoscopic Microsurgeries cze0061074 transanální mikroskopická chirurgie 2015 01 16 cze Thesaurus D000067390 poškození chladem[Cold Injury] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 C26.212 M000599150 poškození chladem[Cold Injury] A physical injury caused by exposure of the body to extremely low ambient temperatures that may lead to loss of body parts, or in extreme cases, death. Examples of cold injury are FROSTBITE and CHILBLAINS. T000869087 Cold Injury 2014 10 20 NLM (2016) T000869087 Cold Injuries T000869087 Injuries, Cold T000869087 Injury, Cold cze0060711 poškození chladem 2014 12 04 cze Thesaurus cze0060712 poranění chladem 2014 12 04 cze Thesaurus D000067393 osobní ochranné prostředky[Personal Protective Equipment] 2015 07 01 2014 12 02 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000941 ethics ES Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 E07.662 M000599156 osobní ochranné prostředky[Personal Protective Equipment] Specialized clothing or equipment worn for protection against health hazards. Personal Protective Equipment (PPE) may include MASKS, RESPIRATORY PROTECTIVE DEVICES, HEAD PROTECTIVE DEVICES, EYE PROTECTIVE DEVICES, PROTECTIVE CLOTHING and protective footwear. T000869095 Personal Protective Equipment 2014 10 20 NLM (2016) T000869095 Equipment, Personal Protective T000869095 Protective Equipment, Personal cze0061179 osobní ochranné prostředky 2015 02 05 cze Thesaurus D000067397 nervová bojová látka[Nerve Agents] 2015 07 01 2014 12 02 2016 01 01 Q000493 pharmacokinetics PK Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Organophosphorus Compounds (1982-2015) D27.720.599 D27.720.777.300.500 M000599163 nervová bojová látka[Nerve Agents] 0 A class of compounds that adversely affect the transmission of impulses through the NERVOUS SYSTEM. T000869121 Nerve Agents 2014 10 20 NLM (2016) T000869121 Agents, Nerve T000870453 Nerve Gas 2014 11 03 NLM (2016) T000870453 Gas, Nerve cze0061501 nervová bojová látka 2015 02 26 cze Thesaurus cze0061502 nervový plyn 2015 02 26 cze Thesaurus D000067398 válečná poranění[War-Related Injuries] 2015 07 06 2015 06 29 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 D013313 Stress Disorders, Post-Traumatic C26.946 I01.880.735.950.500.951.500 N06.850.460.350.600.903.500 M000599167 válečná poranění[War-Related Injuries] WOUNDS and INJURIES and PSYCHOLOGICAL TRAUMA sustained during WAR. M000599167 M000599553 T000869128 War-Related Injuries 2014 10 20 NLM (2016) T000869128 Injuries, War-Related T000869128 Injury, War-Related T000869128 War Related Injuries T000869128 War-Related Injury cze0064251 válečná poranění 2015 11 05 cze Thesaurus cze0060687 válečná zranění 2014 12 03 cze Thesaurus cze0060688 zranění z války 2014 12 03 cze Thesaurus M000599553 válečné trauma[War-Related Trauma] Distress resulting from severe injuries. M000599167 M000599553 T000870514 War-Related Trauma 2014 11 04 NLM (2016) T000870514 Trauma, War-Related T000870514 War Related Trauma cze0060689 válečné trauma 2014 12 03 cze Thesaurus cze0060690 trauma způsobené válkou 2014 12 03 cze Thesaurus D000067399 škála hodnotící mimovolní pohyby[Abnormal Involuntary Movement Scale] 2015 07 09 2015 07 07 2016 01 01 2016 2016 E01.370.600.550.162 M000599182 škála hodnotící mimovolní pohyby[Abnormal Involuntary Movement Scale] A rating scale that measures INVOLUNTARY MOVEMENTS known as TARDIVE DYSKINESIA. T000869189 Abnormal Involuntary Movement Scale 2014 10 21 NLM (2016) cze0061200 škála hodnotící mimovolní pohyby 2015 02 05 cze Thesaurus D000067401 obsah alkoholu v krvi[Blood Alcohol Content] 2015 07 02 2014 12 02 2016 01 01 2016 2016 D000066448 Driving Under the Influence D000437 Alcoholism D02.033.375.135 M000599184 obsah alkoholu v krvi[Blood Alcohol Content] 0 Mass of alcohol per unit of BLOOD volume. T000869205 Blood Alcohol Content 2014 10 21 NLM (2016) T000869205 Alcohol Content, Blood T000869205 Content, Blood Alcohol T000869208 Blood Alcohol Concentration 2014 10 21 NLM (2016) T000869208 Alcohol Concentration, Blood T000869208 Concentration, Blood Alcohol T000869209 Blood Alcohol Level 2014 10 21 NLM (2016) T000869209 Alcohol Level, Blood T000869209 Level, Blood Alcohol cze0060684 obsah alkoholu v krvi 2014 12 03 cze Thesaurus cze0060686 hladina alkoholu v krvi 2014 12 03 cze Thesaurus cze0060685 koncentrace alkoholu v krvi 2014 12 03 cze Thesaurus D000067404 poruchy sociální komunikace[Social Communication Disorder] 2015 07 01 2015 02 10 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.625.374.250 M000599200 poruchy sociální komunikace[Social Communication Disorder] Persistent difficulties in the social uses of verbal and nonverbal communications. (DSM-V) T000869260 Social Communication Disorder 2014 10 21 NLM (2016) T000869260 Communication Disorder, Social T000869260 Communication Disorders, Social T000869260 Social Communication Disorders T000869261 Pragmatic Communication Disorder 2014 10 21 NLM (2016) T000869261 Communication Disorder, Pragmatic T000869261 Communication Disorders, Pragmatic T000869261 Disorders, Pragmatic Communication T000869261 Pragmatic Communication Disorders cze0061394 poruchy sociální komunikace 2015 02 19 cze Thesaurus D000067408 právní služby[Legal Services] 2015 07 01 2014 12 02 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 I01.880.604.583.482 M000599241 právní služby[Legal Services] Services provided by ATTORNEYS and paralegal staff. T000869413 Legal Services 2014 10 23 NLM (2016) T000869413 Legal Service T000869413 Service, Legal T000869413 Services, Legal cze0060723 právní služby 2014 12 04 cze Thesaurus D000067448 pomluva[Defamation] 2015 07 01 2015 07 01 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 D007603 Jurisprudence I01.198.240.240 I01.880.735.191.051 M000599541 pomluva[Defamation] Public false statements that are illegal and damaging to the reputation of a person, group, business, organization, or institution. M000599541 M000600202 M000599541 M000601365 T000873370 Defamation 2015 01 09 NLM (2016) OBSSR (2016) T000873370 Defamations T000873373 Vilification 2015 01 09 NLM (2016) OBSSR (2016) T000873373 Vilifications T000873372 Calumny 2015 01 09 NLM (2016) OBSSR (2016) T000873372 Calumnies cze0061495 pomluva 2015 02 26 cze Thesaurus cze0061496 hanobení 2015 02 26 cze Thesaurus cze0061493 hanění 2015 02 26 cze Thesaurus cze0061492 pomlouvání 2015 02 26 cze Thesaurus cze0061494 urážení 2015 02 26 cze Thesaurus M000600202 urážka na cti[Slander] Orally communicated statements intended to harm. M000599541 M000600202 T000871604 Slander 2014 12 03 NLM (2016) OBSSR (2016) cze0061497 urážka na cti 2015 02 26 cze Thesaurus M000601365 nactiutrhání[Libel] Written statements intended to harm M000599541 M000601365 T000873371 Libel 2015 01 09 NLM (2016) OBSSR (2016) T000873371 Libels cze0061490 nactiutrhání 2015 02 26 cze Thesaurus D000067449 nácvik zvládání agrese[Anger Management Therapy] 2015 07 01 2015 01 12 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 Anger (1977-2016) F04.754.137.087 M000599545 nácvik zvládání agrese[Anger Management Therapy] System of psychological and/or therapeutic techniques used to control and or reduce the triggers, degrees, and effects of ANGER. T000871922 Anger Management Therapy 2014 12 11 NLM (2016) OBSSR (2016) T000871922 Therapy, Anger Management T000871923 Anger Management Training 2014 12 11 NLM (2016) OBSSR (2016) T000871923 Management Training, Anger T000871923 Training, Anger Management T000870498 Anger Management 2014 11 04 NLM (2016) OBSSR (2016) T000870498 Management, Anger cze0061067 nácvik zvládání agrese 2015 01 16 cze Thesaurus cze0061068 anger management 2015 01 16 cze Thesaurus cze0061070 terapie zvládání hněvu 2015 01 16 cze Thesaurus cze0061069 trénink zvládání vzteku 2015 01 16 cze Thesaurus D000067450 psychologie sportu[Psychology, Sports] 2015 07 01 2015 06 15 2016 01 01 Q000706 statistics & numerical data SN Q000592 standards ST Q000639 trends TD Q000145 classification CL Q000191 economics EC Q000193 education ED Q000941 ethics ES Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG 2016 2016 Sports (1970-2015) D013178 Sports Medicine F04.096.628.914 M000599547 psychologie sportu[Psychology, Sports] Field of research that studies mental factors influencing the attainment of athletic skills and athletic performance. T000871607 Psychology, Sports 2014 12 03 NLM (2016) OBSSR (2016) T000870502 Sports Psychology 2014 11 04 NLM (2016) OBSSR (2016) T000870507 Sport Psychology 2014 11 04 NLM (2016) OBSSR (2016) T000870507 Psychology, Sport cze0061095 psychologie sportu 2015 01 16 cze Thesaurus cze0061096 sportovní psychologie 2015 01 16 cze Thesaurus D000067453 vystavení válce[War Exposure] 2015 07 07 2015 07 06 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000009 adverse effects AE Q000706 statistics & numerical data SN Q000266 history HI Q000145 classification CL Q000191 economics EC Warfare (1996-2015) D058014 Veterans Health I01.880.735.950.500.951 N06.850.460.350.600.903 M000599159 vystavení válce[War Exposure] The health and other ramifications of military and civilian exposure to WAR . T000869114 War Exposure 2014 10 20 NLM (2016) T000869114 Exposure, War T000869114 Exposures, War T000869114 War Exposures cze0060897 vystavení válce 2015 01 08 cze Thesaurus D000067454 porucha plynulosti řeči objevující se v dětství[Childhood-Onset Fluency Disorder] 2015 07 01 2015 06 30 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 Communication Disorders (1990-2015) F03.625.374.125 M000599565 porucha plynulosti řeči objevující se v dětství[Childhood-Onset Fluency Disorder] Disturbances in the normal fluency and time patterning of speech that are inappropriate for the individual's age and language skills. (DSM-V) T000870525 Childhood-Onset Fluency Disorder 2014 11 05 NLM (2016) T000870525 Childhood Onset Fluency Disorder T000870525 Childhood-Onset Fluency Disorders T000870525 Disorder, Childhood-Onset Fluency T000870525 Disorders, Childhood-Onset Fluency T000870525 Fluency Disorder, Childhood-Onset T000870525 Fluency Disorders, Childhood-Onset cze0060703 porucha plynulosti řeči objevující se v dětství 2014 12 04 cze Thesaurus D000067455 pacient no-show[No-Show Patients] 2015 07 06 2014 12 02 2016 01 01 Q000191 economics EC Q000941 ethics ES Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD 2016 2016 D010352 Patient Dropouts F01.145.488.500.750 N04.452.758.635.500 N05.300.150.600.600.750 M000599566 pacient no-show[No-Show Patients] PATIENTS who do not turn up for scheduled healthcare appointments. Do not confuse with PATIENT DROPOUTS. T000870526 No-Show Patients 2014 11 05 NLM (2016) T000870526 No Show Patients T000870526 No-Show Patient T000870526 Patient, No-Show T000870526 Patients, No-Show T000870529 Patient Non-Attendance 2014 11 05 NLM (2016) T000870529 Non-Attendance, Patient T000870529 Patient Non Attendance T000870528 Patient No-Show 2014 11 05 NLM (2016) T000870528 No-Show, Patient T000870528 No-Shows, Patient T000870528 Patient No Show cze0064180 pacient no-show 2015 10 26 cze Thesaurus cze0064182 pacient, který nepřišel na kontrolu 2015 10 26 cze Thesaurus cze0064181 pacient, který se nedostavil 2015 10 26 cze Thesaurus D000067470 techniky buněčného přeprogramování[Cellular Reprogramming Techniques] 2015 07 06 2015 06 26 2016 01 01 Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST 2016 2016 Cell Dedifferentiation (2008-2015) Cellular Reprogramming (2015) D065150 Cellular Reprogramming E05.200.500.380 E05.242.378 E05.393.085 M000599707 techniky buněčného přeprogramování[Cellular Reprogramming Techniques] Procedures used for the induction of CELLULAR REPROGRAMMING to change the terminal phenotype of a cell, such as the generation of INDUCED PLURIPOTENT STEM CELLS from differentiated adult cells by the forced expression of specific genes. M000599707 M000599717 M000599707 M000599719 T000870793 Cellular Reprogramming Techniques 2014 11 12 NLM (2016) T000870793 Cellular Reprogramming Technique T000870793 Reprogramming Technique, Cellular T000870793 Reprogramming Techniques, Cellular T000870793 Technique, Cellular Reprogramming T000870793 Techniques, Cellular Reprogramming T000870795 Cell Programming Techniques 2014 11 12 NLM (2016) T000870795 Cell Programming Technique T000870795 Programming Technique, Cell T000870795 Programming Techniques, Cell T000870795 Technique, Cell Programming T000870795 Techniques, Cell Programming T000870794 Cell Reprogramming Techniques 2014 11 12 NLM (2016) T000870794 Cell Reprogramming Technique T000870794 Reprogramming Technique, Cell T000870794 Reprogramming Techniques, Cell T000870794 Technique, Cell Reprogramming T000870794 Techniques, Cell Reprogramming cze0061038 techniky buněčného přeprogramování 2015 01 12 cze Thesaurus cze0061039 techniky přeprogramování buněk 2015 01 12 cze Thesaurus M000599717 Directed Differentiation Techniques The manipulation of STEM CELL culture conditions to induce cell differentiation into a particular cell type. M000599707 M000599717 T000870815 Directed Differentiation Techniques 2014 11 12 NLM (2016) T000870815 Differentiation Technique, Directed T000870815 Differentiation Techniques, Directed T000870815 Directed Differentiation Technique T000870815 Technique, Directed Differentiation T000870815 Techniques, Directed Differentiation M000599719 techniky přímého přeprogramování buněk[Direct Cell Reprogramming Techniques] The creation of a pluripotent stem cell or other cell type from an adult somatic cell by the forced expression of specific genes or other methods. M000599707 M000599719 T000870817 Direct Cell Reprogramming Techniques 2014 11 12 NLM (2016) cze0061040 techniky přímého přeprogramování buněk 2015 01 12 cze Thesaurus D000067489 metakognice[Metacognition] 2015 07 06 2015 01 09 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016 2016 Cognition (1982-2015) Self-Concept (1985-2015) D012647 Self-Assessment F02.463.188.756 M000599741 metakognice[Metacognition] Awareness and understanding of one's own thought processes. M000599741 M000599745 M000599741 M000599744 M000599741 M000599742 M000599741 M000599743 T000870854 Metacognition 2014 11 18 NLM (2016) T000870854 Metacognitions cze0061043 metakognice 2015 01 12 cze Thesaurus M000599745 Metacognitive Awareness M000599741 M000599745 T000870858 Metacognitive Awareness 2014 11 18 NLM (2016) T000870858 Awareness, Metacognitive T000870858 Awarenesses, Metacognitive T000870858 Metacognitive Awarenesses M000599744 Metacognitive Control M000599741 M000599744 T000870857 Metacognitive Control 2014 11 18 NLM (2016) T000870857 Control, Metacognitive T000870857 Controls, Metacognitive T000870857 Metacognitive Controls M000599742 Metamemory M000599741 M000599742 T000870855 Metamemory 2014 11 18 NLM (2016) T000870855 Metamemories T000870859 Metacognitive Knowledge 2014 11 18 NLM (2016) T000870859 Knowledge, Metacognitive T000870859 Knowledges, Metacognitive T000870859 Metacognitive Knowledges M000599743 Metacognitive Monitoring M000599741 M000599743 T000870856 Metacognitive Monitoring 2014 11 18 NLM (2016) T000870856 Metacognitive Monitorings T000870856 Monitoring, Metacognitive T000870856 Monitorings, Metacognitive D000067490 předávkování léky na předpis[Prescription Drug Overuse] 2015 07 01 2015 01 13 2016 01 01 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000941 ethics ES Q000266 history HI Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000451 nursing NU Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD 2016 2016 E02.319.754.750 M000599765 předávkování léky na předpis[Prescription Drug Overuse] The use of a medication in an amount more than as prescribed. T000870892 Prescription Drug Overuse 2014 11 18 NLM (2016) T000870892 Drug Overuse, Prescription T000870892 Drug Overuses, Prescription T000870892 Overuse, Prescription Drug T000870892 Overuses, Prescription Drug T000870892 Prescription Drug Overuses T000870894 Medication Overutilization 2014 11 18 NLM (2016) T000870894 Medication Overutilizations T000870894 Overutilization, Medication T000870894 Overutilizations, Medication T000870897 Medication Overuse 2014 11 18 NLM (2016) T000870897 Medication Overuses T000870897 Overuse, Medication T000870897 Overuses, Medication T000870893 Prescription Drug Overutilization 2014 11 18 NLM (2016) T000870893 Drug Overutilization, Prescription T000870893 Drug Overutilizations, Prescription T000870893 Overutilization, Prescription Drug T000870893 Overutilizations, Prescription Drug T000870893 Prescription Drug Overutilizations cze0061196 předávkování léky na předpis 2015 02 05 cze Thesaurus cze0061197 nadměrné užívání léků na předpis 2015 02 05 cze Thesaurus D000067491 nedokonané pochybení při zdravotní péči[Near Miss, Healthcare] 2015 07 01 2015 06 26 2016 01 01 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 E02.319.529.750 N02.421.450.500.750 N02.421.450.550 N04.761.700.594 N05.700.513 M000599770 nedokonané pochybení při zdravotní péči[Near Miss, Healthcare] Event that presented a risk but did not result in a patient harm. Událost, která představovala nebezpečí, ale nevedla k poškození pacienta. T000871585 Near Miss, Healthcare 2014 12 03 NLM (2016) T000871585 Healthcare Near Miss T000871585 Healthcare Near Misses T000871585 Near Misses, Healthcare T000871586 Close Call, Healthcare 2014 12 03 NLM (2016) T000871586 Close Calls, Healthcare T000871586 Healthcare Close Call T000871586 Healthcare Close Calls cze0061044 nedokonané pochybení při zdravotní péči 2015 01 12 cze Thesaurus cze0061048 near-miss 2015 01 12 cze Thesaurus cze0061047 nedokonané chyby ve zdravotní péči 2015 01 12 cze Thesaurus D000067492 terapie založená na RNAi[RNAi Therapeutics] 2015 07 02 2015 06 16 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST Q000331 legislation & jurisprudence LJ 2016 2016 RNA Interference (2004-2015) D005786 Gene Expression Regulation E02.095.301.250 M000599772 terapie založená na RNAi[RNAi Therapeutics] A form of disease treatment which involves the silencing of genes that are associated with a disease by the process of RNA INTERFERENCE. T000870924 RNAi Therapeutics 2014 11 18 NLM (2016) T000870926 RNAi-Based Therapeutics 2014 11 18 NLM (2016) T000870925 RNAi-Based Therapy 2014 11 18 NLM (2016) T000870925 RNAi Based Therapy T000870925 RNAi-Based Therapies T000870925 Therapies, RNAi-Based T000870925 Therapy, RNAi-Based T000870923 RNAi Therapy 2014 11 18 NLM (2016) T000870923 RNAi Therapies T000870923 Therapies, RNAi T000870923 Therapy, RNAi cze0061178 terapie založená na RNAi 2015 02 05 cze Thesaurus cze0061177 RNAi terapie 2015 02 05 cze Thesaurus cze0061176 terapie s využitím RNA interference 2015 02 05 cze Thesaurus D000067493 dynamický rozptyl světla[Dynamic Light Scattering] 2015 07 01 2015 01 21 2016 01 01 Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST 2016 2016 Scattering, Radiation (1974-2015) E05.196.822.325 M000599773 dynamický rozptyl světla[Dynamic Light Scattering] An analytical technique for measuring particle size of molecules that are less than a micron in diameter dispersed or dissolved in a liquid. M000599773 M000599774 T000870927 Dynamic Light Scattering 2014 11 18 NLM (2016) T000870927 Light Scattering, Dynamic T000870927 Scattering, Dynamic Light cze0061131 dynamický rozptyl světla 2015 01 23 cze Thesaurus cze0061132 fotonová korelační spektroskopie 2015 01 23 cze Thesaurus M000599774 kvazi-elastický rozptyl světla[Quasi-Elastic Light Scattering (QELS)] M000599773 M000599774 T000870928 Quasi-Elastic Light Scattering (QELS) 2014 11 18 NLM (2016) T000870928 Light Scattering, Quasi-Elastic (QELS) T000870928 Quasi Elastic Light Scattering (QELS) T000870928 Quasi-Elastic Light Scatterings (QELS) T000870928 Scattering, Quasi-Elastic Light (QELS) T000870928 Scatterings, Quasi-Elastic Light (QELS) cze0061133 kvazi-elastický rozptyl světla 2015 01 23 cze Thesaurus D000067494 time out ve zdravotní péči[Time Out, Healthcare] 2015 07 01 2015 01 09 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000379 methods MT 2016 2016 N04.761.700.635 N05.700.739 M000599811 time out ve zdravotní péči[Time Out, Healthcare] A period of time away from normal workflow taken to ensure key procedural details have been reviewed for better PATIENT SAFETY and help prevent MEDICAL ERRORS. M000599811 M000600463 T000870984 Time Out, Healthcare 2014 11 19 NLM (2016) T000870984 Healthcare Time Out T000870984 Healthcare Time Outs T000870984 Time Outs, Healthcare T000872099 Timeout, Healthcare 2014 12 15 NLM (2016) T000872099 Healthcare Timeout T000872099 Healthcare Timeouts T000872099 Timeouts, Healthcare cze0061088 time out ve zdravotní péči 2015 01 16 cze Thesaurus cze0061084 oddechový čas pro bezpečnější zdravotní péči 2015 01 16 cze Thesaurus M000600463 chirurgický timeout[Surgical Time Out] M000599811 M000600463 T000871981 Surgical Time Out 2014 12 12 NLM (2016) T000871981 Surgical Time Outs T000871981 Time Out, Surgical T000871981 Time Outs, Surgical T000872100 Surgical Timeout 2014 12 15 NLM (2016) T000872100 Surgical Timeouts T000872100 Timeout, Surgical T000872100 Timeouts, Surgical cze0061085 chirurgický timeout 2015 01 16 cze Thesaurus cze0061086 bezpečnost chirurgických výkonů pro pacienta 2015 01 16 cze Thesaurus cze0061087 time-out operačního týmu před zákrokem 2015 01 16 cze Thesaurus D000067495 FMEA ve zdravotní péči[Healthcare Failure Mode and Effect Analysis] 2015 07 01 2015 01 09 2016 01 01 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 Risk Assessment (2002-2015) E05.318.740.600.800.715.500 N04.452.871.715.400 N05.715.360.750.625.700.690.400 N06.850.505.715.500 N06.850.520.830.600.800.715.500 M000599816 FMEA ve zdravotní péči[Healthcare Failure Mode and Effect Analysis] Prospective risk assessment tool aimed at identifying potential risks and their impact in healthcare settings. M000599816 M000599815 T000870993 Healthcare Failure Mode and Effect Analysis 2014 11 19 NLM (2016) T000871010 HFMEA 2014 11 19 NLM (2016) T000871168 Failure Mode and Effect Analysis, Healthcare 2014 11 24 NLM (2016) cze0061605 FMEA ve zdravotní péči 2015 03 12 cze Thesaurus cze0061604 analýza možného výskytu a vlivu vad ve zdravotní péči 2015 03 12 cze Thesaurus M000599815 FMEA[Failure Mode and Effect Analysis] M000599816 M000599815 T000870989 Failure Mode and Effect Analysis 2014 11 19 NLM (2016) cze0061606 FMEA 2015 03 12 cze Thesaurus cze0061607 analýza možného výskytu a vlivu vad 2015 03 12 cze Thesaurus D000067496 posedlost duchem[Spirit Possession] 2015 07 01 2015 05 22 2016 01 01 Q000266 history HI 2016 2016 D010268 Parapsychology D013483 Superstitions K01.844.619.500 M000599848 posedlost duchem[Spirit Possession] The idea that abnormal behavior or a medical condition is evidence that a person is under the control of a supernatural power or spirit. This belief was most commonly held in religion and medicine of the medieval period and is also held in many tribal cultures today. T000871040 Spirit Possession 2014 11 20 NLM (2016) OBSSR (2016) T000871040 Possession, Spirit T000871040 Possessions, Spirit T000871040 Spirit Possessions T000871042 Demonic Possession 2014 11 20 NLM (2016) OBSSR (2016) T000871042 Demonic Possessions T000871042 Possession, Demonic T000871042 Possessions, Demonic T000871041 Demon Possession 2014 11 20 NLM (2016) OBSSR (2016) T000871041 Demon Possessions T000871041 Possession, Demon T000871041 Possessions, Demon cze0062400 posedlost duchem 2015 06 12 cze Thesaurus cze0062401 posedlost zlým duchem 2015 06 12 cze Thesaurus D000067498 CRM marketing pro zdravotnictví[Crew Resource Management, Healthcare] 2015 07 01 2015 01 09 2016 01 01 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 Patient Care Team (2000-2015) N04.590.254 M000599866 CRM marketing pro zdravotnictví[Crew Resource Management, Healthcare] A range of healthcare related training designed to reduce MEDICAL ERRORS and improve PATIENT SAFETY by emphasizing TEAMWORK and human factors (see HUMAN ENGINEERING). T000871064 Crew Resource Management, Healthcare 2014 11 20 NLM (2016) T000871070 Healthcare Crisis Resource Management 2014 11 20 NLM (2016) T000871069 Crisis Resource Management, Healthcare 2014 11 20 NLM (2016) T000871065 Healthcare Crew Resource Management 2014 11 20 NLM (2016) T000871066 Healthcare CRM 2014 11 20 NLM (2016) T000871066 CRM, Healthcare T000871066 CRMs, Healthcare T000871066 Healthcare CRMs cze0064145 CRM marketing pro zdravotnictví 2015 10 22 cze Thesaurus D000067508 heuristická analýza[Computer Heuristics] 2015 07 07 2015 07 06 2016 01 01 Q000523 psychology PX D000066506 Heuristics L01.224.050.375.095 M000599948 heuristická analýza[Computer Heuristics] Trial-and-error methods of problem-solving used when an algorithmic approach is impractical T000871166 Computer Heuristics 2014 11 24 NLM (2016) OBSSR (2016) T000871166 Computer Heuristic T000871166 Heuristic, Computer T000871166 Heuristics, Computer cze0060716 heuristická analýza 2014 12 04 cze Thesaurus cze0060717 počítačová heuristika 2014 12 04 cze Thesaurus D000067528 ataxiny[Ataxins] 2015 07 06 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Nerve Tissue Proteins (1995-2015) Nuclear Proteins (1995-2015) D020754 Spinocerebellar Ataxias D12.776.641.069 D12.776.660.075 M000599991 ataxiny[Ataxins] 0 A family of predominantly nuclear proteins that regulate gene transcription and protein degradation. The expansion of CAG trinucleotide repeats in genes that encode Ataxins is associated with SPINOCEREBELLAR ATAXIAS (SCA). In SCA patients, the number of CAG repeats correlates with the severity of disease and inversely correlates with the age of disease onset. T000871238 Ataxins 2014 11 25 NLM (2016) T000874561 Spinocerebellar Ataxia Proteins 2015 02 02 NLM (2016) T000874561 Ataxia Proteins, Spinocerebellar T000874561 Proteins, Spinocerebellar Ataxia T000872147 Ataxin Proteins 2014 12 15 NLM (2016) T000872147 Proteins, Ataxin cze0061417 ataxiny 2015 02 20 cze Thesaurus cze0061418 proteiny při spinocerebelární ataxii 2015 02 20 cze Thesaurus D000067531 alarminy[Alarmins] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 HMGB1 Protein (2004-2015) D12.644.276.087 D12.776.467.087 D23.529.087 M000599994 alarminy[Alarmins] 0 A structurally diverse group of endogenous molecules that includes the HMGB1 PROTEIN; S100 PROTEINS; HSP60, Hsp70, Cathelicidin, IL-33, and DEFENSINS. They are constitutively available, released upon tissue damage, and activate the immune system. Uncontrolled and excessive release of alarmins may contribute to INFLAMMATION; CARCINOGENESIS, and NEOPLASM METASTASIS. Alarmins are also critical for heart and nerve tissue homeostasis. T000871241 Alarmins 2014 11 25 NLM (2016) T000871618 Alarmin 2014 12 03 NLM (2016) T000871617 Alarmin Proteins 2014 12 03 NLM (2016) T000871617 Proteins, Alarmin cze0061416 alarminy 2015 02 20 cze Thesaurus D000067548 dermální výplně[Dermal Fillers] 2015 07 01 2015 01 21 2016 01 01 Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D000279 Administration, Cutaneous D003357 Cosmetic Techniques D007279 Injections, Subcutaneous D27.720.102.461 M000600114 dermální výplně[Dermal Fillers] 0 Materials such as COLLAGEN or HYALURONIC ACID that are injected or deposited into the DERMIS for the purpose of skin augmentation. T000873668 Dermal Fillers 2015 01 15 NLM (2016) T000873668 Fillers, Dermal T000873667 Skin Filler 2015 01 15 NLM (2016) T000873667 Filler, Skin T000873665 Skin Fillers 2015 01 15 NLM (2016) T000873665 Fillers, Skin T000873666 Dermal Filler 2015 01 15 NLM (2016) T000873666 Filler, Dermal cze0061124 dermální výplně 2015 01 23 cze Thesaurus cze0061125 tkáňové výplně 2015 01 23 cze Thesaurus D000067549 akční spektrum[Action Spectrum] 2015 07 01 2015 06 16 2016 01 01 Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST 2016 2016 E05.196.867.826.150 M000600120 akční spektrum[Action Spectrum] A technique used to measure the rate of physiological activity plotted against wavelength of light. An action spectrum depicts the most effective wavelength of light (also known as spectral sensitivity) that is required for each specific process. T000871470 Action Spectrum 2014 12 01 NLM (2016) T000871470 Spectrum, Action cze0061603 akční spektrum 2015 03 12 cze Thesaurus D000067551 diplomacie[Diplomacy] 2015 07 01 2015 06 16 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 F01.829.316.171 F02.463.785.373.520.500 I01.738.305 M000600122 diplomacie[Diplomacy] The art and practice of conducting negotiations between people, nations or other parties such as organizations. M000600122 M000600124 T000871474 Diplomacy 2014 12 01 NLM (2016) cze0061126 diplomacie 2015 01 23 cze Thesaurus M000600124 diplomat[Diplomat] M000600122 M000600124 T000871476 Diplomat 2014 12 01 NLM (2016) T000871476 Diplomats cze0061127 diplomat 2015 01 23 cze Thesaurus D000067552 akumulace mutací[Mutation Accumulation] 2015 07 01 2015 01 21 2016 01 01 2016 2016 Mutation (1977-2015) D000375 Aging D016296 Mutagenesis G05.365.590.594 M000600556 akumulace mutací[Mutation Accumulation] Concept which describes the incremental effects of MUTATION in living organisms. M000600556 M000600126 T000871479 Mutation Accumulation 2014 12 01 NLM (2016) T000871479 Accumulation, Mutation T000871479 Accumulations, Mutation T000871479 Mutation Accumulations cze0061171 akumulace mutací 2015 02 05 cze Thesaurus M000600126 akumulace spontánních mutací[Spontaneous Mutation Accumulation] M000600556 M000600126 T000871478 Spontaneous Mutation Accumulation 2014 12 01 NLM (2016) T000871478 Accumulation, Spontaneous Mutation T000871478 Accumulations, Spontaneous Mutation T000871478 Mutation Accumulation, Spontaneous T000871478 Mutation Accumulations, Spontaneous T000871478 Spontaneous Mutation Accumulations cze0061172 akumulace spontánních mutací 2015 02 05 cze Thesaurus D000067556 IRES[Internal Ribosome Entry Sites] 2015 07 01 2015 01 12 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 D13.444.735.790.878.942.250 G02.111.570.080.689.687.093 G05.360.080.689.687.093 M000600153 IRES[Internal Ribosome Entry Sites] 0 Sequences within MESSENGER RNA that enable PROTEIN TRANSLATION INITIATION independent of 5' CAPPED RNA. T000871524 Internal Ribosome Entry Sites 2014 12 02 NLM (2016) T000873493 Internal Ribosome Entry Site 2015 01 12 NLM (2016) cze0061660 IRES 2015 03 13 cze Thesaurus cze0061661 interní ribosomální vstupní místo 2015 03 13 cze Thesaurus cze0061663 vnitřní místo pro vstup ribozomu 2015 03 13 cze Thesaurus cze0061662 vnitřní vazebné místo pro ribosom 2015 03 13 cze Thesaurus D000067558 mimikry[Biological Mimicry] 2015 07 06 2015 01 21 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 D032701 Biomimetics G16.100.057.750 M000600168 mimikry[Biological Mimicry] Resemblance in appearance, structure, function, sound, scent or behavior between related or unrelated species, occurring in the same geographic location. M000600168 M000600496 T000872022 Biological Mimicry 2014 12 14 NLM (2016) T000872022 Mimicry, Biological T000872028 Crypses 2014 12 14 NLM (2016) T000872026 Aposematism 2014 12 14 NLM (2016) T000872026 Aposematisms T000872023 Batesian Mimicry 2014 12 14 NLM (2016) T000872023 Batesian Mimicries T000872023 Mimicries, Batesian T000872023 Mimicry, Batesian T000872024 Mullerian Mimicry 2014 12 14 NLM (2016) T000872024 Mimicries, Mullerian T000872024 Mimicry, Mullerian T000872024 Mullerian Mimicries cze0061116 mimikry 2015 01 23 cze Thesaurus cze0061120 Batesovské mimikry 2015 01 23 cze Thesaurus cze0061121 Müllerovské mimikry 2015 01 23 cze Thesaurus cze0061117 aposematismus 2015 01 23 cze Thesaurus cze0061118 mimetismus 2015 01 23 cze Thesaurus cze0061119 mimeze 2015 01 23 cze Thesaurus M000600496 biologická kamufláž[Biological Camouflage] The blending in of an organism with the colors and patterns of its physical environment or surroundings, such that it becomes indistinguishable from the latter. M000600168 M000600496 T000872029 Biological Camouflage 2014 12 14 NLM (2016) T000872029 Biological Camouflages T000872029 Camouflage, Biological T000872029 Camouflages, Biological cze0061122 biologická kamufláž 2015 01 23 cze Thesaurus D000067559 specifické poruchy učení[Specific Learning Disorder] 2015 07 01 2015 02 10 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.625.562.700 M000600172 specifické poruchy učení[Specific Learning Disorder] Diagnosed when there are specific deficits in an individual’s ability to perceive or process information efficiently and accurately. This disorder first manifests during the years of formal schooling and is characterized by persistent and impairing difficulties with learning foundational academic skills in reading, writing, and/or math. The individual’s performance of the affected academic skills is well below average for age, or acceptable performance levels are achieved only with extraordinary effort. Specific learning disorder may occur in individuals identified as intellectually gifted and manifest only when the learning demands or assessment procedures (e.g., timed tests) pose barriers that cannot be overcome by their innate intelligence and compensatory strategies. For all individuals, specific learning disorder can produce lifelong impairments in activities dependent on the skills, including occupational performance. (from DSM-V) T000871549 Specific Learning Disorder 2014 12 03 NLM (2016) T000871549 Disorder, Specific Learning T000871549 Learning Disorder, Specific T000871549 Learning Disorders, Specific T000871549 Specific Learning Disorders cze0061393 specifické poruchy učení 2015 02 19 cze Thesaurus D000067561 seznam potenciálně nevhodných léčiv[Potentially Inappropriate Medication List] 2015 07 09 2015 07 09 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 Inappropriate Prescribing (2010-2015) Medication Errors (2003-2015) D000069340 Deprescriptions D057970 Inappropriate Prescribing N04.761.700.615 N05.700.594 M000600188 seznam potenciálně nevhodných léčiv[Potentially Inappropriate Medication List] A list, criteria, or screening tool designed to improve PATIENT SAFETY by determining an individual's exposure to potentially inappropriate drugs. They are designed to prevent MEDICATION ERRORS by INAPPROPRIATE PRESCRIBING. Analysis for a list includes factors such as DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; AGE FACTORS; GENDER; and existing medical conditions. M000600188 M000600191 M000600188 M000600192 M000600188 M000600190 T000871568 Potentially Inappropriate Medication List 2014 12 03 NLM (2016) T000871584 PIM List 2014 12 03 NLM (2016) T000871584 PIM Lists T000871572 Potentially Inappropriate Medications 2014 12 03 NLM (2016) T000871572 Inappropriate Medication, Potentially T000871572 Inappropriate Medications, Potentially T000871572 Medication, Potentially Inappropriate T000871572 Medications, Potentially Inappropriate T000871572 Potentially Inappropriate Medication cze0061182 seznam potenciálně nevhodných léčiv 2015 02 05 cze Thesaurus M000600191 Beersova kritéria[Beers Criteria] M000600188 M000600191 T000871574 Beers Criteria 2014 12 03 NLM (2016) T000871576 Beers Potentially Inappropriate Medications 2014 12 03 NLM (2016) T000871575 de Beers Criteria 2014 12 03 NLM (2016) T000871575 Beers Criteria, de cze0061183 Beersova kritéria 2015 02 05 cze Thesaurus M000600192 STOPP (Screening Tool of Older Person's Potentially Inappropriate Prescriptions) M000600188 M000600192 T000871579 STOPP (Screening Tool of Older Person's Potentially Inappropriate Prescriptions) 2014 12 03 NLM (2016) T000871579 STOPPs (Screening Tool of Older Person's Potentially Inappropriate Prescriptions) T000871582 Screening Tool of Older Person's Potentially Inappropriate Prescriptions 2014 12 03 NLM (2016) T000871580 STOPP 2014 12 03 NLM (2016) T000873398 STOPP START Criteria 2015 01 09 NLM (2016) T000873398 Criteria, STOPP START T000873398 Criterias, STOPP START T000873398 START Criteria, STOPP T000873398 START Criterias, STOPP T000873398 STOPP START Criterias M000600190 seznamy vhodných léčiv[Medication Appropriateness Index] M000600188 M000600190 T000871573 Medication Appropriateness Index 2014 12 03 NLM (2016) T000871573 Appropriateness Index, Medication T000871573 Appropriateness Indices, Medication T000871573 Index, Medication Appropriateness T000871573 Indices, Medication Appropriateness T000871573 Medication Appropriateness Indices cze0061184 seznamy vhodných léčiv 2015 02 05 cze Thesaurus D000067562 nemoci s pozdním počátkem[Late Onset Disorders] 2015 07 09 2015 07 08 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016; use AGE OF ONSET 1997-2015 2016; see AGE OF ONSET 1997-2015 Age of Onset (1984-2015) C23.550.291.883 M000600189 nemoci s pozdním počátkem[Late Onset Disorders] Pathological conditions (Disorder, SYNDROME, or DISEASE) whose SIGNS AND SYMPTOMS manifest late in the life of an individual. T000871570 Late Onset Disorders 2014 12 03 NLM (2016) T000871570 Disorder, Late Onset T000871570 Disorders, Late Onset T000871570 Late Onset Disorder T000871570 Onset Disorder, Late T000871570 Onset Disorders, Late T000873702 Later Onset Disorders 2015 01 15 NLM (2016) T000873702 Disorder, Later Onset T000873702 Disorders, Later Onset T000873702 Later Onset Disorder T000873702 Onset Disorder, Later T000873702 Onset Disorders, Later T000873704 Late-Onset Disorders 2015 01 15 NLM (2016) T000873704 Disorder, Late-Onset T000873704 Disorders, Late-Onset T000873704 Late-Onset Disorder T000871571 Late Onset Diseases 2014 12 03 NLM (2016) T000871571 Disease, Late Onset T000871571 Diseases, Late Onset T000871571 Late Onset Disease T000871571 Onset Disease, Late T000871571 Onset Diseases, Late cze0061134 nemoci s pozdním počátkem 2015 01 23 cze Thesaurus D000067563 Phakopsora pachyrhizi[Phakopsora pachyrhizi] 2015 07 01 2015 01 21 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY 2016 2016 Basidiomycota (1980-2015) B01.300.179.110 M000600193 Phakopsora pachyrhizi[Phakopsora pachyrhizi] Fungal pathogen which causes Soybean Rust disease in Soybeans (Glycine max). T000871587 Phakopsora pachyrhizi 2014 12 03 NLM (2016) T000871587 Phakopsora pachyrhizus T000871587 pachyrhizi, Phakopsora T000871587 pachyrhizus, Phakopsora T000873707 Asian Soybean Rust 2015 01 15 NLM (2016) T000873707 Rust, Asian Soybean T000873707 Soybean Rust, Asian T000873707 Soybean Rusts, Asian cze0061115 Phakopsora pachyrhizi 2015 01 23 cze Thesaurus D000067565 zemědělci[Farmers] 2015 07 09 2015 07 07 2016 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016; for AGRICULTURAL WORKERS use AGRICULTURE 1981-2015 2016; for AGRICULTURAL WORKERS see AGRICULTURE 1981-2015 Agriculture (1963-2015) M01.526.390 M000600200 zemědělci[Farmers] Persons who cultivate land or crops, or raise LIVESTOCK. M000600200 M000601422 T000871602 Farmers 2014 12 03 NLM (2016) T000871602 Farmer T000871654 Farm Workers 2014 12 04 NLM (2016) T000871654 Farm Worker T000871654 Worker, Farm T000871654 Workers, Farm T001199 Agricultural Workers 1993 11 29 NLM (1981) T001199 Agricultural Worker T001199 Worker, Agricultural T001199 Workers, Agricultural T000871653 Farmworkers 2014 12 04 NLM (2016) T000871653 Farmworker cze0061285 zemědělci 2015 02 11 cze Thesaurus cze0061287 farmáři 2015 02 12 cze Thesaurus cze0061286 zemědělští dělníci 2015 02 12 cze Thesaurus M000601422 Ranchers M000600200 M000601422 T000873488 Ranchers 2015 01 12 NLM (2016) T000873488 Rancher D000067568 technologie přizpůsobená podmínkám[Culturally Appropriate Technology] 2015 07 01 2015 01 21 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 D004059 Diffusion of Innovation J01.897.052 M000601530 technologie přizpůsobená podmínkám[Culturally Appropriate Technology] A SCIENCE or TECHNOLOGY that promotes self-sufficiency and is suitable to the cultural, environmental, economic and social conditions of the geographic area in which it is applied. Věda nebo technologie, která podporuje soběstačnost a je vhodná pro kulturní, environmentální, ekonomické a sociální podmínky v geografické oblasti, ve které se aplikuje. M000601530 M000600207 M000601530 M000601531 T000873708 Culturally Appropriate Technology 2015 01 15 NLM (2016) T000873708 Appropriate Technologies, Culturally T000873708 Appropriate Technology, Culturally T000873708 Culturally Appropriate Technologies T000873708 Technologies, Culturally Appropriate T000873708 Technology, Culturally Appropriate cze0064529 technologie přizpůsobená podmínkám 2015 11 16 cze Thesaurus cze0064530 kulturně přizpůsobené technologie 2015 11 16 cze Thesaurus M000600207 přizpůsobená technologie[Intermediate Technology] M000601530 M000600207 T000871615 Intermediate Technology 2014 12 03 NLM (2016) T000871615 Intermediate Technologies T000871615 Technologies, Intermediate T000871615 Technology, Intermediate cze0064528 přizpůsobená technologie 2015 11 16 cze Thesaurus M000601531 Soft Technology M000601530 M000601531 T000873709 Soft Technology 2015 01 15 NLM (2016) T000873709 Soft Technologies T000873709 Technologies, Soft T000873709 Technology, Soft D000067570 sociální učení[Social Learning] 2015 07 01 2015 01 21 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016 2016 Learning (1963-2015) D012951 Socialization F02.784.629.529.663 M000600210 sociální učení[Social Learning] The concept of new knowledge acquisition through observation and interaction with others. Koncepce získávání nových znalostí pozorováním ostatních a interakcí s nimi. T000871620 Social Learning 2014 12 03 NLM (2016) T000871620 Learning, Social cze0061201 sociální učení 2015 02 05 cze Thesaurus D000067571 finanční výkazy[Financial Statements] 2015 07 01 2015 07 02 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000379 methods MT 2016 2016 D005376 Financial Management N03.219.463.030.140 M000600211 finanční výkazy[Financial Statements] Formal and structured record of financial activities of a business, person, or other entity. M000600211 M000600508 M000600211 M000600214 M000600211 M000600212 M000600211 M000600215 M000600211 M000600213 M000600211 M000600507 M000600211 M000600509 T000871670 Financial Statements 2014 12 04 NLM (2016) T000871670 Financial Statement T000871670 Statement, Financial T000871670 Statements, Financial cze0061135 finanční výkazy 2015 01 23 cze Thesaurus M000600508 Assets, Financial M000600211 M000600508 T000873714 Assets, Financial 2015 01 15 NLM (2016) T000873714 Asset, Financial T000873714 Financial Asset T000873714 Financial Assets M000600214 Cash Flow Statement M000600211 M000600214 T000871624 Cash Flow Statement 2014 12 03 NLM (2016) T000871624 Cash Flow Statements T000871624 Flow Statement, Cash T000871624 Flow Statements, Cash T000871624 Statement, Cash Flow T000871624 Statements, Cash Flow T000871627 Net Worth 2014 12 03 NLM (2016) T000871627 Worth, Net M000600212 Balance Sheet M000600211 M000600212 T000871622 Balance Sheet 2014 12 03 NLM (2016) T000871622 Balance Sheets T000871622 Sheet, Balance T000871622 Sheets, Balance M000600215 Expense Statement M000600211 M000600215 T000871629 Expense Statement 2014 12 03 NLM (2016) T000871629 Expense Statements T000871629 Statement, Expense T000871629 Statements, Expense M000600213 Income Statement M000600211 M000600213 T000871623 Income Statement 2014 12 03 NLM (2016) T000871623 Income Statements T000871623 Statement, Income T000871623 Statements, Income M000600507 Equity, Financial M000600211 M000600507 T000873715 Equity, Financial 2015 01 15 NLM (2016) T000873715 Equities, Financial T000873715 Financial Equities T000873715 Financial Equity M000600509 Liabilities, Financial M000600211 M000600509 T000873716 Liabilities, Financial 2015 01 15 NLM (2016) T000873716 Financial Liabilities T000873716 Financial Liability T000873716 Liability, Financial D000067572 horníci[Miners] 2015 07 01 2015 01 12 2016 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016 2016 Mining (1963-2015) M01.526.693 M000600230 horníci[Miners] Persons who work in a mine to extract ore or MINERALS from the earth. T000871650 Miners 2014 12 04 NLM (2016) T000871650 Miner T000871652 Mine Workers 2014 12 04 NLM (2016) T000871652 Mine Worker T000871652 Worker, Mine T000871652 Workers, Mine T000871651 Mineworkers 2014 12 04 NLM (2016) T000871651 Mineworker cze0061093 horníci 2015 01 16 cze Thesaurus cze0061094 horník 2015 01 16 cze Thesaurus D000067573 chronofarmakokinetika[Chronopharmacokinetics] 2015 07 01 2015 01 21 2016 01 01 2016 2016 D055870 Drug Chronotherapy G07.690.725.249 M000600243 chronofarmakokinetika[Chronopharmacokinetics] Absorption, metabolism and elimination of drugs in relation to time of day at which they are administered, and the mechanisms responsible for time-dependent variations. T000871671 Chronopharmacokinetics 2014 12 04 NLM (2016) T000871671 Chronopharmacokinetic cze0061123 chronofarmakokinetika 2015 01 23 cze Thesaurus D000067575 administrativní požadavky na zdravotní péči[Administrative Claims, Healthcare] 2015 07 01 2015 01 21 2016 01 01 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000706 statistics & numerical data SN 2016 2016 N04.452.859.564.137 M000600249 administrativní požadavky na zdravotní péči[Administrative Claims, Healthcare] Information relating to itemized coding of procedures and costs associated with healthcare delivery, used as a means for tracking healthcare utilization, patterns of care, and treatment outcomes. T000871690 Administrative Claims, Healthcare 2014 12 04 NLM (2016) T000871690 Administrative Claim, Healthcare T000871690 Claim, Healthcare Administrative T000871690 Claims, Healthcare Administrative T000871690 Healthcare Administrative Claim T000871690 Healthcare Administrative Claims cze0061138 administrativní požadavky na zdravotní péči 2015 01 23 cze Thesaurus cze0061139 zdravotní péče, administrativní nároky 2015 01 23 cze Thesaurus D000067576 zdraví dítěte[Child Health] 2015 07 10 2015 07 07 2016 01 01 Q000191 economics EC Q000208 ethnology EH Q000941 ethics ES Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000639 trends TD Q000145 classification CL Q000266 history HI Q000706 statistics & numerical data SN 2016; use CHILD WELFARE 1978-2015 2016; see CHILD WELFARE 1978-2015 Child Health Services (1978-2015) Child Welfare (1978-2015) D002662 Child Health Services D002669 Child Welfare N01.400.225 M0004075 zdraví dítěte[Child Health] The concept covering the physical and mental conditions of CHILDREN. T007741 Child Health 1991 02 21 NLM (1978) T007741 Health, Child T000873859 Children's Health 2015 01 20 NLM (2016) T000873859 Health, Children's T000873950 Childrens Health 2015 01 21 NLM (2016) T000873950 Health, Childrens cze0048216 zdraví dítěte 2012 05 17 cze Thesaurus cze0048217 dítě - zdraví 2012 05 17 cze Thesaurus D000067596 interleukin 33[Interleukin-33] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; INTERLEUKIN-33 was indexed under INTERLEUKINS 2005-2015 Interleukins (2005-2015) D12.644.276.087.597 D12.644.276.374.465.850 D12.776.467.087.813 D12.776.467.374.465.850 D23.529.087.780 D23.529.374.465.850 M000600385 interleukin 33[Interleukin-33] 0 A member of the INTERLEUKIN-1 protein family involved in the maturation of TH2 CELLS and the activation of MAST CELLS; BASOPHILS; EOSINOPHILS and NK CELLS. It is also produced by ENDOTHELIAL CELLS; EPITHELIAL CELLS and FIBROBLASTS; where it can function as an alarmin to modulate immune and inflammatory responses to tissue damage. T000874477 Interleukin-33 2015 01 30 INTERLEUKIN 033 NLM (2016) T000874477 Interleukin 33 T000871873 IL33 2014 12 10 NLM (2016) T000871874 IL-33 2014 12 10 NLM (2016) cze0061419 interleukin 33 2015 02 20 cze Thesaurus cze0061421 IL-1F11 2015 02 20 cze Thesaurus cze0061420 IL-33 2015 02 20 cze Thesaurus D000067616 protein S100A12[S100A12 Protein] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; S100A12 PROTEIN was indexed under S100 PROTEINS 2003-2015, and under CALCIUM-BINDING PROTEINS 1994-2002 Calcium-Binding Proteins (1994-2002) S100 Proteins (2003-2015) D12.644.276.087.901 D12.776.157.125.750.875 D12.776.467.087.937 D23.529.087.943 M000600476 protein S100A12[S100A12 Protein] 0 A member of the S100 PROTEIN FAMILY that regulates INFLAMMATION and the immune response. It recruits LEUKOCYTES, promotes cytokine and chemokine production, and regulates leukocyte adhesion and migration. S100A12 can also function via binding to ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTORS, to stimulate innate immune cells. Protein vázající vápník S100A12 – nově identifikovaný extracelulární protein vážící se na receptor pro konečné produkty pokročilé glykace (EN-RAGE) a amfoterin (HMGB-1). S100A12 vazbou na receptor RAGE stimuluje makrofágy. Kalgranulin C, známý též jako S100A12 protein, MRP6 nebo EN-RAGE, je vápník vážící prozánětlivý protein produkovaný téměř výhradně v neutrofilních granulocytech. Humánní S100A12 byl poprvé popsán v roce 1995. V současné době je znám jako významný biomarker neutrofilního zánětu. S100A12 má významné chemotaktické vlastnosti, aktivuje intracelulární cytokinové kaskády a podílí se na indukci reakcí oxidačního stresu. T000872000 S100A12 Protein 2014 12 12 NLM (2016) T000872000 Protein, S100A12 T000872001 S100 A12 Protein 2014 12 12 NLM (2016) T000872001 A12 Protein, S100 T000872001 Protein, S100 A12 T000872006 MRP-6 Protein 2014 12 12 NLM (2016) T000872006 MRP 6 Protein T000872006 Protein, MRP-6 T000872003 Calgranulin C Protein 2014 12 12 NLM (2016) T000872003 C Protein, Calgranulin T000872003 Protein, Calgranulin C T000872004 EN-RAGE Protein 2014 12 12 NLM (2016) T000872004 EN RAGE Protein T000872004 Protein, EN-RAGE T000872005 ENRAGE Protein 2014 12 12 NLM (2016) T000872005 Protein, ENRAGE T000871999 S100A12 2014 12 12 NLM (2016) T000872002 CAAF1 Protein 2014 12 12 NLM (2016) T000872002 Protein, CAAF1 cze0061422 protein S100A12 2015 02 20 cze Thesaurus cze0061424 EN-RAGE protein 2015 02 20 cze Thesaurus cze0061423 kalgranulin C 2015 02 20 cze Thesaurus D000067617 telopody[Telopodes] 2015 07 01 2015 06 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016 2016 A11.284.180.900 A11.329.830.750.500 M000600480 telopody[Telopodes] The very long and thin extensions of telocytes' cell surface, that have alternating thick and thin sections called podoms and podomers. M000600480 M000600482 M000600480 M000600481 T000872010 Telopodes 2014 12 12 NLM (2016) T000872010 Telopode cze0064196 telopody 2015 10 26 cze Thesaurus cze0064197 telopoda 2015 10 26 cze Thesaurus M000600482 podomery[Podomers] The thinner sections of telopodes. M000600480 M000600482 T000872012 Podomers 2014 12 12 NLM (2016) T000872012 Podomer cze0064194 podomery 2015 10 26 cze Thesaurus M000600481 podomy[Podoms] The thicker sections of telopodes. M000600480 M000600481 T000872011 Podoms 2014 12 12 NLM (2016) T000872011 Podom cze0064195 podomy 2015 10 26 cze Thesaurus D000067636 Drosophila simulans[Drosophila simulans] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME Q000472 pathogenicity PY 2016 2016 Drosophila (1963-2015) B01.050.500.131.617.289.310.250.750 M000600199 Drosophila simulans[Drosophila simulans] A species of fruit fly. T000871601 Drosophila simulans 2014 12 03 NLM (2016) T000871601 simulans, Drosophila cze0061130 Drosophila simulans 2015 01 23 cze Thesaurus D000067656 optimismus[Optimism] 2015 07 01 2015 02 25 2016 01 01 Q000523 psychology PX 2016 2016 F01.100.787 M000600545 optimismus[Optimism] Mental attitude that interprets life events as generally being positive. T000872101 Optimism 2014 12 15 NLM (2016) OBSSR (2016) cze0061478 optimismus 2015 02 26 cze Thesaurus D000067657 pesimismus[Pessimism] 2015 07 01 2015 02 25 2016 01 01 Q000523 psychology PX 2016 2016 F01.100.893 M000600546 pesimismus[Pessimism] Mental attitude that interprets life events as generally being negative. T000872102 Pessimism 2014 12 15 NLM (2016) OBSSR (2016) cze0061479 pesimismus 2015 02 26 cze Thesaurus D000067696 ataxin-1[Ataxin-1] 2015 07 06 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1995) 2016; ATAXIN-1 was indexed under NERVE TISSUE PROTEINS AND NUCLEAR PROTEINS 1995-2015 Nerve Tissue Proteins (1995-2015) Nuclear Proteins (1995-2015) D020754 Spinocerebellar Ataxias D12.776.641.069.500 D12.776.660.075.500 M0250931 ataxin-1[Ataxin-1] 0 A chromatin-binding factor that represses Notch signaling and associates with RNA. Expansion of the polyglutamine tract by expanded CAG repeats in the ATXN1 gene coding region is associated with SPINOCEREBELLAR ATAXIA 1. T000872352 Ataxin-1 2014 12 17 ATAXIN001 NLM (2016) T000872352 Ataxin 1 T000874484 SCA1 Protein 2015 01 30 NLM (2016) T000874484 Protein, SCA1 T000874482 Atxn-1 Protein 2015 01 30 NLM (2016) T000874482 Atxn 1 Protein T000874482 Protein, Atxn-1 T000874483 Atxn1 Protein 2015 01 30 NLM (2016) T000874483 Protein, Atxn1 T000873995 Spinocerebellar Ataxia Type 1 Protein 2015 01 21 NLM (2016) T000874481 Ataxin-1 Protein 2015 01 30 NLM (2016) T000874481 Ataxin 1 Protein T000874481 Protein, Ataxin-1 cze0061544 ataxin-1 2015 03 09 cze Thesaurus cze0061543 ataxin 1 2015 03 09 cze Thesaurus cze0061545 protein spinocerebelární ataxie typu 1 2015 03 09 cze Thesaurus D000067697 zdraví dospívajících[Adolescent Health] 2015 07 06 2015 03 05 2016 01 01 Q000145 classification CL Q000266 history HI Q000706 statistics & numerical data SN Q000191 economics EC Q000208 ethnology EH Q000941 ethics ES Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000639 trends TD 2016 2016 D000295 Adolescent Medicine D016497 Adolescent Health Services N01.400.075 M000600677 zdraví dospívajících[Adolescent Health] The concept covering the physical and mental conditions of ADOLESCENTS. T000872338 Adolescent Health 2014 12 17 NLM (2016) T000872338 Health, Adolescent T000873948 Teen Health 2015 01 21 NLM (2016) T000873948 Health, Teen cze0061535 zdraví dospívajících 2015 03 05 cze Thesaurus cze0061536 zdraví adolescentů 2015 03 05 cze Thesaurus cze0061537 zdraví mladistvých 2015 03 05 cze Thesaurus D000067698 ataxin-2[Ataxin-2] 2015 07 06 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016; use SCA2 PROTEIN (NM) 1996-2015 2016; ATAXIN-2 was indexed under PROTEINS 1996-2005, and under NERVE TISSUE PROTEINS 2005-2015 Nerve Tissue Proteins (2005-2015) Proteins (1996-2005) D020754 Spinocerebellar Ataxias D12.776.157.725.452.125 D12.776.641.069.750 D12.776.660.075.750 D12.776.664.962.452.125 M0394791 ataxin-2[Ataxin-2] 0 A Poly(A) RNA-binding protein that negatively regulates EGFR ENDOCYTOSIS. An increased risk for developing AMYOTROPHIC LATERAL SCLEROSIS 13 is observed in patients who have more than 23 CAG repeats in the ATXN2 gene coding sequence. Larger CAG expansions in the ATXN2 gene occur in SPINOCEREBELLAR ATAXIA 2 patients. T000872353 Ataxin-2 2014 12 17 ATAXIN002 NLM (2016) T000872353 Ataxin 2 T000874500 Ataxin-2 Protein 2015 01 30 NLM (2016) T000874500 Ataxin 2 Protein T000874500 Protein, Ataxin-2 T000873998 Spinocerebellar Ataxia Type 2 Protein 2015 01 21 NLM (2016) T000874499 ATXN2 Protein 2015 01 30 NLM (2016) T000874499 Protein, ATXN2 T000873996 Atx-2 Protein 2015 01 21 NLM (2016) T000873996 Atx 2 Protein T000873996 Protein, Atx-2 T000873997 SCA2 Protein 2015 01 21 NLM (2016) T000873997 Protein, SCA2 cze0061546 ataxin-2 2015 03 09 cze Thesaurus cze0061547 ataxin 2 2015 03 09 cze Thesaurus cze0061548 protein spinocerebelární ataxie typu 2 2015 03 09 cze Thesaurus D000067699 ataxin-3[Ataxin-3] 2015 07 06 2015 02 19 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1995) 2016; ATAXIN-3 was indexed under NERVE TISSUE PROTEINS AND NUCLEAR PROTEINS 1998-2015, and under PROTEINS 1995-1997 Nerve Tissue Proteins (1998-2015) Nuclear Proteins (1998-2015) Proteins (1995-1997) D020754 Spinocerebellar Ataxias D08.811.277.656.300.887.500 D12.776.641.069.875 D12.776.660.075.875 M000600684 ataxin-3[Ataxin-3] 0 A DEUBIQUITINASE involved in protein homeostasis, transcription, cytoskeleton regulation, and myogenesis. It also acts as a histone-binding protein that represses transcription. CAG repeat expansions in the ATXN3 gene coding region are associated with SPINOCEREBELLAR ATAXIA 3 (SCA3). T000872358 Ataxin-3 2014 12 17 ATAXIN003 NLM (2016) T000872358 Ataxin 3 T000874504 SCA3 Protein 2015 01 30 NLM (2016) T000874504 Protein, SCA3 T000874502 Ataxin-3 Protein 2015 01 30 NLM (2016) T000874502 Ataxin 3 Protein T000874502 Protein, Ataxin-3 T000874503 Machado-Joseph Disease Protein 2015 01 30 NLM (2016) T000874503 Disease Protein, Machado-Joseph T000874503 Machado Joseph Disease Protein T000874503 Protein, Machado-Joseph Disease T000873999 Spinocerebellar Ataxia 3 Protein 2015 01 21 NLM (2016) T000874501 ATXN3 Protein 2015 01 30 NLM (2016) T000874501 Protein, ATXN3 cze0061549 ataxin-3 2015 03 09 cze Thesaurus cze0061550 ataxin 3 2015 03 09 cze Thesaurus cze0061552 protein Machado-Josephovy nemoci 2015 03 09 cze Thesaurus cze0061551 protein spinocerebelární ataxie typu 3 2015 03 09 cze Thesaurus D000067716 point of care testing[Point-of-Care Testing] 2015 07 10 2015 07 10 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016; for BEDSIDE TESTING use POINT-OF-CARE SYSTEMS 1995-2015 2016; for BEDSIDE TESTING see POINT-OF-CARE SYSTEMS 1995-2015 N04.590.874.500 M000600741 point of care testing[Point-of-Care Testing] Allows patient diagnoses in the physician’s office, in other ambulatory setting or at bedside. The results of care are timely, and allow rapid treatment to the patient. (from NIH Fact Sheet Point-of-Care Diagnostic Testing, 2010.) M000600741 M0028503 T000874689 Point-of-Care Testing 2015 02 04 NLM (2016) T000874689 Point-of-Care Testings T000874689 Testing, Point-of-Care T000874689 Testings, Point-of-Care T000872424 Point of Care Testing 2014 12 19 NLM (2016) cze0061503 point of care testing 2015 02 26 cze Thesaurus cze0061504 testování v místě péče o pacienta 2015 02 26 cze Thesaurus M0028503 Bedside Testing M000600741 M0028503 T057039 Bedside Testing 1995 03 13 NLM (1996) T057039 Bedside Testings T057039 Testing, Bedside D000067719 ataxin-7[Ataxin-7] 2015 07 06 2015 07 06 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016; ATAXIN-7 was indexed under NERVE TISSUE PROTEINS 1997-2015 Nerve Tissue Proteins (1997-2015) D020754 Spinocerebellar Ataxias D12.776.641.069.901 D12.776.660.075.900 M000600756 ataxin-7[Ataxin-7] 0 A component of the STAGA transcription coactivator-HAT complex that functions in Cone Rod Homeobox Protein (CRX)-dependent gene activation. It also stabilizes MICROTUBULES. CAG repeat expansion in the ATXN-7 coding region is associated with the development of SPINOCEREBELLAR ATAXIA 7. T000872464 Ataxin-7 2014 12 19 ATAXIN007 NLM (2016) T000872464 Ataxin 7 T000874507 SCA7 Protein 2015 01 30 NLM (2016) T000874507 Protein, SCA7 T000874506 Atxn-7 Protein 2015 01 30 NLM (2016) T000874506 Atxn 7 Protein T000874506 Protein, Atxn-7 T000874001 Spinocerebellar Ataxia 7 Protein 2015 01 21 NLM (2016) T000874505 ATXN7 Protein 2015 01 30 NLM (2016) T000874505 Protein, ATXN7 cze0061553 ataxin-7 2015 03 09 cze Thesaurus cze0061554 ataxin 7 2015 03 09 cze Thesaurus cze0061555 protein spinocerebelární ataxie typu 7 2015 03 09 cze Thesaurus D000067736 ataxin-10[Ataxin-10] 2015 07 01 2015 04 15 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016; ATAXIN-10 was indexed under NERVE TISSUE PROTEINS 2006-2015 Nerve Tissue Proteins (2006-2015) D12.776.641.069.950 M000600758 ataxin-10[Ataxin-10] 0 An ataxin that is associated with the survival of cerebellar neurons. Expansion of the ATTCT pentanucleotide in the ATXN10 coding region is associated with SPINOCEREBELLAR ATAXIA 10. T000872473 Ataxin-10 2014 12 19 ATAXIN010 NLM (2016) T000872473 Ataxin 10 T000874509 SCA10 Protein 2015 01 30 NLM (2016) T000874509 Protein, SCA10 T000874511 Atxn-10 Protein 2015 01 30 NLM (2016) T000874511 Atxn 10 Protein T000874511 Protein, Atxn-10 T000874508 ATXN10 Protein 2015 01 30 NLM (2016) T000874508 Protein, ATXN10 T000874510 Spinocerebellar Ataxia 10 Protein 2015 01 30 NLM (2016) cze0061904 ataxin-10 2015 04 22 cze Thesaurus cze0061905 ataxin 10 2015 04 22 cze Thesaurus D000067756 receptory glukagon-like peptidu[Glucagon-Like Peptide Receptors] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000008 administration & dosage AD Q000819 agonists AG Q000097 blood BL Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME 2016 2016 Receptors, Cell Surface (1987-1995) Receptors, Glucagon (1995-2015) D12.776.543.750.100.021 D12.776.543.750.750.360.100 M000600816 receptory glukagon-like peptidu[Glucagon-Like Peptide Receptors] 0 G-PROTEIN COUPLED CELL SURFACE RECEPTORS that bind GLUCAGON-LIKE PEPTIDES and are expressed by cells in pancreatic, intestinal, and neural tissues. These receptors regulate cellular responses to BLOOD GLUCOSE, INSULIN, and INFLAMMATION signals. T000872559 Glucagon-Like Peptide Receptors 2014 12 22 NLM (2016) T000872559 Glucagon Like Peptide Receptors T000872559 Peptide Receptors, Glucagon-Like T000872559 Receptors, Glucagon-Like Peptide T000874580 Glucagon-Like Receptors 2015 02 02 NLM (2016) T000874580 Glucagon Like Receptors T000874580 Receptors, Glucagon-Like T000874579 GLPR Proteins 2015 02 02 NLM (2016) T000874579 Proteins, GLPR cze0061572 receptory glukagon-like peptidu 2015 03 09 cze Thesaurus cze0061575 glpr proteiny 2015 03 09 cze Thesaurus cze0061576 glukagonu podobný peptid - receptory 2015 03 09 cze Thesaurus cze0061573 receptory peptidu podobného glukagonu 2015 03 09 cze Thesaurus D000067757 receptor pro glukagonu podobný peptid 1[Glucagon-Like Peptide-1 Receptor] 2015 07 01 2015 07 30 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000008 administration & dosage AD Q000819 agonists AG Q000097 blood BL Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME 2016 2016; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR was indexed under RECEPTORS, GLUCAGON 1995-2015, and under RECEPTORS, CELL SURFACE 1987-1995 Receptors, Cell Surface (1987-1995) Receptors, Glucagon (1995-2015) D12.776.543.750.100.021.500 D12.776.543.750.750.360.100.500 M000600817 receptor pro glukagonu podobný peptid 1[Glucagon-Like Peptide-1 Receptor] 0 A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS). T000872561 Glucagon-Like Peptide-1 Receptor 2014 12 22 NLM (2016) T000872561 Glucagon Like Peptide 1 Receptor T000872561 Peptide-1 Receptor, Glucagon-Like T000872561 Receptor, Glucagon-Like Peptide-1 T000874587 GLP-1R Receptor 2015 02 02 NLM (2016) T000874587 GLP 1R Receptor T000874587 Receptor, GLP-1R T000874583 GLP1R Protein 2015 02 02 NLM (2016) T000874583 Protein, GLP1R T000874581 GLP-1 Receptor 2015 02 02 NLM (2016) T000874581 GLP 1 Receptor T000874581 Receptor, GLP-1 T000874582 GLP1R Receptor 2015 02 02 NLM (2016) T000874582 Receptor, GLP1R cze0061442 receptor pro glukagonu podobný peptid 1 2015 02 23 cze Thesaurus cze0061443 receptor GLP-1 2015 02 23 cze Thesaurus cze0061571 receptor glukagon-like peptidu 1 2015 03 09 cze Thesaurus D000067758 receptor pro glukagonu podobný peptid 2[Glucagon-Like Peptide-2 Receptor] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000008 administration & dosage AD Q000819 agonists AG Q000097 blood BL Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME 2016 2016; GLUCAGON-LIKE PEPTIDE-2 RECEPTOR was indexed under RECEPTORS, GLUCAGON 2000-2015 Receptors, Glucagon (2000-2015) D12.776.543.750.100.021.600 D12.776.543.750.750.360.100.600 M000600818 receptor pro glukagonu podobný peptid 2[Glucagon-Like Peptide-2 Receptor] 0 A receptor for GLUCAGON-LIKE PEPTIDE 2 (GLP-2) that is expressed on the surface of intestinal cells as well as neural cells. GLP-2 and other peptides act through GLP-2R to regulate cellular responses to BLOOD GLUCOSE, INFLAMMATION, and FOOD INTAKE. T000873894 Glucagon-Like Peptide-2 Receptor 2015 01 20 NLM (2016) T000873894 Peptide-2 Receptor, Glucagon-Like T000873894 Receptor, Glucagon-Like Peptide-2 T000874586 GLP-2 Receptor 2015 02 02 NLM (2016) T000874586 GLP 2 Receptor T000874586 Receptor, GLP-2 T000874585 GLP2R Protein 2015 02 02 NLM (2016) T000874585 Protein, GLP2R T000872565 Glucagon-Like Peptide 2 Receptor 2014 12 22 NLM (2016) T000872565 Glucagon Like Peptide 2 Receptor T000874584 GLP-2R Receptor 2015 02 02 NLM (2016) T000874584 GLP 2R Receptor T000874584 Receptor, GLP-2R cze0061657 receptor pro glukagonu podobný peptid 2 2015 03 13 cze Thesaurus cze0061659 receptor GLP-2 2015 03 13 cze Thesaurus cze0061658 receptor glukagon-like peptidu 2 2015 03 13 cze Thesaurus D000067759 specifické receptory pro konečné produkty pokročilé glykace[Advanced Glycosylation End Product-Specific Receptor] 2015 07 01 2015 02 19 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000008 administration & dosage AD Q000819 agonists AG Q000097 blood BL Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME 2016 (1991) 2016; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR was indexed under RECEPTORS, IMMUNOLOGIC 1993-2015, and under RECEPTORS, ENDOGENOUS SUBSTANCES (1991-1993) Receptors, Endogenous Substances (1991-1993) Receptors, Immunologic (1993-2015) D12.776.543.750.006 M000600821 specifické receptory pro konečné produkty pokročilé glykace[Advanced Glycosylation End Product-Specific Receptor] 0 A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCOSYLATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2 . It also binds AMYLOID BETA PEPTIDES and the alarmins S100A12 and S100 CALCIUM BINDING PROTEIN BETA SUBUNIT. T000874386 Advanced Glycosylation End Product-Specific Receptor 2015 01 28 NLM (2016) T000874386 Advanced Glycosylation End Product Specific Receptor T000873968 AGE Receptor 2015 01 21 NLM (2016) T000873968 Receptor, AGE T000873969 RAGE (Receptor for Advanced Glycation End Products) 2015 01 21 NLM (2016) T000873970 Advanced Glycosylation End Product Receptors 2015 01 21 NLM (2016) T000873971 Advanced Glycosylation End-Product Receptor 2015 01 21 NLM (2016) T000873971 Advanced Glycosylation End Product Receptor T000873973 Amphoterin Receptor 2015 01 21 NLM (2016) T000873973 Receptor, Amphoterin T000873975 Receptor for Advanced Glycation End Products (RAGE) 2015 01 21 NLM (2016) T000873976 Receptor for Advanced Glycation Endproducts 2015 01 21 NLM (2016) T000873977 Receptor, Advanced Glycosylation End-Product 2015 01 21 NLM (2016) T000873977 Receptor, Advanced Glycosylation End Product T000873978 Receptor, Advanced Glycosylation End-Products 2015 01 21 NLM (2016) T000873978 Receptor, Advanced Glycosylation End Products T000873745 AGER Protein 2015 01 16 NLM (2016) T000873745 Protein, AGER T000873972 Advanced Glycosylation End-Product Receptors 2015 01 21 NLM (2016) cze0061473 specifické receptory pro konečné produkty pokročilé glykace 2015 02 26 cze Thesaurus cze0061474 AGE receptor 2015 02 26 cze Thesaurus cze0061475 RAGE receptor 2015 02 26 cze Thesaurus cze0061477 amfoterin 2015 02 26 cze Thesaurus cze0061476 receptor pro konečné produkty pokročilé glykace 2015 02 26 cze Thesaurus D000067776 RRM proteiny[RNA Recognition Motif (RRM) Proteins] 2015 07 01 2015 02 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 RNA-Binding Proteins (1993-2015) D12.776.157.725.813 D12.776.664.962.813 M000600947 RRM proteiny[RNA Recognition Motif (RRM) Proteins] 0 A family of RNA-BINDING PROTEINS which contain a motif consisting of two ribonucleoprotein (RNP) domains that bind RNA, and other domains that allow for high affinity binding, sequence specificity, and protein interactions. Examples of RRM proteins include HETEROGENEOUS NUCLEAR RIBONUCLEARPROTEINS (hnRNP) and EMBRYONIC LETHAL ABNORMAL-VISION (ELAV) proteins. T000872730 RNA Recognition Motif (RRM) Proteins 2014 12 26 NLM (2016) T000874564 RRM Proteins 2015 02 02 NLM (2016) T000874564 Proteins, RRM T000874565 Ribonucleoprotein Domain (RNP) Proteins 2015 02 02 NLM (2016) T000874562 RNA-Binding Domain (RBD) Proteins 2015 02 02 NLM (2016) cze0061827 RRM proteiny 2015 04 09 cze Thesaurus D000067777 ELAV-like protein 2[ELAV-Like Protein 2] 2015 07 10 2015 07 09 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016; use ELAV PROTEINS 2012-2015 2016; see HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS 2012-2015 ELAV Proteins (2005-2015) D12.776.157.725.813.500.500 D12.776.641.520.500 D12.776.664.962.813.500.500 M0553965 ELAV-like protein 2[ELAV-Like Protein 2] 0 A neural-specific RRM protein that binds to several 3'UTRs, including its own as well as that of PROTO-ONCOGENE PROTEINS C-FOS and ID DNA BINDING PROTEIN INHIBITOR. It binds through the recognition of a GAAA motif in the RNAs. T784537 ELAV-Like Protein 2 2011 01 25 NLM (2012) T784537 2, ELAV-Like Protein T784537 ELAV Like Protein 2 T784537 Protein 2, ELAV-Like T000874568 ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 2 (Hu Antigen B) 2015 02 02 NLM (2016) T784535 HuB Antigen 2011 01 25 NLM (2012) T784535 Antigen, HuB T784536 HuB Protein 2011 01 25 NLM (2012) T784536 Protein, HuB T000873540 ELAVL2 protein 2015 01 13 NLM (2016) T000873540 protein, ELAVL2 T784534 HuB Paraneoplastic Encephalomyelitis Antigen 2011 01 25 NLM (2012) cze0061561 ELAV-like protein 2 2015 03 09 cze Thesaurus cze0061562 ELAVL2 protein 2015 03 09 cze Thesaurus cze0061563 antigen HuB paraneoplastické encefalomyelitidy 2015 03 09 cze Thesaurus cze0061567 paraneoplastická encefalomyelitida - antigen HuB 2015 03 09 cze Thesaurus D000067778 ELAV-like protein 3[ELAV-Like Protein 3] 2015 07 10 2015 07 10 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016; use ELAV PROTEINS 2012-2015 2016; see HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS 2012-2015 ELAV Proteins (2005-2015) D12.776.157.725.813.500.750 D12.776.641.520.750 D12.776.664.962.813.500.750 M0553964 ELAV-like protein 3[ELAV-Like Protein 3] 0 A neural-specific RRM protein which contains three RNP-type RNA recognition motifs (RRMs). Human ELAVL3 is recognized by the anti-Hu serum antibody from patients with paraneoplastic encephalomyelitis and sensory neuronopathy (PEM/PSN). It also functions in neurogenesis. T784539 ELAV-Like Protein 3 2011 01 25 NLM (2012) T784539 3, ELAV-Like Protein T784539 ELAV Like Protein 3 T784539 Protein 3, ELAV-Like T784532 HuC Paraneoplastic Encephalomyelitis Antigen 2011 01 25 NLM (2012) T784538 HuC Protein 2011 01 25 NLM (2012) T784538 Protein, HuC T000873541 ELAVL3 Protein 2015 01 13 NLM (2016) T000873541 Protein, ELAVL3 T784533 HuC Antigen 2011 01 25 NLM (2012) T784533 Antigen, HuC cze0061564 ELAV-like protein 3 2015 03 09 cze Thesaurus cze0061565 ELAVL3 protein 2015 03 09 cze Thesaurus cze0061566 paraneoplastická encefalomyelitida - antigen HuC 2015 03 09 cze Thesaurus D000067779 ELAV-like protein 4[ELAV-Like Protein 4] 2015 07 10 2015 07 10 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016; use ELAV PROTEINS 2012-2015 2016; see HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS 2012-2015 ELAV Proteins (2005-2015) D12.776.157.725.813.500.875 D12.776.641.520.875 D12.776.664.962.813.500.875 M0193828 ELAV-like protein 4[ELAV-Like Protein 4] 0 An RRM protein which binds AU-rich sequences in the 3' UNTRANSLATED REGIONS of mRNAs for PROTO-ONCOGENE PROTEINS C-FOS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; and GAP-43 PROTEIN. It functions in neuron-specific RNA processing. T784541 ELAV-Like Protein 4 2011 01 25 NLM (2012) T784541 ELAV Like Protein 4 T223830 HuD Paraneoplastic Encephalomyelitis Antigen NLM (2006) T784540 HuD Protein 2011 01 25 NLM (2012) T784540 Protein, HuD T000873542 ELAVL4 Protein 2015 01 13 NLM (2016) T000873542 Protein, ELAVL4 T223833 HuD Antigen NLM (2006) T223833 Antigen, HuD cze0061568 ELAV-like protein 4 2015 03 09 cze Thesaurus cze0061559 ELAVL4 protein 2015 03 09 cze Thesaurus cze0061560 antigen HuD 2015 03 09 cze Thesaurus cze0030705 encefalomyelitida paraneoplastická - HuD antigen 2006 05 29 cze Thesaurus D000067780 HuR protein[ELAV-Like Protein 1] 2015 07 10 2015 07 10 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016; use ELAV PROTEINS 2012-2015 2016; see HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS 2012-2015 ELAV Proteins (2005-2015) RNA-Binding Proteins (2000-2015) D12.776.157.725.813.500.250 D12.776.664.962.813.500.250 M0553966 HuR protein[ELAV-Like Protein 1] 0 An RRM protein that binds to the 3'-UTR region of mRNAs and increases their stability. In EMBRYONIC STEM CELLS, it binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs and preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), to stabilize them and promote differentiation. T784545 ELAV-Like Protein 1 2011 01 25 NLM (2012) T784545 ELAV Like Protein 1 T000875899 HuR Paraneoplastic Encephalomyelitis Antigen 2015 02 26 NLM (2016) T784544 HuR Protein 2011 01 25 NLM (2012) T784544 Protein, HuR T000873539 ELAVL1 protein 2015 01 13 NLM (2016) T000873539 protein, ELAVL1 T784543 HuR Antigen 2011 01 25 NLM (2012) T784543 Antigen, HuR cze0061508 HuR protein 2015 02 27 cze Thesaurus cze0061509 ELAV-like protein 1 2015 02 27 cze Thesaurus cze0061569 ELAVL1 protein 2015 03 09 cze Thesaurus cze0061510 RNA vazebný protein 2015 02 27 cze Thesaurus cze0061570 paraneoplastická encefalomyelitida - antigen HuR 2015 03 09 cze Thesaurus D000067796 syrovátka[Whey] 2015 07 01 2015 06 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000378 metabolism ME Q000008 administration & dosage AD Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000506 poisoning PO Q000600 supply & distribution SD Q000706 statistics & numerical data SN Q000592 standards ST Q000633 toxicity TO Q000656 utilization UT 2016 2016 Dairy Products (1964-2015) G07.203.100.700.750 G07.203.300.350.525.760 J02.200.700.750 J02.500.350.525.760 M000601016 syrovátka[Whey] The liquid components of milk that remain after the CASEIN, fat, and fat soluble components have been removed. It is also a byproduct of cheese production. T000872859 Whey 2014 12 30 NLM (2016) cze0062441 syrovátka 2015 06 15 cze Thesaurus D000067816 syrovátkové proteiny[Whey Proteins] 2015 07 01 2015 06 12 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1984) 2016; WHEY PROTEIN (NM) was indexed as MILK PROTEINS (1984-2015) D12.776.256.626.816 G07.203.300.350.525.520.500 G07.203.300.350.525.760.500 G07.203.300.428.626.500 J02.500.350.525.520.500 J02.500.350.525.760.500 J02.500.428.626.500 M000601067 syrovátkové proteiny[Whey Proteins] 0 The protein components of milk obtained from the whey. T000872939 Whey Proteins 2014 12 31 NLM (2016) T000872939 Protein, Whey T000872939 Proteins, Whey T000873620 Whey Protein 2015 01 14 NLM (2016) cze0062442 syrovátkové proteiny 2015 06 15 cze Thesaurus cze0062444 syrovátkové bílkoviny 2015 06 15 cze Thesaurus cze0062443 syrovátkový protein 2015 06 15 cze Thesaurus D000067836 syndrom hromadění[Hoarding Disorder] 2015 07 01 2015 06 30 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.080.600.250 M000601122 syndrom hromadění[Hoarding Disorder] Persistent difficulty discarding or parting with possessions due to a perceived need to save the items and distress associated with discarding them. (from DSM-V) T000873004 Hoarding Disorder 2015 01 02 NLM (2016) T000873004 Disorder, Hoarding T000873004 Disorders, Hoarding T000873004 Hoarding Disorders cze0064412 syndrom hromadění 2015 11 12 cze Thesaurus cze0064414 Diogenův syndrom 2015 11 12 cze Thesaurus D000067856 PARP inhibitory[Poly(ADP-ribose) Polymerase Inhibitors] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D27.505.519.389.739 D27.505.954.248.692 M000601132 PARP inhibitory[Poly(ADP-ribose) Polymerase Inhibitors] 0 Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. T000873036 Poly(ADP-ribose) Polymerase Inhibitors 2015 01 02 NLM (2016) T000873038 Inhibitors of Poly(ADP-ribose) Polymerases 2015 01 02 NLM (2016) T000873039 Poly(ADP-ribosylation) Inhibitors 2015 01 02 NLM (2016) T000873037 PARP Inhibitors 2015 01 02 NLM (2016) T000873037 Inhibitors, PARP cze0064254 PARP inhibitory 2015 11 05 cze Thesaurus cze0064255 inhibitory poly(ADP-riboza) polymerázy 2015 11 05 cze Thesaurus cze0064256 inhibitory poly-ADP-ribosylace 2015 11 05 cze Thesaurus D000067877 poruchy autistického spektra[Autism Spectrum Disorder] 2015 07 09 2015 07 07 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016; use CHILD DEVELOPMENT DISORDERS, PERVASIVE 2010-2015 2016; see CHILD DEVELOPMENT DISORDERS, PERVASIVE 2010-2015 Child Development Disorders, Pervasive (2010-2015) F03.625.164.113 M0535163 poruchy autistického spektra[Autism Spectrum Disorder] Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V) T000876248 Autism Spectrum Disorder 2015 03 05 NLM (2016) T000876248 Spectrum Disorders, Autism T750206 Autism Spectrum Disorders 2009 04 28 OMIM (2013) cze0049401 poruchy autistického spektra 2012 08 20 cze Thesaurus cze0056119 PAS 2014 04 04 cze Thesaurus D000067878 CELF proteiny[CELF Proteins] 2015 07 01 2015 02 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 RNA-Binding Proteins (2005-2015) Ribonucleoproteins (1997-2004) D12.776.157.725.813.250 D12.776.664.962.813.250 M000601217 CELF proteiny[CELF Proteins] 0 A family of RRM proteins which contain two N-terminal RNA RECOGNITION MOTIF (RRM) domains, one C-terminal RRM domain, and a divergent segment of 160-230 amino acids between the second and third RRM domains. They regulate pre-mRNA ALTERNATIVE SPLICING and also function in RNA EDITING and PROTEIN BIOSYNTHESIS. T000873160 CELF Proteins 2015 01 05 NLM (2016) T000873160 Proteins, CELF T000874569 BRUNOL Proteins 2015 02 02 NLM (2016) T000874569 Proteins, BRUNOL T000874573 CUGBP, Elav-Like Family Member Proteins 2015 02 02 NLM (2016) T000874573 CUGBP, Elav Like Family Member Proteins T000874571 CUG Triplet Repeat, RNA-Binding Proteins 2015 02 02 NLM (2016) T000874571 CUG Triplet Repeat, RNA Binding Proteins T000874572 CUG-BP Proteins 2015 02 02 NLM (2016) T000874572 CUG BP Proteins T000874572 Proteins, CUG-BP T000873161 CUGBP Proteins 2015 01 05 NLM (2016) T000873161 Proteins, CUGBP T000874570 Bruno-Like Family Member Proteins 2015 02 02 NLM (2016) T000874570 Bruno Like Family Member Proteins cze0061556 CELF proteiny 2015 03 09 cze Thesaurus D000067879 CELF1 protein[CELF1 Protein] 2015 07 01 2015 02 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 RNA-Binding Proteins (2005-2015) Ribonucleoproteins (1997-2004) D12.776.157.725.813.250.500 D12.776.664.962.813.250.500 M000601218 CELF1 protein[CELF1 Protein] 0 A member of the CELF PROTEINS family which binds GU rich elements (GREs) and CUG-triplet repeats in the 3'UTR of mammalian mRNA transcripts that undergo rapid turnover. It also binds AU-rich elements (AREs or EDEN-like) in the 3'UTR of JUN and FOS mRNAs. Mutations in the human CELF1 gene are associated with MYOTONIC DYSTROPHY type 1. T000873177 CELF1 Protein 2015 01 05 NLM (2016) T000873177 Protein, CELF1 T000874578 Bruno-Like 2 Protein 2015 02 02 NLM (2016) T000874578 2 Protein, Bruno-Like T000874578 Bruno Like 2 Protein T000874578 Protein, Bruno-Like 2 T000874576 CUGBP, Elav-Like Family Member 1 Protein 2015 02 02 NLM (2016) T000874576 CUGBP, Elav Like Family Member 1 Protein T000874577 CUGBP1 Protein 2015 02 02 NLM (2016) T000874577 Protein, CUGBP1 T000874574 BRUNOL2 Protein 2015 02 02 NLM (2016) T000874574 Protein, BRUNOL2 T000874575 CUG Triplet Repeat, RNA-Binding Protein 1 2015 02 02 NLM (2016) T000874575 CUG Triplet Repeat, RNA Binding Protein 1 cze0061557 CELF1 protein 2015 03 09 cze Thesaurus cze0061558 CUG-BP1 protein 2015 03 09 cze Thesaurus D000067896 rozvoj průmyslu[Industrial Development] 2015 07 10 2015 07 10 2016 01 01 Q000941 ethics ES Q000266 history HI Q000331 legislation & jurisprudence LJ Q000706 statistics & numerical data SN Q000639 trends TD 2016; for INDUSTRIALIZATION use INDUSTRY 2000-2015 2016; for INDUSTRIALIZATION see INDUSTRY 2000-2015 I01.261.262.500 J01.576.519 M000601285 rozvoj průmyslu[Industrial Development] Activity concerned with the planning and building of industries through manufacturing, provision of specialized services, and COMMERCE. M000601285 M000601286 M000601285 M0011259 T000873254 Industrial Development 2015 01 07 NLM (2016) T000873254 Development, Industrial T000873254 Developments, Industrial T000873254 Industrial Developments cze0061595 rozvoj průmyslu 2015 03 12 cze Thesaurus cze0061594 průmyslový rozvoj 2015 03 12 cze Thesaurus M000601286 rozvoj výroby[Technology Development] M000601285 M000601286 T000873256 Technology Development 2015 01 07 NLM (2016) T000873256 Development, Technology T000873256 Technology Developments cze0061596 rozvoj výroby 2015 03 12 cze Thesaurus cze0061597 vývoj technologií 2015 03 12 cze Thesaurus M0011259 industrializace[Industrialization] M000601285 M0011259 T021651 Industrialization 1996 12 02 NLM (1978) cze0051865 industrializace 2012 11 09 cze Thesaurus D000067917 cloud computing[Cloud Computing] 2015 07 01 2015 06 22 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D013672 Technology L01.224.097 M000601370 cloud computing[Cloud Computing] Storing and processing data on multiple servers that can be accessed through the Internet. T000873396 Cloud Computing 2015 01 09 NLM (2016) OBSSR (2016) T000873396 Computing, Cloud T000876738 Cloud Processing 2015 03 12 NLM (2016) OBSSR (2016) T000876738 Processing, Cloud T000876739 Cloud Storage 2015 03 12 NLM (2016) OBSSR (2016) T000876739 Cloud Storages T000876739 Storage, Cloud T000876739 Storages, Cloud T000873397 Cloud Service 2015 01 09 NLM (2016) OBSSR (2016) T000873397 Service, Cloud cze0063149 cloud computing 2015 08 17 cze Thesaurus cze0063150 cloud storage 2015 08 17 cze Thesaurus D000067936 přírodní zdroje[Natural Resources] 2015 07 09 2015 07 07 2016 01 01 Q000600 supply & distribution SD coordinate with specific natural resource if pertinent 2016; use CONSERVATION OF NATURAL RESOURCES 1991-2015; for LAND SUPPLY use AGRICULTURE 1978-2015 2016; see CONSERVATION OF NATURAL RESOURCES 1991-2015; for LAND SUPPLY see AGRICULTURE 1978-2015 D003247 Conservation of Natural Resources G16.500.275.553 J01.728 N06.230.350 M0005037 přírodní zdroje[Natural Resources] Materials or substances such as land, timber, fresh water, fossil fuels, or mineral deposits that occur in a natural state and have economic value or usefulness to humans. M0005037 M0000585 T009458 Natural Resources 1990 01 25 NLM (1983) T009458 Natural Resource T009458 Resource, Natural T009458 Resources, Natural cze0041668 přírodní zdroje 2010 09 20 cze Thesaurus M0000585 Land Supply The amount of land available for use or development. M0005037 M0000585 T001198 Land Supply 1986 12 31 NLM (1982) T001198 Land Supplies T001198 Supplies, Land T001198 Supply, Land D000067940 glykemická nálož[Glycemic Load] 2015 07 07 2015 07 07 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000208 ethnology EH GLYCEMIC INDEX is also available Glycemic Index (2003-2015) G07.203.650.660.750 J01.576.423.850.730.750.750 N06.850.601.750.750 M000598783 glykemická nálož[Glycemic Load] A quantitative value of a measured amount of a specific food that is equal to the GLYCEMIC INDEX of that food multiplied by the carbohydrate content of that food. T000867946 Glycemic Load 2014 10 06 NLM (2016) T000867946 Load, Glycemic cze0062782 glykemická nálož 2015 07 13 cze Thesaurus D000067956 inhibitory adenylylcyklázy[Adenylyl Cyclase Inhibitors] 2015 07 01 2015 04 02 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Adenylyl Cyclase/antagonists & inhibitors (1968-2015) D27.505.519.389.108 M000601456 inhibitory adenylylcyklázy[Adenylyl Cyclase Inhibitors] 0 Compounds that bind to and inhibit the action of ADENYLYL CYCLASES. T000873565 Adenylyl Cyclase Inhibitors 2015 01 13 NLM (2016) T000873565 Cyclase Inhibitors, Adenylyl T000873565 Inhibitors, Adenylyl Cyclase T000873566 Adenylate Cyclase Inhibitors 2015 01 13 NLM (2016) T000873566 Cyclase Inhibitors, Adenylate T000873566 Inhibitors, Adenylate Cyclase cze0061825 inhibitory adenylylcyklázy 2015 04 09 cze Thesaurus cze0061826 inhibitory adenylcyklázy 2015 04 09 cze Thesaurus cze0061824 inhibitory adenylátcyklázy 2015 04 09 cze Thesaurus D000067996 RAW 264.7 buňky[RAW 264.7 Cells] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA almost always NIM with no subheadings; check ANIMALS and MICE 2016 2016 Cell Line (1983-2015) Macrophages (1983-2015) A11.251.210.172.875 A11.733.397.815 M000601491 RAW 264.7 buňky[RAW 264.7 Cells] A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. T000873625 RAW 264.7 Cells 2015 01 14 NLM (2016) T000873625 264.7 Cell, RAW T000873625 264.7 Cells, RAW T000873625 Cell, RAW 264.7 T000873625 Cells, RAW 264.7 T000873625 RAW 264.7 Cell T000873626 RAW 264.7 Cell Line 2015 01 14 NLM (2016) cze0061989 RAW 264.7 buňky 2015 04 30 cze Thesaurus cze0061990 buněčná linie RAW 264.7 2015 04 30 cze Thesaurus D000068 akreditace[Accreditation] 1999 01 01 1994 06 03 1966 01 01 Q000379 methods MT Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST by the profession; do not confuse with LICENSURE (by the state) 66(64) 66 D002568 Certification D008004 Licensure N03.706.110.070 N05.700.200.100 M0000097 akreditace[Accreditation] Certification as complying with a standard set by non-governmental organizations, applied for by institutions, programs, and facilities on a voluntary basis. T000173 Accreditation 1999 01 01 NLM (1964) T000173 Accreditations cze0000075 akreditace 2006 03 22 D000068016 Clostridiales[Clostridiales] 2015 07 07 2015 07 06 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY 2016 2016 Bacteria (2001-2015) B03.353.625 M000601524 Clostridiales[Clostridiales] An order of anaerobic bacteria that are predominantly GRAM POSITIVE within the phylum Firmicutes. It includes the Clostridium and Eubacterium genera. T000873690 Clostridiales 2015 01 15 NLM (2016) cze0061939 Clostridiales 2015 04 22 cze Thesaurus D000068036 grafický román[Graphic Novels] 2015 07 01 2015 06 29 2016 01 01 This heading is used as a Publication Type. INDEXER: Do not use 2016; use CARTOONS 2014-2015 Cartoons (2014-2015) V02.503 V02.700.375 M000601534 grafický román[Graphic Novels] Book-length narratives told using a combination of words and sequential art, often presented in comic book style. from (Fletcher-Spear et al., ALA Review, Winter 2005) T000873721 Graphic Novels 2015 01 16 NLM (2016) cze0061498 grafický román 2015 02 26 cze Thesaurus cze0061499 ilustrovaný román 2015 02 26 cze Thesaurus cze0061500 komiksový román 2015 02 26 cze Thesaurus D000068037 Jižní Súdán[South Sudan] 2015 07 01 2015 02 10 2016 01 01 Q000208 ethnology EH Q000453 epidemiology EP 2016 Susan (1988-2015) Z01.058.290.120.745 M000601546 Jižní Súdán[South Sudan] A nation located in East-Central Africa; south of Sudan, north of Uganda and Kenya, west of Ethiopia. Independence from SUDAN was attained on 9 July 2011. The capital is Juba. (from CIA. World Factbook, 2014.) T000873740 South Sudan 2015 01 16 NLM (2016) cze0061348 Jižní Súdán 2015 02 16 cze Thesaurus D000068079 motorické poruchy[Motor Disorders] 2015 07 01 2015 02 10 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016; use MOTOR SKILLS DISORDERS 1998-2015 2016; see MOTOR SKILLS DISORDERS 1998-2015 Motor Skills Disorders (1998-2015) F03.608 M000601627 motorické poruchy[Motor Disorders] Motor skills deficits that significantly and persistently interfere with ACTIVITIES OF DAILY LIVING appropriate to chronological age. (from DSM-V) T000873855 Motor Disorders 2015 01 20 NLM (2016) cze0061288 motorické poruchy 2015 02 12 cze Thesaurus cze0061289 poruchy hybnosti 2015 02 12 cze Thesaurus cze0061290 poruchy motoriky 2015 02 12 cze Thesaurus D000068097 zdraví matek[Maternal Health] 2015 07 07 2015 07 06 2016 01 01 Q000145 classification CL Q000266 history HI Q000706 statistics & numerical data SN Q000191 economics EC Q000208 ethnology EH Q000941 ethics ES Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000639 trends TD 2016 (1974); use MATERNAL WELFARE 1974-2015 2016; see MATERNAL WELFARE 1974-2015 Maternal Welfare (1974-2015) D008427 Maternal Health Services D008429 Maternal Welfare N01.400.900.500 M0013117 zdraví matek[Maternal Health] The health of women during PREGNANCY; childbirth and the POSTPARTUM PERIOD. T025060 Maternal Health 1991 01 15 BIOETHICS (1974) NLM (1992) T025060 Health, Maternal cze0048311 zdraví matek 2012 05 25 cze Thesaurus D000068098 semenná banka[Seed Bank] 2015 07 01 2015 03 02 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Seeds (2000-2015) N02.278.065.650 M000601663 semenná banka[Seed Bank] A repository of seeds maintained under optimal conditions that ensure long term storage, intended for use as a source of replenishment of seed stock or plant genetic material. M000601663 M000601664 T000873974 Seed Bank 2015 01 21 NLM (2016) T000873974 Bank, Seed T000873974 Banks, Seed T000873974 Seed Banks T000873982 Seeds Bank 2015 01 21 NLM (2016) T000873982 Bank, Seeds T000873981 Seedbank 2015 01 21 NLM (2016) T000873981 Seedbanks cze0061589 semenná banka 2015 03 12 cze Thesaurus cze0061593 banka rostlinných semen 2015 03 12 cze Thesaurus cze0061590 banka semen 2015 03 12 cze Thesaurus M000601664 banka zárodečné plasmy[Germplasm Bank] M000601663 M000601664 T000873980 Germplasm Bank 2015 01 21 NLM (2016) T000873980 Bank, Germplasm T000873980 Banks, Germplasm T000873980 Germplasm Banks cze0061591 banka zárodečné plasmy 2015 03 12 cze Thesaurus cze0061592 sbírky zárodečné plazmy 2015 03 12 cze Thesaurus D000068099 poruchy související s traumatem a stresem[Trauma and Stressor Related Disorders] 2015 07 01 2015 06 30 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.950 M000601667 poruchy související s traumatem a stresem[Trauma and Stressor Related Disorders] Disorders in which exposure to a traumatic or stressful event is explicitly a diagnostic criterion. T000873985 Trauma and Stressor Related Disorders 2015 01 21 NLM (2016) cze0064183 poruchy související s traumatem a stresem 2015 10 26 cze Thesaurus cze0064184 reakce na těžký stres 2015 10 26 cze Thesaurus D000068101 zdravotní služby pro matku a dítě[Maternal-Child Health Services] 2015 07 07 2015 07 06 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 (1978); use MATERNAL-CHILD HEALTH CENTERS 1978-2015 2016 (1978); see MATERNAL-CHILD HEALTH CENTERS 1978-2015 Maternal-Child Health Centers (1978-2015) N02.421.143.130.660 N02.421.143.620.275 M0013120 zdravotní služby pro matku a dítě[Maternal-Child Health Services] Programs organized for the purpose of providing medical and social services for mothers and children. T025064 Maternal-Child Health Services 1978 12 16 MATERNAL CHILD HEALTH SERV NLM (1978) T025064 Maternal Child Health Services T025063 Health Services, Maternal-Child 1995 03 31 HEALTH SERV MATERNAL CHILD NLM (1996) T025063 Health Service, Maternal-Child T025063 Health Services, Maternal Child T025063 Maternal-Child Health Service T025063 Service, Maternal-Child Health T025063 Services, Maternal-Child Health cze0061608 zdravotní služby pro matku a dítě 2015 03 12 cze Thesaurus cze0061609 zdravotnické služby pro matku a dítě 2015 03 12 cze Thesaurus D000068103 serin-arginin sestřihové faktory[Serine-Arginine Splicing Factors] 2015 07 10 2015 07 10 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1995) 2016; SERINE-ARGININE-RICH SPLICING PROTEINS was indexed under PHOSPHOPROTEINS 1995-2006, under NUCLEAR PROTEINS 2007-2015, and under RNA-BINDING PROTEINS 2007-2015 D12.776.157.725.844 D12.776.664.962.844 M0252299 serin-arginin sestřihové faktory[Serine-Arginine Splicing Factors] 170974-22-8 A family of splicing regulatory factors essential for constitutive and alternative splicing in RNA metabolism. T000881259 Serine-Arginine Splicing Factors 2015 06 03 NLM (2016) T000881259 Factors, Serine-Arginine Splicing T000881259 Serine Arginine Splicing Factors T000881259 Splicing Factors, Serine-Arginine T000874006 Serine-Arginine-Rich Splicing Proteins 2015 01 21 NLM (2016) T000874006 Proteins, Serine-Arginine-Rich Splicing T000874006 Serine Arginine Rich Splicing Proteins T000874006 Splicing Proteins, Serine-Arginine-Rich T000877021 SR-Rich Splicing Proteins 2015 03 19 NLM (2016) T000877021 Proteins, SR-Rich Splicing T000877021 SR Rich Splicing Proteins T000877021 Splicing Proteins, SR-Rich cze0064036 serin-arginin sestřihové faktory 2015 10 15 cze Thesaurus cze0064038 SR proteiny 2015 10 15 cze Thesaurus cze0064037 serin/arginin bohatý sestřihový faktor 2015 10 15 cze Thesaurus cze0064039 sestřihový faktor bohatý na serin a arginin 2015 10 15 cze Thesaurus D000068104 zdraví kojenců[Infant Health] 2015 07 09 2015 07 08 2016 01 01 Q000145 classification CL Q000266 history HI Q000706 statistics & numerical data SN Q000639 trends TD Q000191 economics EC Q000208 ethnology EH Q000941 ethics ES Q000331 legislation & jurisprudence LJ Q000592 standards ST 2016; use INFANT WELFARE 1994-2015 2016; see INFANT WELFARE 1994-2015 Infant Welfare (1994-2015) D007229 Infant Welfare N01.400.388 M0011282 zdraví kojenců[Infant Health] The concept covering the physical and mental conditions of INFANTS. M0011282 M000600250 T021680 Infant Health 1993 02 18 NLM (1994) T021680 Health, Infant T000874004 Baby Health 2015 01 21 NLM (2016) T000874004 Health, Baby cze0060036 zdraví kojenců 2014 11 10 cze Thesaurus cze0050435 kojenci - zdraví 2012 10 23 cze Thesaurus M000600250 Newborn Health M0011282 M000600250 T000871692 Newborn Health 2014 12 04 NLM (2016) T000871692 Health, Newborn T000875660 Neonatal Health 2015 02 23 NLM (2016) T000875660 Health, Neonatal T000871695 Health of Newborn Infants 2014 12 04 NLM (2016) T000871693 Newborn Infant Health 2014 12 04 NLM (2016) T000871693 Health, Newborn Infant T000871693 Infant Health, Newborn T000871694 Health of the Newborn Infant 2014 12 04 NLM (2016) D000068105 bipolární a příbuzné poruchy[Bipolar and Related Disorders] 2015 07 01 2015 06 30 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.084 M000601674 bipolární a příbuzné poruchy[Bipolar and Related Disorders] These disorders are related to both SCHIZOPHRENIA SPECTRUM AND RELATED DISORDERS and DEPRESSIVE DISORDERS in terms of symptomatology, family history, and genetics. (DSM-V) . T000874002 Bipolar and Related Disorders 2015 01 21 NLM (2016) cze0063470 bipolární a příbuzné poruchy 2015 09 09 cze Thesaurus D000068116 gender dysphoria[Gender Dysphoria] 2015 07 01 2015 06 30 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 F03.835.550 M000601713 gender dysphoria[Gender Dysphoria] A marked difference between the individual’s expressed/experienced gender and the gender others would assign him or her, and it must continue for at least six months. (from DSM-5) T000874099 Gender Dysphoria 2015 01 22 NLM (2016) cze0063750 gender dysphoria 2015 10 07 cze Thesaurus cze0063751 porucha genderové identity 2015 10 07 cze Thesaurus D000068156 konstruktivní zpětná vazba[Formative Feedback] 2015 07 01 2015 06 29 2016 01 01 2016 2016 Learning (2010-2015) F02.784.629.529.223 L01.143.283.425.156 M000601936 konstruktivní zpětná vazba[Formative Feedback] Information communicated to the learner that is intended to modify the learner’s thinking or behavior for the purpose of improving learning. Informace sdělovaná studentovi, která je určena ke změně myšlení nebo chování studenta za účelem zlepšení vzdělávání. T000874480 Formative Feedback 2015 01 30 NLM (2016) T000874480 Feedback, Formative T000874478 Feedback (Learning) 2015 01 30 NLM (2016) T000874479 Constructive Feedback 2015 01 30 NLM (2016) T000874479 Feedback, Constructive cze0063800 konstruktivní zpětná vazba 2015 10 08 cze Thesaurus cze0063801 formativní zpětná vazba 2015 10 08 cze Thesaurus cze0064515 zpětná vazba v procesu učení 2015 11 13 cze Thesaurus D000068180 aripiprazol[Aripiprazole] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1995) 2016; ARIPIPRAZOLE was indexed under QUINOLONES 1995-2015 and under PIPERAZINES 1995-2015 D014150 Antipsychotic Agents D03.383.606.170 D03.438.810.835.122 M000602020 aripiprazol[Aripiprazole] 82VFR53I78 An antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. M000602020 M0249360 M000602020 M000602022 T000874649 Aripiprazole 2015 02 03 NLM (2016) T279364 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone NLM (1995) T000874920 Aripiprazol 2015 02 09 NLM (2016) cze0061871 aripiprazol 2015 04 16 cze Thesaurus M0249360 OPC 14597 0 M000602020 M0249360 T279365 OPC 14597 NLM (1995) T279365 14597, OPC T279366 OPC-14597 NLM (1995) M000602022 Abilify[Abilify] 0 M000602020 M000602022 T528594 Abilify 2002 12 17 MX US cze0061873 Abilify 2015 04 16 cze Thesaurus D000068181 mandloň obecná[Prunus dulcis] 2015 07 01 2015 06 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for ALMONDS use PRUNUS 2002-2015 2016; for ALMONDS see PRUNUS 2002-2015 Prunus (2001-2015) B01.650.940.800.575.100.842.500.625.500 M000602031 mandloň obecná[Prunus dulcis] A plant species in the family ROSACEAE, genus Prunus which produces edible seeds called almonds. M000602031 M0381055 T000874660 Prunus dulcis 2015 02 03 NLM (2016) T447899 Almond Tree 2001 05 24 NLM (2002) T447899 Almond Trees T447899 Tree, Almond T447899 Trees, Almond T000874664 Prunis communis 2015 02 03 NLM (2016) T000874665 Sweet Almond 2015 02 03 NLM (2016) T000874665 Almond, Sweet T000874665 Almonds, Sweet T000874665 Sweet Almonds T000874662 Prunus amygdalus 2015 02 03 NLM (2016) T000874663 Amygdalus communis 2015 02 03 NLM (2016) cze0062437 mandloň obecná 2015 06 15 cze Thesaurus cze0062439 Amygdalus communis 2015 06 15 cze Thesaurus cze0062438 Prunus dulcis 2015 06 15 cze Thesaurus cze0062440 mandloň hořká 2015 06 15 cze Thesaurus M0381055 mandle[Almonds] Nuts from almond tree and from which almond oil is pressed. M000602031 M0381055 T447894 Almonds 2001 05 24 NLM (2002) T447894 Almond cze0050328 mandle 2012 10 19 cze Thesaurus D000068196 paklitaxel vázaný na albumin[Albumin-Bound Paclitaxel] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2002) 2016; ALBUMIN-BOUND PACLITAXEL was indexed under ALBUMINS and PACLITAXEL 2005-2015, and under TAXOIDS 2002-2005 D000970 Antineoplastic Agents D02.455.426.392.368.242.888.777.500 D02.455.849.291.850.777.500 D12.776.034.073 M000602078 paklitaxel vázaný na albumin[Albumin-Bound Paclitaxel] 0 An injectable formulation of albumin-bound paclitaxel NANOPARTICLES. M000602078 M000603318 M000602078 M0439935 T000874926 Albumin-Bound Paclitaxel 2015 02 09 NLM (2016) T000874926 Albumin Bound Paclitaxel T000874926 Paclitaxel, Albumin-Bound T000874927 Protein-Bound Paclitaxel 2015 02 09 NLM (2016) T000874927 Paclitaxel, Protein-Bound T000874927 Protein Bound Paclitaxel cze0061980 paklitaxel vázaný na albumin 2015 04 27 cze Thesaurus cze0061982 paklitaxel navázaný na protein 2015 04 27 cze Thesaurus M000603318 Abraxane[Abraxane] 0 M000602078 M000603318 T628830 Abraxane 2005 01 26 NLM (2005) cze0061981 Abraxane 2015 04 27 cze Thesaurus M0439935 ABI007 0 M000602078 M0439935 T522430 ABI007 2002 10 15 NLM (2002) T522431 ABI-007 2002 10 15 NLM (2002) T522431 ABI 007 D000068216 služby péče o dítě[Child Protective Services] 2015 07 09 2015 07 07 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 (2010); use CHILD WELFARE 2010-2015 2016; see CHILD WELFARE 2010-2015 D012947 Social Work I01.409.418.500 N03.540.400.500 M0535008 služby péče o dítě[Child Protective Services] Local governmental offices which investigate reports of abuse and neglect of children, and act to assure a safe environment for minors. T749939 Child Protective Services 2009 04 24 NLM (2010) T749939 Child Protective Service T000870222 Child Welfare Agencies 2014 10 31 NLM (2016) OBSSR (2016) T000870222 Child Welfare Agency T000870222 Welfare Agency, Child cze0048220 služby péče o dítě 2012 05 17 cze Thesaurus D000068217 sociální pracovníci[Social Workers] 2015 07 07 2015 07 07 2016 01 01 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016 (1976); use SOCIAL WORK 1976-2015 2016; see SOCIAL WORK 1976-2015 Social Work (2010-2015) M01.526.919 M0020064 sociální pracovníci[Social Workers] Professionals who work with persons affected by social disadvantages such as POVERTY; mental and physical illness or disability, and social injustice. Their focus is on both the individual and his or her environment, including violations of their civil liberties and human rights. T038132 Social Workers 1977 03 17 BIOETHICS (1976) T038132 Social Worker T038132 Worker, Social T038132 Workers, Social cze0042365 sociální pracovníci 2011 01 24 cze Thesaurus D000068218 Prunus africana[Prunus africana] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 (2002) 2016 (2002); see PYGEUM 2002-2015; for PYGEUM AFRICANUM see PYGEUM 2002-2015; for AFRICAN PRUNE see PYGEUM 2002-2015 B01.650.940.800.575.100.842.500.625.250 M0399293 Prunus africana[Prunus africana] A plant species in the family ROSACEAE. The bark extract known as pygeum is an ingredient in FOLK REMEDIES. T463005 Prunus africana 2001 09 24 NLM (2003) T463007 Prune, African 2001 09 24 NLM (2003) T463006 African Prune 2001 09 24 NLM (2003) T463006 African Prunes T463006 Prunes, African T463004 Pygeum africanum 2001 09 24 NLM (2003) cze0026951 Prunus africana 2006 03 22 cze0031768 Pygeum africanum 2006 12 06 cze Thesaurus cze0044056 slivoň africká 2011 06 17 cze Thesaurus D000068219 meruňka obecná[Prunus armeniaca] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; use PRUNUS 2002-2015; for APRICOT use PRUNUS 2002-2015 and ROSALES 1998-2001 2016; see PRUNUS 2002-2015; for APRICOT see PRUNUS 2002-2015 and ROSALES 1998-2001 Prunus (2001-2015) B01.650.940.800.575.100.842.500.625.375 M0387944 meruňka obecná[Prunus armeniaca] A plant species in the family ROSACEAE. It is the source of apricot fruit. M0387944 M0029220 T439355 Prunus armeniaca 2001 03 15 NLM (2002) T447896 Apricot Tree 2001 05 24 NLM (2002) T447896 Apricot Trees T447896 Tree, Apricot T447896 Trees, Apricot cze0050329 meruňka obecná 2012 10 19 cze Thesaurus cze0025315 Prunus armeniaca 2006 03 22 M0029220 meruňka[Apricot] M0387944 M0029220 T058529 Apricot 1997 02 06 NLM (1983) T447895 Apricots 2001 05 24 NLM (2002) cze0025313 meruňka 2006 03 22 cze0050332 meruňky 2012 10 19 cze Thesaurus D000068220 třešeň obecná[Prunus avium] 2015 07 01 2015 06 12 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for PRUNUS SEROTINA use PRUNUS 2002-2015 2016; for PRUNUS SEROTINA see PRUNUS 2002-2015 Prunus (2001-2015) B01.650.940.800.575.100.842.500.625.400 M000602152 třešeň obecná[Prunus avium] A plant species in the family ROSACEAE. It is the source of the sweet cherry fruit. M000602152 M000602153 M000602152 M000602180 M000602152 M0591126 T000874835 Prunus avium 2015 02 06 NLM (2016) T000874778 Sweet Cherry Tree 2015 02 05 NLM (2016) T000874778 Cherry Tree, Sweet T000874778 Cherry Trees, Sweet T000874778 Sweet Cherry Trees T000874778 Tree, Sweet Cherry T000874778 Trees, Sweet Cherry cze0062429 třešeň obecná 2015 06 15 cze Thesaurus cze0062430 Prunus avium 2015 06 15 cze Thesaurus M000602153 višeň obecná[Prunus cerasus] M000602152 M000602153 T000874779 Prunus cerasus 2015 02 05 NLM (2016) T000874781 Sour Cherry 2015 02 05 NLM (2016) T000874781 Cherries, Sour T000874781 Cherry, Sour T000874781 Sour Cherries T000874780 Pie Cherry 2015 02 05 NLM (2016) T000874780 Cherries, Pie T000874780 Cherry, Pie T000874780 Pie Cherries cze0062432 višeň obecná 2015 06 15 cze Thesaurus cze0062435 Prunus cerasus 2015 06 15 cze Thesaurus M000602180 třešeň ptáčnice[Sweet Cherries] M000602152 M000602180 T000874816 Sweet Cherries 2015 02 06 NLM (2016) T000874816 Cherries, Sweet T000874816 Cherry, Sweet T000874816 Sweet Cherry cze0062436 třešeň ptáčnice 2015 06 15 cze Thesaurus M0591126 střemcha pozdní[Prunus serotina] M000602152 M0591126 T854572 Prunus serotina 2014 02 04 NLM (2015) T854573 Black Cherry 2014 02 04 NLM (2015) T854573 Black Cherries T854573 Cherries, Black T854573 Cherry, Black cze0062433 střemcha pozdní 2015 06 15 cze Thesaurus cze0062434 Prunus serotina 2015 06 15 cze Thesaurus D000068236 refugium[Refugium] 2015 07 01 2015 06 24 2016 01 01 2016 2016 G16.500.275.683 G16.500.819 M000602157 refugium[Refugium] Area in an environment in which a population of organisms can survive through a period of unfavorable conditions. T000874786 Refugium 2015 02 06 NLM (2016) T000874787 Refugia 2015 02 06 NLM (2016) cze0062959 refugium 2015 08 11 cze Thesaurus cze0062960 refugia 2015 08 11 cze Thesaurus cze0062961 útočiště (ekologie) 2015 08 11 cze Thesaurus D000068237 internetové poradenství[Distance Counseling] 2015 07 01 2015 06 29 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 Counseling (2005-2015) F02.784.176.350 F04.408.413.437 N02.421.143.303.175 N02.421.461.363.437 N04.452.758.849.550.500 M000602158 internetové poradenství[Distance Counseling] Counseling conducted via electronic or other non-face-to-face interactions. T000874788 Distance Counseling 2015 02 06 NLM (2016) T000874788 Counseling, Distance T000882079 E-Therapy 2015 06 18 NLM (2016) T000882079 E Therapy T000882079 E-Therapies T000874789 E-Counseling 2015 02 06 NLM (2016) T000874789 E Counseling cze0064235 internetové poradenství 2015 11 04 cze Thesaurus cze0064237 online poradenství 2015 11 04 cze Thesaurus cze0064238 online terapie 2015 11 04 cze Thesaurus cze0064236 poradenství přes internet 2015 11 04 cze Thesaurus D000068238 lubiproston[Lubiprostone] 2015 07 10 2015 07 09 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; LUBIPROSTONE was indexed under ALPROSTADIL 2005-2015 D065101 Chloride Channel Agonists D10.251.355.325.050.500 M0493211 lubiproston[Lubiprostone] 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid 7662KG2R6K Member of a bicyclic fatty acid class of compounds derived from PROSTAGLANDIN E1 involved in chloride channel gating. M0493211 M0493212 M0493211 M0497992 M0493211 M0493213 T000874928 Lubiprostone 2015 02 09 NLM (2016) T698473 Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- 2007 05 30 NLM (2007) cze0063982 lubiproston 2015 10 15 cze Thesaurus M0493212 RU 0211 0 M0493211 M0493212 T662873 RU 0211 2005 12 21 NLM (2005) T662873 0211, RU T662875 RU0211 2005 12 21 NLM (2005) T662874 RU-0211 2005 12 21 NLM (2005) M0497992 Amitiza 0 M0493211 M0497992 T673896 Amitiza 2006 05 16 NLM (2006) M0493213 SPI 0211 0 M0493211 M0493213 T662876 SPI 0211 2005 12 21 NLM (2005) T662876 0211, SPI T662878 SPI0211 2005 12 21 NLM (2005) T662877 SPI-0211 2005 12 21 NLM (2005) D000068239 broskvoň[Prunus persica] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; use PRUNUS 2002-2015; for PEACH use PRUNUS 2002-2015 2016; see PRUNUS 2002-2015; for PEACH see PRUNUS 2002-2015 Prunus (2001-2015) B01.650.940.800.575.100.842.500.625.750 M0387943 broskvoň[Prunus persica] A plant species in the family ROSACEAE. It is a tree that produces peach fruit. M0387943 M0381054 T439356 Prunus persica 2001 03 15 NLM (2002) T447898 Peach Tree 2001 05 24 NLM (2002) T447898 Peach Trees T447898 Tree, Peach T447898 Trees, Peach cze0050327 broskvoň 2012 10 19 cze Thesaurus M0381054 broskev[Peach] Prunus persica (L.) Batsch is the source of peaches. M0387943 M0381054 T439353 Peach 2001 03 15 NLM (2002) T447892 Peaches 2001 05 24 NLM (2002) cze0025314 broskev 2006 03 22 cze0050331 broskve 2012 10 19 cze Thesaurus D000068240 anonymizace dat[Data Anonymization] 2015 07 06 2015 06 29 2016 01 01 Q000941 ethics ES Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000592 standards ST Q000637 transplantation TR 2016 2016 D000068241 Personally Identifiable Information H01.770.644.205 L01.209.500 N03.706.437.650.124.160 N04.452.910.200.500 M000602181 anonymizace dat[Data Anonymization] Making information permanently non-identifiable that is associated with the identity of specific entities via encryption or other methods. M000602181 M000602182 T000874817 Data Anonymization 2015 02 06 NLM (2016) T000874817 Anonymization, Data cze0063591 anonymizace dat 2015 09 24 cze Thesaurus M000602182 maskování dat[Data Masking] M000602181 M000602182 T000874818 Data Masking 2015 02 06 NLM (2016) T000874818 Masking, Data cze0063592 maskování dat 2015 09 24 cze Thesaurus D000068241 osobní údaje[Personally Identifiable Information] 2015 07 06 2015 06 29 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D000068240 Data Anonymization I01.880.604.583.080.660 M000602183 osobní údaje[Personally Identifiable Information] Information that can be used to distinguish or trace an individual’s identity, either alone or when combined with other personal or identifying information that is linked or linkable to a specific individual. T000874819 Personally Identifiable Information 2015 02 06 NLM (2016) cze0064189 osobní údaje 2015 10 26 cze Thesaurus cze0064190 PII 2015 10 26 cze Thesaurus D000068242 slivoň švestka[Prunus domestica] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for PRUNUS CERASIFERA use PRUNUS 2002-2015; for PLUM use PRUNUS 2002-2015 2016; for PRUNUS CERASIFERA see PRUNUS 2002-2015; for PLUM see PRUNUS 2002-2015 Prunus (2001-2015) B01.650.940.800.575.100.842.500.625.450 M000602186 slivoň švestka[Prunus domestica] A plant species in the family ROSACEAE. It is a tree that produces fruits called plums. M000602186 M0381052 M000602186 M000601681 M000602186 M000602187 T000874829 Prunus domestica 2015 02 06 NLM (2016) T000874830 Plum Tree 2015 02 06 NLM (2016) T000874830 Plum Trees T000874830 Tree, Plum T000874830 Trees, Plum cze0062530 slivoň švestka 2015 06 22 cze Thesaurus cze0062531 Prunus domestica 2015 06 22 cze Thesaurus cze0062533 švestka domácí 2015 06 22 cze Thesaurus M0381052 švestka[Plum] M000602186 M0381052 T439351 Plum 2001 03 15 NLM (2002) T447893 Plums 2001 05 24 NLM (2002) cze0025316 švestka 2006 03 22 cze0050333 švestky 2012 10 19 cze Thesaurus M000601681 slivoň myrobalán[Prunus cerasifera] A plant species of the family ROSACEAE. It produces the drupes called cherry plums. M000602186 M000601681 T000874017 Prunus cerasifera 2015 01 21 NLM (2016) T000874018 Cherry Plum Tree 2015 01 21 NLM (2016) T000874018 Cherry Plum Trees T000874018 Plum Tree, Cherry T000874018 Plum Trees, Cherry T000874018 Tree, Cherry Plum T000874018 Trees, Cherry Plum cze0062537 slivoň myrobalán 2015 06 22 cze Thesaurus cze0062535 Prunus cerasifera 2015 06 22 cze Thesaurus cze0062534 myrobalán 2015 06 22 cze Thesaurus cze0062536 slivoň třešňová 2015 06 22 cze Thesaurus M000602187 slivoň vrbová[Prunus salicina] M000602186 M000602187 T000874831 Prunus salicina 2015 02 06 NLM (2016) T000874831 Prunus salicinas T000874831 salicina, Prunus T000874831 salicinas, Prunus T000874832 Japanese Plum 2015 02 06 NLM (2016) T000874832 Japanese Plums T000874832 Plum, Japanese T000874832 Plums, Japanese cze0062538 slivoň vrbová 2015 06 22 cze Thesaurus cze0062539 Prunus salicina 2015 06 22 cze Thesaurus D000068256 darbepoetin alfa[Darbepoetin alfa] 2015 07 10 2015 10 06 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2000) 2016; DARBEPOETIN ALFA was indexed under ERYTHROPOIETIN 2000-2015 D006397 Hematinics D12.776.395.240.150.500 M0374902 darbepoetin alfa[Darbepoetin alfa] 30-l-Asparagine-32-l-threonine-87-l-valine-88-l-asparagine-90-l-threonineerythropoietin (human) 15UQ94PT4P A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA. 209810-58-2 (darbepoetin alfa) M0374902 M0432471 M0374902 M0500808 T000874935 Darbepoetin alfa 2015 02 09 NLM (2016) T000874937 Novel Erythropoiesis Stimulating Protein 2015 02 09 NLM (2016) T000880425 NESP 2015 05 26 NLM (2016) T000874936 Darbepoietin alfa 2015 02 09 NLM (2016) cze0063471 darbepoetin alfa 2015 09 09 cze Thesaurus M0432471 Aranesp[Aranesp] 0 M0374902 M0432471 T483383 Aranesp 2002 02 25 NLM (2016) T623364 Aranest 2004 12 10 NLM (2016) cze0063472 Aranesp 2015 09 09 cze Thesaurus M0500808 KRN 321 0 M0374902 M0500808 T679698 KRN 321 2006 08 14 NLM (2006) T679700 KRN321 2006 08 14 NLM (2006) T679699 KRN-321 2006 08 14 NLM (2006) D000068257 kombinace léků efavirenz, emtricitabin a tenofovir[Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 2015 07 10 2015 07 09 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2007) 2016; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination was indexed under ADENINE 2007-2015, under DEOXYCYTIDINE 2007-2015, under OXAZINES 2007-2015, under ORGANOPHOSPHATES 2007-2015, and under DRUG COMBINATIONS 2007-2015 D023241 Antiretroviral Therapy, Highly Active D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D02.705.429.906.125 D03.383.533.375 D03.383.742.680.245.500.600.125 D03.438.759.138.881.125 D26.310.375 M0548057 kombinace léků efavirenz, emtricitabin a tenofovir[Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 0 Inhibitor or Reverse Transcriptases or of RNA-dIrected DNA polymerase. M0548057 M0507695 T000874947 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 2015 02 09 NLM (2016) cze0063805 kombinace léků efavirenz, emtricitabin a tenofovir 2015 10 08 cze Thesaurus cze0063806 kombinace léků efavirenz, emtricitabin a tenofovir disoproxil fumarát 2015 10 08 cze Thesaurus M0507695 Atripla[Atripla] 0 M0548057 M0507695 T774004 Atripla 2010 07 09 NLM (2010) UK US cze0063804 Atripla 2015 10 08 cze Thesaurus D000068258 bevacizumab[Bevacizumab] 2015 07 10 2015 07 09 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2002) 2016; BEVACIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2015, and under ANTIBODIES, MONOCLONAL 2002-2011 D020533 Angiogenesis Inhibitors D12.776.124.486.485.114.224.060.375 M0443627 bevacizumab[Bevacizumab] 2S9ZZM9Q9V An anti-VEGF recombinant monoclonal antibody consisting of humanized murine antibody. It inhibits VEGF receptors and prevents the proliferation of blood vessels. Bevacizumab (Avastin) je humanizovaná monoklonální protilátka proti ligandu VEGF (vaskulárnímu endoteliálnímu růstovému faktoru). Bevacizumab váže volný VEGF-A, -B i -C a účinně blokuje novotvorbu cév u mnoha typů nádorů inhibicí signální dráhy VEGF-VEGFR. M0443627 M0446630 T000874953 Bevacizumab 2015 02 09 NLM (2016) cze0062631 bevacizumab 2015 06 26 cze Thesaurus M0446630 Avastin[Avastin] 0 M0443627 M0446630 T534903 Avastin 2003 03 10 NLM (2003) cze0062632 Avastin 2015 06 26 cze Thesaurus D000068276 žirafy[Giraffes] 2015 07 01 2015 05 22 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000097 blood BL Q000134 cerebrospinal fluid CF Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000601 surgery SU 2016 2016 Artiodactyla (1963-2015) B01.050.150.900.649.077.380.443 M000602311 žirafy[Giraffes] Four-legged hoofed mammals with extremely long necks and legs belonging to the family Giraffidae. M000602311 M000602313 T000875016 Giraffes 2015 02 10 NLM (2016) OBSSR (2016) T000875016 Giraffe cze0062197 žirafy 2015 06 05 cze Thesaurus cze0062200 Giraffa camelopardalis 2015 06 05 cze Thesaurus cze0062201 žirafa 2015 06 05 cze Thesaurus M000602313 okapi[Okapis] Four-legged hoofed mammals that are closely related to giraffes, although they bear stripes similar to zebras. M000602311 M000602313 T000875018 Okapis 2015 02 10 NLM (2016) OBSSR (2016) T000875018 Okapi cze0062198 okapi 2015 06 05 cze Thesaurus cze0062199 Okapia johnstoni 2015 06 05 cze Thesaurus D000068296 risedronát sodný[Risedronate Sodium] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2014) 2016; RISEDRONATE SODIUM was indexed under ETIDRONIC ACID 2014-2015 D002121 Calcium Channel Blockers D050071 Bone Density Conservation Agents D02.705.429.500.830.500 M000602344 risedronát sodný[Risedronate Sodium] OFG5EXG60L An aminobisphosphonate derivative of etidronic acid and CALCIUM CHANNEL BLOCKER that inhibits BONE RESORPTION and is used for the treatment of OSTEOPOROSIS. KM2Z91756Z (Risedronic Acid) M000602344 M000594877 M000602344 M000603388 M000602344 M000603519 M000602344 M0557666 T000875081 Risedronate Sodium 2015 02 11 BAN (19XX) INN (19XX) NLM (2016) USAN (19XX) T000875081 Sodium, Risedronate T646305 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate 2005 07 19 NLM (2005) T000876931 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate 2015 03 17 NLM (2016) T227530 2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate NLM (1992) T000875082 Risedronic Acid, Monosodium Salt 2015 02 11 NLM (2016) T000875084 Risedronate 2015 02 11 NLM (1992) cze0061940 risedronát sodný 2015 04 22 cze Thesaurus M000594877 Bisphosphate Risedronate Sodium 0 M000602344 M000594877 T000875083 Bisphosphate Risedronate Sodium 2015 02 11 NLM (2016) T000875083 Risedronate Sodium, Bisphosphate T000875083 Sodium, Bisphosphate Risedronate M000603388 Risedronic Acid KM2Z91756Z M000602344 M000603388 T000875085 Risedronic Acid 2015 02 11 NLM (1992) T000875085 Acid, Risedronic M000603519 Actonel 0 M000602344 M000603519 T403887 Actonel 1999 12 28 AU CA DE ES FR IE UK US M0557666 Atelvia 0 M000602344 M0557666 T790615 Atelvia 2011 05 16 NLM (2011) D000068297 kombinace léků flutikason a salmeterol[Fluticasone Propionate, Salmeterol Xinafoate Drug Combination] 2015 07 01 2015 09 14 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; FLUTICASONE PROPRIONATE-SALMETEROL XINAFOATE DRUG COMBINATION was indexed under ALBUTEROL 2001-2015; and under ANDROSTADIENES 2001-2015. D001993 Bronchodilator Agents D005938 Glucocorticoids D013566 Sympathomimetics D02.033.100.291.057.750.500 D02.092.063.291.057.750.500 D02.092.471.683.061.750.500 D04.808.054.079.129.114.500 D26.310.438 M000602345 kombinace léků flutikason a salmeterol[Fluticasone Propionate, Salmeterol Xinafoate Drug Combination] 0 A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. M000602345 M0413150 M000602345 M000602351 M000602345 M000602353 M000602345 M000603319 T000875098 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination 2015 02 11 NLM (2016) T000875099 Fluticasone Propionate-Salmeterol Xinafoate Combination 2015 02 11 NLM (2016) T000875099 Fluticasone Propionate Salmeterol Xinafoate Combination T000875102 Fluticasone Propionate - Salmeterol 2015 02 11 NLM (2016) T000875102 Fluticasone Propionate Salmeterol T000886595 Fluticasone Propionate-Salmeterol Drug Combination 2015 09 14 NLM (2016) T000886595 Fluticasone Propionate Salmeterol Drug Combination T000875106 Fluticasone - Salmeterol 2015 02 11 NLM (2016) T000875106 Fluticasone Salmeterol T000875107 Fluticasone-Salmeterol Combination 2015 02 11 NLM (2016) T000875107 Combination, Fluticasone-Salmeterol T000875107 Fluticasone Salmeterol Combination T000876683 Fluticasone Propionate-Salmeterol Xinafoate Drug Combination 2015 03 11 NLM (2016) T000876683 Fluticasone Propionate Salmeterol Xinafoate Drug Combination T000876935 Fluticasone-Salmeterol Drug Combination 2015 03 17 NLM (2016) T000876935 Combination, Fluticasone-Salmeterol Drug T000876935 Drug Combination, Fluticasone-Salmeterol T000876935 Fluticasone Salmeterol Drug Combination T000875097 Fluticasone Propionate - Salmeterol Xinafoate 2015 02 11 NLM (2016) T000875097 Fluticasone Propionate Salmeterol Xinafoate T000875104 Fluticasone Propionate - Salmeterol Combination 2015 02 11 NLM (2016) T000875104 Fluticasone Propionate Salmeterol Combination cze0063904 kombinace léků flutikason a salmeterol 2015 10 15 cze Thesaurus M0413150 Seretide[Seretide] 0 M000602345 M0413150 T441307 Seretide 2001 03 30 NLM (2001) cze0063906 Seretide 2015 10 15 cze Thesaurus M000602351 Advair Diskus 0 A dry powdered inhaler formulation of fluticasone-salmeterol drug combination. M000602345 M000602351 T000875108 Advair Diskus 2015 02 11 NLM (2016) M000602353 Airflusan Forspiro[Advair HFA] 0 A metered dose inhaler formulation of fluticasone-salmeterol drug combination. M000602345 M000602353 T000875110 Advair HFA 2015 02 11 NLM (2016) cze0063908 Airflusan Forspiro 2015 10 15 cze Thesaurus cze0063911 Fullhale 2015 10 15 cze Thesaurus M000603319 Advair 0 M000602345 M000603319 T441306 Advair 2001 03 30 NLM (2001) D000068298 flutikason[Fluticasone] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1990) 2016; FLUTICASONE was indexed under ANDROSTADIENES 1990-2015 D000893 Anti-Inflammatory Agents D001993 Bronchodilator Agents D003879 Dermatologic Agents D018926 Anti-Allergic Agents D04.808.054.079.129.114 M000602354 flutikason[Fluticasone] CUT2W21N7U A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. M000602354 M0179830 M000602354 M000603891 M000602354 M0179828 M000602354 M000603403 M000602354 M0365914 M000602354 M0179829 M000602354 M0361267 T000875115 Fluticasone 2015 02 11 NLM (2016) cze0061925 flutikason 2015 04 22 cze Thesaurus cze0061927 flutikason furoát 2015 04 22 cze Thesaurus M0179830 Flonase 0 M000602354 M0179830 T209835 Flonase NLM (1990) M000603891 Flovent HFA 0 M000602354 M000603891 T000877425 Flovent HFA 2015 03 26 NLM (2016) T000877425 HFA, Flovent M0179828 Cutivate[Cutivate] 0 M000602354 M0179828 T209833 Cutivate NLM (1990) cze0061929 Cutivate 2015 04 22 cze Thesaurus M000603403 flutikason propionát[Fluticasone Propionate] O2GMZ0LF5W M000602354 M000603403 T000875117 Fluticasone Propionate 2015 02 11 NLM (2016) T000875117 Propionate, Fluticasone cze0061926 flutikason propionát 2015 04 22 cze Thesaurus M0365914 Nasofan[Flixonase] 0 M000602354 M0365914 T419001 Flixonase 2000 07 14 NLM (2000) cze0061931 Nasofan 2015 04 22 cze Thesaurus M0179829 Flixotide[Flixotide] 0 M000602354 M0179829 T209834 Flixotide NLM (1990) cze0061928 Flixotide 2015 04 22 cze Thesaurus M0361267 Avamys[Flovent] 0 M000602354 M0361267 T412904 Flovent 2000 04 28 NLM (2000) cze0061930 Avamys 2015 04 22 cze Thesaurus D000068299 salmeterol xinafoát[Salmeterol Xinafoate] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1989) 2016; SALMETEROL XINAFOATE was indexed under ALBUTEROL 1989-2015 D001993 Bronchodilator Agents D058666 Adrenergic beta-2 Receptor Agonists D02.033.100.291.057.750 D02.092.063.291.057.750 D02.092.471.683.061.750 M000602359 salmeterol xinafoát[Salmeterol Xinafoate] 6EW8Q962A5 A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2I4BC502BT (Salmeterol) M000602359 M000603335 M000602359 M000603386 T000875119 Salmeterol Xinafoate 2015 02 11 FDA SRS (2015) INN (19XX) NLM (1989) USAN (19XX) T000875119 Xinafoate, Salmeterol cze0061934 salmeterol xinafoát 2015 04 22 cze Thesaurus cze0061935 salmeterol-xinafoát 2015 04 22 cze Thesaurus M000603335 Serevent[Serevent] 0 M000602359 M000603335 T191615 Serevent NLM (1989) cze0061936 Serevent 2015 04 22 cze Thesaurus M000603386 Salmeterol 0 M000602359 M000603386 T000875121 Salmeterol 2015 02 11 FDA SRS (2013) INN (19XX) NLM (2016) USAN (1985) D000068316 veřejné parky[Parks, Recreational] 2015 07 01 2015 05 22 2016 01 01 Q000266 history HI Q000331 legislation & jurisprudence LJ Q000706 statistics & numerical data SN Q000592 standards ST Q000145 classification CL Q000191 economics EC 2016 2016 Recreation (1989-2015) N06.850.860.410.375 M000602387 veřejné parky[Parks, Recreational] An area of land open to the public for enjoyment. M000602387 M000605188 M000602387 M000605186 M000602387 M000605185 T000875169 Parks, Recreational 2015 02 12 NLM (2016) T000875169 Park, Recreational T000875169 Recreational Park T000875169 Recreational Parks cze0064045 veřejné parky 2015 10 16 cze Thesaurus M000605188 obecní parky[Community Parks] M000602387 M000605188 T000879041 Community Parks 2015 05 01 NLM (2016) T000879041 Community Park T000879041 Park, Community T000879041 Parks, Community cze0064048 obecní parky 2015 10 16 cze Thesaurus M000605186 národní parky[National Parks] M000602387 M000605186 T000879039 National Parks 2015 05 01 NLM (2016) T000879039 National Park T000879039 Park, National T000879039 Parks, National cze0064046 národní parky 2015 10 16 cze Thesaurus M000605185 městské parky[Urban Parks] M000602387 M000605185 T000879038 Urban Parks 2015 05 01 NLM (2016) T000879038 Park, Urban T000879038 Parks, Urban T000879038 Urban Park cze0064047 městské parky 2015 10 16 cze Thesaurus D000068336 válečné a ozbrojené konflikty[Warfare and Armed Conflicts] 2015 07 01 2015 07 01 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH used for searching; INDEXER: Do not use; CATALOGER: Do not use 2016 2016 I01.880.735.950 M000602388 válečné a ozbrojené konflikty[Warfare and Armed Conflicts] Engaging in any type of conflict including war or military conflict against another nation or organized group.. T000875179 Warfare and Armed Conflicts 2015 02 12 NLM (2016) T000875180 Armed Conflicts and Warfare 2015 02 12 NLM (2016) cze0062722 válečné a ozbrojené konflikty 2015 07 02 cze Thesaurus D000068337 ozbrojené konflikty[Armed Conflicts] 2015 07 01 2015 06 29 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 I01.880.735.950.250 M000602392 ozbrojené konflikty[Armed Conflicts] Any differences arising between two nations or groups and leading to the intervention of armed forces. T000875187 Armed Conflicts 2015 02 12 NLM (2016) T000875187 Armed Conflict T000875187 Conflict, Armed T000875187 Conflicts, Armed cze0062715 ozbrojené konflikty 2015 07 02 cze Thesaurus D000068338 everolimus[Everolimus] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; EVEROLIMUS was indexed under SIROLIMUS 1998-2015; and under POLYENES 1997-1998 D000970 Antineoplastic Agents D007166 Immunosuppressive Agents D02.540.505.760.500 M000602394 everolimus[Everolimus] 9HW64Q8G6G A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT. Inhibitor kinázy mTOR užívaný v současnosti jako imunosupresivum v transplantologii, zkouší se u některých nádorů (např. karcinomu ledviny). (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) M000602394 M0375756 M000602394 M000603402 M000602394 M0446654 T000875190 Everolimus 2015 02 12 NLM (2016) T308864 SDZ RAD NLM (1997) T308864 RAD, SDZ T544057 SDZ-RAD 2003 06 23 NLM (2003) T308863 40-O-(2-hydroxyethyl)-rapamycin NLM (1997) cze0061874 everolimus 2015 04 16 cze Thesaurus M0375756 RAD001[RAD 001] 0 M000602394 M0375756 T432424 RAD 001 2001 01 05 NLM (2001) T432424 001, RAD T754038 RAD001 2009 07 08 NLM (2009) cze0061878 RAD001 2015 04 16 cze Thesaurus M000603402 Afinitor[Afinitor] 0 M000602394 M000603402 T000875191 Afinitor 2015 02 12 NLM (2016) cze0061877 Afinitor 2015 04 16 cze Thesaurus M0446654 Certican[Certican] 0 M000602394 M0446654 T534925 Certican 2003 03 10 NLM (2003) cze0061876 Certican 2015 04 16 cze Thesaurus D000068342 kombinace kyseliny acetylsalicylové s dipyridamolem[Aspirin, Dipyridamole Drug Combination] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1986) 2016; ASPIRIN-DIPYRIDAMOLE DRUG COMBINATION was indexed under ASPIRIN and DIPYRIDAMOLE 1986-2015 D010975 Platelet Aggregation Inhibitors D02.455.426.559.389.657.410.595.176.500 D03.383.742.175.500 D26.310.125 M0539734 kombinace kyseliny acetylsalicylové s dipyridamolem[Aspirin, Dipyridamole Drug Combination] 0 A drug combination of aspirin and dipyridamole that functions as a PLATELET AGGREGATION INHIBITOR, used to prevent THROMBOSIS and STROKE in TRANSIENT ISCHEMIC ATTACK patients. M0539734 M0359403 M0539734 M0397744 M0539734 M0137473 M0539734 M0397745 M0539734 M0137475 T000875197 Aspirin, Dipyridamole Drug Combination 2015 02 12 NLM (2016) T000876679 Aspirin-Dipyridamole Drug Combination 2015 03 11 NLM (2016) T000876679 Aspirin Dipyridamole Drug Combination T000876679 Combination, Aspirin-Dipyridamole Drug T000876679 Drug Combination, Aspirin-Dipyridamole cze0062033 kombinace kyseliny acetylsalicylové s dipyridamolem 2015 05 11 cze Thesaurus cze0062035 dipyridamol a aspirin v kombinaci 2015 05 11 cze Thesaurus cze0062034 kombinace ASA s dipyridamolem 2015 05 11 cze Thesaurus cze0062040 kombinace kyseliny acetylsalicylové a dipyridamolu 2015 05 11 cze Thesaurus M0359403 Aggrenox[Aggrenox] 0 M0539734 M0359403 T410189 Aggrenox 2000 03 23 NLM (2000) cze0062039 Aggrenox 2015 05 11 cze Thesaurus M0397744 Extended-Release Dipyridamole-Aspirin 0 M0539734 M0397744 T000875199 Extended-Release Dipyridamole-Aspirin 2015 02 12 NLM (2016) T000875199 Dipyridamole-Aspirin, Extended-Release T000875199 Extended Release Dipyridamole Aspirin M0137473 Asasantin 0 M0539734 M0137473 T167478 Asasantin NLM (1986) M0397745 Asasantin Retard 0 M0539734 M0397745 T410190 Asasantin Retard 2000 03 23 NLM (2000) T410190 Retard, Asasantin M0137475 TX 3301 0 M0539734 M0137475 T167480 TX 3301 NLM (1986) T167480 3301, TX T167479 TX-3301 NLM (1986) D000068356 sebekontrola[Self-Control] 2015 07 10 2015 07 09 2016 01 01 Q000523 psychology PX 2016; for SELF REGULATION use SOCIAL CONTROL, INFORMAL 1997-2015 2016; for SELF REGULATION see SOCIAL CONTROL, INFORMAL 1997-2015 D013695 Temperance F01.145.813.595 M000602570 sebekontrola[Self-Control] An individual's ability to manage and monitor their emotions, behaviors, and desires in the face of external demands in order to function in society. T000875449 Self-Control 2015 02 19 NLM (2016) OBSSR (2016) T000875451 Self-Regulation 2015 02 19 NLM (2016) OBSSR (2016) T000875452 Self Control 2015 02 19 NLM (2016) OBSSR (2016) T000875452 Control, Self T000875450 Self Regulation 2015 02 19 NLM (2016) OBSSR (2016) T000875450 Regulation, Self cze0064154 sebekontrola 2015 10 22 cze Thesaurus D000068357 slané vody[Saline Waters] 2015 07 07 2015 07 06 2016 01 01 Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D006982 Hypertonic Solutions G16.500.275.725 M000602575 slané vody[Saline Waters] Water from natural sources which contain significant concentrations of dissolved salts such as sodium chloride. M000602575 M000606780 T000875471 Saline Waters 2015 02 19 NLM (2016) T000875471 Saline Water T000875471 Water, Saline T000875471 Waters, Saline cze0061586 slané vody 2015 03 12 cze Thesaurus cze0061588 salinická voda 2015 03 12 cze Thesaurus cze0061587 salinické vody 2015 03 12 cze Thesaurus M000606780 Brackish Water M000602575 M000606780 T000881849 Brackish Water 2015 06 15 NLM (2016) T000881849 Brackish Waters T000881849 Water, Brackish T000881849 Waters, Brackish D000068376 sekundární traumatický stres[Compassion Fatigue] 2015 07 06 2015 05 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000601 surgery SU Q000208 ethnology EH 2016 2016 D002055 Burnout, Professional D013313 Stress Disorders, Post-Traumatic C23.888.369.500.500 F01.145.126.937.500 F01.145.126.990.469 F02.830.900.333 M000602637 sekundární traumatický stres[Compassion Fatigue] Stress response that occurs in individuals working in care giving professions. T000875560 Compassion Fatigue 2015 02 20 NLM (2016) T000875560 Fatigue, Compassion T000880217 Secondary Traumatization 2015 05 21 NLM (2016) T000880217 Secondary Traumatizations T000880217 Traumatization, Secondary T000880217 Traumatizations, Secondary T000875562 Vicarious Traumatization 2015 02 20 NLM (2016) T000875562 Traumatization, Vicarious T000875561 Secondary Traumatic Stress 2015 02 20 NLM (2016) T000875561 Stress, Secondary Traumatic T000875561 Stresses, Secondary Traumatic T000875561 Traumatic Stress, Secondary T000880216 Secondary Trauma 2015 05 21 NLM (2016) T000880216 Secondary Traumas T000880216 Trauma, Secondary T000880216 Traumas, Secondary T000880218 Vicarious Trauma 2015 05 21 NLM (2016) T000880218 Trauma, Vicarious T000880218 Traumas, Vicarious T000880218 Vicarious Traumas cze0063613 sekundární traumatický stres 2015 09 24 cze Thesaurus cze0063614 zástupné trauma 2015 09 24 cze Thesaurus D000068377 jitrocelovité[Plantaginaceae] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for GLOBULARIA and STEMODIA use SCROPHULARIACEAE 2003-2015 2016; for GLOBULARIA and STEMODIA see SCROPHULARIACEAE 2003-2015 B01.650.940.800.575.100.583.700 M0016966 jitrocelovité[Plantaginaceae] A plant family of order Lamiales. The Plantago genus is best known. Lesser known members include Hippuris, Littorella and Callitriche. M0016966 M0418970 M0016966 M0418971 T032228 Plantaginaceae 1996 10 21 NLM (1998) T000875563 Speedwell Family 2015 02 20 NLM (2016) T000875563 Families, Speedwell T000875563 Family, Speedwell T000875563 Speedwell Families cze0063993 jitrocelovité 2015 10 15 cze Thesaurus cze0063994 Plantaginaceae 2015 10 15 cze Thesaurus cze0063995 rozrazil (rod) 2015 10 15 cze Thesaurus M0418970 Globularia[Globularia] M0016966 M0418970 T487824 Globularia 2002 03 28 NLM (2003) cze0025380 Globularia 2006 03 22 M0418971 Stemodia[Stemodia] M0016966 M0418971 T487825 Stemodia 2002 03 28 NLM (2003) cze0025379 Stemodia 2006 03 22 D000068378 hluchavkotvaré[Lamiales] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for PROBOSCIDEA PLANT use PEDALIACEAE 2003-2015 2016; for PROBOSCIDEA PLANT see PEDALIACEAE 2003-2015 Angiosperms (2004-2015) B01.650.940.800.575.100.583 M000602638 hluchavkotvaré[Lamiales] An order of the Lamiidae clade. Lamiales is one of the largest orders of flowering plants and includes pot-herbs in the mint family (MINT; SAGE; OREGANO; BASIL); SESAME, foxgloves; SNAPDRAGONS; and the olive family. M000602638 M0398620 T000875564 Lamiales 2015 02 20 NLM (2016) cze0063868 hluchavkotvaré 2015 10 14 cze Thesaurus cze0063869 Lamiales 2015 10 14 cze Thesaurus cze0063870 krtičníkotvaré 2015 10 14 cze Thesaurus M0398620 Proboscidea[Proboscidea Plant] A plant genus of the family Martyniaceae, order Lamiales. Common name devilsclaw is also a common name of the genus HARPAGOPHYTUM PROCUMBENS. M000602638 M0398620 T461999 Proboscidea Plant 2001 09 18 NLM (2003) T461999 Plant, Proboscidea T461999 Plants, Proboscidea T461999 Proboscidea Plants cze0051745 Proboscidea 2012 11 07 cze Thesaurus D000068397 klinická studie[Clinical Study] 2015 07 01 2015 06 29 2016 01 01 This heading is used as a Publication Type for original report of the conduct or results of a specific clinical study. A different heading CLINICAL STUDIES AS TOPIC is used for general design, methodology, economics, etc. of clinical studies. Prefer the specifics: CLINICAL TRIAL or OBSERVATIONAL STUDY. 2016 V03.175 M000602720 klinická studie[Clinical Study] A work that reports on the results of a research study to evaluate interventions or exposures on biomedical or health-related outcomes. The two main types of clinical studies are interventional studies (clinical trials) and observational studies. While most clinical studies concern humans, this publication type may be used for clinical veterinary articles meeting the requisites for humans. T000876178 Clinical Study 2015 03 04 NLM (2016) cze0061947 klinická studie 2015 04 23 cze Thesaurus D000068436 předoperační vyšetření[Surgical Clearance] 2015 07 01 2015 06 26 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 D010808 Physical Examination E01.370.505 M000602817 předoperační vyšetření[Surgical Clearance] Process of evaluating the health of a patient and determining if they are healthy enough for surgery. T000875808 Surgical Clearance 2015 02 25 NLM (2016) OBSSR (2016) T000875808 Clearance, Surgical T000875808 Clearances, Surgical T000875808 Surgical Clearances T000875807 Medical Clearance 2015 02 25 NLM (2016) OBSSR (2016) T000875807 Clearance, Medical T000875807 Clearances, Medical T000875807 Medical Clearances cze0064252 předoperační vyšetření 2015 11 05 cze Thesaurus cze0064253 zhodnocení stavu pacienta před operací 2015 11 05 cze Thesaurus D000068437 pemetrexed[Pemetrexed] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; PEMETREXED was indexed under GLUTAMATES 1994-2015, and under GUANINE 1994-2015 D000970 Antineoplastic Agents D004791 Enzyme Inhibitors D005493 Folic Acid Antagonists D019384 Nucleic Acid Synthesis Inhibitors D03.438.759.758.399.454.650 D12.125.067.625.525 D12.125.119.409.525 M0227083 pemetrexed[Pemetrexed] L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)- 04Q9AIZ7NO A guanine-derived ANTINEOPLASTIC AGENT that functions as a NUCLEIC ACID SYNTHESIS INHIBITOR through its binding to, and inhibition of, THYMIDYLATE SYNTHASE. 137281-23-3 (pemetrexed) 2PKU919BA9 M0227083 M000603406 M0227083 M0227084 M0227083 M0407271 T000875812 Pemetrexed 2015 02 25 FDA SRS (2013) INN (19XX) NLM (2001) T403381 MTA 1999 12 21 NLM (1999) T257088 N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid NLM (1994) cze0061966 pemetrexed 2015 04 27 cze Thesaurus M000603406 pemetrexed disodium[Pemetrexed Disodium] 2PKU919BA9 M0227083 M000603406 T000875813 Pemetrexed Disodium 2015 02 25 NLM (2000) T000875813 Disodium, Pemetrexed cze0061969 pemetrexed disodium 2015 04 27 cze Thesaurus M0227084 LY 231514 0 M0227083 M0227084 T257089 LY 231514 NLM (1994) T257089 231514, LY T257085 LY-231,514 NLM (1994) T257087 LY231514 NLM (1994) T257084 LY 231,514 NLM (1994) T257084 231,514, LY T257086 LY-231514 NLM (1994) M0407271 Alimta[Alimta] 0 M0227083 M0407271 T000876684 Alimta 2015 03 11 NLM (2000) cze0061968 Alimta 2015 04 27 cze Thesaurus D000068438 brimonidin tartrát[Brimonidine Tartrate] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1978) 2016; BRIMONIDINE TARTRATE was indexed under QUINOXALINES 1980-2015, and under IMIDAZOLES 1978-1980 D000959 Antihypertensive Agents D058647 Adrenergic alpha-2 Receptor Agonists D03.438.857.070 M0065049 brimonidin tartrát[Brimonidine Tartrate] 6-quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- 4S9CL2DY2H A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 59803-98-4 59803-99-5 70359-46-5 79570-19-7 E6GNX3HHTE M0065049 M0065042 M0065049 M000603399 M0065049 M0065043 M0065049 M0065045 M0065049 M0312901 M0065049 M000603397 M0065049 M0312902 M0065049 M0312903 M0065049 M0517501 M0065049 M000603526 M0065049 M000603394 M0065049 M0065040 M0065049 M000603395 T000875824 Brimonidine Tartrate 2015 02 25 NLM (1978) USAN (19XX) T000875824 Tartrate, Brimonidine T095041 5-bromo-6-(imidazolidinylideneamino)quinoxaline NLM (1978) T095042 5-bromo-6-(imidazolin-2-ylamino)quinoxaline NLM (1978) T000876771 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate 2015 03 13 NLM (2016) cze0061906 brimonidin tartrát 2015 04 22 cze Thesaurus M0065042 UK 14,304 0 M0065049 M0065042 T095045 UK 14,304 NLM (1978) T095051 UK-14304 NLM (1978) T095051 UK14304 T095047 UK 14304 NLM (1978) M000603399 Ratio-Brimonidine 0 M0065049 M000603399 T000875829 Ratio-Brimonidine 2015 02 25 CA T000875829 Ratio Brimonidine T000875829 RatioBrimonidine M0065043 UK 14,304-18 0 M0065049 M0065043 T095046 UK 14,304-18 NLM (1978) T095046 UK 14,304 18 T095046 UK 14,30418 T095049 UK-14,304-18 NLM (1978) T095049 UK14,30418 M0065045 UK 14308 0 M0065049 M0065045 T095048 UK 14308 NLM (1978) T095050 UK-14,308 NLM (1978) T095050 UK 14,308 T095050 UK14,308 M0312901 Brimonidine Tartrate, (R-(R*,R*))-Isomer 59803-99-5 M0065049 M0312901 T000875827 Brimonidine Tartrate, (R-(R*,R*))-Isomer 2015 02 25 NLM (1978) M000603397 Mirvaso 0 M0065049 M000603397 T000875828 Mirvaso 2015 02 25 NLM (2014) M0312902 Brimonidine Tartrate (1:1) 70359-46-5 M0065049 M0312902 T000875825 Brimonidine Tartrate (1:1) 2015 02 25 NLM (1978) M0312903 Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer 79570-19-7 M0065049 M0312903 T000875826 Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer 2015 02 25 NLM (1978) M0517501 Brimonidine Purite 0 M0065049 M0517501 T000875823 Brimonidine Purite 2015 02 25 NLM (2008) T000875823 Purite, Brimonidine M000603526 Sanrosa 0 M0065049 M000603526 T000876946 Sanrosa 2015 03 17 NLM (2015) M000603394 Alphagan[Alphagan] 0 M0065049 M000603394 T463996 Alphagan 2001 10 01 AU CA DE ES FR IE MX NL UK T000875820 Alphagan P 2015 02 25 NLM (2016) cze0061907 Alphagan 2015 04 22 cze Thesaurus M0065040 AGN 190342 0 M0065049 M0065040 T095043 AGN 190342 NLM (1978) T095043 190342, AGN T095044 AGN-190342 NLM (1978) T095044 AGN190342 M000603395 Luxfen[Brimonidine] E6GNX3HHTE M0065049 M000603395 T000875818 Brimonidine 2015 02 25 FDA SRS (2015) NLM (1978) USAN (19XX) T000875819 Bromoxidine 2015 02 25 NLM (1978) cze0061920 Luxfen 2015 04 22 cze Thesaurus D000068456 klinická studie jako téma[Clinical Studies as Topic] 2015 07 01 2015 06 29 2016 01 01 Q000145 classification CL Q000191 economics EC Q000941 ethics ES Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000523 psychology PX Q000706 statistics & numerical data SN Q000592 standards ST Q000656 utilization UT Q000662 veterinary VE for general design, methodology, economics, etc. of clinical studies; a different heading CLINICAL STUDY is used for reports of a specific clinical study 2016 2016 (1963) E05.318.760.250 N05.715.360.775.088 N06.850.520.450.250 M000602856 klinická studie jako téma[Clinical Studies as Topic] Works about research studies that evaluate interventions or exposures on biomedical or health-related outcomes. The two main types of clinical studies are interventional studies (clinical trials) and observational studies. T000878007 Clinical Studies as Topic 2015 04 09 NLM (2016) cze0061948 klinická studie jako téma 2015 04 23 cze Thesaurus D000068476 Peking[Beijing] 2015 07 01 2015 05 27 2016 01 01 Q000208 ethnology EH Q000453 epidemiology EP 2016 China (1966-2015) Z01.252.474.164.225 Z01.433.114 M000602903 Peking[Beijing] Capital of CHINA. Hlavní město Číny. T000875952 Beijing 2015 03 01 NLM (2016) T000875953 Peking 2015 03 01 NLM (2016) cze0062101 Peking 2015 06 01 cze Thesaurus D000068516 Africká unie[African Union] 2015 07 01 2015 06 29 2016 01 01 Q000191 economics EC Q000266 history HI Q000458 organization & administration OG Q000592 standards ST Cataloger: Use NAF entry 2016 2016 I01.615.500.125 N03.540.089 M000602983 Africká unie[African Union] A geopolitical organization of African nations with a mission to integrate vital interests, promote international relations, political stability, and economic development among member states. T000876090 African Union 2015 03 03 NLM (2016) T000876090 Union, African cze0062100 Africká unie 2015 06 01 cze Thesaurus D000068536 Firmicutes[Firmicutes] 2015 07 07 2015 07 07 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY 2016 2016 Gram-Positive Bacteria (2004-2015) B03.353 M000603052 Firmicutes[Firmicutes] A phylum of predominantly GRAM-POSITIVE BACTERIA that includes the orders Bacillales and Clostridiales. Firmicutes and BACTEROIDETES are the two bacterial phyla that constitute the majority of the human gut MICROBIOTA. T000876184 Firmicutes 2015 03 04 NLM (2016) cze0061970 Firmicutes 2015 04 27 cze Thesaurus D000068538 dutasterid[Dutasteride] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1998) 2016; DUTASTERIDE was indexed under AZASTEROIDS 1998-2015. D058891 5-alpha Reductase Inhibitors D04.808.925.100.125 M0281571 dutasterid[Dutasteride] O0J6XJN02I A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA. 164656-23-9 M0281571 M0477724 M0281571 M0281572 M0281571 M0398765 T000876188 Dutasteride 2015 03 04 FDA SRS (2013) INN (19XX) NLM (1997) USAN (19XX) T311573 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one NLM (1997) cze0061921 dutasterid 2015 04 22 cze Thesaurus M0477724 Avodart[Avodart] 0 M0281571 M0477724 T623947 Avodart 2004 12 14 DE US cze0061922 Avodart 2015 04 22 cze Thesaurus M0281572 GG 745 0 M0281571 M0281572 T311577 GG 745 NLM (1997) T311577 745, GG T311574 GG-745 NLM (1997) T311575 GG745 NLM (1997) M0398765 GI198745 0 M0281571 M0398765 T462227 GI198745 2001 09 19 NLM (2001) D000068543 Calceolariaceae[Calceolariaceae] 2015 07 01 2015 06 16 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for CALCEOLARIA use SCROPHULARIACEAE 2004-2015 2016; for CALCEOLARIA see SCROPHULARIACEAE 2004-2015 B01.650.940.800.575.100.583.190 M000603068 Calceolariaceae[Calceolariaceae] A family in the order Lamiales with several species that are used in TRADITIONAL MEDICINE. M000603068 M0449070 M000603068 M000603070 M000603068 M000603069 T000876202 Calceolariaceae 2015 03 04 NLM (2016) cze0062486 Calceolariaceae 2015 06 18 cze Thesaurus M0449070 Calceolaria[Calceolaria] M000603068 M0449070 T539974 Calceolaria 2003 05 06 NLM (2004) cze0025378 Calceolaria 2006 03 22 cze0062485 pantoflíček 2015 06 18 cze Thesaurus cze0062490 rod Calceolaria 2015 06 18 cze Thesaurus M000603070 Stemotria[Porodittia] M000603068 M000603070 T000876204 Porodittia 2015 03 04 NLM (2016) cze0062488 Stemotria 2015 06 18 cze Thesaurus cze0062489 Porodittia 2015 06 18 cze Thesaurus M000603069 Jovellana[Jovellana] M000603068 M000603069 T000876203 Jovellana 2015 03 04 NLM (2016) cze0062487 Jovellana 2015 06 18 cze Thesaurus D000068556 interferon beta 1a[Interferon beta-1a] 2015 07 01 2015 06 05 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; INTERFERON BETA 1A was indexed under INTERFERON-BETA 1994-2015 D000276 Adjuvants, Immunologic D000970 Antineoplastic Agents D000998 Antiviral Agents D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500 M0230367 interferon beta 1a[Interferon beta-1a] XRO4566Q4R An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS. 145258-61-3 74899-71-1 M0230367 M0129579 M0230367 M0230365 T000878936 Interferon beta-1a 2015 04 29 NLM (2016) T000878936 beta-1a, Interferon T000878937 Interferon beta 1a 2015 04 29 NLM (2016) T000878937 1a, Interferon beta T000878937 beta 1a, Interferon cze0062402 interferon beta 1a 2015 06 12 cze Thesaurus cze0062403 interferon beta-1a 2015 06 12 cze Thesaurus M0129579 Rebif[Rebif] 0 M0230367 M0129579 T159584 Rebif NLM (1994) US cze0062405 Rebif 2015 06 12 cze Thesaurus M0230365 Avonex[Avonex] 0 M0230367 M0230365 T260370 Avonex NLM (1994) T000876262 Avonex Pen 2015 03 05 NLM (2016) T000876262 Pen, Avonex cze0062404 Avonex 2015 06 12 cze Thesaurus D000068557 olmesartan medoxomil[Olmesartan Medoxomil] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; OLMESARTAN MEDOXOMIL was indexed under IMIDAZOLES 1996-2015, and under TETRAZOLES 1996-2015 D000959 Antihypertensive Agents D047228 Angiotensin II Type 1 Receptor Blockers D03.383.129.308.674 D03.383.129.617.584 M0257341 olmesartan medoxomil[Olmesartan Medoxomil] 6M97XTV3HD An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION. 144689-24-7 (olmesartan medoxomil) M0257341 M0423469 M0257341 M0257343 M0257341 M0464789 T000876265 Olmesartan Medoxomil 2015 03 05 FDA SRS (2013) INN (19XX) NLM (2001) USAN (19XX) T000876265 Medoxomil, Olmesartan T000876927 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346 2015 03 17 NLM (2016) cze0063956 olmesartan medoxomil 2015 10 15 cze Thesaurus cze0063957 olmesartan-medoxomil 2015 10 15 cze Thesaurus M0423469 Sarten[Benicar] 0 M0257341 M0423469 T493220 Benicar 2002 05 09 US T584175 Olmetec 2004 04 20 DE T000876266 Benicar HCT 2015 03 05 NLM (2016) T000876266 HCT, Benicar cze0063958 Sarten 2015 10 15 cze Thesaurus cze0063961 Olmedix 2015 10 15 cze Thesaurus cze0063959 Sintonyn 2015 10 15 cze Thesaurus cze0063960 Zeota 2015 10 15 cze Thesaurus M0257343 CS 866 0 M0257341 M0257343 T287348 CS 866 NLM (1996) T287348 866, CS T287347 CS-866 NLM (1996) M0464789 Votum 0 M0257341 M0464789 T584176 Votum 2004 04 20 DE D000068558 kombinace léků amlodipin a olmesartan[Amlodipine Besylate, Olmesartan Medoxomil Drug Combination] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Amlodipine (2010-2015) Antihypertensive Agents (2012-2015) D000959 Antihypertensive Agents D002121 Calcium Channel Blockers D047228 Angiotensin II Type 1 Receptor Blockers D03.383.129.308.674.500 D03.383.129.617.584.500 D03.383.725.203.065.500 D26.310.063 M000603113 kombinace léků amlodipin a olmesartan[Amlodipine Besylate, Olmesartan Medoxomil Drug Combination] 0 A pharmaceutical preparation of amlodipine besylate and olmesartan medoxomil that combines ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST and CALCIUM CHANNEL BLOCKER activities. It is used in the management of HYPERTENSION. M000603113 M000603407 T000876270 Amlodipine Besylate, Olmesartan Medoxomil Drug Combination 2015 03 05 NLM (2016) T000876725 Amlodipine Besylate-Olmesartan Medoxomil Drug Combination 2015 03 12 NLM (2016) T000876725 Amlodipine Besylate Olmesartan Medoxomil Drug Combination T000876726 Amlodipine Besylate-Olmesartan Medoxomil 2015 03 12 NLM (2016) T000876726 Amlodipine Besylate Olmesartan Medoxomil T000876726 Besylate-Olmesartan Medoxomil, Amlodipine T000876726 Medoxomil, Amlodipine Besylate-Olmesartan T000876271 Amlodipine Besylate, Olmesartan Medoxomil 2015 03 05 NLM (2016) cze0063370 kombinace léků amlodipin a olmesartan 2015 09 04 cze Thesaurus cze0063371 kombinace léků amlodipin a olmesartan-medoxomil 2015 09 04 cze Thesaurus M000603407 Azor 0 M000603113 M000603407 T000876268 Azor 2015 03 05 NLM (2016) D000068576 interferon beta 1b[Interferon beta-1b] 2015 07 01 2015 06 05 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1985) 2016; INTERFERON BETA-1B was previously indexed under INTERFERON BETA, 1991-2015; RECOMBINANT PROTEINS, 1988-1991; and under INTERFERON TYPE I, 1985-1988 D000276 Adjuvants, Immunologic D12.644.276.374.440.890.275.750 D12.776.467.374.440.890.275.750 D23.529.374.440.890.275.750 M0129586 interferon beta 1b[Interferon beta-1b] 145155-23-3 A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS. M0129586 M0129576 M0129586 M0552159 M0129586 M0556963 T000878938 Interferon beta-1b 2015 04 29 NLM (2016) T000878938 beta-1b, Interferon T000876326 Beta-IFN-1b 2015 03 06 NLM (1985) T000876327 Interferon Beta, Ser(17) 2015 03 06 NLM (1985) T159585 Ser(17) IFN-beta NLM (1985) T000876329 Serine(17) Interferon Beta 2015 03 06 NLM (1985) T000878939 Interferon beta 1b 2015 04 29 NLM (2016) T000878939 1b, Interferon beta T000878939 beta 1b, Interferon T000876325 IFN-Beta Ser 2015 03 06 NLM (1985) T000876328 Interferon Beta, Serine(17) 2015 03 06 NLM (1985) cze0062406 interferon beta 1b 2015 06 12 cze Thesaurus cze0062407 interferon beta-1b 2015 06 12 cze Thesaurus M0129576 Betaseron 0 M0129586 M0129576 T159582 Betaseron NLM (1985) T159581 Beta-Seron NLM (1985) T159581 Beta Seron M0552159 Extavia[Extavia] 0 M0129586 M0552159 T781455 Extavia 2010 12 01 NLM (2011) cze0062409 Extavia 2015 06 12 cze Thesaurus M0556963 Betaferon[Betaferon] 0 M0129586 M0556963 T447732 Betaferon 2001 05 24 NLM (2001) cze0062408 Betaferon 2015 06 12 cze Thesaurus D000068577 nebivolol[Nebivolol] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1987) 2016; NEBIVOLOL was indexed under BENZOPYRANS, 1987-2015; and under ETHANOLAMINES 1987-2015 D000959 Antihypertensive Agents D014665 Vasodilator Agents D058665 Adrenergic beta-1 Receptor Agonists D02.033.100.291.491 D02.092.063.291.503 D03.383.663.283.755 D03.438.150.755 M0149652 nebivolol[Nebivolol] 030Y90569U A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. 118457-14-0 169293-50-9 (nebivolol hydrochloride) 99200-09-6 (nebivolol) JGS34J7L9I M0149652 M000603155 M0149652 M0462938 M0149652 M0462940 M0149652 M0476683 M0149652 M0149649 M0149652 M000603516 T000876336 Nebivolol 2015 03 06 FDA SRS (2013) INN (19XX) USAN (1987) T000876920 Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol 2015 03 17 NLM (1987) cze0062323 nebivolol 2015 06 12 cze Thesaurus M000603155 Bystolic 0 M0149652 M000603155 T000876335 Bystolic 2015 03 06 NLM (2016) M0462938 Nebilet[Nebilet] 0 M0149652 M0462938 T578743 Nebilet 2004 03 24 DE IE NL UK cze0062321 Nebilet 2015 06 12 cze Thesaurus M0462940 Silostar 0 M0149652 M0462940 T578748 Silostar 2004 03 24 ES M0476683 nebivolol hydrochlorid[Nebivolol Hydrochloride] JGS34J7L9I M0149652 M0476683 T000876337 Nebivolol Hydrochloride 2015 03 06 FDA SRS (2013) NLM (2004) NLM (2011) USAN (19XX) T000876337 Hydrochloride, Nebivolol cze0062326 nebivolol hydrochlorid 2015 06 12 cze Thesaurus cze0062328 nebivolol-hydrochlorid 2015 06 12 cze Thesaurus cze0062327 nebivololi hydrochloridum 2015 06 12 cze Thesaurus M0149649 R 67555 0 M0149652 M0149649 T179654 R 67555 NLM (1987) T179654 67555, R T179655 R-67555 NLM (1987) T179655 R67555 M000603516 Lobivon 0 M0149652 M000603516 T578744 Lobivon 2004 03 24 ES D000068579 celekoxib[Celecoxib] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; CELECOXIB was indexed under PYRAZOLES 1997-2015, and under SULFONAMIDES 1997-2015 D052246 Cyclooxygenase 2 Inhibitors D02.065.884.247 D02.886.590.700.247 D03.383.129.539.160 M0276185 celekoxib[Celecoxib] JCX84Q7J1L A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN. 169590-42-5 M0276185 M0276182 M0276185 M0276183 T000876340 Celecoxib 2015 03 06 FDA SRS (2013) INN (19XX) NLM (1997) USAN (19XX) T306186 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide NLM (1997) cze0062124 celekoxib 2015 06 01 cze Thesaurus M0276182 Celebrex[Celebrex] 0 M0276185 M0276182 T306187 Celebrex AU CA DE ES FR IE MX UK US cze0062126 Celebrex 2015 06 01 cze Thesaurus M0276183 SC 58635 0 M0276185 M0276183 T306188 SC 58635 NLM (1997) T306188 58635, SC T306189 SC-58635 NLM (1997) T306189 SC58635 D000068580 vareniklin[Varenicline] 2015 07 06 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; VARENICLINE was indexed under BENZAZEPINES, 2005-2015 and under QUINOXALINES, 2005-2015 D061485 Tobacco Use Cessation Products D018722 Nicotinic Agonists D03.438.079.900 D03.438.857.942 M0485421 vareniklin[Varenicline] W6HS99O8ZO A benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION. 249296-44-4 375815-87-5 82269ASB48 M0485421 M0540610 M0485421 M0497892 M0485421 M0511350 T000876345 Varenicline 2015 03 06 FDA SRS (2013) INN (19XX) USAN (2005) T000876919 6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine 2015 03 17 NLM (2016) cze0062102 vareniklin 2015 06 01 cze Thesaurus M0540610 vareniklin tartrát[Varenicline Tartrate] 82269ASB48 M0485421 M0540610 T000876346 Varenicline Tartrate 2015 03 06 FDA SRS (2015) INN (19XX) USAN (2009) T000876346 Tartrate, Varenicline cze0062104 vareniklin tartrát 2015 06 01 cze Thesaurus M0497892 Chantix[Chantix] 0 M0485421 M0497892 T673654 Chantix 2006 05 11 NLM (2006) cze0062105 Chantix 2015 06 01 cze Thesaurus M0511350 Champix[Champix] 0 M0485421 M0511350 T701646 Champix 2007 07 11 NLM (2007) cze0062103 Champix 2015 06 01 cze Thesaurus D000068581 tadalafil[Tadalafil] 2015 07 06 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; TADALAFIL was indexed under CARBOLINES 2001-2015; and under PHOSPHODIESTERASE INHIBITORS 2001-2003 D000068677 Sildenafil Citrate D014665 Vasodilator Agents D058986 Phosphodiesterase 5 Inhibitors D064804 Urological Agents D03.383.725.150.500 D03.438.473.155.500 D03.494.154.672 M0431130 tadalafil[Tadalafil] Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)- 742SXX0ICT A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION. 171596-29-5 M0431130 M0392386 M0431130 M0392387 T000876348 Tadalafil 2015 03 06 FDA SRS (2015) INN (19XX) NLM (2002) USAN (2001) cze0062386 tadalafil 2015 06 12 cze Thesaurus M0392386 IC351 0 M0431130 M0392386 T453058 IC351 2001 07 02 NLM (2001) T546967 IC-351 2003 07 26 NLM (2003) T453059 IC 351 2001 07 02 NLM (2001) T453059 351, IC M0392387 Cialis[Cialis] 0 M0431130 M0392387 T453060 Cialis 2001 07 02 DE ES FR IE NL UK cze0062389 Cialis 2015 06 12 cze Thesaurus D000068582 certolizumab pegol[Certolizumab Pegol] 2015 07 10 2015 07 09 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2003) 2016; CERTILIZUMAB PEGOL was indexed under IMMUNOGLOBULIN FAB FRAGMENTS 2003-2015, POLYETHYLENE GLYCOLS 2003-2015, and under ANTIBODIES, MONOCLONAL, HUMANIZED 2003-2015 D007166 Immunosuppressive Agents D018501 Antirheumatic Agents D05.750.741.125 D12.644.541.500.650.250 D12.776.124.486.485.114.224.060.500 D12.776.124.486.485.680.650.250 D12.776.124.790.651.114.224.060.500 D12.776.124.790.651.680.650.250 D12.776.377.715.548.114.224.200.500 D12.776.377.715.548.680.650.250 D25.720.741.125 J01.637.051.720.741.125 M0507051 certolizumab pegol[Certolizumab Pegol] UMD07X179E A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS. 428863-50-7 M0507051 M0522752 M0507051 M0442269 T000876351 Certolizumab Pegol 2015 03 06 FDA SRS (2013) NLM (2007) USAN (19XX) T000876351 Certolizumab Pegols T000876351 Pegol, Certolizumab T000876351 Pegols, Certolizumab cze0062341 certolizumab pegol 2015 06 12 cze Thesaurus cze0062345 certolizumab pegovaný 2015 06 12 cze Thesaurus cze0062344 kertolizumab pegol 2015 06 12 cze Thesaurus M0522752 Cimzia[Cimzia] 0 M0507051 M0522752 T794930 Cimzia 2011 08 05 NLM (2012) T794930 Cimzias cze0062343 Cimzia 2015 06 12 cze Thesaurus M0442269 CDP870 0 M0507051 M0442269 T526395 CDP870 2002 11 19 NLM (2002) T526395 CDP870s T526396 CDP 870 2002 11 19 NLM (2002) T526396 870, CDP T526396 870s, CDP T526396 CDP 870s D000068597 cenzura ve výzkumu[Censorship, Research] 2015 07 06 2015 06 16 2016 01 01 2016 2016 D000068601 Dual Use Research D004989 Ethics I01.880.604.238 K01.752.566.479.173.200 N05.350.670.250 M000603222 cenzura ve výzkumu[Censorship, Research] The act or practice of scrutinizing the practice of scientific research for the purpose of preventing or suppressing the unethical applications as well knowledge derived from it. Zkoumání postupu vědeckého výzkumu za účelem zabránění nebo potlačení neetické aplikace i poznatků z ní získaných. T000876417 Censorship, Research 2015 03 09 NLM (2016) T000876417 Research Censorship cze0064575 cenzura ve výzkumu 2015 11 16 cze Thesaurus cze0064576 cenzura vědeckého výzkumu 2015 11 16 cze Thesaurus D000068598 správnost dat[Data Accuracy] 2015 07 10 2015 07 10 2016 01 01 2016; for DATA QUALITY use RESEARCH DESIGN 1995-2015 2016; for DATA QUALITY see RESEARCH DESIGN 1995-2015 E05.318.308.028 E05.318.780.725.250 L01.280.202 N05.715.360.300.202 N05.715.360.780.685.250 M000603226 správnost dat[Data Accuracy] A measure of scientific precision, exactness, or correctness of quantitative or qualitative values, relative to the actual or true measurements. M000603226 M000605976 T000876439 Data Accuracy 2015 03 09 NLM (2016) T000876439 Accuracies, Data T000876439 Accuracy, Data T000876439 Data Accuracies cze0063588 správnost dat 2015 09 24 cze Thesaurus cze0063589 přesnost údajů 2015 09 24 cze Thesaurus M000605976 kvalita dat[Data Quality] M000603226 M000605976 T000880428 Data Quality 2015 05 26 NLM (2016) T000880428 Data Qualities T000880428 Qualities, Data T000880428 Quality, Data cze0063590 kvalita dat 2015 09 24 cze Thesaurus D000068599 kombinace léků brimonidin a timolol[Brimonidine Tartrate, Timolol Maleate Drug Combination] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; BRIMONIDINE TARTRATE-TIMOLOL MALEATE DRUG COMBINATION was indexed under QUINOXALINES 2011-2015, under TIMOLOL 2011-2015, and under DRUG COMBINATIONS 2011-2015 D000319 Adrenergic beta-Antagonists D058647 Adrenergic alpha-2 Receptor Agonists D02.033.100.624.915.500 D02.033.755.624.915.500 D02.092.063.624.915.500 D02.886.675.867.768.500 D03.383.129.708.867.768.500 D03.438.857.070.500 D26.310.312 M000603237 kombinace léků brimonidin a timolol[Brimonidine Tartrate, Timolol Maleate Drug Combination] 0 A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients. M000603237 M000603401 T000876462 Brimonidine Tartrate, Timolol Maleate Drug Combination 2015 03 09 NLM (2016) T000876730 Brimonidine Tartrate-Timolol Maleate 2015 03 12 NLM (2016) T000876730 Brimonidine Tartrate Timolol Maleate T000876730 Maleate, Brimonidine Tartrate-Timolol T000876730 Tartrate-Timolol Maleate, Brimonidine T000876729 Brimonidine Tartrate-Timolol Maleate Drug Combination 2015 03 12 NLM (2016) T000876729 Brimonidine Tartrate Timolol Maleate Drug Combination cze0063392 kombinace léků brimonidin a timolol 2015 09 04 cze Thesaurus cze0063393 kombinace léků brimonidin tartrát a timolol 2015 09 04 cze Thesaurus M000603401 Combigan[Combigan] 0 M000603237 M000603401 T000876458 Combigan 2015 03 09 NLM (2011) cze0063395 Combigan 2015 09 04 cze Thesaurus D000068600 kombinace léků albuterol a ipratropium[Albuterol, Ipratropium Drug Combination] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1999) 2016; ALBUTEROL-IPRATROPIUM was indexed under ALBUTEROL 1999-2015, and under IPRATROPIUM 1999-2015 D02.033.100.291.057.125 D02.092.063.291.057.125 D02.092.471.683.061.125 D02.145.074.722.229.400.500 D03.132.760.180.572.400.500 D03.132.889.180.648.400.500 D03.605.869.229.400.500 D04.075.080.875.099.722.229.400.500 D26.310.344 M0299247 kombinace léků albuterol a ipratropium[Albuterol, Ipratropium Drug Combination] 0 A combined pharmaceutical preparation of Ipratropium Bromide and Albuterol Sulfate that is used to treat the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. M0299247 M000603239 M0299247 M0299246 M0299247 M0523139 T000881385 Albuterol, Ipratropium Drug Combination 2015 06 05 NLM (2016) T000876587 Albuterol-Ipratropium 2015 03 10 NLM (1999) T000876587 Albuterol Ipratropium T000876727 Albuterol-Ipratropium Drug Combination 2015 03 12 NLM (2016) T000876727 Albuterol Ipratropium Drug Combination T000876727 Combination, Albuterol-Ipratropium Drug T000876727 Drug Combination, Albuterol-Ipratropium cze0063369 kombinace léků albuterol a ipratropium 2015 09 04 cze Thesaurus M000603239 Combivent Respimat 0 M0299247 M000603239 T000876467 Combivent Respimat 2015 03 09 NLM (2016) T000876467 Respimat, Combivent M0299246 Dey Combination 0 M0299247 M0299246 T000876728 Dey Combination 2015 03 12 NLM (1999) T000876728 Combination, Dey M0523139 Combivent 0 M0299247 M0523139 T722832 Combivent 2008 07 20 NLM (2008) D000068601 výzkum dvojího užití[Dual Use Research] 2015 07 06 2015 06 16 2016 01 01 Q000941 ethics ES Q000266 history HI Q000331 legislation & jurisprudence LJ Q000706 statistics & numerical data SN 2016 2016 D000068597 Censorship, Research H01.770.644.217 M000603244 výzkum dvojího užití[Dual Use Research] Concept relating to technologies and/or information emanating from research that holds the potential for both benevolent and malevolent applications to humanity and the environment. T000876472 Dual Use Research 2015 03 09 NLM (2016) T000876472 Research, Dual Use T000876472 Use Research, Dual cze0064084 výzkum dvojího užití 2015 10 21 cze Thesaurus D000068616 profesionalita[Professionalism] 2015 07 06 2015 06 26 2016 01 01 Q000191 economics EC Q000193 education ED Q000941 ethics ES Q000266 history HI Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000639 trends TD 2016 2016 D004992 Ethics, Medical D011361 Professional Competence K01.752.566.479.171.566 N05.350.340.581 M000603262 profesionalita[Professionalism] The level of skill, good judgment, and polite behavior expected from people trained to do their jobs well. M000603262 M000606500 M000603262 M000603266 M000603262 M000606499 T000876486 Professionalism 2015 03 10 NLM (2016) cze0064035 profesionalita 2015 10 15 cze Thesaurus cze0064034 profesionálnost 2015 10 15 cze Thesaurus M000606500 Medical Professionalism M000603262 M000606500 T000881366 Medical Professionalism 2015 06 05 NLM (2016) T000881366 Professionalism, Medical M000603266 Professionalism Education M000603262 M000603266 T000876493 Professionalism Education 2015 03 10 NLM (2016) T000876493 Education, Professionalism M000606499 Surgical Professionalism M000603262 M000606499 T000881365 Surgical Professionalism 2015 06 05 NLM (2016) T000881365 Professionalism, Surgical D000068617 genetické pozadí[Genetic Background] 2015 07 01 2015 06 26 2016 01 01 2016 2016 Genetics (1963-2015) D040941 Heredity G05.346 M000603267 genetické pozadí[Genetic Background] The entire genetic composition of a strain or individual that interacts with a gene of interest. T000876494 Genetic Background 2015 03 10 NLM (2016) OBSSR (2016) T000876494 Background, Genetic T000876494 Backgrounds, Genetic T000876494 Genetic Backgrounds cze0063615 genetické pozadí 2015 09 24 cze Thesaurus D000068618 výběrové šlechtění[Selective Breeding] 2015 07 01 2015 06 26 2016 01 01 Q000235 genetics GE Q000266 history HI 2016 2016 D005053 Eugenics D012099 Reproductive Techniques E05.820.150.760 G05.355.090.701 M000603271 výběrové šlechtění[Selective Breeding] A process in which offspring possessing desired genetic traits are produced. T000876498 Selective Breeding 2015 03 10 NLM (2016) OBSSR (2016) T000876498 Breeding, Selective T000876498 Breedings, Selective T000876498 Selective Breedings cze0062741 výběrové šlechtění 2015 07 02 cze Thesaurus cze0062739 selektivní šlechtění 2015 07 02 cze Thesaurus D000068636 legendární bytosti[Legendary Creatures] 2015 07 01 2015 04 09 2016 01 01 Q000266 history HI 2016 2016 I01.076.201.450.515.500 M000603320 legendární bytosti[Legendary Creatures] An unverified animal or humanoid, sometimes supernatural, often believed to be real and described in MYTHOLOGY, FOLKLORE, or legends. Some legendary creatures, such as the unicorn, were documented in scholarly antiquarian accounts of natural history. M000603320 M000600597 M000603320 M000603330 M000603320 M000603332 M000603320 M000600596 M000603320 M000603329 T000876660 Legendary Creatures 2015 03 11 NLM (2016) OBSSR (2016) T000876660 Creature, Legendary T000876660 Creatures, Legendary T000876660 Legendary Creature T000876663 Mythical Creatures 2015 03 11 NLM (2016) OBSSR (2016) T000876663 Creature, Mythical T000876663 Creatures, Mythical T000876663 Mythical Creature T000877951 Mythical Animals 2015 04 08 NLM (2016) OBSSR (2016) T000877951 Animal, Mythical T000877951 Animals, Mythical T000877951 Mythical Animal cze0061846 legendární bytosti 2015 04 10 cze Thesaurus cze0061847 mytická zvířata 2015 04 10 cze Thesaurus cze0061848 mýtická stvoření 2015 04 10 cze Thesaurus M000600597 vlkodlaci[Werewolves] Mythical humans believed to have the ability to shape-shift into a wolf or wolf-like creature during a full moon. This condition, also known as lycanthropy, may be historically based on persons suffering from HYPERTRICHOSIS. Clinical lycanthropy refers to the psychiatric syndrome where individuals are under the delusion that they can transform, or have transformed into an animal. M000603320 M000600597 T000872200 Werewolves 2014 12 16 NLM (2016) OBSSR (2016) cze0061852 vlkodlaci 2015 04 10 cze Thesaurus M000603330 jednorožci[Unicorns] Mythical creatures commonly described as horses with a long single horn on their foreheads that symbolized purity. It was believed that their horns could be used for medicinal purposes and dust or liquid from the horns could protect a human from diseases and poisons. M000603320 M000603330 T000876674 Unicorns 2015 03 11 NLM (2016) OBSSR (2016) T000876674 Unicorn cze0061850 jednorožci 2015 04 10 cze Thesaurus M000603332 yetti[Yeti, Himalayan] A tall, ape-like creature that is suggested to be descended from humans and that lives in the Himalayan regions of Nepal and Tibet. M000603320 M000603332 T000876676 Yeti, Himalayan 2015 03 11 NLM (2016) OBSSR (2016) T000876676 Himalayan Yeti T000876678 Bigfoot 2015 03 11 NLM (2016) T000876678 Bigfoots T000876677 Sasquatch 2015 03 11 NLM (2016) OBSSR (2016) cze0061853 yetti 2015 04 10 cze Thesaurus cze0061854 sněžný muž 2015 04 10 cze Thesaurus M000600596 upíři[Vampires] Mythical blood-sucking humans who rise from the grave at night to prey on the living. Historically, vampire legend dates from ancient times and may be based on persons suffering from RABIES; PELLAGRA; or especially PORPHYRIAS, who exhibit sensitivity to sunlight, abnormal, reddish-brown discoloration of the TEETH, and madness or melancholy disposition. Clinical vampirism includes persons who drink the blood of others or themselves. M000603320 M000600596 T000872199 Vampires 2014 12 16 NLM (2016) OBSSR (2016) T000872199 Vampire cze0061851 upíři 2015 04 10 cze Thesaurus M000603329 mořské panny[Mermaids] Half-human sea creatures with the head and torso of a woman and the tail of a fish. Commonly believed in FOLKLORE, these creatures have relevance to the disorder known as SIRENOMELIA in which the legs or other bones and limbs are fused together. M000603320 M000603329 T000876673 Mermaids 2015 03 11 NLM (2016) OBSSR (2016) T000876673 Mermaid cze0061849 mořské panny 2015 04 10 cze Thesaurus D000068656 mometason furoát[Mometasone Furoate] 2015 07 10 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1987) 2016; MOMETASONE FUROATE was indexed under PREGNADIENEDIOLS 1987-2015 D000068759 Formoterol Fumarate D000893 Anti-Inflammatory Agents D003879 Dermatologic Agents D018926 Anti-Allergic Agents D04.808.745.432.719.526 M0152540 mometason furoát[Mometasone Furoate] 04201GDN4R A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders. 83919-23-7 8HR4QJ6DW8 MTW0WEG809 M0152540 M0398664 M0152540 M0398665 M0152540 M0152537 M0152540 M0424552 M0152540 M000603479 M0152540 M0503528 M0152540 M0152538 T000876893 Mometasone Furoate 2015 03 16 FDA SRS (2015) INN (19XX) USAN (1987) T000876893 Furoate, Mometasone cze0061972 mometason furoát 2015 04 27 cze Thesaurus M0398664 Nasonex[Nasonex] 0 M0152540 M0398664 T462055 Nasonex 2001 09 18 NLM (2001) cze0061975 Nasonex 2015 04 27 cze Thesaurus M0398665 monohydrát mometason furoátu[Mometasone Furoate Monohydrate] MTW0WEG809 M0152540 M0398665 T000876894 Mometasone Furoate Monohydrate 2015 03 16 NLM (2001) T000876894 Furoate Monohydrate, Mometasone T000876894 Monohydrate, Mometasone Furoate cze0061974 monohydrát mometason furoátu 2015 04 27 cze Thesaurus M0152537 Elocon[Elocon] 0 M0152540 M0152537 T182542 Elocon NLM (1987) cze0061976 Elocon 2015 04 27 cze Thesaurus M0424552 Momesalic[Mometasone] 8HR4QJ6DW8 M0152540 M0424552 T000876892 Mometasone 2015 03 16 FDA SRS (2013) INN (19XX) NLM (2002) cze0061978 Momesalic 2015 04 27 cze Thesaurus M000603479 Asmanex[Asmanex] 0 M0152540 M000603479 T000876895 Asmanex 2015 03 16 NLM (2016) T000876896 Asmanex Twisthaler 2015 03 16 NLM (2016) T000876896 Twisthaler, Asmanex cze0061977 Asmanex 2015 04 27 cze Thesaurus M0503528 Mommox[Rinelon] 0 M0152540 M0503528 T685277 Rinelon 2006 10 30 NLM (2006) cze0061979 Mommox 2015 04 27 cze Thesaurus M0152538 Sch 32088 0 M0152540 M0152538 T182543 Sch 32088 NLM (1987) T182544 Sch-32088 NLM (1987) T182544 Sch32088 D000068676 Fallopia multiflora[Fallopia multiflora] 2015 07 01 2015 06 16 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 2016 Polygonaceae (2002-2015) B01.650.940.800.575.100.825.359.590 M000603517 Fallopia multiflora[Fallopia multiflora] A species of Fallopia in the buckwheat family (Polygonaceae). Its roots are used in TRADITIONAL CHINESE MEDICINE. T000876922 Fallopia multiflora 2015 03 17 NLM (2016) T000879225 Fo-Ti 2015 05 05 NLM (2016) T000879225 Fo Ti T000876923 Polygonum multiflorum 2015 03 17 NLM (2016) cze0062542 Fallopia multiflora 2015 06 22 cze Thesaurus cze0062544 Fo-Ti kořen 2015 06 22 cze Thesaurus cze0062543 Polygonum multiflorum 2015 06 22 cze Thesaurus cze0062545 rdesno mnohokvěté 2015 06 22 cze Thesaurus D000068677 sildenafil citrát[Sildenafil Citrate] 2015 07 10 2015 07 09 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; SILDENAFIL CITRATE was indexed under PIPERAZINES; PURINES; and under SULFONAMIDES 1997-2015 D000068581 Tadalafil D014665 Vasodilator Agents D058986 Phosphodiesterase 5 Inhibitors D064804 Urological Agents D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.438.759.824 M0327633 sildenafil citrát[Sildenafil Citrate] BW9B0ZE037 A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION. 0Z3JH0S0QK 139755-83-2 3M7OB98Y7H 80X7B1F6NW L6WO34R9YG TP0E2BW57H M0327633 M0478031 M0327633 M0491272 M0327633 M0265894 M0327633 M0265890 M0327633 M0502632 M0327633 M0502633 M0327633 M0265892 M0327633 M0502634 M0327633 M0560733 M0327633 M0478030 M0327633 M0492948 T000876985 Sildenafil Citrate 2015 03 18 FDA SRS (2014) NLM (1996) USAN (19XX) T000876985 Citrate, Sildenafil T000876986 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate 2015 03 18 NLM (1996) cze0062283 sildenafil citrát 2015 06 11 cze Thesaurus cze0062284 sildenafili citras 2015 06 11 cze Thesaurus M0478031 NCX-911 0 M0327633 M0478031 T624770 NCX-911 2004 12 20 NLM (2004) T624770 NCX 911 T624770 NCX911 M0491272 Revatio[Revatio] 0 M0327633 M0491272 T657653 Revatio 2005 11 03 US cze0062289 Revatio 2015 06 11 cze Thesaurus M0265894 Sildenafil[Sildenafil] 3M7OB98Y7H M0327633 M0265894 T000876984 Sildenafil 2015 03 18 FDA SRS (2013) INN (19XX) USAN (1998) cze0062288 Sildenafil 2015 06 11 cze Thesaurus M0265890 UK 92480-10 0 M0327633 M0265890 T295895 UK 92480-10 NLM (1996) T295895 UK 92480 10 T295895 UK 9248010 T295896 UK-92,480-10 NLM (1996) T295896 UK 92,480 10 M0502632 Homosildenafil 0Z3JH0S0QK M0327633 M0502632 T000876982 Homosildenafil 2015 03 18 NLM (2006) M0502633 Hydroxyhomosildenafil 80X7B1F6NW M0327633 M0502633 T000876983 Hydroxyhomosildenafil 2015 03 18 NLM (2006) M0265892 Viagra[Viagra] 0 M0327633 M0265892 T295897 Viagra AU CA DE ES FR IE MX NL UK US cze0062285 Viagra 2015 06 11 cze Thesaurus M0502634 Acetildenafil TP0E2BW57H M0327633 M0502634 T000876979 Acetildenafil 2015 03 18 NLM (2006) M0560733 Sildenafil Lactate 0 M0327633 M0560733 T000876987 Sildenafil Lactate 2015 03 18 NLM (2011) T000876987 Lactate, Sildenafil M0478030 Sildenafil Nitrate 0 M0327633 M0478030 T000876988 Sildenafil Nitrate 2015 03 18 NLM (2016) T000876988 Nitrate, Sildenafil M0492948 Desmethyl Sildenafil L6WO34R9YG M0327633 M0492948 T000876980 Desmethyl Sildenafil 2015 03 18 NLM (2005) T000876980 Sildenafil, Desmethyl T000876981 Desmethylsildenafil 2015 03 18 NLM (2002) D000068678 kombinace léků emtricitabin, rilpivirin a tenofovir[Emtricitabine, Rilpivirine, Tenofovir Drug Combination] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2012) 2016; EMTRICITABINE, RILPIVIRINE, TENOFOVIR DRUG COMBINATION was indexed under NITRILES; PYRIMIDINES; ORGANOPHOSPHONATES; ADENINE; and DEOXYCYTIDINE 2012-2015 D000998 Antiviral Agents D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D02.626.809.500 D02.705.429.906.500 D03.383.742.680.245.500.600.500 D03.383.742.755.500 D03.438.759.138.881.500 D26.310.407 M000603524 kombinace léků emtricitabin, rilpivirin a tenofovir[Emtricitabine, Rilpivirine, Tenofovir Drug Combination] 0 A pharmaceutical preparation that contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate. It is used to treat HIV INFECTIONS. M000603524 M0573815 T000878941 Emtricitabine, Rilpivirine, Tenofovir Drug Combination 2015 04 29 NLM (2016) T000880048 Emtricitabine Rilpivirine Tenofovir Drug Combination 2015 05 20 NLM (2016) T000876941 Emtricitabine-Rilpivirine-Tenofovir Drug Combination 2015 03 17 NLM (2016) T000876941 Combination, Emtricitabine-Rilpivirine-Tenofovir Drug T000876941 Drug Combination, Emtricitabine-Rilpivirine-Tenofovir cze0062373 kombinace léků emtricitabin, rilpivirin a tenofovir 2015 06 12 cze Thesaurus M0573815 Eviplera[Complera] 0 M000603524 M0573815 T822460 Complera 2012 05 21 NLM (2012) cze0062372 Eviplera 2015 06 12 cze Thesaurus D000068679 emtricitabin[Emtricitabine] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1999) 2016; EMTRICITABINE was indexed under DEOXYCYTIDINE 1999-2015 D000998 Antiviral Agents D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D03.383.742.680.245.500.600 D13.570.230.329.525 D13.570.685.245.500.600 M0337569 emtricitabin[Emtricitabine] G70B4ETF4S A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. Antivirový lék, nukleosidový inhibitor reverzní transkriptázy, užívá se k léčbě infekcí HIV. Účinkuje i proti hepatitidě B. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) M0337569 M0361790 M0337569 M0451777 T000876944 Emtricitabine 2015 03 17 FDA SRS (2015) INN (19XX) NLM (1999) USAN (19XX) T000876945 Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine 2015 03 17 NLM (1999) T000876945 Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine cze0062281 emtricitabin 2015 06 11 cze Thesaurus M0361790 Coviracil 0 M0337569 M0361790 T413568 Coviracil 2000 05 08 NLM (2000) M0451777 Emtriva[Emtriva] 0 M0337569 M0451777 T546334 Emtriva 2003 07 17 NLM (2003) cze0062282 Emtriva 2015 06 11 cze Thesaurus D000068696 rilpivirin[Rilpivirine] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; RILPIVIRINE was indexed under NITRILES 2005-2015, and under PYRIMIDINES 2005-2015 D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D02.626.809 D03.383.742.755 M0482137 rilpivirin[Rilpivirine] FI96A8X663 A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone. 212WAX8KDD 500287-72-9 M0482137 M000603537 M0482137 M0482138 M0482137 M0493524 T633778 Rilpivirine 2005 03 18 FDA SRS (2015) INN (2005) USAN (19XX) cze0062312 rilpivirin 2015 06 11 cze Thesaurus M000603537 Edurant[Rilpivirine Hydrochloride] 212WAX8KDD M0482137 M000603537 T000876961 Rilpivirine Hydrochloride 2015 03 18 BAN (19XX) INN (19XX) NLM (2016) USAN (19XX) T000876961 Hydrochloride, Rilpivirine T000876962 Rilpivirine HCl 2015 03 18 NLM (2016) T000876962 HCl, Rilpivirine cze0062315 Edurant 2015 06 11 cze Thesaurus cze0062316 rilpivirini hydrochloridum 2015 06 11 cze Thesaurus M0482138 R278474 0 M0482137 M0482138 T633779 R278474 2005 03 18 NLM (2005) M0493524 TMC 278 0 M0482137 M0493524 T663554 TMC 278 2006 01 01 NLM (2006) T663554 278, TMC T663556 TMC278 2006 01 01 NLM (2006) T663555 TMC-278 2006 01 01 NLM (2006) D000068698 tenofovir[Tenofovir] 2015 07 09 2015 07 08 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; TENOFOVIR DIDOPROXIL was indexed under ORGANOPHOSPHONATES 2004-2015, ADENINE 2004-2015, and under ORGANOPHOSPHOROUS COMPOUNDS 2001-2004 D000998 Antiviral Agents D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D02.705.429.906 D03.438.759.138.881 M0254881 tenofovir[Tenofovir] 99YXE507IL An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. 121149-89-1 ((+-)-isomer) 147127-19-3 ((S)-isomer) 147127-20-6 ((R)-isomer) OTT9J7900I M0254881 M0407969 M0254881 M0327097 M0254881 M0407970 M0254881 M0327096 M0254881 M0327098 T000876969 Tenofovir 2015 03 18 BAN (19XX) INN (19XX) NLM (2000) USAN (19XX) T854996 9-PMPA (tenofovir) 2014 02 10 NLM (2014) T000876971 9-(2-Phosphonylmethoxypropyl)adenine 2015 03 18 NLM (1995) T000876965 Tenofovir Disoproxil 2015 03 18 NLM (2001) T000876965 Disoproxil, Tenofovir T000876970 9-(2-Phosphonomethoxypropyl)adenine 2015 03 18 NLM (1995) cze0062374 tenofovir 2015 06 12 cze Thesaurus cze0062376 tenofoviri disoproxilum 2015 06 12 cze Thesaurus M0407969 tenofovir disoproxil fumarát[Tenofovir Disoproxil Fumarate] OTT9J7900I M0254881 M0407969 T000876967 Tenofovir Disoproxil Fumarate 2015 03 18 BAN (19XX) INN (19XX) NLM (2001) USAN (19XX) T000876967 Disoproxil Fumarate, Tenofovir T000876967 Fumarate, Tenofovir Disoproxil cze0062380 tenofovir disoproxil fumarát 2015 06 12 cze Thesaurus M0327097 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer 147127-19-3 M0254881 M0327097 T000876974 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer 2015 03 18 NLM (1995) M0407970 Viread[Viread] 0 M0254881 M0407970 T474041 Viread 2001 12 17 DE FR UK US cze0062379 Viread 2015 06 12 cze Thesaurus M0327096 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer 121149-89-1 M0254881 M0327096 T000876972 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer 2015 03 18 NLM (1995) M0327098 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 147127-20-6 M0254881 M0327098 T000876973 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 2015 03 18 NLM (1995) T284883 (R)-9-(2-phosphonylmethoxypropyl)adenine NLM (1995) D000068717 glatiramer acetát[Glatiramer Acetate] 2015 07 01 2015 06 05 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; GLATIRAMER ACETATE was indexed under PEPTIDES 1994-2015 D000276 Adjuvants, Immunologic D007166 Immunosuppressive Agents D018501 Antirheumatic Agents D12.644.219 M000603606 glatiramer acetát[Glatiramer Acetate] 5M691HL4BO A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS. U782C039QP M000603606 M0397771 M000603606 M000603608 M000603606 M0535182 T000877034 Glatiramer Acetate 2015 03 19 BAN (19XX) NLM (1994) USAN (19XX) T000877034 Acetate, Glatiramer cze0062317 glatiramer acetát 2015 06 11 cze Thesaurus M0397771 Copaxone[Copaxone] 0 M000603606 M0397771 T267869 Copaxone AU CA DE FR UK US cze0062318 Copaxone 2015 06 11 cze Thesaurus M000603608 Glatiramer U782C039QP M000603606 M000603608 T000877039 Glatiramer 2015 03 19 FDA SRS (2015) NLM (2016) M0535182 TV 5010 0 M000603606 M0535182 T750231 TV 5010 2009 04 28 NLM (2009) T750231 5010, TV T750233 TV5010 2009 04 28 NLM (2009) T750232 TV-5010 2009 04 28 NLM (2009) D000068718 rosuvastatin kalcium[Rosuvastatin Calcium] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; ROSUVASTATIN CALCIUM was indexed under FLUOROBENZENES; PYRIMIDINES; and SULFONAMIDES 2001-2015 D019821 Simvastatin D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors D02.065.884.650 D02.455.526.510.432.500 D02.886.590.700.650 D03.383.742.775 M0402344 rosuvastatin kalcium[Rosuvastatin Calcium] 83MVU38M7Q A HYDROXYMETHYLGLUTARYL-COA-REDUCTASE INHIBITOR, or statin, that reduces the plasma concentrations of LDL-CHOLESTEROL; APOLIPOPROTEIN B, and TRIGLYCERIDES while increasing HDL-CHOLESTEROL levels in patients with HYPERCHOLESTEROLEMIA and those at risk for CARDIOVASCULAR DISEASES. 287714-41-4 (Rosuvastatin) 413KH5ZJ73 M0402344 M0402345 M0402344 M0382713 M0402344 M0402343 T000877041 Rosuvastatin Calcium 2015 03 19 FDA SRS (2015) INN (19XX) USAN (2001) T000877041 Calcium, Rosuvastatin cze0062422 rosuvastatin kalcium 2015 06 12 cze Thesaurus M0402345 Crestor[Crestor] 0 M0402344 M0402345 T466953 Crestor 2001 10 19 NLM (2001) cze0062423 Crestor 2015 06 12 cze Thesaurus M0382713 Rosuvastatin[Rosuvastatin] 413KH5ZJ73 M0402344 M0382713 T000877042 Rosuvastatin 2015 03 19 FDA SRS (2015) INN (19XX) NLM (2001) USAN (19XX) cze0062425 Rosuvastatin 2015 06 12 cze Thesaurus cze0062426 Rosucard 2015 06 12 cze Thesaurus cze0062427 Tintaros 2015 06 12 cze Thesaurus M0402343 ZD4522 0 M0402344 M0402343 T441303 ZD4522 2001 03 30 NLM (2001) T441304 ZD 4522 2001 03 30 NLM (2001) D000068736 duloxetinum hydrochlorid[Duloxetine Hydrochloride] 2015 07 09 2015 07 08 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1989) 2016; DULOXETINE was indexed under THIOPHENES 1989-2015 D000068760 Serotonin and Noradrenaline Reuptake Inhibitors D000700 Analgesics D000928 Antidepressive Agents D015259 Dopamine Agents D02.886.778.260 D03.383.903.260 M0473681 duloxetinum hydrochlorid[Duloxetine Hydrochloride] 9044SC542W A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA. 116539-58-3 116539-59-4 116539-60-7 118625-29-9 136434-34-9 (Duloxetine Hydrochloride) O5TNM5N07U M0473681 M0162455 M0473681 M0323987 M0473681 M0162462 M0473681 M0162461 M0473681 M0323985 M0473681 M0473682 T000877084 Duloxetine Hydrochloride 2015 03 20 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (2004) USAN (19XX) T000877084 Hydrochloride, Duloxetine T000877085 Duloxetine HCl 2015 03 20 NLM (2016) T000877085 HCl, Duloxetine cze0062346 duloxetinum hydrochlorid 2015 06 12 cze Thesaurus M0162455 LY 248686 0 M0473681 M0162455 T192460 LY 248686 NLM (1989) T192462 LY-248686 NLM (1989) T192462 LY248686 M0323987 Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 118625-29-9 M0473681 M0323987 T000877083 Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 2015 03 20 NLM (1989) M0162462 LY 227942 0 M0473681 M0162462 T192467 LY 227942 NLM (1989) T192461 LY-227942 NLM (1989) T192463 LY227942 NLM (1989) M0162461 duloxetin[Duloxetine] O5TNM5N07U M0473681 M0162461 T000877082 Duloxetine 2015 03 20 FDA SRS (2013) INN (19XX) NLM (1989) T192465 N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide NLM (1989) T192464 N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine NLM (1989) cze0062347 duloxetin 2015 06 12 cze Thesaurus M0323985 Duloxetine, (+)-isomer 116539-59-4 M0473681 M0323985 T000877086 Duloxetine, (+)-isomer 2015 03 20 NLM (1989) M0473682 Cymbalta[Cymbalta] 0 M0473681 M0473682 T612434 Cymbalta 2004 10 07 US cze0062348 Cymbalta 2015 06 12 cze Thesaurus D000068737 tolterodin tartrát[Tolterodine Tartrate] 2015 07 09 2015 07 08 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; TOLTERODINE TARTRATE was indexed under BENZHYDRYL COMPOUNDS, CRESOLS, and PHENYLPROPANOLAMINE 1996-2015 D018727 Muscarinic Antagonists D064804 Urological Agents D02.033.100.624.706.750 D02.033.755.624.706.750 D02.092.063.624.706.800 D02.455.426.559.389.115.900 D02.455.426.559.389.657.239.756 M0386986 tolterodin tartrát[Tolterodine Tartrate] 5T619TQR3R An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE. 124937-51-5 124937-52-6 (tolterodine tartrate) WHE7A56U7K M0386986 M0260056 M0386986 M0380200 M0386986 M000603631 M0386986 M0489937 M0386986 M0502652 M0386986 M000603632 T000877102 Tolterodine Tartrate 2015 03 20 FDA SRS (2014) NLM (2001) USAN (19XX) T000877102 Tartrate, Tolterodine cze0062353 tolterodin tartrát 2015 06 12 cze Thesaurus M0260056 Tolterodine[Tolterodine] WHE7A56U7K M0386986 M0260056 T000877101 Tolterodine 2015 03 20 FDA SRS (2013) INN (19XX) USAN (1996) cze0062356 Tolterodine 2015 06 12 cze Thesaurus M0380200 Detrol 0 M0386986 M0380200 T438226 Detrol 2001 03 07 CA US T000877098 Detrol LA 2015 03 20 NLM (2016) T000877098 LA, Detrol M000603631 Detrusitol[Detrusitol] 0 M0386986 M000603631 T583323 Detrusitol 2004 04 15 DE ES FR IE MX NL UK cze0062355 Detrusitol 2015 06 12 cze Thesaurus M0489937 Uroflow[Urotrol] 0 M0386986 M0489937 T653479 Urotrol 2005 09 29 ES cze0062357 Uroflow 2015 06 12 cze Thesaurus M0502652 PHA-686464B 0 M0386986 M0502652 T683298 PHA-686464B 2006 10 10 NLM (2006) T683298 PHA 686464B T683298 PHA686464B M000603632 Unidet 0 M0386986 M000603632 T653476 Unidet 2005 09 29 CA D000068756 valsartran[Valsartan] 2015 07 06 2015 06 15 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1993) 2016; VALSARTAN was indexed under TETRAZOLES and VALINE 1993-2015 D019808 Losartan D000959 Antihypertensive Agents D047228 Angiotensin II Type 1 Receptor Blockers D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500 M0217346 valsartran[Valsartan] L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)- 80M03YXJ7I A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. 137862-53-4 M0217346 M0217344 M0217346 M0476490 M0217346 M000603638 M0217346 M0476492 M0217346 M0476493 M0217346 M0476494 M0217346 M0217343 M0217346 M0476491 T000877108 Valsartan 2015 03 20 FDA SRS (2015) INN (19XX) USAN (1993) T247350 N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine NLM (1993) cze0062106 valsartran 2015 06 01 cze Thesaurus M0217344 Diovan 0 M0217346 M0217344 T247349 Diovan CA DE ES IE MX NL UK US M0476490 Kalpress 0 M0217346 M0476490 T620417 Kalpress 2004 11 29 ES M000603638 Tareg 0 M0217346 M000603638 T620415 Tareg 2004 11 29 FR M0476492 Nisis 0 M0217346 M0476492 T620421 Nisis 2004 11 29 FR M0476493 Provas 0 M0217346 M0476493 T620423 Provas 2004 11 29 DE M0476494 Vals 0 M0217346 M0476494 T620426 Vals 2004 11 29 ES M0217343 CGP 48933 0 M0217346 M0217343 T247348 CGP 48933 NLM (1993) T247348 48933, CGP M0476491 Miten 0 M0217346 M0476491 T620419 Miten 2004 11 29 ES D000068757 jehlice (rod)[Ononis] 2015 07 01 2015 06 16 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 2016 B01.650.940.800.575.100.401.604 M000603640 jehlice (rod)[Ononis] A genus of the pea family (Fabaceae), native from Europe to Central Asia and used in TRADITIONAL MEDICINE. T000877110 Ononis 2015 03 20 NLM (2016) T000877112 Rest-Harrow 2015 03 20 NLM (2016) T000877112 Rest Harrow T000877112 Rest-Harrows T000877111 Restharrow 2015 03 20 NLM (2016) T000877111 Restharrows cze0063952 jehlice (rod) 2015 10 15 cze Thesaurus cze0063953 Ononis 2015 10 15 cze Thesaurus D000068758 kombinace léků mometason furoát a formoterol fumarát[Mometasone Furoate, Formoterol Fumarate Drug Combination] 2015 07 01 2015 06 15 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; MOMETASONE FUROATE, FORMOTEROL FUMARATE DRUG COMBINATION was indexed under ETHANOLAMINES and PREGNADIENEDIOLS 2011-2015 D001993 Bronchodilator Agents D02.033.100.291.425.500 D02.092.063.291.425.500 D04.808.745.432.719.526.500 D26.310.469 M000603642 kombinace léků mometason furoát a formoterol fumarát[Mometasone Furoate, Formoterol Fumarate Drug Combination] 0 A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA. M000603642 M0552349 M000603642 M000603644 T000881864 Mometasone Furoate, Formoterol Fumarate Drug Combination 2015 06 15 NLM (2016) T000880049 Mometasone Furoate Formoterol Fumarate Drug Combination 2015 05 20 NLM (2016) T000877114 Mometasone Furoate-Formoterol Fumarate Drug Combination 2015 03 20 NLM (2016) cze0064005 kombinace léků mometason furoát a formoterol fumarát 2015 10 15 cze Thesaurus M0552349 Dulera 0 M000603642 M0552349 T000877118 Dulera 2015 03 20 NLM (2016) M000603644 Zenhale 0 M000603642 M000603644 T000877119 Zenhale 2015 03 20 NLM (2016) D000068759 formoterol fumarát[Formoterol Fumarate] 2015 07 10 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1976) 2016; FORMOTEROL FUMARATE was indexed under ETHANOLAMINES 1976-2015 D000068656 Mometasone Furoate D000420 Albuterol D001993 Bronchodilator Agents D058666 Adrenergic beta-2 Receptor Agonists D02.033.100.291.425 D02.092.063.291.425 M0311929 formoterol fumarát[Formoterol Fumarate] W34SHF8J2K An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 43229-80-7 (formoterol fumarate) 5ZZ84GCW8B F91H02EBWT M0311929 M0059791 M0311929 M0059794 M0311929 M0446657 M0311929 M0398106 M0311929 M0398107 T000877283 Formoterol Fumarate 2015 03 24 FDA SRS (2013) NLM (1976) USAN (19XX) USP (19XX) T000877285 Formoterol Fumarate, ((R*,R*)-(+-))-isomer 2015 03 24 NLM (1976) T000877284 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate 2015 03 24 NLM (1976) cze0062364 formoterol fumarát 2015 06 12 cze Thesaurus M0059791 BD 40A 0 M0311929 M0059791 T089794 BD 40A NLM (1976) M0059794 Formoterol[Formoterol] 5ZZ84GCW8B M0311929 M0059794 T000877288 Formoterol 2015 03 24 FDA SRS (2013) INN (1976) INN (19XX) T000877290 Eformoterol 2015 03 24 NLM (1976) cze0062367 Formoterol 2015 06 12 cze Thesaurus cze0062371 Formovent 2015 06 12 cze Thesaurus M0446657 Atimos[Oxis] 0 M0311929 M0446657 T534934 Oxis 2003 03 10 AU DE ES MX NL NLM (2003) UK cze0062368 Atimos 2015 06 12 cze Thesaurus M0398106 Forotel[Arformoterol] F91H02EBWT M0311929 M0398106 T000877286 Arformoterol 2015 03 24 FDA SRS (2013) INN (19XX) NLM (2006) T000877287 Formoterol, ((R*,R*)-(+-))-isomer 2015 03 24 NLM (1976) cze0062369 Forotel 2015 06 12 cze Thesaurus cze0062370 Formano 2015 06 12 cze Thesaurus M0398107 Foradil[Foradil] 0 M0311929 M0398107 T461304 Foradil 2001 09 13 NLM (2001) cze0062365 Foradil 2015 06 12 cze Thesaurus D000068760 inhibitory zpětného vychytávání serotoninu a noradrenalinu[Serotonin and Noradrenaline Reuptake Inhibitors] 2015 07 01 2015 05 20 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Adrenergic Uptake Inhibitors (1999-2015) Serotonin Uptake Inhibitors (1999-2015) D27.505.519.562.437.693 D27.505.519.625.600.693 D27.505.696.577.600.693 M000603649 inhibitory zpětného vychytávání serotoninu a noradrenalinu[Serotonin and Noradrenaline Reuptake Inhibitors] 0 Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. T000877133 Serotonin and Noradrenaline Reuptake Inhibitors 2015 03 20 NLM (2016) T000879250 SSRIs and NRIs 2015 05 06 NLM (2016) T000879250 NRIs and SSRIs T000877137 Serotonin and Noradrenaline Uptake Inhibitors 2015 03 20 NLM (2016) T000879071 SNRIs 2015 05 01 NLM (2016) T000877134 Serotonin and Norepinephrine Reuptake Inhibitors 2015 03 20 NLM (2016) T000877136 Serotonin and Norepinephrine Uptake Inhibitors 2015 03 20 NLM (2016) cze0062069 inhibitory zpětného vychytávání serotoninu a noradrenalinu 2015 05 22 cze Thesaurus cze0062070 SSRI a SNRI 2015 05 22 cze Thesaurus D000068776 látky navozující spánek[Sleep Aids, Pharmaceutical] 2015 07 02 2015 06 18 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Sleep Wake Disorders (1999-2015) D27.505.954.842 M000603757 látky navozující spánek[Sleep Aids, Pharmaceutical] 0 Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. T000880555 Sleep Aids, Pharmaceutical 2015 05 27 NLM (2016) T000880555 Pharmaceutical Sleep Aids T000879004 Sleep Promoting Agents 2015 04 30 NLM (2016) T000879004 Agents, Sleep Promoting T000879005 Sleep Inducers 2015 04 30 NLM (2016) cze0064050 látky navozující spánek 2015 10 16 cze Thesaurus D000068796 antagonisté orexinového receptoru[Orexin Receptor Antagonists] 2015 07 02 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Orexin Receptors (2014-2015) D27.505.519.625.663 D27.505.696.577.663 D27.505.954.842.500 M000603796 antagonisté orexinového receptoru[Orexin Receptor Antagonists] 0 Substances that bind to and inhibit the action of OREXIN RECEPTORS. Drugs in this class have been used as SLEEP AIDS. M000603796 M000603958 T000877289 Orexin Receptor Antagonists 2015 03 24 NLM (2016) T000877289 Antagonists, Orexin Receptor T000877289 Receptor Antagonists, Orexin T000877506 Orexin Receptor Blockers 2015 03 27 NLM (2016) T000877506 Blockers, Orexin Receptor T000877506 Receptor Blockers, Orexin cze0064147 antagonisté orexinového receptoru 2015 10 22 cze Thesaurus cze0064148 blokátory orexinových receptorů 2015 10 22 cze Thesaurus M000603958 Dual Orexin Receptor Antagonists 0 M000603796 M000603958 T000877507 Dual Orexin Receptor Antagonists 2015 03 27 NLM (2016) D000068797 orexiny[Orexins] 2015 07 10 2015 07 10 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016; OREXINS was indexed under NEUROPEPTIDES & INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS 2005-2015, and under CARRIER PROTEINS 1998-2004 D064446 Orexin Receptors D12.644.400.360 D12.776.641.650.363 M000603797 orexiny[Orexins] 0 Neuropeptide hormones that play a role in regulating a variety of behavioral and physiological processes in response to motivational stimuli. M000603797 M0287277 M000603797 M0287275 T000877294 Orexins 2015 03 24 NLM (2016) T000879008 Hypocretins 2015 04 30 NLM (2016) cze0064149 orexiny 2015 10 22 cze Thesaurus cze0064150 hypokretiny 2015 10 22 cze Thesaurus M0287277 orexin B[Orexin-B] 0 M000603797 M0287277 T000877454 Orexin-B 2015 03 27 NLM (2016) T000877454 Orexin B T000877456 Hypocretin-2 2015 03 27 NLM (2016) T000877456 Hypocretin 2 cze0064152 orexin B 2015 10 22 cze Thesaurus M0287275 orexin A[Orexin-A] 0 M000603797 M0287275 T000877453 Orexin-A 2015 03 27 NLM (2016) T000877453 Orexin A T000877452 Hypocretin-1 2015 03 27 NLM (2016) T000877452 Hypocretin 1 cze0064151 orexin A 2015 10 22 cze Thesaurus D000068798 Hoodia[Hoodia] 2015 07 01 2015 06 15 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 2016 Apocynaceae (2007-2015) B01.650.940.800.575.100.081.389 M000603798 Hoodia[Hoodia] A genus in the dogbane family (Apocynaceae) used in TRADITIONAL MEDICINE for appetite-suppressant properties. M000603798 M000603800 T000877295 Hoodia 2015 03 24 NLM (2016) cze0062780 Hoodia 2015 07 13 cze Thesaurus M000603800 Hoodia gordonii[Hoodia gordonii] M000603798 M000603800 T000877297 Hoodia gordonii 2015 03 24 NLM (2016) cze0062781 Hoodia gordonii 2015 07 13 cze Thesaurus D000068799 prasugrel hydrochlorid[Prasugrel Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2000) 2016; PRASUGREL HYDROCHLORIDE was indexed under PIPERAZINES and THIOPHENES 2000-2015 D010975 Platelet Aggregation Inhibitors D02.886.778.315 D03.383.606.420 D03.383.903.315 M000603803 prasugrel hydrochlorid[Prasugrel Hydrochloride] G89JQ59I13 A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS. 34K66TBT99 389574-19-0 (prasugrel hydrochloride) M000603803 M0492367 M000603803 M0362841 M000603803 M0584826 M000603803 M000603799 M000603803 M0489250 T000877308 Prasugrel Hydrochloride 2015 03 24 NLM (2016) T000877308 Hydrochloride, Prasugrel T000877309 Prasugrel HCl 2015 03 24 NLM (2016) T000877309 HCl, Prasugrel cze0062391 prasugrel hydrochlorid 2015 06 12 cze Thesaurus M0492367 CS 747 0 M000603803 M0492367 T415037 CS 747 2000 05 22 NLM (2000) T415037 747, CS T415038 CS-747 2000 05 22 NLM (2000) T415038 CS747 M0362841 prasugrel[Prasugrel] 34K66TBT99 M000603803 M0362841 T000877307 Prasugrel 2015 03 24 FDA SRS (2013) INN (19XX) NLM (2005) cze0062396 prasugrel 2015 06 12 cze Thesaurus M0584826 Efient[Efient] 0 M000603803 M0584826 T000877306 Efient 2015 03 24 NLM (2013) cze0062394 Efient 2015 06 12 cze Thesaurus M000603799 Effient 0 M000603803 M000603799 T000877296 Effient 2015 03 24 NLM (2016) M0489250 LY 640315 0 M000603803 M0489250 T651481 LY 640315 2005 09 14 NLM (2005) T651481 640315, LY T651483 LY640315 2005 09 14 NLM (2005) T651482 LY-640315 2005 09 14 NLM (2005) D000068800 etanercept[Etanercept] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; ETANERCEPT was indexed under IMMUNOGLOBULIN G and RECEPTORS, TUMOR NECROSIS FACTOR 1997-2015 D000894 Anti-Inflammatory Agents, Non-Steroidal D005765 Gastrointestinal Agents D007166 Immunosuppressive Agents D018501 Antirheumatic Agents D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232 M0276736 etanercept[Etanercept] OP401G7OJC A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS. 185243-69-0 M0276736 M0276735 M0276736 M0276734 M0276736 M0276737 M0276736 M0276738 T000877312 Etanercept 2015 03 24 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1997) USAN (19XX) cze0062135 etanercept 2015 06 01 cze Thesaurus M0276735 TNF Receptor Type II-IgG Fusion Protein 0 M0276736 M0276735 T000877314 TNF Receptor Type II-IgG Fusion Protein 2015 03 24 NLM (1997) T000877314 TNF Receptor Type II IgG Fusion Protein M0276734 Enbrel[Enbrel] 0 M0276736 M0276734 T306739 Enbrel CA DE ES NL US cze0062136 Enbrel 2015 06 01 cze Thesaurus M0276737 Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein 0 M0276736 M0276737 T000877316 Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein 2015 03 24 NLM (1997) T000877316 Recombinant Human Dimeric TNF Receptor Type II IgG Fusion Protein M0276738 TNFR-Fc Fusion Protein 185243-69-0 M0276736 M0276738 T000877315 TNFR-Fc Fusion Protein 2015 03 24 NLM (1997) T000877315 Fusion Protein, TNFR-Fc T000877315 Protein, TNFR-Fc Fusion T000877315 TNFR Fc Fusion Protein T403900 TNR-001 1999 12 28 NLM (1999) T403900 TNR001 T403899 TNR 001 1999 12 28 NLM (1999) T403899 001, TNR T000877313 TNT Receptor Fusion Protein 2015 03 24 NLM (1999) T403898 TNTR-Fc 1999 12 28 NLM (1999) D000068801 kombinace léků adapalen a benzoyl peroxid[Adapalene, Benzoyl Peroxide Drug Combination] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Benzoyl Peroxide (2007-2015) Naphthalenes (2007-2015) D000894 Anti-Inflammatory Agents, Non-Steroidal D003879 Dermatologic Agents D02.241.223.100.133.500 D02.455.426.559.389.127.133.500 D02.455.426.559.847.638.090.500 D04.615.638.090.500 D26.310.032 M000603810 kombinace léků adapalen a benzoyl peroxid[Adapalene, Benzoyl Peroxide Drug Combination] 0 A pharmaceutical preparation of adapalene and benzoyl peroxide that is used as a DERMATOLOGIC AGENT for the topical treatment of ACNE. M000603810 M000603809 T000881915 Adapalene, Benzoyl Peroxide Drug Combination 2015 06 16 NLM (2016) T000877325 Adapalene-Benzoyl Peroxide Drug Combination 2015 03 24 NLM (2016) T000880034 Adapalene - Benzoyl Peroxide Drug Combination 2015 05 20 NLM (2016) T000881916 Adapalene Benzoyl Peroxide Drug Combination 2015 06 16 NLM (2016) cze0063380 kombinace léků adapalen a benzoyl peroxid 2015 09 04 cze Thesaurus M000603809 Epiduo 0 M000603810 M000603809 T000877323 Epiduo 2015 03 24 NLM (2016) D000068816 adapalen[Adapalene] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1990) 2016; ADAPALENE was indexed under NAPHTHALENES 1990-2015 D000894 Anti-Inflammatory Agents, Non-Steroidal D003879 Dermatologic Agents D02.455.426.559.847.638.090 D04.615.638.090 M0175560 adapalen[Adapalene] 1L4806J2QF A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE. 106685-40-9 (adapalene) M0175560 M0175557 M0175560 M0477010 M0175560 M0398585 T000877361 Adapalene 2015 03 25 FDA SRS (2013) INN (19XX) NLM (1990) USAN (19XX) T205561 6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid NLM (1990) cze0062092 adapalen 2015 05 28 cze Thesaurus cze0062093 adapalenum 2015 05 28 cze Thesaurus M0175557 CD 271 0 M0175560 M0175557 T205562 CD 271 NLM (1990) T205562 271, CD T205564 CD271 NLM (1990) T205563 CD-271 NLM (1990) M0477010 Adaferin 0 M0175560 M0477010 T621875 Adaferin 2004 12 06 MX M0398585 Differine[Differin] 0 M0175560 M0398585 T461936 Differin 2001 09 17 AU CA DE IE UK US T621874 Differine 2004 12 06 ES FR cze0062094 Differine 2015 05 28 cze Thesaurus cze0062095 Belakne 2015 05 28 cze Thesaurus D000068817 epoetin alfa[Epoetin Alfa] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; EPOETIN ALFA was indexed under ERYTHROPOIETIN 2011-2015 D006397 Hematinics D12.644.276.374.410.240.150.500 D12.776.395.240.150.750 D12.776.467.374.410.240.150.500 D23.529.374.410.240.150.750 M0028770 epoetin alfa[Epoetin Alfa] 1-165-Erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform alpha 64FS3BFH5W A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients. 113427-24-0 M0028770 M0593995 M0028770 M0028767 M0028770 M0494900 M0028770 M000606819 M0028770 M0593993 M0028770 M0593994 M0028770 M0373310 M0028770 M0542538 T000877365 Epoetin Alfa 2015 03 25 BAN (19XX) INN (19XX) NLM (1997) USAN (19XX) T000877365 Alfa, Epoetin T000877366 Recombinant 1-165 Erythropoietin, Glycoform Alpha 2015 03 25 NLM (2012) T000877366 Recombinant 1 165 Erythropoietin, Glycoform Alpha cze0062127 epoetin alfa 2015 06 01 cze Thesaurus M0593995 Epoetin Alfa Hexal 0 M0028770 M0593995 T000877367 Epoetin Alfa Hexal 2015 03 25 NLM (2014) T000877367 Alfa Hexal, Epoetin T000877367 Hexal, Epoetin Alfa M0028767 Eprex[Eprex] 0 M0028770 M0028767 T057589 Eprex 1996 01 17 NLM (1997) cze0062128 Eprex 2015 06 01 cze Thesaurus M0494900 Heberitro 0 M0028770 M0494900 T666196 Heberitro 2006 02 13 NLM (2006) M000606819 Procrit 0 M0028770 M000606819 T000881939 Procrit 2015 06 16 NLM (2016) M0593993 Binocrit[Binocrit] 0 M0028770 M0593993 T000877363 Binocrit 2015 03 25 NLM (2014) cze0062131 Binocrit 2015 06 01 cze Thesaurus M0593994 HX575 Compound 0 M0028770 M0593994 T000877364 HX575 Compound 2015 03 25 NLM (2014) T000877364 Compound, HX575 M0373310 Epogen[Epogen] 0 M0028770 M0373310 T057593 Epogen 1995 12 18 NLM (1997) cze0062134 Epogen 2015 06 01 cze Thesaurus M0542538 HX575 0 M0028770 M0542538 T763865 HX575 2010 01 11 NLM (2010) D000068818 cetuximab[Cetuximab] 2015 07 01 2015 06 16 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD 2016 (2000) 2016; CETUXIMAB was indexed under ANTIBODIES, MONOCLONAL 2000-2013; and under ANTIBODIES, MONOCLONAL, HUMANIZED 2013-2015 D000970 Antineoplastic Agents D12.776.124.486.485.114.224.060.750 D12.776.124.790.651.114.224.060.750 D12.776.377.715.548.114.224.200.750 M0422675 cetuximab[Cetuximab] PQX0D8J21J A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. 205923-56-4 M0422675 M0444717 M0422675 M0366638 T000877369 Cetuximab 2015 03 25 FDA SRS (2013) INN (19XX) NLM (2000) USAN (19XX) cze0062112 cetuximab 2015 06 01 cze Thesaurus M0444717 Erbitux[Erbitux] 0 M0422675 M0444717 T530357 Erbitux 2003 01 15 NLM (2003) cze0062113 Erbitux 2015 06 01 cze Thesaurus M0366638 IMC C225 0 M0422675 M0366638 T419981 IMC C225 2000 07 26 NLM (2000) T419981 C225, IMC T530356 IMC-C225 2003 01 15 NLM (2003) T530356 IMCC225 T304829 MAb C225 NLM (2000) T304829 C225, MAb T304830 C225 NLM (2000) D000068819 Hyssopus[Hyssopus Plant] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; for HYSSOP use LAMIACEAE 2003-2015 2016; for HYSSOP see LAMIACEAE 2003-2015 Lamiaceae (2002-2015) B01.650.940.800.575.100.583.520.330 M0418658 Hyssopus[Hyssopus Plant] A genus in the mint family (Lamiaceae). Members contain thujone and PHENOL. Distinguished from AGASTACHE (giant hyssop) and BACOPA (water hyssop). Also distinguished from the genus of WASPS with the same genus name Hyssopus. M0418658 M000603860 T000877377 Hyssopus Plant 2015 03 25 NLM (2016) T000877377 Hyssopus Plants T000877377 Plant, Hyssopus T000877377 Plants, Hyssopus cze0022063 Hyssopus 2006 03 22 cze0051483 yzop 2012 11 02 cze Thesaurus M000603860 Hyssopus officinalis M0418658 M000603860 T000877376 Hyssopus officinalis 2015 03 25 NLM (2016) T487475 Hyssop 2002 03 26 NLM (2003) T487475 Hyssops D000068836 rivastigmin[Rivastigmine] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1992) 2016; RIVASTIGMINE was indexed under PHENYLCARBAMATES 2004-2015; and under CARBAMATES 1992-2004 D002800 Cholinesterase Inhibitors D018696 Neuroprotective Agents D02.241.081.251.583.899 M0196402 rivastigmin[Rivastigmine] Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1) PKI06M3IW0 A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE. Látka používaná k léčbě demence (kognitivum), zejm. Alzheimerovy nemoci. Karbamátový derivát, patří k selektivním inhibitorům acetylcholinesterázy. Chemicky příbuzný fysostigminu, ovšem s delším poločasem, možností perorálního podávání a dobrou tolerancí. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) 123441-03-2 (rivastigmine) 129101-54-8 (rivastigmine hydrogen tartrate) 9IY2357JPE M0196402 M0398521 M0196402 M0398224 T000877411 Rivastigmine 2015 03 26 BAN (19XX) INN (19XX) NLM (1992) USAN (19XX) T000877412 (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate 2015 03 26 NLM (1992) cze0062411 rivastigmin 2015 06 12 cze Thesaurus M0398521 rivastigmin tartrát[RivastigmineTartrate] 9IY2357JPE M0196402 M0398521 T000877413 RivastigmineTartrate 2015 03 26 FDA SRS (2015) NLM (2001) T226408 SDZ ENA 713 NLM (1992) T226408 713, SDZ ENA T226408 ENA 713, SDZ T226406 ENA-713 NLM (1992) T226406 ENA713 T000877414 Rivastigmine Hydrogen Tartrate 2015 03 26 BAN (19XX) INN (19XX) T000877414 Hydrogen Tartrate, Rivastigmine T000877414 Tartrate, Rivastigmine Hydrogen T226405 ENA 713 NLM (1992) T226405 713, ENA cze0062413 rivastigmin tartrát 2015 06 12 cze Thesaurus M0398224 Exelon[Exelon] 0 M0196402 M0398224 T427901 Exelon 2000 11 02 NLM (2000) cze0062412 Exelon 2015 06 12 cze Thesaurus D000068837 terčovkovité[Parmeliaceae] 2015 07 01 2015 06 15 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY 2016 2016 Ascomycota (2004-2015) B01.300.107.685 B01.300.340.458 M000603887 terčovkovité[Parmeliaceae] The largest family of lichen-forming fungi. M000603887 M000603889 M000603887 M000603888 T000877415 Parmeliaceae 2015 03 26 NLM (2016) cze0063970 terčovkovité 2015 10 15 cze Thesaurus cze0063971 Parmeliaceae 2015 10 15 cze Thesaurus M000603889 pukléřka islandská[Cetraria islandica] M000603887 M000603889 T000877417 Cetraria islandica 2015 03 26 NLM (2016) T000877418 Iceland Moss 2015 03 26 NLM (2016) T000877418 Iceland Mosses T000877418 Moss, Iceland T000877418 Mosses, Iceland cze0063974 pukléřka islandská 2015 10 15 cze Thesaurus cze0063975 Cetraria islandica 2015 10 15 cze Thesaurus M000603888 pukléřka[Cetraria] M000603887 M000603888 T000877416 Cetraria 2015 03 26 NLM (2016) cze0063972 pukléřka 2015 10 15 cze Thesaurus cze0063973 Cetraria 2015 10 15 cze Thesaurus D000068838 kombinace léků amlodipin a valsartan[Amlodipine, Valsartan Drug Combination] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2008) 2016; AMLODIPINE, VALSARTAN DRUG COMBINATION was indexed under DRUG COMBINATIONS, TETRAZOLES, and AMLODIPINE 2008-2015 D000959 Antihypertensive Agents D03.383.129.617.850.500 D03.383.725.203.065.750 D12.125.070.950.550.500 D12.125.142.930.500.500 D26.310.094 M0522574 kombinace léků amlodipin a valsartan[Amlodipine, Valsartan Drug Combination] 0 A pharmaceutical preparation of amlodipine and valsartan that is used for the treatment of HYPERTENSION. M0522574 M0522575 T000877422 Amlodipine, Valsartan Drug Combination 2015 03 26 NLM (2010) T000877424 Amlodipine - Valsartan 2015 03 26 NLM (2010) T000877424 - Valsartan, Amlodipine T000877424 Valsartan, Amlodipine - T000877423 Amlodipine-Valsartan 2015 03 26 NLM (2010) T000877423 Amlodipine Valsartan T000877420 Amlodipine-Valsartan Drug Combination 2015 03 26 NLM (2010) T000877420 Amlodipine Valsartan Drug Combination T000877420 Combination, Amlodipine-Valsartan Drug T000877420 Drug Combination, Amlodipine-Valsartan cze0062398 kombinace léků amlodipin a valsartan 2015 06 12 cze Thesaurus M0522575 Exforge[Exforge] 0 M0522574 M0522575 T721684 Exforge 2008 06 30 NLM (2008) UK US cze0062397 Exforge 2015 06 12 cze Thesaurus D000068856 hřebíkovec[Eugenia] 2015 07 07 2015 07 07 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016; see SYZYGIUM 2005-2015; see CLOVE 2002-2004 2016; see CLOVE 2002-2004 Syzygium (2002-2015) B01.650.940.800.575.100.773.374 M000603941 hřebíkovec[Eugenia] A genus in the family Myrtaceae sometimes known as "stoppers" in FOLK MEDICINE. Many species of the genus SYZYGIUM have synonymous names that begin with the Eugenia genus name. M000603941 M000603943 T439291 Eugenia 2001 03 15 NLM (2002) T439291 Eugenias cze0062641 hřebíkovec 2015 06 26 cze Thesaurus cze0062642 martej 2015 06 26 cze Thesaurus M000603943 Eugenia uniflora[Euginia uniflora] M000603941 M000603943 T000877484 Euginia uniflora 2015 03 27 NLM (2016) T000877486 Brazilian Cherry Tree 2015 03 27 NLM (2016) T000877486 Brazilian Cherry Trees T000877486 Cherry Tree, Brazilian T000877486 Cherry Trees, Brazilian T000877486 Tree, Brazilian Cherry T000877486 Trees, Brazilian Cherry T000877488 Pitanga 2015 03 27 NLM (2016) T000877488 Pitangas T000877485 Surinam Cherry Tree 2015 03 27 NLM (2016) T000877485 Cherry Tree, Surinam T000877485 Cherry Trees, Surinam T000877485 Surinam Cherry Trees T000877485 Tree, Surinam Cherry T000877485 Trees, Surinam Cherry cze0062643 Eugenia uniflora 2015 06 26 cze Thesaurus cze0062644 martej jednokvětá 2015 06 26 cze Thesaurus D000068857 rekombinantní kvadrivalentní vakcína proti lidskému papilomaviru typu 6, 11, 16, 18[Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2006) 2016; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT (TYPES 6, 11, 16, 18) was indexed under PAPILLOMAVIRUS VACCINES 2006-2015 D20.215.894.899.498.500 M000603960 rekombinantní kvadrivalentní vakcína proti lidskému papilomaviru typu 6, 11, 16, 18[Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18] 0 A vaccine containing L1 capsid proteins from four types of HPV (ALPHAPAPILLOMAVIRUS), types 6, 11, 16 and 18 that is used to prevent infections from HUMAN PAPILLOMAVIRUSES of these subtypes. M000603960 M000604018 M000603960 M0501047 T000880055 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2015 05 20 NLM (2016) cze0062310 rekombinantní kvadrivalentní vakcína proti lidskému papilomaviru typu 6, 11, 16, 18 2015 06 11 cze Thesaurus M000604018 Silgard[Gardasil] 0 M000603960 M000604018 T000877609 Gardasil 2015 03 30 NLM (2006) cze0062309 Silgard 2015 06 11 cze Thesaurus cze0062308 Gardasil 2015 06 11 cze Thesaurus M0501047 kvadrivalentní vakcína proti lidským papilomavirům[Human Papillomavirus Vaccine L1, Type 6,11,16,18] 0 M000603960 M0501047 T000877510 Human Papillomavirus Vaccine L1, Type 6,11,16,18 2015 03 27 NLM (2006) T000877513 HPV L1 Vaccine, Quadrivalent 6,11,16,18 2015 03 27 NLM (2006) cze0062311 kvadrivalentní vakcína proti lidským papilomavirům 2015 06 11 cze Thesaurus D000068858 kombucha[Kombucha Tea] 2015 07 01 2015 06 16 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Tea (1995-2015) D20.215.784.844.500 G07.203.100.831.500 J02.200.831.500 M000603965 kombucha[Kombucha Tea] 0 A beverage made by FERMENTATION of black tea and/or green tea. T000877521 Kombucha Tea 2015 03 27 NLM (2016) T000877521 Kombucha Teas T000877521 Tea, Kombucha T000877521 Teas, Kombucha cze0063864 kombucha 2015 10 14 cze Thesaurus cze0063865 čaj z kombuchy 2015 10 14 cze Thesaurus D000068876 fingolimod hydrochlorid[Fingolimod Hydrochloride] 2015 07 06 2015 07 02 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; FINGOLIMOD HYDROCHLORIDE was indexed under PROPYLENE GLYCOLS and SPHINGOSINE 1996-2015 D007166 Immunosuppressive Agents D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350 M0259274 fingolimod hydrochlorid[Fingolimod Hydrochloride] G926EC510T A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS. 162359-56-0 (fingolimod hydrochloride) 3QN8BYN5QF M0259274 M0521995 M0259274 M0587375 M0259274 M0259277 T000877612 Fingolimod Hydrochloride 2015 03 30 NLM (2008) USAN (19XX) T000877612 Hydrochloride, Fingolimod T000877616 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride 2015 03 30 NLM (1996) cze0062360 fingolimod hydrochlorid 2015 06 12 cze Thesaurus M0521995 FTY-720 0 M0259274 M0521995 T289280 FTY-720 NLM (1996) T289282 FTY 720 NLM (1996) T289281 FTY720 NLM (1996) M0587375 Gilenya[Gilenya] 0 M0259274 M0587375 T848628 Gilenya 2013 08 30 NLM (2014) T000877613 Gilenia 2015 03 30 NLM (2016) cze0062361 Gilenya 2015 06 12 cze Thesaurus M0259277 Fingolimod 3QN8BYN5QF M0259274 M0259277 T000877611 Fingolimod 2015 03 30 FDA SRS (2013) INN (19XX) NLM (2006) D000068877 imatinib mesylát[Imatinib Mesylate] 2015 07 09 2015 07 08 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; IMATINIB MESYLATE was indexed under BENZAMIDES, PIPERAZINES, and PYRIMIDINES 1996-2015 D000970 Antineoplastic Agents D047428 Protein Kinase Inhibitors D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349 M0391958 imatinib mesylát[Imatinib Mesylate] 8A1O1M485B A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. 220127-57-1 (imatinib mesilate) BKJ8M8G5HI M0391958 M0368581 M0391958 M0392345 M0391958 M0400371 M0391958 M0256578 M0391958 M0424454 T000877622 Imatinib Mesylate 2015 03 30 FDA SRS (2013) NLM (2001) NLM (2013) USAN (19XX) T000877622 Mesylate, Imatinib T000877623 Imatinib Methanesulfonate 2015 03 30 NLM (2014) T000877623 Methanesulfonate, Imatinib cze0062202 imatinib mesylát 2015 06 05 cze Thesaurus M0368581 STI571 0 M0391958 M0368581 T422611 STI571 2000 08 25 NLM (2000) T422230 STI-571 2000 08 21 NLM (2000) T422231 STI 571 2000 08 21 NLM (2000) M0392345 Glivec[Gleevec] 0 M0391958 M0392345 T453015 Gleevec 2001 07 02 CA MX US T454053 Glivec 2001 07 13 DE FR UK cze0062206 Glivec 2015 06 05 cze Thesaurus M0400371 ST 1571 0 M0391958 M0400371 T464315 ST 1571 2001 10 03 NLM (2001) T464316 ST1571 2001 10 03 NLM (2001) M0256578 CGP 57148 0 M0391958 M0256578 T286583 CGP 57148 NLM (1996) T415637 CGP57148B 2000 05 31 NLM (2000) T286582 CGP-57148 NLM (1996) T286582 CGP57148 M0424454 Imatinib BKJ8M8G5HI M0391958 M0424454 T000877618 Imatinib 2015 03 30 FDA SRS (2013) INN (19XX) NLM (2002) T000877621 Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide 2015 03 30 NLM (2013) D000068878 trastuzumab[Trastuzumab] 2015 07 01 2015 06 16 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD 2016 (1998) 2016; TRASTUZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 1998-2015 D000970 Antineoplastic Agents D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875 M0291428 trastuzumab[Trastuzumab] P188ANX8CK A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed. 180288-69-1 M0291428 M0291429 T000877625 Trastuzumab 2015 03 30 FDA SRS (2013) INN (19XX) NLM (1998) USAN (19XX) cze0062339 trastuzumab 2015 06 12 cze Thesaurus M0291429 Herceptin[Herceptin] 0 M0291428 M0291429 T321434 Herceptin AU CA DE ES FR IE UK US cze0062340 Herceptin 2015 06 12 cze Thesaurus D000068879 adalimumab[Adalimumab] 2015 07 01 2015 06 16 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD 2016 (2002) 2016; ADALIMUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2002-2015 D000893 Anti-Inflammatory Agents D018501 Antirheumatic Agents D12.776.124.486.485.114.224.060.250 D12.776.124.790.651.114.224.060.250 D12.776.377.715.548.114.224.200.250 M0422769 adalimumab[Adalimumab] FYS6T7F842 A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. M0422769 M0444260 T000877628 Adalimumab 2015 03 30 FDA SRS (2013) INN (19XX) NLM (2002) USAN (19XX) T000877629 D2E7 Antibody 2015 03 30 NLM (2002) T000877629 Antibody, D2E7 cze0062098 adalimumab 2015 06 01 cze Thesaurus M0444260 Humira[Humira] 0 M0422769 M0444260 T529546 Humira 2003 01 02 US cze0062099 Humira 2015 06 01 cze Thesaurus D000068880 NPH insulin lidský[Isophane Insulin, Human] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; ISOPHANE INSULIN, HUMAN was indexed under INSULIN, ISOPHANE and INSULIN, REGULAR, HUMAN 2011-2015 D007004 Hypoglycemic Agents D06.472.699.587.200.300.200.500 D06.472.699.587.200.500.625.500.500 D12.644.548.586.200.300.200.500 D12.644.548.586.200.500.625.500.500 M0423933 NPH insulin lidský[Isophane Insulin, Human] 0 Human isophane insulin that is used to manage BLOOD GLUCOSE levels in patients with DIABETES. M0423933 M0557450 M0423933 M0557451 T000877631 Isophane Insulin, Human 2015 03 30 NLM (2012) T000877631 Human Isophane Insulin T000877631 Insulin, Human Isophane T789332 Protophane 2011 04 19 DE NLM (2012) T021986 Protophan 1984 09 19 DE UNK (19XX) T000877633 NPH Insulin, Human 2015 03 30 NLM (2012) T000877633 Human NPH Insulin T000877633 Insulin, Human NPH T000877634 Insulin, NPH, Human 2015 03 30 NLM (2016) cze0037532 NPH insulin lidský 2009 01 28 cze Thesaurus M0557450 Humulin N 0 M0423933 M0557450 T790193 Humulin N 2011 05 05 NLM (2012) US T790193 N, Humulin M0557451 Novolin N 0 M0423933 M0557451 T790199 Novolin N 2011 05 05 NLM (2012) T790199 N, Novolin T000877632 Insulatard 2015 03 30 NLM (2004) D000068881 exotická zvířata[Animals, Exotic] 2015 07 01 2015 06 16 2016 01 01 Q000276 immunology IM Q000502 physiology PH Q000201 enzymology EN Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000145 classification CL Q000235 genetics GE Q000254 growth & development GD Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY use only when specified by author; coordinate with ANIMALS, WILD or ANIMALS, ZOO as needed 2016 2016 B01.050.050.126 M000604028 exotická zvířata[Animals, Exotic] Animals native to a foreign country or of foreign origin or character, that are not native to the United States. M000604028 M000604029 T000877657 Animals, Exotic 2015 03 31 NLM (2016) T000877635 Exotic Animals 2015 03 30 NLM (2016) T000877635 Animal, Exotic T000877635 Exotic Animal cze0062481 exotická zvířata 2015 06 18 cze Thesaurus M000604029 exotičtí mazlíčci[Exotic Pets] M000604028 M000604029 T000877636 Exotic Pets 2015 03 30 NLM (2016) T000877636 Exotic Pet T000877636 Pet, Exotic T000877636 Pets, Exotic cze0062482 exotičtí mazlíčci 2015 06 18 cze Thesaurus D000068882 paliperidon palmitát[Paliperidone Palmitate] 2015 07 06 2015 07 02 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1993) 2016; PALIPERIDONE was indexed under PYRIMIDINES and ISOXAZOLES, 1993-2015; PALIPERIDONE PALMITATE was indexed under ISOXAZOLES and PALMITATE 2010-2015. D014150 Antipsychotic Agents D058830 Serotonin 5-HT2 Receptor Antagonists D065127 Dopamine D2 Receptor Antagonists D03.383.129.385.650 D03.383.742.592 M0546009 paliperidon palmitát[Paliperidone Palmitate] R8P8USM8FR A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA. 199739-10-1 (paliperidone palmitate) 838F01T721 M0546009 M0211957 M0546009 M0505003 M0546009 M000604030 M0546009 M0211960 T000877670 Paliperidone Palmitate 2015 03 31 FDA SRS (2013) NLM (2010) USAN (19XX) T000877670 Palmitate, Paliperidone cze0063985 paliperidon palmitát 2015 10 15 cze Thesaurus M0211957 paliperidon[Paliperidone] 838F01T721 M0546009 M0211957 T000877667 Paliperidone 2015 03 31 FDA SRS (2015) INN (19XX) NLM (2006) USAN (19XX) T735473 9-OH-risperidone 2009 02 21 NLM (2009) T735473 9 OH risperidone T241961 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one NLM (1993) T000877668 9-Hydroxy-risperidone 2015 03 31 NLM (1993) T000877668 9 Hydroxy risperidone T000877669 9-Hydroxyrisperidone 2015 03 31 NLM (1993) T000877669 9 Hydroxyrisperidone cze0063989 paliperidon 2015 10 15 cze Thesaurus M0505003 Invega[Invega] 0 M0546009 M0505003 T688313 Invega 2006 12 21 NLM (2006) cze0063987 Invega 2015 10 15 cze Thesaurus cze0063988 Xeplion 2015 10 15 cze Thesaurus M000604030 Invega Sustenna 0 M0546009 M000604030 T000877637 Invega Sustenna 2015 03 30 NLM (2016) T000877637 Sustenna, Invega M0211960 R 76477 0 M0546009 M0211960 T241965 R 76477 NLM (1993) T241964 R-76477 NLM (1993) T241964 R76477 D000068884 imunosenescence[Immunosenescence] 2015 07 01 2015 06 16 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Aging (2015) G07.700.320.124.390 G12.460.500 M000604044 imunosenescence[Immunosenescence] The decline in the function of the IMMUNE SYSTEM during aging. T000877671 Immunosenescence 2015 03 31 NLM (2016) cze0063732 imunosenescence 2015 10 07 cze Thesaurus D000068896 canagliflozin[Canagliflozin] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2014) 2016; CANAGLIFLOZIN was indexed under GLUCOSIDES and THIOPHENES 2014-2015 D007004 Hypoglycemic Agents D02.886.778.075 D03.383.903.075 D09.408.348.113 M0550188 canagliflozin[Canagliflozin] 0SAC974Z85 A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES. 928672-86-0 M0550188 M000604077 T000877692 Canagliflozin 2015 04 01 FDA SRS (2013) NLM (2010) USAN (19XX) T000877695 Canagliflozin Hemihydrate 2015 04 01 NLM (2016) T000877695 Hemihydrate, Canagliflozin T000877693 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973 2015 04 01 NLM (2016) cze0062111 canagliflozin 2015 06 01 cze Thesaurus M000604077 Invokana[Invokana] 0 M0550188 M000604077 T000864357 Invokana 2014 08 13 NLM (2014) cze0062110 Invokana 2015 06 01 cze Thesaurus D000068897 iridescence[Iridescence] 2015 07 10 2015 07 09 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016; for OPALESCENCE (NM) use CARBAMIDE PEROXIDE (NM) 1969-2015 2016; OPALESCENCE was indexed under PEROXIDES 1969-2015 G01.590.310 M000604081 iridescence[Iridescence] The changing of the color of an object due to variations in the angle of illumination or observation. M000604081 M000604092 T000877704 Iridescence 2015 04 01 NLM (2016) T000877727 Goniochromism 2015 04 01 NLM (2016) T000877726 Iridescent Coloring 2015 04 01 NLM (2016) T000877726 Coloring, Iridescent T000877726 Colorings, Iridescent T000877726 Iridescent Colorings cze0063728 iridescence 2015 10 07 cze Thesaurus cze0063729 barvoměna 2015 10 07 cze Thesaurus M000604092 opalescence[Opalescence] M000604081 M000604092 T000877728 Opalescence 2015 04 01 NLM (2016) T000877774 Pearlescence 2015 04 02 NLM (2016) cze0063730 opalescence 2015 10 07 cze Thesaurus D000068898 raltegravirum kalicum[Raltegravir Potassium] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2006) 2016; RALTEGRAVIR POTASSIUM was indexed under PYRROLIDINONES 2008-2015; and under ORGANIC CHEMICALS 2006-2008 D019380 Anti-HIV Agents D019428 HIV Integrase Inhibitors D03.383.773.812.752 M000604085 raltegravirum kalicum[Raltegravir Potassium] 43Y000U234 A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION. 22VKV8053U 518048-05-0 (raltegravir) 871038-72-1 (raltegravir potassium) M000604085 M0508784 M000604085 M0495015 M000604085 M0523537 T000877711 Raltegravir Potassium 2015 04 01 FDA SRS (2015) NLM (2016) USAN (19XX) T000877711 Potassium, Raltegravir cze0064025 raltegravirum kalicum 2015 10 15 cze Thesaurus cze0064026 draselná sůl raltegraviru 2015 10 15 cze Thesaurus M0508784 raltegravir[Raltegravir] 22VKV8053U M000604085 M0508784 T000877709 Raltegravir 2015 04 01 FDA SRS (2013) INN (19XX) NLM (2007) cze0064024 raltegravir 2015 10 15 cze Thesaurus M0495015 MK 0518 0 M000604085 M0495015 T666406 MK 0518 2006 02 15 NLM (2006) T666406 0518, MK T666408 MK0518 2006 02 15 NLM (2006) T666407 MK-0518 2006 02 15 NLM (2006) M0523537 Isentress[Isentress] 0 M000604085 M0523537 T723454 Isentress 2008 08 01 NLM (2008) cze0064022 Isentress 2015 10 15 cze Thesaurus D000068899 kombinace léků sitagliptin a metformin[Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2008) 2016; SITAGLIPTIN PHOSPHATE, METFORMIN HYDROCHLORIDE DRUG COMBINATION was indexed under METFORMIN and PYRAZINES 2008-2015 D02.078.370.141.450.500 D03.383.129.799.725.500 D03.383.679.875.500 D26.310.750 M000604087 kombinace léků sitagliptin a metformin[Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination] 0 A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES. M000604087 M0527089 T000881929 Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination 2015 06 16 NLM (2016) T000877713 Sitagliptin Phosphate-Metformin Hydrochloride Drug Combination 2015 04 01 NLM (2016) T000880057 Sitagliptin Phosphate Metformin Hydrochloride Drug Combination 2015 05 20 NLM (2016) cze0062447 kombinace léků sitagliptin a metformin 2015 06 15 cze Thesaurus cze0062446 fixní kombinace fosfátu sitagliptinu a hydrochloridu metforminu 2015 06 15 cze Thesaurus M0527089 Janumet[Janumet] 0 M000604087 M0527089 T000877716 Janumet 2015 04 01 NLM (2008) cze0062445 Janumet 2015 06 15 cze Thesaurus D000068900 sitagliptin fosfát[Sitagliptin Phosphate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; SITAGLIPTIN PHOSPHATE was indexed under PYRAZINES and TRIAZOLES 2005-2015 D000069476 Linagliptin D007004 Hypoglycemic Agents D054795 Incretins D054873 Dipeptidyl-Peptidase IV Inhibitors D03.383.129.799.725 D03.383.679.875 M0498840 sitagliptin fosfát[Sitagliptin Phosphate] TS63EW8X6F A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES. 486460-32-6 (sitagliptin) 494P4635I6 654671-77-9 (sitagliptin phosphate) QFP0P1DV7Z M0498840 M0480816 M0498840 M0584641 M0498840 M0480815 M0498840 M0495062 T000877722 Sitagliptin Phosphate 2015 04 01 FDA SRS (2013) NLM (2006) USAN (19XX) T000877722 Phosphate, Sitagliptin T000877724 Sitagliptin Phosphate Monohydrate 2015 04 01 FDA SRS (2013) NLM (2013) T000877724 Monohydrate, Sitagliptin Phosphate T000877724 Phosphate Monohydrate, Sitagliptin T000877723 Sitagliptin Monophosphate Monohydrate 2015 04 01 FDA SRS (2013) NLM (2013) T000877723 Monohydrate, Sitagliptin Monophosphate T000877723 Monophosphate Monohydrate, Sitagliptin cze0062414 sitagliptin fosfát 2015 06 12 cze Thesaurus cze0062415 fosfát sitagliptinu 2015 06 12 cze Thesaurus M0480816 MK 0431 0 M0498840 M0480816 T630747 MK 0431 2005 02 16 NLM (2005) T630747 0431, MK T630749 MK0431 2005 02 16 NLM (2005) T630748 MK-0431 2005 02 16 NLM (2005) M0584641 Sitagliptin Phosphate Anhydrous 494P4635I6 M0498840 M0584641 T000877725 Sitagliptin Phosphate Anhydrous 2015 04 01 FDA SRS (2013) NLM (2016) T000877725 Anhydrous, Sitagliptin Phosphate T000877725 Phosphate Anhydrous, Sitagliptin M0480815 sitagliptin[Sitagliptin] QFP0P1DV7Z M0498840 M0480815 T000877719 Sitagliptin 2015 04 01 FDA SRS (2013) INN (19XX) NLM (2016) T000877721 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine 2015 04 01 NLM (2005) cze0062418 sitagliptin 2015 06 12 cze Thesaurus M0495062 Januvia[Januvia] 0 M0498840 M0495062 T666530 Januvia 2006 02 16 NLM (2006) cze0062416 Januvia 2015 06 12 cze Thesaurus cze0062419 Tesavel 2015 06 12 cze Thesaurus D000068916 prostorová regrese[Spatial Regression] 2015 07 01 2015 06 16 2016 01 01 2016 2016 Regression Analysis (1996-2015) E05.318.740.750.862 E05.318.740.933.375 N05.715.360.750.695.825 N05.715.360.750.746.375 N06.850.520.830.750.862 N06.850.520.830.933.375 M000604179 prostorová regrese[Spatial Regression] Methods used to take into account and incorporate spatial autocorrelation and regional variation into regression analysis models of data that has spatial dependency, and also to provide information on the spatial relationships among the variables. M000604179 M000604191 T000877821 Spatial Regression 2015 04 03 NLM (2016) T000877821 Regression, Spatial T000877821 Regressions, Spatial T000877821 Spatial Regressions cze0064447 prostorová regrese 2015 11 13 cze Thesaurus M000604191 geograficky vážená regrese[Geographically Weighted Regression] M000604179 M000604191 T000877837 Geographically Weighted Regression 2015 04 03 NLM (2016) T000877837 Geographically Weighted Regressions T000877837 Regression, Geographically Weighted T000877837 Regressions, Geographically Weighted T000877837 Weighted Regression, Geographically T000877837 Weighted Regressions, Geographically cze0064448 geograficky vážená regrese 2015 11 13 cze Thesaurus D000068936 teranostická nanomedicína[Theranostic Nanomedicine] 2015 07 07 2015 07 07 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 Nanomedicine (2013-2015) E01.894 E02.921 H01.603.600.500 H02.403.845 J01.897.520.600.600.500 M000604247 teranostická nanomedicína[Theranostic Nanomedicine] An integrated nano-scale approach to MEDICINE which involves concurrent diagnosis, drug delivery, therapy, and monitoring of therapeutic response. Teranostika - složenina slov terapie a diagnostika. Jedná se o diagnostiku terapie u individuálního pacienta, tzn. o určení, zda zvolená terapie bude účinná, a to ještě před jejím zahájením. Tento moderní termín trefně vystihuje mnoho desetiletí rutinně využívaný diagnostický a terapeutický proces při léčbě vybraných onemocnění na pracovištích nukleární medicíny. (stránky České společnosti nukleární medicíny - cit. http://www.csnm.cz/article/show/aboutDomain/term-dictionary) M000604247 M000605978 T000877891 Theranostic Nanomedicine 2015 04 06 NLM (2016) T000877891 Nanomedicine, Theranostic T000877891 Nanomedicines, Theranostic T000877891 Theranostic Nanomedicines cze0062526 teranostická nanomedicína 2015 06 22 cze Thesaurus cze0062527 theranostická nanomedicína 2015 06 22 cze Thesaurus M000605978 teranostika[Theranostics] M000604247 M000605978 T000880431 Theranostics 2015 05 26 NLM (2016) T000880431 Theranostic cze0062528 teranostika 2015 06 22 cze Thesaurus cze0062529 theranostika 2015 06 22 cze Thesaurus D000068937 kosmeceutika[Cosmeceuticals] 2015 07 01 2015 06 16 2016 01 01 Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Cosmetics (2000-2015) D003358 Cosmetics D26.074 D27.720.269.285 M000604248 kosmeceutika[Cosmeceuticals] 0 COSMETICS that are associated with therapeutic effects. T000877899 Cosmeceuticals 2015 04 06 NLM (2016) cze0063513 kosmeceutika 2015 09 14 cze Thesaurus D000068956 vězňovo dilema[Prisoner Dilemma] 2015 07 09 2015 07 08 2016 01 01 2016; use GAME THEORY 1985-2015 2016; see GAME THEORY 1985-2015 E05.385.500 M0008970 vězňovo dilema[Prisoner Dilemma] A scenario in decision analysis in which two individuals motivated entirely by self-preservation at the expense of the other, end up in a worse state than if they had cooperated with each other in the decision-making process. T017265 Prisoner Dilemma 1984 06 18 UNK (19XX) T017265 Dilemma, Prisoner T017267 Prisoner's Dilemma 1978 03 10 UNK (19XX) T017267 Dilemma, Prisoner's T017266 Prisoners Dilemma 1984 06 18 UNK (19XX) T017266 Dilemma, Prisoners cze0051397 vězňovo dilema 2012 11 02 cze Thesaurus D000068957 rekreační hry[Games, Recreational] 2015 07 01 2015 06 16 2016 01 01 Q000293 injuries IN Q000523 psychology PX 2016 D018910 Video Games I03.450.642.693.465 M000604276 rekreační hry[Games, Recreational] Activity typically involving several individuals for the purpose of leisure, amusement, entertainment or pleasure. T000877919 Games, Recreational 2015 04 07 NLM (2016) T000877919 Game, Recreational T000877919 Recreational Game T000877919 Recreational Games cze0063739 rekreační hry 2015 10 07 cze Thesaurus D000068958 návrat ke sportu[Return to Sport] 2015 07 01 2015 06 16 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000592 standards ST Q000502 physiology PH 2016 2016 I03.450.642.845.605 M000604277 návrat ke sportu[Return to Sport] Resumption of sporting activity following a hiatus or period of absence due to injury or other reasons. M000604277 M000605999 T000877920 Return to Sport 2015 04 07 NLM (2016) T000877920 Return to Sports T000877920 Sport, Return to T000877920 Sports, Return to T000877920 to Sport, Return T000877920 to Sports, Return T000877925 Return to Play 2015 04 07 NLM (2016) T000877925 Play, Return to T000877925 to Play, Return cze0062479 návrat ke sportu 2015 06 18 cze Thesaurus M000605999 návrat ke sportovním aktivitám[Return to Sporting Activities] M000604277 M000605999 T000880481 Return to Sporting Activities 2015 05 26 NLM (2016) cze0062478 návrat ke sportovním aktivitám 2015 06 18 cze Thesaurus D000068959 udržení váhy[Body Weight Maintenance] 2015 07 01 2015 06 15 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 G07.700.320.249.314.120.250 M000604282 udržení váhy[Body Weight Maintenance] Sustaining BODY WEIGHT after BODY WEIGHT CHANGES have been achieved. T000877926 Body Weight Maintenance 2015 04 07 NLM (2016) T000877926 Body Weight Maintenances T000877926 Maintenance, Body Weight T000877926 Maintenances, Body Weight T000877926 Weight Maintenance, Body T000877926 Weight Maintenances, Body cze0062483 udržení váhy 2015 06 18 cze Thesaurus cze0062484 udržení tělesné hmotnosti 2015 06 18 cze Thesaurus D000068960 psychologie funkčního chování[Functional Behavior, Psychology] 2015 07 01 2015 12 02 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 2016 2016 F01.145.437 M000604283 psychologie funkčního chování[Functional Behavior, Psychology] Behaviors driven by distinct MOTIVATION factors that have functionally specific consequences for PERCEPTION; COGNITION, and behavior. Functional behavior often refers to behaviors that appear to be problematic or situationally inappropriate, but have a functional purpose based on the cognitive or motivational state of the individual. T000880483 Functional Behavior, Psychology 2015 05 26 NLM (2016) T000880483 Behavior, Psychology Functional T000880483 Behaviors, Psychology Functional T000880483 Psychology Functional Behavior cze0064086 psychologie funkčního chování 2015 10 21 cze Thesaurus D000068977 concierge medicína[Concierge Medicine] 2015 07 01 2015 06 16 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 Health Services Accessibility (2000-2015) N04.452.758.708.450.500 M000604307 concierge medicína[Concierge Medicine] An arrangement in which a patient pays an annual fee to a physician in exchange for services over and beyond normal insurance-reimbursed services. T000877953 Concierge Medicine 2015 04 08 NLM (2016) T000877953 Medicine, Concierge T000877956 Retainer Medicine 2015 04 08 NLM (2016) T000877956 Medicine, Retainer T000877955 Boutique Medicine 2015 04 08 NLM (2016) T000877955 Medicine, Boutique cze0064517 concierge medicína 2015 11 13 cze Thesaurus cze0064518 concierge zdravotnické služby 2015 11 13 cze Thesaurus D000068997 chytrý telefon[Smartphone] 2015 07 10 2015 07 09 2016 01 01 Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use CELL PHONES 2015 2016; see CELL PHONES 2015 D034201 Computers, Handheld L01.178.847.698.300.250 L01.224.230.260.550.500.500 M0588140 chytrý telefon[Smartphone] A cellular phone with advanced computing and connectivity capability built on an operating system. T849813 Smartphone 2013 09 30 NLM (2015) T849813 Smartphones T852044 Smart Phones 2013 12 13 NLM (2015) T852043 Smart Phone 2013 12 13 NLM (2015) T852043 Phone, Smart T852043 Phones, Smart cze0058645 chytrý telefon 2014 09 19 cze Thesaurus D000068998 zvlhčovače vzduchu[Humidifiers] 2015 07 06 2015 06 23 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 D012121 Respiration, Artificial E07.451 J01.494.650 M000604402 zvlhčovače vzduchu[Humidifiers] Machines that add moisture to the air. T000878053 Humidifiers 2015 04 10 NLM (2016) OBSSR (2016) T000878053 Humidifier cze0063765 zvlhčovače vzduchu 2015 10 07 cze Thesaurus D000069 kulturní asimilace[Acculturation] 1999 01 01 2010 06 25 Q000266 history HI 1963 I01.076.201.450.050 I01.880.853.100.079 M0000098 kulturní asimilace[Acculturation] Process of cultural change in which one group or members of a group assimilate various cultural patterns from another. M0000098 M0000099 T000174 Acculturation 1999 01 01 POPLINE (1986) cze0000076 kulturní asimilace 2006 03 22 M0000099 Assimilation, Cultural M0000098 M0000099 T662103 Assimilation, Cultural 2005 12 13 NLM (2007) T662103 Cultural Assimilation D000069036 inzulin glargin[Insulin Glargine] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; INSULIN GLARGINE was indexed under INSULIN, LONG ACTING 2011-2015; and under INSULIN 1997-2011 D007004 Hypoglycemic Agents D06.472.699.587.200.300.100 D12.644.548.586.200.300.100 M0361589 inzulin glargin[Insulin Glargine] 2ZM8CX04RZ A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS. 160337-95-1 M0361589 M0277529 M0361589 M0398522 T000878229 Insulin Glargine 2015 04 14 FDA SRS (2015) INN (19XX) NLM (2006) USAN (19XX) T000878229 Glargine, Insulin T307530 A21-Gly-B31-Arg-B32-Arg-insulin NLM (1997) T307530 A21 Gly B31 Arg B32 Arg insulin T000878232 Insulin, Glycyl(A21)-Arginyl(B31,B32) 2015 04 14 NLM (1997) T000878230 Glargine 2015 04 14 NLM (2000) T000878231 Insulin, Gly(A21)-Arg(B31,B32) 2015 04 14 NLM (1997) cze0062304 inzulin glargin 2015 06 11 cze Thesaurus cze0062305 insulin glargin 2015 06 11 cze Thesaurus M0277529 HOE 901 0 M0361589 M0277529 T307534 HOE 901 NLM (1997) T307534 901, HOE T307531 HOE-901 NLM (1997) T307531 HOE901 M0398522 Lantus[Lantus] 0 M0361589 M0398522 T458490 Lantus 2001 08 22 NLM (2001) T000878233 Lantus Solostar 2015 04 14 NLM (2016) T000878233 Solostar, Lantus cze0062307 Lantus 2015 06 11 cze Thesaurus D000069056 lurasidon hydrochlorid[Lurasidone Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2008) 2016; LURASIDONE HYDROCHLORIDE was indexed under ISOINDOLES and THIAZOLES 2008-2015 D014150 Antipsychotic Agents D058669 Adrenergic alpha-2 Receptor Antagonists D058830 Serotonin 5-HT2 Receptor Antagonists D065127 Dopamine D2 Receptor Antagonists D02.886.675.414 D03.383.129.708.414 D03.438.513.437 M000604584 lurasidon hydrochlorid[Lurasidone Hydrochloride] O0P4I5851I A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER. 22IC88528T 367514-87-2 (lurasidone) 367514-88-3 (lurasidone hydrochloride) M000604584 M0517366 M000604584 M0517365 M000604584 M000604585 T000878247 Lurasidone Hydrochloride 2015 04 15 FDA SRS (2015) INN (19XX) NLM (2016) USAN (19XX) T000878247 Hydrochloride, Lurasidone T000878248 Lurasidone HCl 2015 04 15 NLM (2016) T000878248 HCl, Lurasidone cze0062381 lurasidon hydrochlorid 2015 06 12 cze Thesaurus M0517366 SM 13496 0 M000604584 M0517366 T712574 SM 13496 2008 01 10 NLM (2008) T712574 13496, SM T712576 SM13496 2008 01 10 NLM (2008) T712575 SM-13496 2008 01 10 NLM (2008) T848249 SM-13,496 2013 08 22 NLM (2014) T848249 SM 13,496 T848249 SM13,496 M0517365 lurasidon[Lurasidone] 22IC88528T M000604584 M0517365 T000878249 Lurasidone 2015 04 15 FDA SRS (2013) INN (19XX) USAN (2008) T712572 N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide 2008 01 10 NLM (2008) cze0062385 lurasidon 2015 06 12 cze Thesaurus M000604585 Latuda[Latuda] 0 M000604584 M000604585 T000878250 Latuda 2015 04 15 NLM (2014) cze0062384 Latuda 2015 06 12 cze Thesaurus D000069057 inzulin detemir[Insulin Detemir] 2015 07 01 2015 06 16 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; INSULIN DETEMIR was indexed under INSULIN, LONG-ACTING 2011-2015; under INSULIN 1997-2011; and under CARRIER PROTEINS 1997-2004 D007004 Hypoglycemic Agents D06.472.699.587.200.300.050 D12.644.548.586.200.300.050 M0274330 inzulin detemir[Insulin Detemir] 4FT78T86XV A recombinant long-acting insulin and HYPOGLYCEMIC AGENT in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS. 169148-63-4 M0274330 M0274327 M0274330 M0454108 T000878252 Insulin Detemir 2015 04 15 FDA SRS (2015) INN (19XX) NLM (2003) USAN (19XX) T000878252 Detemir, Insulin T000878254 Des-(B30)-insulin, Lys(B29)-tetradecanoyl 2015 04 15 NLM (1997) T304331 B29-tetradecanoyl-Lys-B30-des-Ala-insulin NLM (1997) T304331 B29 tetradecanoyl Lys B30 des Ala insulin T000878256 Insulin, Tetradecanoyllysyl(B29)-desalanyl(B30) 2015 04 15 NLM (1997) T304330 12C-Lys(B29)-DB30I NLM (1997) T000878253 Basal Insulin Detemir 2015 04 15 NLM (2008) T000878253 Detemir, Basal Insulin T000878253 Insulin Detemir, Basal T000878255 Insulin, Tetradecanoyl-Lys(B29)-des-Ala(B30) 2015 04 15 NLM (1997) cze0062300 inzulin detemir 2015 06 11 cze Thesaurus cze0062303 insulin detemir 2015 06 11 cze Thesaurus M0274327 NN304 0 M0274330 M0274327 T304332 NN304 NLM (1997) T546267 NN-304 2003 07 16 NLM (2003) T546266 NN 304 2003 07 16 NLM (2003) T546266 304, NN M0454108 Levemir[Levemir] 0 M0274330 M0454108 T546268 Levemir 2003 07 16 NLM (2003) cze0062301 Levemir 2015 06 11 cze Thesaurus D000069058 vardenafil[Vardenafil Dihydrochloride] 2015 07 10 2015 07 10 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; VARDENAFIL DIHYDROCHLORIDE was indexed under IMIDAZOLES and PIPERAZINES 2001-2015 D014665 Vasodilator Agents D058986 Phosphodiesterase 5 Inhibitors D064804 Urological Agents D03.383.129.308.980 D03.383.606.960 M0387384 vardenafil[Vardenafil Dihydrochloride] 5O8R96XMH7 A piperazine derivative, PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION. 224785-90-4 224789-15-5 5M8S2CU0TS IF61NL91H3 UCE6F4125H M0387384 M0446921 M0387384 M0387383 M0387384 M0574171 M0387384 M0574172 T000878259 Vardenafil Dihydrochloride 2015 04 15 FDA SRS (2013) NLM (2011) USAN (19XX) T000878259 Dihydrochloride, Vardenafil cze0062117 vardenafil 2015 06 01 cze Thesaurus M0446921 Levitra[Levitra] 0 M0387384 M0446921 T535402 Levitra 2003 03 13 DE MX NL UK cze0062116 Levitra 2015 06 01 cze Thesaurus M0387383 Vardenafil UCE6F4125H M0387384 M0387383 T000878258 Vardenafil 2015 04 15 FDA SRS (2013) INN (19XX) NLM (2001) USAN (19XX) T447214 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine 2001 05 21 NLM (2001) M0574171 Vardenafil Hydrochloride Trihydrate 5M8S2CU0TS M0387384 M0574171 T000878262 Vardenafil Hydrochloride Trihydrate 2015 04 15 FDA SRS (2015) NLM (2012) T000878262 Hydrochloride Trihydrate, Vardenafil T000878262 Trihydrate, Vardenafil Hydrochloride M0574172 vardenafil hydrochlorid[Vardenafil Hydrochloride] IF61NL91H3 M0387384 M0574172 T000878261 Vardenafil Hydrochloride 2015 04 15 NLM (2012) USAN (2001) T000878261 Hydrochloride, Vardenafil T000878260 Vardenafil Hydrochloride Anhydrous 2015 04 15 FDA SRS (2015) NLM (2012) T000878260 Anhydrous, Vardenafil Hydrochloride T000878260 Hydrochloride Anhydrous, Vardenafil cze0062115 vardenafil hydrochlorid 2015 06 01 cze Thesaurus D000069059 atorvastatin vápník[Atorvastatin Calcium] 2015 07 10 2015 07 10 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1990) 2016; ATORVASTATIN CALCIUM was indexed under HEPTANOIC ACIDS and PYRROLES 1990-2015 D000924 Anticholesteremic Agents D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors D03.383.129.578.075 D10.251.450.200 M0324841 atorvastatin vápník[Atorvastatin Calcium] 48A5M73Z4Q A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors. 110862-48-1 48A5M73Z4Q A0JWA85V8F C0GEJ5QCSO M0324841 M0589476 M0324841 M0179294 M0324841 M0179290 M0324841 M0179293 M0324841 M000604589 T000878266 Atorvastatin Calcium 2015 04 15 NLM (1990) USAN (19XX) USP (19XX) T000878266 Calcium, Atorvastatin T000878268 Atorvastatin Calcium Trihydrate 2015 04 15 NLM (2014) T000878268 Calcium Trihydrate, Atorvastatin T000878268 Trihydrate, Atorvastatin Calcium T000878269 Atorvastatin, Calcium Salt 2015 04 15 NLM (1990) T000878269 Calcium Salt Atorvastatin T000878267 Atorvastatin Calcium Hydrate 2015 04 15 NLM (2014) T000878267 Calcium Hydrate, Atorvastatin T000878267 Hydrate, Atorvastatin Calcium cze0062118 atorvastatin vápník 2015 06 01 cze Thesaurus M0589476 Atorvastatin Calcium Anhydrous C0GEJ5QCSO M0324841 M0589476 T000878270 Atorvastatin Calcium Anhydrous 2015 04 15 NLM (2014) T000878270 Anhydrous, Atorvastatin Calcium T000878270 Calcium Anhydrous, Atorvastatin M0179294 atorvastatin[Atorvastatin] A0JWA85V8F M0324841 M0179294 T000878264 Atorvastatin 2015 04 15 FDA SRS (2013) INN (19XX) USAN (1994) cze0062120 atorvastatin 2015 06 01 cze Thesaurus M0179290 CI 981 0 M0324841 M0179290 T209295 CI 981 NLM (1990) T209296 CI-981 NLM (1990) T209296 CI981 M0179293 Lipitor[Lipitor] 0 M0324841 M0179293 T209298 Lipitor NLM (1990) cze0062119 Lipitor 2015 06 01 cze Thesaurus M000604589 Liptonorm 0 M0324841 M000604589 T000878265 Liptonorm 2015 04 15 NLM (2016) D000069076 mnohočetné zlomeniny[Fractures, Multiple] 2015 07 01 2015 05 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 C26.404.280 C26.640.500 M000604636 mnohočetné zlomeniny[Fractures, Multiple] Injuries involving the breaking of either several bones or one bone in two or more places. T000878315 Fractures, Multiple 2015 04 16 NLM (2016) T000878315 Fracture, Multiple T000878315 Multiple Fracture T000878315 Multiple Fractures cze0062296 mnohočetné zlomeniny 2015 06 11 cze Thesaurus cze0062297 mnohočetné fraktury 2015 06 11 cze Thesaurus cze0062298 vícečetné fraktury 2015 06 11 cze Thesaurus D000069077 konsolidace paměti[Memory Consolidation] 2015 07 01 2015 05 22 2016 01 01 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE 2016 2016 D007858 Learning F02.463.425.540.305.500 M000604637 konsolidace paměti[Memory Consolidation] Neurological process involving the conversion of learned information into long-term memory. T000878317 Memory Consolidation 2015 04 16 NLM (2016) T000878317 Consolidation, Memory T000878317 Consolidations, Memory T000878317 Memory Consolidations cze0062421 konsolidace paměti 2015 06 12 cze Thesaurus D000069078 sérokonverze[Seroconversion] 2015 07 06 2015 07 02 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000502 physiology PH Q000528 radiation effects RE 2016 2016 D055633 Immune System Phenomena G12.425.900 M000604638 sérokonverze[Seroconversion] The appearance of antibodies against causative agents in the blood of individuals during the course of an infection or following immunization. T000878318 Seroconversion 2015 04 16 NLM (2016) T000878318 Seroconversions cze0062639 sérokonverze 2015 06 26 cze Thesaurus D000069079 radiační expozice[Radiation Exposure] 2015 07 01 2015 05 22 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000009 adverse effects AE Q000706 statistics & numerical data SN Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST 2016 2016 D004785 Environmental Pollutants G01.750.748 N06.850.460.350.850 M000604639 radiační expozice[Radiation Exposure] Phenomenon in which organisms are subjected to radiation. T000878319 Radiation Exposure 2015 04 16 NLM (2016) T000878319 Exposure, Radiation cze0064071 radiační expozice 2015 10 20 cze Thesaurus D000069098 čipové karty ve zdravotnictví[Health Smart Cards] 2015 07 01 2015 05 22 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 E05.318.308.940.968.625.750 L01.280.900.968.775.500 L01.313.500.750.300.695.300 N04.452.653.250 N04.452.859.564.650.250 N05.715.360.300.715.500.530.500 N06.850.520.308.940.968.625.500 M000604658 čipové karty ve zdravotnictví[Health Smart Cards] Hand-sized cards with built-in computer chips used for accessing, storing, and protecting patients' medical information. T000878341 Health Smart Cards 2015 04 17 NLM (2016) T000878341 Health Smart Card T000878341 Smart Card, Health T000878341 Smart Cards, Health T000878344 Patient Identification Cards 2015 04 17 NLM (2016) T000878344 Card, Patient Identification T000878344 Cards, Patient Identification T000878344 Identification Card, Patient T000878344 Identification Cards, Patient T000878344 Patient Identification Card T000878343 Smart Cards 2015 04 17 NLM (2016) T000878343 Card, Smart T000878343 Cards, Smart T000878343 Smart Card cze0064080 čipové karty ve zdravotnictví 2015 10 21 cze Thesaurus cze0064083 identifikační čipová karta pacienta 2015 10 21 cze Thesaurus cze0064082 zdravotní čipové karty 2015 10 21 cze Thesaurus D000069177 sekreční systém typu I[Type I Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.500 M000604917 sekreční systém typu I[Type I Secretion Systems] 0 Gram-negative bacterial secretion systems which translocate effectors in a single step across the inner and outer membranes. The one-step secretion is carried out by a channel that passes from the CYTOPLASM, through the inner membrane, PERIPLASMIC SPACE, and outer membrane, to the EXTRACELLULAR SPACE. The specificity of type I secretions systems are determined by the specificity of the three subcomponents forming the channel - an ATP transporter (ATP-BINDING CASSETTE TRANSPORTERS); a membrane fusion protein (MEMBRANE FUSION PROTEINS); and an outer membrane protein (BACTERIAL OUTER MEMBRANE PROTEINS.) T000878676 Type I Secretion Systems 2015 04 22 NLM (2016) T000881666 T1SS Secretion System 2015 06 11 NLM (2016) T000881666 Secretion System, T1SS T000881666 System, T1SS Secretion T000878680 Bacterial Secretion Systems, Type I 2015 04 22 NLM (2016) T000879776 Type 1 Secretion Systems 2015 05 15 NLM (2016) T000878678 Type I Secretion System 2015 04 22 NLM (2016) T000878679 Type 1 Secretion System 2015 04 22 NLM (2016) cze0064129 sekreční systém typu I 2015 10 22 cze Thesaurus D000069178 sekreční systém typu II[Type II Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.750 M000604919 sekreční systém typu II[Type II Secretion Systems] 0 Gram-negative bacterial secretion systems which carry out the secretion of folded proteins.T2SSs secrete folded proteins from the PERIPLASMIC SPACE that have been exported there by SEC TRANSLOCASE or TAT SECRETION SYSTEMS, or they secrete folded proteins directly from the CYTOPLASM. The T2SSs have four substructures, an ATPase, an inner membrane platform, a pseudopilin, and secretin, an outer membrane complex which is a channel for secretion. (This bacterial secretin is not the same as the mammalian hormone also named SECRETIN.) T000878682 Type II Secretion Systems 2015 04 22 NLM (2016) T000881669 T2SS Secretion System 2015 06 11 NLM (2016) T000881669 Secretion System, T2SS T000881669 System, T2SS Secretion T000879779 Type 2 Secretion System 2015 05 15 NLM (2016) T000879780 Bacterial Secretion System, Type II 2015 05 15 NLM (2016) T000879777 Type II Secretion System 2015 05 15 NLM (2016) T000879778 Type 2 Secretion Systems 2015 05 15 NLM (2016) cze0064130 sekreční systém typu II 2015 10 22 cze Thesaurus D000069196 gastrointestinální mikrobiom[Gastrointestinal Microbiome] 2015 07 01 2015 06 16 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 G06.755.375 G16.500.275.157.049.100.500.375 N06.230.124.049.100.500.250 M000604969 gastrointestinální mikrobiom[Gastrointestinal Microbiome] All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. M000604969 M000604970 T000878738 Gastrointestinal Microbiome 2015 04 23 NLM (2016) T000878738 Gastrointestinal Microbiomes T000878738 Microbiome, Gastrointestinal T000878738 Microbiomes, Gastrointestinal T000878739 Gut Microflora 2015 04 23 NLM (2016) T000878739 Microflora, Gut T000878744 Gut Microbiota 2015 04 23 NLM (2016) T000878744 Gut Microbiotas T000878744 Microbiota, Gut T000878744 Microbiotas, Gut T000878741 Gastrointestinal Flora 2015 04 23 NLM (2016) T000878741 Flora, Gastrointestinal T000878742 Gut Flora 2015 04 23 NLM (2016) T000878742 Flora, Gut T000878743 Gastrointestinal Microbiota 2015 04 23 NLM (2016) T000878743 Gastrointestinal Microbiotas T000878743 Microbiota, Gastrointestinal T000878743 Microbiotas, Gastrointestinal T000878737 Gut Microbiome 2015 04 23 NLM (2016) T000878737 Gut Microbiomes T000878737 Microbiome, Gut T000878737 Microbiomes, Gut T000878740 Gastrointestinal Microflora 2015 04 23 NLM (2016) T000878740 Microflora, Gastrointestinal cze0063754 gastrointestinální mikrobiom 2015 10 07 cze Thesaurus cze0063757 gastrointestinální mikroflóra 2015 10 07 cze Thesaurus cze0063758 střevní mikrobiota 2015 10 07 cze Thesaurus M000604970 střevní mikrobiom[Intestinal Microbiome] M000604969 M000604970 T000878745 Intestinal Microbiome 2015 04 23 NLM (2016) T000878745 Intestinal Microbiomes T000878745 Microbiome, Intestinal T000878745 Microbiomes, Intestinal T000878747 Intestinal Microbiota 2015 04 23 NLM (2016) T000878747 Intestinal Microbiotas T000878747 Microbiota, Intestinal T000878747 Microbiotas, Intestinal T000878748 Intestinal Microflora 2015 04 23 NLM (2016) T000878748 Microflora, Intestinal T000878746 Intestinal Flora 2015 04 23 NLM (2016) T000878746 Flora, Intestinal cze0063755 střevní mikrobiom 2015 10 07 cze Thesaurus cze0063756 intestinální mikrobiom 2015 10 07 cze Thesaurus D000069216 výzkum antikoncepčního chování[Contraceptive Prevalence Surveys] 2015 07 07 2015 07 06 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use DATA COLLECTION 1987-2015 2016; see DATA COLLECTION 1987-2015 E05.318.308.980.313 L01.280.960.233 N05.715.360.300.800.313 N06.850.520.308.980.313 M0005665 výzkum antikoncepčního chování[Contraceptive Prevalence Surveys] Surveys that measure the usage rate of CONTRACEPTIVE DEVICES or CONTRACEPTIVE AGENTS. Průzkumy, které měří stupeň využití antikoncepčních prostředků nebo antikoncepčních látek. T010547 Contraceptive Prevalence Surveys 1986 12 31 POPLINE (1980) T010547 Contraceptive Prevalence Survey T010547 Survey, Contraceptive Prevalence T010547 Surveys, Contraceptive Prevalence cze0064563 výzkum antikoncepčního chování 2015 11 16 cze Thesaurus cze0064561 contraceptive prevalence surveys 2015 11 16 cze Thesaurus cze0064562 výzkum CPS 2015 11 16 cze Thesaurus D000069236 perikardiální tekutina[Pericardial Fluid] 2015 07 01 2015 06 26 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000166 cytology CY Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000378 metabolism ME 2016 2016 Pericardial Effusion (1967-2015) Pericardium (1964-2015) A07.541.795.500 A10.615.789.470.500 A12.207.270.651 M000605189 perikardiální tekutina[Pericardial Fluid] Watery fluid produced in the serous and visceral pericardium surrounding the surface of the HEART. T000881544 Pericardial Fluid 2015 06 09 NLM (2016) T000881544 Fluid, Pericardial T000881544 Fluids, Pericardial T000881544 Pericardial Fluids T000879042 Pericardium Fluid 2015 05 01 NLM (2016) T000879042 Fluid, Pericardium T000879042 Fluids, Pericardium T000879042 Pericardium Fluids cze0063992 perikardiální tekutina 2015 10 15 cze Thesaurus D000069237 artrocentéza[Arthrocentesis] 2015 07 09 2015 07 09 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Paracentesis (1996-2015) E01.370.225.998.329.465 E02.800.550.310 E04.665.600.465 E05.200.998.329.465 M000605536 artrocentéza[Arthrocentesis] Puncture and aspiration of fluid (e.g., SYNOVIAL FLUID) from a joint cavity. It is used sometimes to irrigate or administer drugs into a joint cavity. Punkce kloubu. Provádí se k odběru kloubní tekutiny (srov. hydrartros) pro její vyšetření či pro snížení napětí kloubního pouzdra (např. po úrazu), ev. k vpravení léku do kloubu. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) M000605536 M000605192 T000879662 Arthrocentesis 2015 05 14 NLM (2016) T000879662 Arthrocenteses cze0062572 artrocentéza 2015 06 24 cze Thesaurus cze0062577 punkce kloubu 2015 06 24 cze Thesaurus M000605192 artrocentéza čelistního kloubu[Arthrocentesis,Temporomandibular Joint] Aspiration of SYNOVIAL FLUID from the TEMPOROMANDIBULAR JOINT cavity. M000605536 M000605192 T000879051 Arthrocentesis,Temporomandibular Joint 2015 05 01 NLM (2016) T000879051 Arthrocentesis,Temporomandibular Joints T000879051 Joint, Arthrocentesis,Temporomandibular T000879051 Joints, Arthrocentesis,Temporomandibular T000879140 Arthrocentesis, TMJ 2015 05 04 NLM (2016) T000879140 Arthrocenteses, TMJ T000879140 TMJ Arthrocenteses T000879140 TMJ Arthrocentesis T000879069 Temporomandibular Joint Aspiration 2015 05 01 NLM (2016) T000879069 Aspiration, Temporomandibular Joint T000879069 Aspirations, Temporomandibular Joint T000879069 Joint Aspiration, Temporomandibular T000879069 Joint Aspirations, Temporomandibular T000879069 Temporomandibular Joint Aspirations T000879047 Temporomandibular Joint Arthrocentesis 2015 05 01 NLM (2016) T000879047 Arthrocenteses, Temporomandibular Joint T000879047 Arthrocentesis, Temporomandibular Joint T000879047 Joint Arthrocenteses, Temporomandibular T000879047 Joint Arthrocentesis, Temporomandibular T000879047 Temporomandibular Joint Arthrocenteses T000879068 Aspiration,Temporomandibular Joint 2015 05 01 NLM (2016) T000879068 Aspiration,Temporomandibular Joints T000879068 Joint, Aspiration,Temporomandibular T000879068 Joints, Aspiration,Temporomandibular cze0062573 artrocentéza čelistního kloubu 2015 06 24 cze Thesaurus cze0062574 artrocentéza temporomandibulárního kloubu 2015 06 24 cze Thesaurus cze0062576 punkce temporomandibulárního kloubu 2015 06 24 cze Thesaurus cze0062575 výplach čelistního kloubu 2015 06 24 cze Thesaurus D000069258 thorakocentéza[Thoracentesis] 2015 07 09 2015 07 09 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Paracentesis (1966-2015) D010996 Pleural Effusion D011030 Pneumothorax E01.370.225.998.329.810 E02.800.550.810 E04.665.600.810 E05.200.998.329.810 M000605267 thorakocentéza[Thoracentesis] Aspiration of fluid or air from the THORACIC CAVITY. It is coupled sometimes with the administration of drugs into the PLEURAL CAVITY. T000879146 Thoracentesis 2015 05 04 NLM (2016) T000879146 Thoracenteses T000879666 Pleural Aspiration 2015 05 14 NLM (2016) T000879666 Aspiration, Pleural T000879666 Aspirations, Pleural T000879666 Pleural Aspirations T000879665 Chest Aspiration 2015 05 14 NLM (2016) T000879665 Aspiration, Chest T000879665 Aspirations, Chest T000879665 Chest Aspirations T000879148 Thoracocentesis 2015 05 04 NLM (2016) T000879148 Thoracocenteses T000879664 Pleurocentesis 2015 05 14 NLM (2016) T000879664 Pleurocenteses cze0062665 thorakocentéza 2015 06 26 cze Thesaurus cze0062667 hrudní punkce 2015 06 26 cze Thesaurus cze0062666 vyšetření pleurální tekutiny 2015 06 26 cze Thesaurus D000069259 superficiální muskuloaponeurotický systém[Superficial Musculoaponeurotic System] 2015 07 09 2015 07 08 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU 2016 2016 Face (1976-2015) Neck (1976-2015) D015361 Rhytidoplasty A01.456.505.875 A01.598.500 M000605269 superficiální muskuloaponeurotický systém[Superficial Musculoaponeurotic System] Layer between the superficial fat compartment and superficial facial muscles in the head and the neck. SMAS je podkožní vazivověsvalový obal pokrývající hlavu a krk. Je pokračováním temporální fascie, rozprostírá se přes parotidální fascii a platysma. Jeho vlákna se upínají do nad ním uložené kůže. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) M000605269 M000605714 T000879149 Superficial Musculoaponeurotic System 2015 05 04 NLM (2016) T000879149 Musculoaponeurotic System, Superficial T000879149 Musculoaponeurotic Systems, Superficial T000879149 Superficial Musculoaponeurotic Systems T000879149 System, Superficial Musculoaponeurotic T000879149 Systems, Superficial Musculoaponeurotic T000879973 Superficial Musculo-Aponeurotic System 2015 05 19 NLM (2016) T000879973 Musculo-Aponeurotic System, Superficial T000879973 Musculo-Aponeurotic Systems, Superficial T000879973 Superficial Musculo Aponeurotic System T000879973 Superficial Musculo-Aponeurotic Systems T000879973 System, Superficial Musculo-Aponeurotic T000879973 Systems, Superficial Musculo-Aponeurotic T000879972 Superficial Musculo-aponeurotic System (SMAS) 2015 05 19 NLM (2016) T000879972 Superficial Musculo aponeurotic System (SMAS) T000879972 Superficial Musculo-aponeurotic Systems (SMAS) T000879972 System, Superficial Musculo-aponeurotic (SMAS) cze0063892 superficiální muskuloaponeurotický systém 2015 10 15 cze Thesaurus cze0063894 SMAS 2015 10 15 cze Thesaurus cze0063899 povrchní muskuloaponeurotický systém obličeje 2015 10 15 cze Thesaurus cze0063893 superficiální muskuloaponeurotický systém tváře 2015 10 15 cze Thesaurus M000605714 sval kožní[Platysma Muscle] M000605269 M000605714 T000879975 Platysma Muscle 2015 05 19 NLM (2016) T000879975 Muscle, Platysma T000879975 Muscles, Platysma T000879975 Platysma Muscles cze0063895 sval kožní 2015 10 15 cze Thesaurus cze0063896 platysma 2015 10 15 cze Thesaurus cze0063897 platyzma 2015 10 15 cze Thesaurus D000069261 invadopodia[Podosomes] 2015 07 09 2015 07 09 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA Q000235 genetics GE 2016 2016 Cell Surface Extensions (2006-2015) Extracellular Matrix (1996-2015) D040542 Mechanotransduction, Cellular A11.284.180.695 A11.436.275.841 M000605276 invadopodia[Podosomes] Actin-rich adhesive structures found at the ventral surface of metazoan ENDOTHELIAL CELLS. When found in cultured cancer cells they are referred to as invadopodia. These are matrix-degrading structures composed of an ACTIN CYTOSKELETON core and an INTEGRINS-containing ring complex. T000879160 Podosomes 2015 05 05 NLM (2016) T000879160 Podosome T000879168 Invadopodium 2015 05 05 NLM (2016) T000879168 Invadopodiums T000879161 Invadopodia 2015 05 05 NLM (2016) T000879163 Invadosomes 2015 05 05 NLM (2016) T000879163 Invadosome cze0063998 invadopodia 2015 10 15 cze Thesaurus cze0064000 invadosomy 2015 10 15 cze Thesaurus cze0063999 podozomy 2015 10 15 cze Thesaurus D000069262 plantární plocha[Plantar Plate] 2015 07 09 2015 07 09 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU 2016 2016 Metatarsophalangeal Joint (1979-2015) A02.165.308.650 A02.513.514.538 A02.835.583.378.531.500 A02.835.583.378.900.500 A02.835.583.512.538 A10.165.382.350.400 M000605286 plantární plocha[Plantar Plate] Fibrocartilaginous ligament at the metatarsophalangeal and the interphalangeal joint of the toe. T000879179 Plantar Plate 2015 05 05 NLM (2016) T000879179 Plantar Plates T000879179 Plate, Plantar T000879179 Plates, Plantar T000879181 Plantar Ligament 2015 05 05 NLM (2016) T000879181 Ligament, Plantar T000879181 Ligaments, Plantar T000879181 Plantar Ligaments T000879185 Ligamenta Tarsometatarsea Plantaria 2015 05 05 NLM (2016) T000879185 Ligamenta Tarsometatarsea Plantarias T000879185 Tarsometatarsea Plantaria, Ligamenta T000879183 Ligamenta Plantaria 2015 05 05 NLM (2016) T000879183 Ligamenta Plantarias T000879183 Plantaria, Ligamenta T000879183 Plantarias, Ligamenta T000879184 Volar Ligament, Toe 2015 05 05 NLM (2016) T000879180 Toe Volar Plate 2015 05 05 NLM (2016) T000879180 Plate, Toe Volar T000879180 Plates, Toe Volar T000879180 Toe Volar Plates T000879180 Volar Plate, Toe T000879180 Volar Plates, Toe T000879182 Toe Volar Ligament 2015 05 05 NLM (2016) T000879182 Ligament, Toe Volar T000879182 Ligaments, Toe Volar T000879182 Toe Volar Ligaments T000879182 Volar Ligaments, Toe cze0064531 plantární plocha 2015 11 16 cze Thesaurus cze0064200 ligamenta plantaria 2015 10 26 cze Thesaurus cze0064532 ligamenta tarsometatarsea plantaria 2015 11 16 cze Thesaurus D000069263 Fallopia[Fallopia] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000633 toxicity TO Q000201 enzymology EN Q000166 cytology CY Q000506 poisoning PO Q000009 adverse effects AE Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000821 virology VI Q000528 radiation effects RE Q000033 anatomy & histology AH Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000378 metabolism ME 2016 2016 B01.650.940.800.575.100.825.359 M000605290 Fallopia[Fallopia] Genus of flowering herbaceous perennial plants and vines in the family Polygonaceae. T000879200 Fallopia 2015 05 05 NLM (2016) cze0062540 Fallopia 2015 06 22 cze Thesaurus cze0062541 opletka 2015 06 22 cze Thesaurus D000069278 korekce transpozice velkých arterií[Arterial Switch Operation] 2015 07 06 2015 06 22 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Cardiac Surgical Procedures (1990-2015) Transposition of Great Vessels (1971-2015) D014188 Transposition of Great Vessels E04.100.376.031 E04.928.220.055 M000605313 korekce transpozice velkých arterií[Arterial Switch Operation] Surgical procedure for anatomical correction of transposed great arteries (e.g., DOUBLE OUTLET RIGHT VENTRICLE). M000605313 M000605678 M000605313 M000605824 M000605313 M000605677 M000605313 M000605676 T000879268 Arterial Switch Operation 2015 05 06 NLM (2016) T000879268 Arterial Switch Operations T000879268 Operation, Arterial Switch T000879268 Operations, Arterial Switch T000879271 Atrial Switch Operation 2015 05 06 NLM (2016) T000879271 Atrial Switch Operations T000879271 Operation, Atrial Switch T000879271 Operations, Atrial Switch T000879273 Atrial Switch Procedure 2015 05 06 NLM (2016) T000879273 Atrial Switch Procedures T000879273 Procedure, Atrial Switch T000879273 Procedures, Atrial Switch T000879922 Atrial Switch Repair 2015 05 18 NLM (2016) T000879922 Atrial Switch Repairs T000879922 Repair, Atrial Switch T000879922 Repairs, Atrial Switch T000879275 Double-Switch Technique 2015 05 06 NLM (2016) T000879275 Double Switch Technique T000879275 Double-Switch Techniques T000879275 Technique, Double-Switch T000879275 Techniques, Double-Switch T000879276 Double-Switch Operation 2015 05 06 NLM (2016) T000879276 Double Switch Operation T000879276 Double-Switch Operations T000879276 Operation, Double-Switch T000879276 Operations, Double-Switch T000879277 Arterial Switch Technique 2015 05 06 NLM (2016) T000879277 Arterial Switch Techniques T000879277 Technique, Arterial Switch T000879277 Techniques, Arterial Switch T000879912 Atrial Switch Technique 2015 05 18 NLM (2016) T000879912 Atrial Switch Techniques T000879912 Technique, Atrial Switch T000879912 Techniques, Atrial Switch T000879270 Arterial Switch Procedure 2015 05 06 NLM (2016) T000879270 Arterial Switch Procedures T000879270 Procedure, Arterial Switch T000879270 Procedures, Arterial Switch T000879274 Double-Switch Procedure 2015 05 06 NLM (2016) T000879274 Double Switch Procedure T000879274 Double-Switch Procedures T000879274 Procedure, Double-Switch T000879274 Procedures, Double-Switch cze0064667 korekce transpozice velkých arterií 2015 11 20 cze Thesaurus cze0063564 arteriální switch operace 2015 09 18 cze Thesaurus cze0063563 korekce transpozice velkých artérií 2015 09 18 cze Thesaurus M000605678 Rastelliho operace[Rastelli Operation] M000605313 M000605678 T000879278 Rastelli Operation 2015 05 06 NLM (2016) T000879278 Operation, Rastelli T000879919 Rastelli Technique 2015 05 18 NLM (2016) T000879919 Technique, Rastelli T000879921 Rastelli Repair 2015 05 18 NLM (2016) T000879921 Repair, Rastelli T000879279 Rastelli Procedure 2015 05 06 NLM (2016) T000879279 Procedure, Rastelli cze0063569 Rastelliho operace 2015 09 18 cze Thesaurus cze0063570 Rastelliho korekce 2015 09 18 cze Thesaurus M000605824 Senningova operace[Senning Operation] M000605313 M000605824 T000880214 Senning Operation 2015 05 21 NLM (2016) T000880214 Operation, Senning T000880215 Senning Procedure 2015 05 21 NLM (2016) T000880215 Procedure, Senning cze0063568 Senningova operace 2015 09 18 cze Thesaurus M000605677 Jateneho operace[Jatene Procedure] M000605313 M000605677 T000879915 Jatene Procedure 2015 05 18 NLM (2016) T000879915 Procedure, Jatene T000879917 Jatene Technique 2015 05 18 NLM (2016) T000879917 Technique, Jatene T000879916 Jatene Operation 2015 05 18 NLM (2016) T000879916 Operation, Jatene cze0063566 Jateneho operace 2015 09 18 cze Thesaurus M000605676 Mustardova operace[Mustard Repair] M000605313 M000605676 T000879913 Mustard Repair 2015 05 18 NLM (2016) T000879913 Repair, Mustard T000879920 Mustard Operation 2015 05 18 NLM (2016) T000879920 Operation, Mustard T000879914 Mustard Procedure 2015 05 18 NLM (2016) T000879914 Procedure, Mustard cze0063565 Mustardova operace 2015 09 18 cze Thesaurus cze0063567 Mustardova korekce 2015 09 18 cze Thesaurus D000069279 refrakterní epilepsie[Drug Resistant Epilepsy] 2015 07 01 2015 06 26 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Epilepsy (1968-2015) C10.228.140.490.125 M000605316 refrakterní epilepsie[Drug Resistant Epilepsy] Epileptic condition in which adequate trials of two tolerated and appropriately chosen and used ANTIEPILEPTIC DRUGS schedules to achieve sustained seizure freedom failed. T000879280 Drug Resistant Epilepsy 2015 05 06 NLM (2016) T000879280 Drug Resistant Epilepsies T000879280 Epilepsies, Drug Resistant T000879280 Resistant Epilepsies, Drug T000879280 Resistant Epilepsy, Drug T000879281 Epilepsy, Drug Resistant 2015 05 06 NLM (2016) T000879286 Epilepsy, Intractable 2015 05 06 NLM (2016) T000879283 Intractable Epilepsy 2015 05 06 NLM (2016) T000879283 Epilepsies, Intractable T000879283 Intractable Epilepsies T000879285 Epilepsy, Drug Refractory 2015 05 06 NLM (2016) T000882556 Medication Resistant Epilepsy 2015 06 26 NLM (2016) T000882556 Epilepsies, Medication Resistant T000882556 Epilepsy, Medication Resistant T000882556 Medication Resistant Epilepsies T000882556 Resistant Epilepsies, Medication T000882556 Resistant Epilepsy, Medication T000879282 Drug Refractory Epilepsy 2015 05 06 NLM (2016) T000879282 Drug Refractory Epilepsies T000879282 Epilepsies, Drug Refractory T000879282 Refractory Epilepsies, Drug T000879282 Refractory Epilepsy, Drug cze0062611 refrakterní epilepsie 2015 06 24 cze Thesaurus cze0062612 epilepsie odolávající léčbě 2015 06 24 cze Thesaurus cze0062613 farmakorezistentní epilepsie 2015 06 24 cze Thesaurus D000069280 elektrokortikografie[Electrocorticography] 2015 07 01 2015 06 22 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000187 drug effects DE Q000706 statistics & numerical data SN Q000639 trends TD Q000528 radiation effects RE Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Electroencephalography (1965-2015) E01.370.376.300.294 E01.370.405.245.431 M000605317 elektrokortikografie[Electrocorticography] Recording of brain electrical activities in which the electrodes are placed directly on the CEREBRAL CORTEX. Snímání elektrické aktivity mozku pomocí elektrod umístěných na povrchu kůry mozkové. M000605317 M000605320 M000605317 M000605318 T000879287 Electrocorticography 2015 05 06 NLM (2016) T000879287 Electrocorticographies T000879293 Electrocorticography (EcoG) 2015 05 06 NLM (2016) T000879293 Electrocorticographies (EcoG) T000879296 Intracranial Electroencephalography 2015 05 06 NLM (2016) T000879296 Electroencephalographies, Intracranial T000879296 Electroencephalography, Intracranial T000879296 Intracranial Electroencephalographies T000879292 Intracranial EEG 2015 05 06 NLM (2016) T000879292 EEG, Intracranial T000879292 EEGs, Intracranial T000879292 Intracranial EEGs cze0062605 elektrokortikografie 2015 06 24 cze Thesaurus cze0062607 EcoG 2015 06 24 cze Thesaurus cze0062606 intrakraniální elektroencefalografie 2015 06 24 cze Thesaurus M000605320 extraoperativní elektrokortikografie[Extraoperative Electrocorticography] M000605317 M000605320 T000879299 Extraoperative Electrocorticography 2015 05 06 NLM (2016) T000879299 Electrocorticographies, Extraoperative T000879299 Electrocorticography, Extraoperative T000879299 Extraoperative Electrocorticographies T000879295 Extraoperative ECoG 2015 05 06 NLM (2016) T000879295 ECoG, Extraoperative T000879295 ECoGs, Extraoperative T000879295 Extraoperative ECoGs cze0064066 extraoperativní elektrokortikografie 2015 10 20 cze Thesaurus cze0064068 extraoperativní ECoG 2015 10 20 cze Thesaurus M000605318 intraoperativní elektrokortikografie[Intraoperative Electrocorticography] M000605317 M000605318 T000879288 Intraoperative Electrocorticography 2015 05 06 NLM (2016) T000879288 Electrocorticographies, Intraoperative T000879288 Electrocorticography, Intraoperative T000879288 Intraoperative Electrocorticographies T000879291 Intraoperative ECoG 2015 05 06 NLM (2016) T000879291 ECoG, Intraoperative T000879291 ECoGs, Intraoperative T000879291 Intraoperative ECoGs cze0064067 intraoperativní elektrokortikografie 2015 10 20 cze Thesaurus cze0064069 intraoperativní ECoG 2015 10 20 cze Thesaurus D000069281 autoimunitní hypofyzitida[Autoimmune Hypophysitis] 2015 07 01 2015 06 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Pituitary Diseases (1967-2015) C10.228.140.617.738.100 C19.700.080 C20.111.273 M000605321 autoimunitní hypofyzitida[Autoimmune Hypophysitis] Immune-mediated inflammation of the PITUITARY GLAND often associated with other autoimmune diseases (e.g., HASHIMOTO DISEASE; GRAVES DISEASE; and ADDISON DISEASE). M000605321 M000605885 M000605321 M000605880 M000605321 M000605325 M000605321 M000605323 M000605321 M000605884 M000605321 M000605322 T000879300 Autoimmune Hypophysitis 2015 05 06 NLM (2016) T000879300 Autoimmune Hypophysitides T000879300 Hypophysitides, Autoimmune T000879306 Lymphoid Hypophysitis 2015 05 06 NLM (2016) T000879306 Hypophysitides, Lymphoid T000879306 Hypophysitis, Lymphoid T000879306 Lymphoid Hypophysitides T000879303 Hypophysitis, Lymphocytic 2015 05 06 NLM (2016) T000879301 Hypophysitis, Autoimmune 2015 05 06 NLM (2016) T000879302 Lymphocytic Hypophysitis 2015 05 06 NLM (2016) T000879302 Hypophysitides, Lymphocytic T000879302 Lymphocytic Hypophysitides cze0062584 autoimunitní hypofyzitida 2015 06 24 cze Thesaurus cze0062585 lymfocytární hypofyzitida 2015 06 24 cze Thesaurus M000605885 Lymphocytic Panhypophysitis M000605321 M000605885 T000880329 Lymphocytic Panhypophysitis 2015 05 22 NLM (2016) T000880329 Lymphocytic Panhypophysitides T000880329 Panhypophysitides, Lymphocytic T000880329 Panhypophysitis, Lymphocytic M000605880 Anti-PIT-1 Antibody Syndrome M000605321 M000605880 T000880314 Anti-PIT-1 Antibody Syndrome 2015 05 22 NLM (2016) T000880314 Anti PIT 1 Antibody Syndrome T000880314 Anti-PIT-1 Antibody Syndromes T000880314 Antibody Syndrome, Anti-PIT-1 T000880314 Antibody Syndromes, Anti-PIT-1 T000880314 Syndrome, Anti-PIT-1 Antibody T000880314 Syndromes, Anti-PIT-1 Antibody M000605325 granulomatózní hypofyzitida[Idiopathic Granulomatous Hypophysitis] M000605321 M000605325 T000879309 Idiopathic Granulomatous Hypophysitis 2015 05 06 NLM (2016) T000879309 Granulomatous Hypophysitides, Idiopathic T000879309 Granulomatous Hypophysitis, Idiopathic T000879309 Hypophysitides, Idiopathic Granulomatous T000879309 Hypophysitis, Idiopathic Granulomatous T000879309 Idiopathic Granulomatous Hypophysitides cze0062587 granulomatózní hypofyzitida 2015 06 24 cze Thesaurus M000605323 IgG4-Related Hypophysitis M000605321 M000605323 T000879305 IgG4-Related Hypophysitis 2015 05 06 NLM (2016) T000879305 Hypophysitides, IgG4-Related T000879305 Hypophysitis, IgG4-Related T000879305 IgG4 Related Hypophysitis T000879305 IgG4-Related Hypophysitides M000605884 lymfocytární infundibuloneurohypofyzitida[Lymphocytic Infundibuloneurohypophysitis] M000605321 M000605884 T000880328 Lymphocytic Infundibuloneurohypophysitis 2015 05 22 NLM (2016) T000880328 Infundibuloneurohypophysitides, Lymphocytic T000880328 Infundibuloneurohypophysitis, Lymphocytic T000880328 Lymphocytic Infundibuloneurohypophysitides cze0062589 lymfocytární infundibuloneurohypofyzitida 2015 06 24 cze Thesaurus M000605322 lymfocytární adenohypofyzitida[Lymphocytic Adenohypophysitis] M000605321 M000605322 T000879304 Lymphocytic Adenohypophysitis 2015 05 06 NLM (2016) T000879304 Adenohypophysitides, Lymphocytic T000879304 Adenohypophysitis, Lymphocytic T000879304 Lymphocytic Adenohypophysitides cze0062588 lymfocytární adenohypofyzitida 2015 06 24 cze Thesaurus D000069282 kanalikulitida[Canaliculitis] 2015 07 09 2015 07 07 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 (2010) 2016; was indexed under CORNEAL ULCER 2010-2015 and DACRYOCYSTITIS 2010-2015 Dacryocystitis (1977-2015) Lacrimal Apparatus Diseases (1973-2015) D003320 Corneal Ulcer C11.496.221.500 M000605328 kanalikulitida[Canaliculitis] Inflammation and infection of the lacrimal canaliculus area in the LACRIMAL APPARATUS. T745715 Canaliculitis 2009 02 24 ORD (2010) T745715 Canaliculitides T000879317 Lacrimal Canaliculitis 2015 05 06 NLM (2016) T000879317 Canaliculitides, Lacrimal T000879317 Canaliculitis, Lacrimal T000879317 Lacrimal Canaliculitides cze0062580 kanalikulitida 2015 06 24 cze Thesaurus cze0062582 infekce slzného kanálku 2015 06 24 cze Thesaurus cze0062581 zánět odvodných slzných cest 2015 06 24 cze Thesaurus cze0062583 zánět slzných kanálků 2015 06 24 cze Thesaurus D000069283 rituximab[Rituximab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (1995) 2016; RITUXIMAB was indexed under ANTIBODIES, MONOCLONAL, MURINE-DERIVED 1995-2016 D000970 Antineoplastic Agents D007155 Immunologic Factors D018501 Antirheumatic Agents D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785 M0244307 rituximab[Rituximab] 4F4X42SYQ6 A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. 174722-31-7 M0244307 M0445644 M0244307 M0244308 M0244307 M000603610 M0244307 M0244306 T000879319 Rituximab 2015 05 06 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1995) USAN (19XX) T000879320 CD20 Antibody, Rituximab 2015 05 06 NLM (2006) T000879320 Antibody, Rituximab CD20 T000879320 Rituximab CD20 Antibody cze0063967 rituximab 2015 10 15 cze Thesaurus M0445644 Mabthera[Mabthera] 0 M0244307 M0445644 T532586 Mabthera 2003 02 12 AU DE FR MX UK cze0063968 Mabthera 2015 10 15 cze Thesaurus M0244308 IDEC-C2B8 Antibody 0 M0244307 M0244308 T000879321 IDEC-C2B8 Antibody 2015 05 06 NLM (1995) T000879321 IDEC C2B8 Antibody T000879321 IDECC2B8 Antibody T274310 IDEC-C2B8 NLM (1995) T274310 IDEC C2B8 T274310 IDECC2B8 M000603610 GP2013 0 M0244307 M000603610 T000877062 GP2013 2015 03 19 NLM (2015) M0244306 Rituxan 0 M0244307 M0244306 T274311 Rituxan CA US D000069284 systémy translokace proteinů[Protein Translocation Systems] 2015 07 06 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D026901 Membrane Transport Proteins D05.500.890 M000605401 systémy translokace proteinů[Protein Translocation Systems] 0 Multiprotein complexes that carry out PROTEIN TRANSPORT across CELL MEMBRANES. M000605401 M000605330 T000879447 Protein Translocation Systems 2015 05 08 NLM (2016) T000879447 Systems, Protein Translocation T000879447 Translocation Systems, Protein cze0064527 systémy translokace proteinů 2015 11 16 cze Thesaurus M000605330 systémy sekrece proteinů[Protein Secretion Systems] 0 Multiprotein complexes that carry out protein SECRETION PROCESSES. M000605401 M000605330 T000879322 Protein Secretion Systems 2015 05 06 NLM (2016) T000879322 Secretion Systems, Protein cze0064525 systémy sekrece proteinů 2015 11 16 cze Thesaurus cze0064526 systémy proteinové sekrece 2015 11 16 cze Thesaurus D000069285 infliximab[Infliximab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (1997) 2016; INFLIXIMAB was indexed under ANTIBODIES, MONOCLONAL 1997-2015 D003879 Dermatologic Agents D005765 Gastrointestinal Agents D018501 Antirheumatic Agents D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642 M0282056 infliximab[Infliximab] B72HH48FLU A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Infliximab patří do skupiny tzv. biologické terapie. Je to chimérická humánní monoklonální protilátka proti tumor nekrotizujicímu faktoru alfa, složená z 25% myších a 75% lidských sekvencí. Hlavní současné indikace jeho použití jsou revmatoidní artritida, ankylozujicí spondylartritida a Crohnova nemoc. 170277-31-3 M0282056 M0353684 T000879325 Infliximab 2015 05 06 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1997) USAN (19XX) T312059 MAb cA2 NLM (1997) T000879326 Monoclonal Antibody cA2 2015 05 06 NLM (1997) T000879326 Antibody cA2, Monoclonal T000879326 cA2, Monoclonal Antibody cze0063777 infliximab 2015 10 07 cze Thesaurus M0353684 Remicade[Remicade] 0 M0282056 M0353684 T402865 Remicade 1999 12 16 AU CA DE ES FR IE NL US cze0063778 Remicade 2015 10 07 cze Thesaurus cze0063780 Inflectra 2015 10 07 cze Thesaurus cze0063779 Remsima 2015 10 07 cze Thesaurus D000069286 bortezomib[Bortezomib] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2000) 2016; BORTEZOMIB was indexed under BORONIC ACIDS and PYRAZINES 2000-2015 D000970 Antineoplastic Agents D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450 M0350110 bortezomib[Bortezomib] 69G8BD63PP A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. 179324-69-7 M0350110 M0560884 M0350110 M0446631 M0350110 M0446632 T000879328 Bortezomib 2015 05 06 FDA SRS (2015) INN (19XX) NLM (2002) USAN (19XX) cze0063133 bortezomib 2015 08 17 cze Thesaurus M0560884 LDP-341 0 M0350110 M0560884 T796689 LDP-341 2011 09 09 NLM (2011) T796689 LDP 341 T796689 LDP341 M0446631 PS 341 0 M0350110 M0446631 T400169 PS 341 1999 11 17 NLM (1999) T400169 341, PS T543230 PS-341 2003 06 14 NLM (2003) T543230 PS341 M0446632 Velcade[Velcade] 0 M0350110 M0446632 T534905 Velcade 2003 03 10 NLM (2003) cze0063136 Velcade 2015 08 17 cze Thesaurus D000069287 capecitabinum[Capecitabine] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1998) 2016; CAPECITABINE was indexed under DEOXYCYTIDINE and FLUOROURACIL 1998-2015 D000964 Antimetabolites, Antineoplastic D03.383.742.680.245.500.425 D03.383.742.698.875.404.425 D13.570.230.329.313 D13.570.685.245.500.425 M0287377 capecitabinum[Capecitabine] 6804DJ8Z9U A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER. 154361-50-9 (capecitabine) M0287377 M0374572 T000879330 Capecitabine 2015 05 06 BAN (19XX) FDA SRS (2013) INN (19XX) USAN (1997) T317381 N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine NLM (1998) cze0063127 capecitabinum 2015 08 17 cze Thesaurus cze0063129 kapecitabin 2015 08 17 cze Thesaurus M0374572 Xeloda[Xeloda] 0 M0287377 M0374572 T400883 Xeloda 1999 11 26 NLM (1999) cze0063130 Xeloda 2015 08 17 cze Thesaurus cze0063128 Capecitabine 2015 08 17 cze Thesaurus cze0063132 Coloxet 2015 08 17 cze Thesaurus cze0063131 Ecansya 2015 08 17 cze Thesaurus D000069289 encystace parazita[Parasite Encystment] 2015 07 06 2015 06 26 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 D053058 Trophozoites G07.700.320.500.550.875 M000605354 encystace parazita[Parasite Encystment] Process by which certain parasites such as GIARDIA and ENTAMOEBA convert from the TROPHOZOITE to SCHIZONT when exposed to stress. T000879369 Parasite Encystment 2015 05 07 NLM (2016) T000879369 Encystment, Parasite T000879369 Encystments, Parasite T000879369 Parasite Encystments T000881543 Protozoan Encystment 2015 06 09 NLM (2016) T000881543 Encystment, Protozoan T000881543 Encystments, Protozoan T000881543 Protozoan Encystments T000879373 Parasite Encystation 2015 05 07 NLM (2016) T000879373 Encystation, Parasite T000879373 Encystations, Parasite T000879373 Parasite Encystations T000879376 Protozoan Encystation 2015 05 07 NLM (2016) T000879376 Encystation, Protozoan T000879376 Encystations, Protozoan T000879376 Protozoan Encystations T000879370 Protozoan Parasite Encysment 2015 05 07 NLM (2016) T000879370 Encysment, Protozoan Parasite T000879370 Encysments, Protozoan Parasite T000879370 Parasite Encysment, Protozoan T000879370 Parasite Encysments, Protozoan T000879370 Protozoan Parasite Encysments T000879372 Protozoan Parasite Encystation 2015 05 07 NLM (2016) T000879372 Encystation, Protozoan Parasite T000879372 Encystations, Protozoan Parasite T000879372 Parasite Encystation, Protozoan T000879372 Parasite Encystations, Protozoan T000879372 Protozoan Parasite Encystations cze0064027 encystace parazita 2015 10 15 cze Thesaurus cze0064028 encystace protozoálních parazitů 2015 10 15 cze Thesaurus D000069290 incizní kýla[Incisional Hernia] 2015 07 01 2015 06 26 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Hernia (1966-2015) C23.300.707.945 C23.550.767.500 M000605359 incizní kýla[Incisional Hernia] Protrusion of tissue at or near the site of an incision from a previous surgery. T000879378 Incisional Hernia 2015 05 07 NLM (2016) T000879378 Hernia, Incisional T000879378 Hernias, Incisional T000879378 Incisional Hernias T000879379 Postoperative Hernia 2015 05 07 NLM (2016) T000879379 Hernia, Postoperative T000879379 Hernias, Postoperative T000879379 Postoperative Hernias cze0063766 incizní kýla 2015 10 07 cze Thesaurus cze0063771 hernia in cicatricae 2015 10 07 cze Thesaurus cze0063770 hernia incisionalis 2015 10 07 cze Thesaurus cze0063767 incizní hernie 2015 10 07 cze Thesaurus cze0063769 kýla v jizvě 2015 10 07 cze Thesaurus cze0063768 pooperační kýla 2015 10 07 cze Thesaurus D000069292 pyroptóza[Pyroptosis] 2015 07 06 2015 06 26 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Apoptosis (2005-2015) D009336 Necrosis G04.299.139.160.530 M000605362 pyroptóza[Pyroptosis] Type of programmed cell death associated with infection by intracellular pathogens. It is characterized by INFLAMMASOME formation; activation of CASPASE 1; and CYTOKINES mediated inflammation. T000879387 Pyroptosis 2015 05 07 NLM (2016) T000879387 Pyroptoses T000879389 Inflammatory Apoptosis 2015 05 07 NLM (2016) T000879389 Apoptoses, Inflammatory T000879389 Apoptosis, Inflammatory T000879389 Inflammatory Apoptoses T000880020 Pyroptotic Cell Death 2015 05 20 NLM (2016) T000880020 Cell Death, Pyroptotic T000880020 Cell Deaths, Pyroptotic T000880020 Death, Pyroptotic Cell T000880020 Deaths, Pyroptotic Cell T000880020 Pyroptotic Cell Deaths T000882574 Caspase-1 Dependent Cell Death 2015 06 26 NLM (2016) T000882574 Caspase 1 Dependent Cell Death cze0062723 pyroptóza 2015 07 02 cze Thesaurus cze0062724 buněčná smrt pomocí pyroptózy 2015 07 02 cze Thesaurus cze0062725 buněčná smrt závislá na aktivaci kaspázy-1 2015 07 02 cze Thesaurus D000069293 plazmablastický lymfom[Plasmablastic Lymphoma] 2015 07 09 2015 07 09 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000648 ultrastructure UL Q000737 chemistry CH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000098 blood supply BS Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Lymphoma, Large B-Cell, Diffuse (1998-2015) C04.557.386.480.150.585.500 C15.604.515.569.480.150.585.500 C20.683.515.761.480.150.585.500 M000605363 plazmablastický lymfom[Plasmablastic Lymphoma] Malignant lymphoma composed of large B lymphoid cells which have the immunophenotype of plasma cells and a predilection for the ORAL CAVITY. T000879390 Plasmablastic Lymphoma 2015 05 07 NLM (2016) T000879390 Lymphoma, Plasmablastic T000879390 Lymphomas, Plasmablastic T000879390 Plasmablastic Lymphomas T000879392 Plasmablasts Diffuse Large B-cell Lymphoma 2015 05 07 NLM (2016) T000879392 Plasmablasts Diffuse Large B cell Lymphoma T000879391 Plasmablastic Diffuse Large B-cell Lymphoma 2015 05 07 NLM (2016) T000879391 Plasmablastic Diffuse Large B cell Lymphoma cze0063996 plazmablastický lymfom 2015 10 15 cze Thesaurus cze0063997 difúzní plazmablastický B-velkobuněčný lymfom 2015 10 15 cze Thesaurus D000069294 TAT systém[Twin-Arginine-Translocation System] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D05.500.890.750 M000605364 TAT systém[Twin-Arginine-Translocation System] 0 Protein translocase in BACTERIA or CHLOROPLASTS that exports or secretes folded proteins. In GRAM-NEGATIVE BACTERIA, twin-arginine translocase (TAT) is involved in the export of folded proteins to the PERIPLASM. In chloroplasts, TAT is involved in transporting folded proteins across the membranes of THYLAKOIDS. T000879393 Twin-Arginine-Translocation System 2015 05 07 NLM (2016) T000879393 Twin Arginine Translocation System T000879798 Twin-Arginine-Translocation Systems 2015 05 15 NLM (2016) T000879798 Systems, Twin-Arginine-Translocation T000879798 Twin Arginine Translocation Systems T000882517 Twin-Arginine-Transport System 2015 06 25 NLM (2016) T000882517 System, Twin-Arginine-Transport T000882517 Twin Arginine Transport System T000879797 TAT Secretion Systems 2015 05 15 NLM (2016) T000879797 Secretion Systems, TAT T000879797 Systems, TAT Secretion cze0064292 TAT systém 2015 11 06 cze Thesaurus cze0064293 TAT sekreční systém 2015 11 06 cze Thesaurus cze0064294 twin-arginin translokace 2015 11 06 cze Thesaurus D000069295 sekreční karcinom slinných žlaz analogický karcinomu prsu[Mammary Analogue Secretory Carcinoma] 2015 07 01 2015 06 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000648 ultrastructure UL Q000737 chemistry CH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000098 blood supply BS Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Carcinoma (2010-2015) C04.557.470.200.588 M000605365 sekreční karcinom slinných žlaz analogický karcinomu prsu[Mammary Analogue Secretory Carcinoma] A malignant neoplasm of epithelial cells of the SALIVARY GLANDS, with microcystic architecture, low-grade nuclei, and granular vacuolated cytoplasm. T000879394 Mammary Analogue Secretory Carcinoma 2015 05 07 NLM (2016) cze0064297 sekreční karcinom slinných žlaz analogický karcinomu prsu 2015 11 06 cze Thesaurus cze0064298 MASC 2015 11 06 cze Thesaurus D000069296 sekreční systém typu III[Type III Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.875 M000605371 sekreční systém typu III[Type III Secretion Systems] 0 Multiprotein transmembrane complexes in GRAM-NEGATIVE BACTERIA involved in either the secretion of effector proteins from the bacterial cytoplasm into host cells, or the secretion and assembly of flagellar components. The major component of the T3SSs is called the injectosome or needle complex. T000879402 Type III Secretion Systems 2015 05 07 NLM (2016) T000881673 T3SS Secretion System 2015 06 11 NLM (2016) T000881673 Secretion System, T3SS T000881673 System, T3SS Secretion T000879783 Type 3 Secretion System 2015 05 15 NLM (2016) T000879784 Bacterial Secretion System, Type III 2015 05 15 NLM (2016) T000879781 Type III Secretion System 2015 05 15 NLM (2016) T000879782 Type 3 Secretion Systems 2015 05 15 NLM (2016) cze0064131 sekreční systém typu III 2015 10 22 cze Thesaurus D000069316 acne conglobata[Acne Conglobata] 2015 07 01 2015 06 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Acne Vulgaris (1964-2015) C17.800.030.150.500 C17.800.794.111.500 M000605396 acne conglobata[Acne Conglobata] Severe and chronic form of acne characterized by large, burrowing abscesses associated with disfigurement. T000879435 Acne Conglobata 2015 05 08 NLM (2016) T000879435 Acne Conglobatas T000879435 Conglobata, Acne T000879435 Conglobatas, Acne cze0062571 acne conglobata 2015 06 24 cze Thesaurus D000069319 sekreční systém typu IV[Type IV Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.937 M000605402 sekreční systém typu IV[Type IV Secretion Systems] 0 Multiprotein complexes that transport single proteins, multiprotein complexes, and nucleoprotein complexes from the CYTOPLASM into the EXTRACELLULAR SPACE or into recipient cells. T4SSs are found in GRAM-NEGATIVE BACTERIA, while homologous components to T4SSs are found in GRAM-POSTIVE BACTERIA. T000879449 Type IV Secretion Systems 2015 05 08 NLM (2016) T000881675 Bacterial Secretion Systems, Type IV 2015 06 11 NLM (2016) T000881676 T4SS Secretion System 2015 06 11 NLM (2016) T000881676 Secretion System, T4SS T000881676 System, T4SS Secretion T000879787 Type 4 Secretion System 2015 05 15 NLM (2016) T000879785 Type IV Secretion System 2015 05 15 NLM (2016) T000879786 Type 4 Secretion Systems 2015 05 15 NLM (2016) T000881674 Bacterial Secretion System, Type IV 2015 06 11 NLM (2016) cze0064132 sekreční systém typu IV 2015 10 22 cze Thesaurus D000069320 sekreční systém typu V[Type V Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.968 M000605406 sekreční systém typu V[Type V Secretion Systems] 0 Secretion systems of GRAM-NEGATIVE BACTERIA (single membrane proteins or multiprotein complexes) that carry out secretion of proteins from the PERIPLASMIC SPACE to the EXTRACELLULAR SPACE via a beta-barrel transmembrane pore. There are several T5SS subtypes: T5aSS monomeric autotransporters, T5bSS two-partner secretions systems (TPSS), T5cSS trimeric autotransporters, T5dSS fused two-partner secretion systems, and T5eSS autotransporters with inverted domains. M000605406 M000605417 M000605406 M000606683 T000879639 Type V Secretion Systems 2015 05 13 NLM (2016) T000879792 Bacterial Secretion System, Type V 2015 05 15 NLM (2016) T000879791 Type 5 Secretion System 2015 05 15 NLM (2016) T000879789 Type V Secretion System 2015 05 15 NLM (2016) T000879790 Type 5 Secretion Systems 2015 05 15 NLM (2016) cze0064133 sekreční systém typu V 2015 10 22 cze Thesaurus M000605417 autotransportéry[Autotransporters] 0 Subtypes of type V secretion systems that contain both a translocator domain and a passenger domain in a single polypeptide. After the passenger domain is transported to the extracellular millieu it is cleaved off as the mature secreted protein. M000605406 M000605417 T000879494 Autotransporters 2015 05 08 NLM (2016) cze0064134 autotransportéry 2015 10 22 cze Thesaurus M000606683 two-partner sekreční systémy[Two-Partner Secretion Systems] 0 M000605406 M000606683 T000881677 Two-Partner Secretion Systems 2015 06 11 NLM (2016) T000881677 Secretion Systems, Two-Partner T000881677 Systems, Two-Partner Secretion T000881677 Two Partner Secretion Systems cze0064135 two-partner sekreční systémy 2015 10 22 cze Thesaurus cze0064136 TPS systémy 2015 10 22 cze Thesaurus D000069321 přenos mitochondriální DNA[Mitochondrial Replacement Therapy] 2015 07 01 2015 06 26 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Cellular Reprogramming (2014-2015) E02.875.800.750.350 E05.200.500.380.250 E05.393.085.250 E05.820.800.750.350 M000605407 přenos mitochondriální DNA[Mitochondrial Replacement Therapy] In vitro fertilization technique that uses mitochondrial DNA from a healthy donor in order to prevent the transmission of MITOCHONDRIAL DISEASE. T000879469 Mitochondrial Replacement Therapy 2015 05 08 NLM (2016) T000879469 Mitochondrial Replacement Therapies T000879469 Replacement Therapies, Mitochondrial T000879469 Replacement Therapy, Mitochondrial T000879469 Therapies, Mitochondrial Replacement T000879469 Therapy, Mitochondrial Replacement T000879471 Pronuclear Transfer Technique 2015 05 08 NLM (2016) T000879471 Pronuclear Transfer Techniques T000879471 Technique, Pronuclear Transfer T000879471 Techniques, Pronuclear Transfer T000879471 Transfer Technique, Pronuclear T000879471 Transfer Techniques, Pronuclear T000879470 Spindle Transfer Technique 2015 05 08 NLM (2016) T000879470 Spindle Transfer Techniques T000879470 Technique, Spindle Transfer T000879470 Techniques, Spindle Transfer T000879470 Transfer Technique, Spindle T000879470 Transfer Techniques, Spindle cze0064198 přenos mitochondriální DNA 2015 10 26 cze Thesaurus cze0064199 transplantace mitochondriálních genů 2015 10 26 cze Thesaurus D000069322 samoexpandibilní metalické stenty[Self Expandable Metallic Stents] 2015 07 01 2015 06 22 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000941 ethics ES Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Stents (2014-2015) E07.695.750.750 M000605408 samoexpandibilní metalické stenty[Self Expandable Metallic Stents] Cylindrical metallic tubes that are inserted to hold open a structure in order to treat vascular, bile duct, esophageal and other tubular organ constrictions. T000879472 Self Expandable Metallic Stents 2015 05 08 NLM (2016) T000879475 Self Expandable Metallic Stent 2015 05 08 NLM (2016) T000879476 Self Expandable Metal Stent 2015 05 08 NLM (2016) T000879473 Self Expandable Metal Stents 2015 05 08 NLM (2016) cze0064072 samoexpandibilní metalické stenty 2015 10 20 cze Thesaurus cze0064073 samoexpandibilní metalický stent 2015 10 20 cze Thesaurus D000069336 neurovaskulární vazba[Neurovascular Coupling] 2015 07 09 2015 07 09 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Cerebrovascular Circulation (1997-2015) D006439 Hemodynamics G09.330.190.163.159.500 M000605476 neurovaskulární vazba[Neurovascular Coupling] Mechanism by which changes in neural activity are tightly associated with regional cortical HEMODYNAMICS and metabolism changes. The association is often inferred from NEUROIMAGING signals (e.g., fMRI; or NIR SPECTROSCOPY). M000605476 M000605582 T000879545 Neurovascular Coupling 2015 05 11 NLM (2016) T000879545 Coupling, Neurovascular T000879545 Couplings, Neurovascular T000879545 Neurovascular Couplings cze0064087 neurovaskulární vazba 2015 10 21 cze Thesaurus M000605582 hemodynamická odezva v mozkové kůře[Cortical Hemodynamic Responses] M000605476 M000605582 T000881541 Cortical Hemodynamic Responses 2015 06 09 NLM (2016) T000881541 Hemodynamic Response, Cortical T000881541 Hemodynamic Responses, Cortical T000881541 Response, Cortical Hemodynamic T000881541 Responses, Cortical Hemodynamic T000881542 Cortical Hemodynamic Response 2015 06 09 NLM (2016) T000879761 Hemodynamic Brain Response 2015 05 15 NLM (2016) T000879761 Brain Response, Hemodynamic T000879761 Brain Responses, Hemodynamic T000879761 Response, Hemodynamic Brain T000879761 Responses, Hemodynamic Brain T000879762 Hemodynamic Brain Responses 2015 05 15 NLM (2016) cze0064510 hemodynamická odezva v mozkové kůře 2015 11 13 cze Thesaurus cze0064511 hemodynamická odpověď mozku 2015 11 13 cze Thesaurus D000069337 fúze ledvin[Fused Kidney] 2015 07 01 2015 06 22 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 Kidney Diseases (1963-2015) C12.706.445 C13.351.875.420 C16.131.939.445 M000605982 fúze ledvin[Fused Kidney] Congenital fusion of two kidneys. M000605982 M000605983 M000605982 M000605980 M000605982 M000605477 T000879548 Fused Kidney 2015 05 11 NLM (2016) T000879548 Fused Kidneys T000879548 Kidney, Fused T000879548 Kidneys, Fused T000879549 Fusion of Kidney 2015 05 11 NLM (2016) T000879549 Kidney Fusion T000879549 Kidney Fusions T000879553 Renal Fusion 2015 05 11 NLM (2016) T000879553 Fusion, Renal T000879553 Fusions, Renal T000879553 Renal Fusions T000879551 Congenital Fusion of Kidneys 2015 05 11 NLM (2016) T000879552 Congenital Lobulation of Kidneys 2015 05 11 NLM (2016) T000879547 Lobulated Kidney 2015 05 11 NLM (2016) T000879547 Kidney, Lobulated T000879547 Kidneys, Lobulated T000879547 Lobulated Kidneys T000879550 Lobulation of Kidney 2015 05 11 NLM (2016) T000879550 Kidney Lobulation T000879550 Kidney Lobulations cze0062736 fúze ledvin 2015 07 02 cze Thesaurus cze0062738 lalůčková ledvina 2015 07 02 cze Thesaurus cze0062737 lobulace ledvin 2015 07 02 cze Thesaurus M000605983 ektopie ledvin zkřížená[Crossed Fused Ectopia] Congenital anomaly in which both kidneys are located on the same side often fused. M000605982 M000605983 T000880436 Crossed Fused Ectopia 2015 05 26 NLM (2016) T000880436 Crossed Fused Ectopias T000880437 Crossed Fused Ectopia of Kidneys 2015 05 26 NLM (2016) cze0062735 ektopie ledvin zkřížená 2015 07 02 cze Thesaurus cze0062734 zkřížená renální ektopie 2015 07 02 cze Thesaurus M000605980 ren discoides[Cake Kidney] Congenital fusion of the embryonic kidneys forming a single renal parenchymal mass. Ren discoides - ledvina koláčová (ren fungiformis, scutulatus) ledviny jsou srostlé celou mediální plochou ve společný okrouhlý útvar (obě ledviny splynuly v jediný orgán). M000605982 M000605980 T000880433 Cake Kidney 2015 05 26 NLM (2016) T000880433 Cake Kidneys T000880433 Kidney, Cake T000880433 Kidneys, Cake T000880438 Pelvic Cake Kidney 2015 05 26 NLM (2016) T000880438 Pelvic Cake Kidneys cze0062731 ren discoides 2015 07 02 cze Thesaurus cze0062732 koláčovitá ledvina 2015 07 02 cze Thesaurus cze0064441 ren fungiformis 2015 11 12 cze Thesaurus cze0062733 ren scutulatus 2015 07 02 cze Thesaurus M000605477 podkovovitá ledvina[Horseshoe Kidney] Congenital fusion of two kidneys in the lower midline. Ren arcuatus, unguliformis - ledvina podkovovitá, vývojová odchylka vzniklá splynutím dolních pólů obou ledvin před velkými cévami. M000605982 M000605477 T000879546 Horseshoe Kidney 2015 05 11 NLM (2016) T000879546 Horseshoe Kidneys T000879546 Kidney, Horseshoe T000879546 Kidneys, Horseshoe cze0062729 podkovovitá ledvina 2015 07 02 cze Thesaurus cze0062728 podkovovité ledviny 2015 07 02 cze Thesaurus cze0062730 ren arcuatus 2015 07 02 cze Thesaurus cze0064533 ren unguliformis 2015 11 16 cze Thesaurus D000069338 neuropatologie[Neuropathology] 2015 07 02 2015 07 01 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST use for the discipline only (education, history, etc.) only 2016 2016 Nervous System Diseases (1965-2015) H01.158.610.184 H02.403.600.250 H02.403.650.375 M000605478 neuropatologie[Neuropathology] The branch of medicine and biomedical science concerned with diseases of the nervous system. M000605478 M000605480 T000879554 Neuropathology 2015 05 11 NLM (2016) T000879554 Neuropathologies cze0063916 neuropatologie 2015 10 15 cze Thesaurus M000605480 neuropatolog[Neuropathologists] M000605478 M000605480 T000879563 Neuropathologists 2015 05 11 NLM (2016) T000879563 Neuropathologist cze0063917 neuropatolog 2015 10 15 cze Thesaurus D000069339 trachelektomie[Trachelectomy] 2015 07 01 2015 06 26 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Hysterectomy (1988-2015) E04.950.300.399.690 M000605483 trachelektomie[Trachelectomy] Surgical removal or resection of the CERVIX UTERI. T000879568 Trachelectomy 2015 05 11 NLM (2016) T000879568 Trachelectomies T000879570 Vaginal Cervicectomy 2015 05 11 NLM (2016) T000879570 Cervicectomies, Vaginal T000879570 Cervicectomy, Vaginal T000879570 Vaginal Cervicectomies T000879571 Vaginal Trachelectomy 2015 05 11 NLM (2016) T000879571 Trachelectomies, Vaginal T000879571 Trachelectomy, Vaginal T000879571 Vaginal Trachelectomies T000879569 Cervicectomy 2015 05 11 NLM (2016) T000879569 Cervicectomies cze0062597 trachelektomie 2015 06 24 cze Thesaurus cze0062598 vaginální cervicektomie 2015 06 24 cze Thesaurus D000069340 depreskripce[Deprescriptions] 2015 07 06 2015 06 26 2016 01 01 2016 2016 Drug Prescriptions (2007-2015) D000067561 Potentially Inappropriate Medication List D057970 Inappropriate Prescribing E02.319.698.500 M000605491 depreskripce[Deprescriptions] Directions written to discontinue use of PRESCRIPTION DRUGS in order to reduce unnecessary and/or excessive medications (see POLYPHARMACY), DRUG SIDE EFFECTS and ADVERSE DRUG REACTION. M000605491 M000605486 T000880333 Deprescriptions 2015 05 22 NLM (2016) T000880333 Deprescription cze0064449 depreskripce 2015 11 13 cze Thesaurus M000605486 snížení množství předepsaných léků[Deprescribing] M000605491 M000605486 T000879574 Deprescribing 2015 05 11 NLM (2016) cze0064450 snížení množství předepsaných léků 2015 11 13 cze Thesaurus D000069341 tranzitní zdravotní péče[Transitional Care] 2015 07 01 2015 06 26 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 Continuity of Patient Care (1987-2015) E02.204.812 E02.760.940 N02.421.192.812 N02.421.585.940 N04.590.233.727.210.812 M000605492 tranzitní zdravotní péče[Transitional Care] Health care provided during a transition to a different mode of care (e.g., TRANSITION TO ADULT CARE). T000879580 Transitional Care 2015 05 11 NLM (2016) T000879580 Care, Transitional T000879580 Cares, Transitional T000879580 Transitional Cares T000879581 Transition Care 2015 05 11 NLM (2016) T000879581 Transition Cares cze0064185 tranzitní zdravotní péče 2015 10 26 cze Thesaurus cze0064186 zdravotní péče při změně režimu, lékaře 2015 10 26 cze Thesaurus D000069342 nadužívání zdravotní péče[Medical Overuse] 2015 07 09 2015 07 07 2016 01 01 Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000517 prevention & control PC Q000706 statistics & numerical data SN Q000639 trends TD 2016; for HEALTH SERVICES OVERUTILIZATION use HEALTH SERVICES MISUSE 1978-2015 2016; for HEALTH SERVICES OVERUTILIZATION see HEALTH SERVICES MISUSE 1978-2015 Unnecessary Procedures (2014-2015) D003951 Diagnostic Errors D019338 Polypharmacy D057970 Inappropriate Prescribing D062787 Drug Overdose N02.421.380.450 N05.300.150.395.450 M000605497 nadužívání zdravotní péče[Medical Overuse] Excessive or unnecessary utilization of health services by patients or physicians. Nadměrné a nadbytečné využívání zdravotnických služeb pacienty nebo lékaři. Overdiagnosis - situace, kdy je prostřednictvím cíleného screeningu u bezpříznakového klienta diagnostikován nádor, který by se v průběhu jeho života klinickými příznaky vůbec neprojevil. Overtreatment - situace, kdy je prostřednictvím cíleného screeningu u bezpříznakového klienta diagnostikován a léčen nádor, který by se v průběhu jeho života klinickými příznaky vůbec neprojevil. M000605497 M000605500 M000605497 M000605503 M000605497 M000605498 M000605497 M000605501 T000879591 Medical Overuse 2015 05 12 NLM (2016) T000879591 Medical Overuses T000879591 Overuse, Medical T000879591 Overuses, Medical T000870973 Overuse, Health Services 2014 11 19 NLM (2016) T019102 Overutilization of Health Services 1977 05 12 OVERUTIL OF HEALTH SERV UNK (19XX) T019101 Health Services Overutilization 1977 05 12 HEALTH SERV OVERUTIL UNK (19XX) T019101 Overutilization, Health Services T000870970 Health Services Overuse 2014 11 19 NLM (2016) T000870970 Health Services Overuses T000870970 Overuses, Health Services cze0064172 nadužívání zdravotní péče 2015 10 26 cze Thesaurus cze0064171 nadužití zdravotní péče 2015 10 26 cze Thesaurus M000605500 zbytečná diagnóza[Overdiagnosis] M000605497 M000605500 T000879597 Overdiagnosis 2015 05 12 NLM (2016) T000879597 Overdiagnoses cze0064173 zbytečná diagnóza 2015 10 26 cze Thesaurus cze0064177 overdiagnosis 2015 10 26 cze Thesaurus M000605503 multimedikamentózní terapie[Overmedication] M000605497 M000605503 T000879600 Overmedication 2015 05 12 NLM (2016) T000879600 Overmedications cze0064178 multimedikamentózní terapie 2015 10 26 cze Thesaurus cze0064179 overmedication 2015 10 26 cze Thesaurus M000605498 Medical Preference Misdiagnosis M000605497 M000605498 T000879592 Medical Preference Misdiagnosis 2015 05 12 NLM (2016) T000879592 Medical Preference Misdiagnoses T000879592 Misdiagnoses, Medical Preference T000879592 Misdiagnosis, Medical Preference T000879592 Preference Misdiagnoses, Medical T000879592 Preference Misdiagnosis, Medical T000879594 Unwanted Medical Care 2015 05 12 NLM (2016) T000879594 Medical Care, Unwanted T000879594 Medical Cares, Unwanted T000879594 Unwanted Medical Cares T000879593 Preference Misdiagnosis 2015 05 12 NLM (2016) T000879593 Misdiagnoses, Preference T000879593 Misdiagnosis, Preference T000879593 Preference Misdiagnoses M000605501 přehnaná péče[Overtreatment] M000605497 M000605501 T000879598 Overtreatment 2015 05 12 NLM (2016) T000879598 Overtreatments cze0064174 přehnaná péče 2015 10 26 cze Thesaurus cze0064176 nadbytečná péče 2015 10 26 cze Thesaurus cze0064175 overtreatment 2015 10 26 cze Thesaurus D000069343 rozhraní kost/implantát[Bone-Implant Interface] 2015 07 06 2015 06 26 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000294 innervation IR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000473 pathology PA Q000601 surgery SU 2016 2016 Osseointegration (1989-2015) D016348 Osseointegration A02.835.232.022 A10.165.265.183 E07.695.125 M000605508 rozhraní kost/implantát[Bone-Implant Interface] Region of interaction between the bone and PROSTHESES AND IMPLANTS which becomes bonded through cellular and extracellular interactions similar to OSSEOINTEGRATION. T000879605 Bone-Implant Interface 2015 05 12 NLM (2016) T000879605 Bone Implant Interface T000879605 Bone-Implant Interfaces T000879605 Interface, Bone-Implant T000879605 Interfaces, Bone-Implant T000879746 Bone-Prosthesis Interface 2015 05 15 NLM (2016) T000879746 Bone Prosthesis Interface T000879746 Bone-Prosthesis Interfaces T000879746 Interface, Bone-Prosthesis T000879746 Interfaces, Bone-Prosthesis cze0062633 rozhraní kost/implantát 2015 06 26 cze Thesaurus cze0062634 interface kost-implantát 2015 06 26 cze Thesaurus cze0062635 rozhraní implantát a kost 2015 06 26 cze Thesaurus cze0062636 rozhraní mezi implantátem a kostním štěpem 2015 06 26 cze Thesaurus D000069347 erlotinib[Erlotinib Hydrochloride] 2015 07 10 2015 07 10 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1999) 2016; ERLOTINIB HYDROCHLORIDE was indexed under QUINAZOLINES 1999-2015 D000970 Antineoplastic Agents D047428 Protein Kinase Inhibitors D03.438.786.375 M0493669 erlotinib[Erlotinib Hydrochloride] DA87705X9K A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER. Lék ze skupiny inhibitorů tyrosinkináz, působí na přenos signálu z receptoru pro EGF (EGF-R). Využívá se především k léčbě karcinomu plic či pankreatu, potenciálně též myeloproliferačních syndromů. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) 183319-69-9 DA87705X9K J4T82NDH7E M0493669 M0433509 M0493669 M0454216 M0493669 M000597783 M0493669 M0350388 M0493669 M0434471 T000879622 Erlotinib Hydrochloride 2015 05 12 FDA SRS (2013) NLM (2013) USAN (19XX) T000879622 Hydrochloride, Erlotinib T000879623 Erlotinib HCl 2015 05 12 NLM (2006) T000879623 HCl, Erlotinib cze0063879 erlotinib 2015 10 15 cze Thesaurus cze0063882 erlotinib hydrochlorid 2015 10 15 cze Thesaurus M0433509 OSI-774 0 M0493669 M0433509 T470797 OSI-774 2001 11 21 NLM (2001) T470797 OSI 774 T470797 OSI774 M0454216 CP 358774 0 M0493669 M0454216 T400566 CP 358774 1999 11 22 NLM (1999) T400566 358774, CP T400568 CP 358,774 1999 11 22 NLM (1999) T400568 358,774, CP T400569 CP-358,774 1999 11 22 NLM (1999) T400569 CP358,774 T400567 CP-358774 1999 11 22 NLM (1999) T400567 CP358774 M000597783 11C-erlotinib 0 M0493669 M000597783 T000866248 11C-erlotinib 2014 09 08 NLM (2014) T000866248 11C erlotinib M0350388 Erlotinib J4T82NDH7E M0493669 M0350388 T000879621 Erlotinib 2015 05 12 FDA SRS (2013) INN (19XX) NLM (2003) T765851 N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine 2010 02 17 NLM (2010) M0434471 Tarceva[Tarceva] 0 M0493669 M0434471 T509893 Tarceva 2002 08 06 NLM (2002) cze0063881 Tarceva 2015 10 15 cze Thesaurus D000069348 quetiapin fumarát[Quetiapine Fumarate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1991) 2016; QUETIAPINE FUMARATE was indexed under DIBENZOTHIAZEPINES 1991-2015 D014150 Antipsychotic Agents D02.886.680.702.500.500 D03.494.276.500 M0398083 quetiapin fumarát[Quetiapine Fumarate] 2S3PL1B6UJ A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER. 111974-72-2 BGL0JSY5SI M0398083 M0189758 M0398083 M0189761 M0398083 M0189762 T000879626 Quetiapine Fumarate 2015 05 12 BAN (19XX) INN (19XX) NLM (2001) USAN (19XX) T000879626 Fumarate, Quetiapine T580538 Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt) 2004 04 01 NLM (2004) cze0064012 quetiapin fumarát 2015 10 15 cze Thesaurus M0189758 ICI 204,636 0 M0398083 M0189758 T219763 ICI 204,636 NLM (1991) T219763 204,636, ICI T219765 ICI-204636 NLM (1991) T219765 ICI204636 T219764 ICI 204636 NLM (1991) T219764 204636, ICI M0189761 Seroquel[Seroquel] 0 M0398083 M0189761 T219766 Seroquel NLM (1991) cze0064015 Seroquel 2015 10 15 cze Thesaurus cze0064016 Kventiax 2015 10 15 cze Thesaurus M0189762 Quetiapin[Quetiapine] BGL0JSY5SI M0398083 M0189762 T000879625 Quetiapine 2015 05 12 FDA SRS (2013) INN (19XX) NLM (1991) T219762 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol NLM (1991) cze0064013 Quetiapin 2015 10 15 cze Thesaurus D000069349 linezolid[Linezolid] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; LINEZOLID was indexed under ACETAMIDES and OXAZOLIDINONES 2000-2015; and under OXAZOLES 1996-2000 D000900 Anti-Bacterial Agents D011500 Protein Synthesis Inhibitors D02.065.064.463 D02.241.081.018.110.525 D03.383.129.462.600.550 M0257529 linezolid[Linezolid] ISQ9I6J12J An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. 165800-03-3 M0257529 M0354773 M0257529 M0257530 T000879628 Linezolid 2015 05 12 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1996) USAN (19XX) T287532 N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide NLM (1996) T000879629 Linezolide 2015 05 12 NLM (1996) cze0063862 linezolid 2015 10 14 cze Thesaurus M0354773 Zyvox 0 M0257529 M0354773 T404097 Zyvox 2000 01 03 NLM (2001) M0257530 U 100766 0 M0257529 M0257530 T287535 U 100766 NLM (1996) T287535 100766, U T468594 PNU-100766 2001 11 02 NLM (2001) T468594 PNU 100766 T468594 PNU100766 T287533 U-100766 NLM (1996) T287533 U100766 D000069350 telerehabilitace[Telerehabilitation] 2015 07 01 2015 06 26 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000295 instrumentation IS Q000364 manpower MA Q000379 methods MT 2016 2016 Telemedicine (1996-2015) E02.831.891 H02.403.680.600.937 H02.403.840.850 L01.178.847.652.850 N02.421.784.840 N04.590.374.800.850 M000605525 telerehabilitace[Telerehabilitation] Delivery of therapeutic rehabilitation at a distance or offsite using telecommunication technologies. Telerehabilitace je poskytování rehabilitačních služeb prostřednictvím telekomunikačních sítí a internetu. Zprostředkovává terapii pacientům, kteří z různých důvodů nemohou cestovat do zdravotnického zařízení. T000879642 Telerehabilitation 2015 05 13 NLM (2016) T000879642 Telerehabilitations T000879644 Virtual Rehabilitation 2015 05 13 NLM (2016) T000879644 Rehabilitation, Virtual T000879644 Rehabilitations, Virtual T000879644 Virtual Rehabilitations T000879645 Tele-rehabilitation 2015 05 13 NLM (2016) T000879645 Tele rehabilitation T000879645 Tele-rehabilitations T000879646 Remote Rehabilitation 2015 05 13 NLM (2016) T000879646 Rehabilitation, Remote T000879646 Rehabilitations, Remote T000879646 Remote Rehabilitations cze0062637 telerehabilitace 2015 06 26 cze Thesaurus cze0062638 e-rehabilitace 2015 06 26 cze Thesaurus D000069356 tympanocentéza[Tympanocentesis] 2015 07 07 2015 07 06 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST Drainage (1973-2015) Paracentesis (1997-2015) D008876 Middle Ear Ventilation D010033 Otitis Media E01.370.225.998.329.905 E02.800.550.905 E04.665.600.905 E05.200.998.329.905 M000605545 tympanocentéza[Tympanocentesis] Needle aspiration of fluid from the MIDDLE EAR through a puncture in the TYMPANIC MEMBRANE. Tympanocentéza, tj. propíchnutí (protětí) bubínku jehlou setu na tympanocentézu s možností současné aspirace sekretu z bubínkové dutiny. T000879679 Tympanocentesis 2015 05 14 NLM (2016) T000879679 Tympanocenteses cze0063764 tympanocentéza 2015 10 07 cze Thesaurus D000069376 sekreční systém typu VI[Type VI Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.984 M000605577 sekreční systém typu VI[Type VI Secretion Systems] 0 Multiprotein complexes in GRAM NEGATIVE BACTERIA that deliver effector proteins into eukaryotic or prokaryotic cells by a mechanism similar to the contractile tail of bacteriophages. They are composed of a cell envelope-spanning tube which is surrounded by a contractile sheath and tipped by a cell puncturing complex; a base plate structure that anchors the assembly to the cell envelope; and an ATPase involved in the sheath contraction and disassembly of the complex. T000879770 Type VI Secretion Systems 2015 05 15 NLM (2016) T000879769 Type VI Secretion System 2015 05 15 NLM (2016) T000879795 Bacterial Secretion System, Type VI 2015 05 15 NLM (2016) T000879793 Type 6 Secretion System 2015 05 15 NLM (2016) T000879794 Type 6 Secretion Systems 2015 05 15 NLM (2016) T000881679 T6SS Secretion Systems 2015 06 11 NLM (2016) T000881679 Secretion Systems, T6SS T000881679 Systems, T6SS Secretion cze0064137 sekreční systém typu VI 2015 10 22 cze Thesaurus D000069377 sekreční systém typu VII[Type VII Secretion Systems] 2015 07 01 2015 06 25 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000172 deficiency DF Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Bacterial Secretion Systems (2010-2015) D05.500.890.500.992 M000605596 sekreční systém typu VII[Type VII Secretion Systems] 0 Bacterial secretion systems found in bacteria that have a MYCOLIC ACID-containing outer membrane such as MYCOBACTERIACEAE; Corynebacteriaceae; and NOCARDIACEAE. These are also known as ESX secretion systems because the first to be discovered is involved in secreting major virulence factors EsxA and EsxB. There are several subtypes of T7SSs including ESX-1, ESX-2, ESX-3, ESX-4, and ESX-5 secretion systems. The subtypes share some core components including an inner membrane channel-forming ATPase complex, a membrane-anchored mycosin, and a second channel that spans the outer mycolic acid-containing membrane. T000879772 Type VII Secretion Systems 2015 05 15 NLM (2016) T000881680 ESX Secretion Systems 2015 06 11 NLM (2016) T000881680 Systems, ESX Secretion T000881681 Secretion Systems, Type VII 2015 06 11 NLM (2016) T000881684 T7SS Secretion System 2015 06 11 NLM (2016) T000881684 Secretion System, T7SS T000881684 System, T7SS Secretion T000879773 Type 7 Secretion Systems 2015 05 15 NLM (2016) T000881682 Secretion Systems, Type 7 2015 06 11 NLM (2016) T000881683 Secretion Systems, ESX 2015 06 11 NLM (2016) cze0064138 sekreční systém typu VII 2015 10 22 cze Thesaurus D000069396 mitochondriální ribozomy[Mitochondrial Ribosomes] 2015 07 01 2015 06 25 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000145 classification CL Q000378 metabolism ME Q000473 pathology PA 2016 2016 Ribosomes (1964-2015) A11.284.430.214.190.875.564.755 A11.284.430.214.190.875.811.370 M000605664 mitochondriální ribozomy[Mitochondrial Ribosomes] Multicomponent ribonucleoprotein structures contained in MITOCHONDRIA that specialize in the PROTEIN BIOSYNTHESIS of a small number of proteins involved in energy production for the cell. T000879878 Mitochondrial Ribosomes 2015 05 18 NLM (2016) T000879878 Mitochondrial Ribosome T000879878 Ribosome, Mitochondrial T000879878 Ribosomes, Mitochondrial T000879893 Mitoribosomes 2015 05 18 NLM (2016) T000879893 Mitoribosome cze0063940 mitochondriální ribozomy 2015 10 15 cze Thesaurus cze0063942 mitochondriální ribosomy 2015 10 15 cze Thesaurus cze0063941 mitoribosomy 2015 10 15 cze Thesaurus D000069416 intravitální mikroskopie[Intravital Microscopy] 2015 07 01 2015 06 25 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Microscopy (1963-2015) E01.370.350.515.277 E05.595.185 M000605684 intravitální mikroskopie[Intravital Microscopy] Microscopic observation of live tissue in situ to study the behavior of individual cells with respect to their in vivo interactions, adhesion, motility, and location. T000879932 Intravital Microscopy 2015 05 18 NLM (2016) T000879932 Intravital Microscopies T000879932 Microscopies, Intravital T000879932 Microscopy, Intravital T000882518 In Vivo Microscopy 2015 06 25 NLM (2016) T000882518 In Vivo Microscopies T000882518 Microscopies, In Vivo T000882518 Microscopy, In Vivo T000882518 Vivo Microscopies, In T000882518 Vivo Microscopy, In cze0063781 intravitální mikroskopie 2015 10 07 cze Thesaurus D000069436 toxikologické jevy[Toxicological Phenomena] 2015 07 07 2015 07 06 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE general or unspecified; prefer specifics 2016 2016 Pharmacological Phenomena (1998-2015) G07.690.936 M000601705 toxikologické jevy[Toxicological Phenomena] The nature and effects of chemical, physical or biological poisons on living organisms. T000874068 Toxicological Phenomena 2015 01 22 NLM (2016) T000874068 Phenomena, Toxicological T000874084 Toxicological Concepts 2015 01 22 NLM (2016) T000874084 Concept, Toxicological T000874084 Concepts, Toxicological T000874084 Toxicological Concept T000874083 Toxicological Phenomenon 2015 01 22 NLM (2016) T000874083 Phenomenon, Toxicological T000874080 Toxicologic Phenomena 2015 01 22 NLM (2016) T000874080 Phenomena, Toxicologic T000874082 Toxicologic Phenomenon 2015 01 22 NLM (2016) T000874082 Phenomenon, Toxicologic cze0063976 toxikologické jevy 2015 10 15 cze Thesaurus D000069437 farmakologické jevy[Pharmacological Phenomena] 2015 07 07 2015 07 06 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE general or unspecified; prefer specifics 2016 (2009); for PHARMACOLOGICAL PROCESSES use PHARMACOLOGICAL PROCESSES 2009-2015; for PHARMACOLOGICAL PHENOMENA use PHARMACOLOGICAL PHENOMENA 2009-2015. 2016 (2009); for PHARMACOLOGICAL PROCESSES see PHARMACOLOGICAL PROCESSES 2009-2015; for PHARMACOLOGICAL PHENOMENA see PHARMACOLOGICAL PHENOMENA 2009-2015. G07.690.773 M000601704 farmakologické jevy[Pharmacological Phenomena] Interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. M000601704 M0519138 T721744 Pharmacological Phenomena 2008 07 01 NLM (2009) T721744 Phenomena, Pharmacological T721747 Pharmacologic Phenomenon 2008 07 01 NLM (2009) T721747 Phenomenon, Pharmacologic T721745 Pharmacological Concepts 2008 07 01 NLM (2009) T721745 Concept, Pharmacological T721745 Concepts, Pharmacological T721745 Pharmacological Concept T721746 Pharmacologic Phenomena 2008 07 01 NLM (2009) T721746 Phenomena, Pharmacologic T721743 Pharmacological Phenomenon 2008 07 01 NLM (2009) T721743 Phenomenon, Pharmacological cze0064004 farmakologické jevy 2015 10 15 cze Thesaurus M0519138 farmakologické procesy[Pharmacological Processes] The metabolism of drugs and their mechanisms of action. M000601704 M0519138 T719921 Pharmacological Processes 2008 05 16 NLM (2009) T719921 Processes, Pharmacological T715833 Pharmacologic Processes 2008 03 06 NLM (2009) T715833 Processes, Pharmacologic T715834 Pharmacologic Process 2008 03 06 NLM (2009) T715834 Process, Pharmacologic cze0037055 farmakologické procesy 2008 12 15 cze Thesaurus D000069438 ezetimib[Ezetimibe] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1998) 2016; EZETIMIBE was indexed under AZETIDINES 1998-2015 D000924 Anticholesteremic Agents D03.383.082.301.550 M0422151 ezetimib[Ezetimibe] EOR26LQQ24 An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS. 163222-33-1 M0422151 M0446922 M0422151 M0282121 M0422151 M0441623 T000879946 Ezetimibe 2015 05 19 FDA SRS (2015) INN (19XX) NLM (2000) USAN (19XX) T417980 (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone) 2000 06 28 NLM (2000) T000879947 Ezetimib 2015 05 19 NLM (2002) cze0063799 ezetimib 2015 10 07 cze Thesaurus M0446922 Ezetrol[Ezetrol] 0 M0422151 M0446922 T535403 Ezetrol 2003 03 13 DE cze0063796 Ezetrol 2015 10 07 cze Thesaurus M0282121 SCH 58235 0 M0422151 M0282121 T312126 SCH 58235 NLM (1997) T312126 58235, SCH T312124 SCH-58235 NLM (1997) T312125 SCH58235 NLM (1997) M0441623 Zient[Zetia] 0 M0422151 M0441623 T525585 Zetia 2002 11 06 US cze0063797 Zient 2015 10 07 cze Thesaurus D000069439 dasatinib[Dasatinib] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2004) 2016; DASATINIB was indexed under PYRIMIDINES and THIAZOLES 2004-2015 D000970 Antineoplastic Agents D047428 Protein Kinase Inhibitors D02.886.675.184 D03.383.129.708.198 D03.383.742.148 M0470497 dasatinib[Dasatinib] RBZ1571X5H A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. 302962-49-8 (dasatinib) M0470497 M0498440 M0470497 M0517195 M0470497 M0470498 T000879951 Dasatinib 2015 05 19 FDA SRS (2013) INN (19XX) NLM (2006) USAN (19XX) T602500 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 2004 08 07 NLM (2004) cze0063400 dasatinib 2015 09 04 cze Thesaurus M0498440 Sprycel[Sprycel] 0 M0470497 M0498440 T674818 Sprycel 2006 05 31 NLM (2006) cze0063403 Sprycel 2015 09 04 cze Thesaurus M0517195 (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 0 M0470497 M0517195 T712295 (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 2008 01 04 NLM (2008) M0470498 BMS 354825 0 M0470497 M0470498 T602501 BMS 354825 2004 08 07 NLM (2004) T602501 354825, BMS T602503 BMS354825 2004 08 07 NLM (2004) T602502 BMS-354825 2004 08 07 NLM (2004) D000069442 natalizumab[Natalizumab] 2015 07 06 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2002) 2016; NATALIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015 and under ANTIBODIES, MONOCLONAL 2002-2011 D039441 Integrin alpha4 D007155 Immunologic Factors D12.776.124.486.485.114.224.060.813 D12.776.124.790.651.114.224.060.813 D12.776.377.715.548.114.224.200.813 M0443607 natalizumab[Natalizumab] 0 A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE. M0443607 M0477090 M0443607 M0444257 T000879965 Natalizumab 2015 05 19 FDA SRS (2015) INN (19XX) NLM (2002) USAN (19XX) cze0063934 natalizumab 2015 10 15 cze Thesaurus M0477090 Tysabri[Tysabri] 0 M0443607 M0477090 T622092 Tysabri 2004 12 06 NLM (2004) cze0063935 Tysabri 2015 10 15 cze Thesaurus M0444257 Antegren 0 M0443607 M0444257 T528510 Antegren 2002 12 16 NLM (2002) D000069443 heptavalentní konjugovaná pnekumokoková vakcína[Heptavalent Pneumococcal Conjugate Vaccine] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1996) 2016; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE was indexed under MENINGOCOCCAL VACCINES 1996-2009; under BACTERIAL VACCINES 1998-2000; under POLYSACCHARIDES BACTERIAL 1996-1997; and under BACTERIAL OUTER MEMBRANE PROTEINS 1996-1997 D007155 Immunologic Factors D20.215.894.135.750.600.500 M0260982 heptavalentní konjugovaná pnekumokoková vakcína[Heptavalent Pneumococcal Conjugate Vaccine] 0 A pneumococcal vaccine which 7 pneumococcal serotypes (6B, 14, 19F, 23F, 18C, 4, 9V), each conjugated individually to the outer membrane protein complex of NEISSERIA MENINGITIDIS. M0260982 M0593636 M0260982 M0364156 T000879967 Heptavalent Pneumococcal Conjugate Vaccine 2015 05 19 NLM (1996) T290985 7-valent PncOMPC vaccine NLM (1996) T290985 7 valent PncOMPC vaccine T290985 PncOMPC vaccine, 7-valent T290985 vaccine, 7-valent PncOMPC T400982 PNCRM7 1999 11 30 NLM (1999) T000879969 Seven-Valent Pneumococcal PS-Meningococcal OMPC Conjugate Vaccine 2015 05 19 NLM (1996) T000879969 Seven Valent Pneumococcal PS Meningococcal OMPC Conjugate Vaccine cze0063782 heptavalentní konjugovaná pnekumokoková vakcína 2015 10 07 cze Thesaurus cze0063783 sedmivalentní pnekumokoková konjugovaná vakcína 2015 10 07 cze Thesaurus M0593636 PCV7[PCV7 vaccine] 0 M0260982 M0593636 T858678 PCV7 vaccine 2014 04 19 NLM (2014) T858678 vaccine, PCV7 cze0063785 PCV7 2015 10 07 cze Thesaurus M0364156 Prevenar[Prevenar] 0 M0260982 M0364156 T416774 Prevenar 2000 06 15 NLM (2000) T416775 Prevnar 2000 06 15 NLM (2000) cze0063784 Prevenar 2015 10 07 cze Thesaurus D000069444 omalizumab[Omalizumab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2001) 2016; OMALIZUMAB was indexed under ANTIBODIES, ANTI-IDIOTYPIC and ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2001-2011 D018926 Anti-Allergic Agents D018927 Anti-Asthmatic Agents D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844 M0387411 omalizumab[Omalizumab] Immunoglobulin G, anti-(human immunoglobulin E Fc region)(human-mouse monoclonal E25 clone pSVIE26 gamma-chain), disulfide with human-mouse monoclonal E25 clone pSVIE26 kappa-chain, dimer 2P471X1Z11 An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. 242138-07-4 M0387411 M0446701 T000879977 Omalizumab 2015 05 19 FDA SRS (2015) NLM (2001) USAN (19XX) cze0063938 omalizumab 2015 10 15 cze Thesaurus M0446701 Xolair[Xolair] 0 M0387411 M0446701 T534977 Xolair 2003 03 10 AU US cze0063939 Xolair 2015 10 15 cze Thesaurus D000069445 atomoxetin[Atomoxetine Hydrochloride] 2015 07 09 2015 07 08 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1984) 2016; ATOMOXETINE HYDROCHLORIDE was indexed under PROPYLAMINES 1984-2015 D018759 Adrenergic Uptake Inhibitors D02.092.831.085 M0124111 atomoxetin[Atomoxetine Hydrochloride] 57WVB6I2W0 A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. 82248-59-7 82857-39-4 82857-40-7 83015-26-3 ASW034S0B8 M0124111 M0321670 M0124111 M0321671 M0124111 M0124112 M0124111 M0450679 M0124111 M0124110 M0124111 M0321672 T000879985 Atomoxetine Hydrochloride 2015 05 19 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (2004) USAN (19XX) T000879985 Hydrochloride, Atomoxetine T154116 N-methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride NLM (1984) T000879986 Atomoxetine HCl 2015 05 19 NLM (2016) T000879986 HCl, Atomoxetine cze0063372 atomoxetin 2015 09 04 cze Thesaurus cze0063373 atomoxetini hydrochloridum 2015 09 04 cze Thesaurus M0321670 Tomoxetine Hydrochloride, (-)-isomer 0 M0124111 M0321670 T000879989 Tomoxetine Hydrochloride, (-)-isomer 2015 05 19 NLM (1984) M0321671 Tomoxetine Hydrochloride, (+)-isomer - T351671 82857-39-4 M0124111 M0321671 T000879987 Tomoxetine Hydrochloride, (+)-isomer - T351671 2015 05 19 NLM (1984) M0124112 Atomoxetine ASW034S0B8 M0124111 M0124112 T000879983 Atomoxetine 2015 05 19 FDA SRS (2013) INN (19XX) NLM (2001) T000879984 Tomoxetine 2015 05 19 NLM (1984) M0450679 Strattera[Strattera] 0 M0124111 M0450679 T544016 Strattera 2003 06 23 US cze0063375 Strattera 2015 09 04 cze Thesaurus M0124110 LY 139603 0 M0124111 M0124110 T154115 LY 139603 NLM (1984) T154115 139603, LY M0321672 Tomoxetine Hydrochloride, (+-)-isomer 82857-40-7 M0124111 M0321672 T000879988 Tomoxetine Hydrochloride, (+-)-isomer 2015 05 19 NLM (1984) D000069446 atazanavir sulfát[Atazanavir Sulfate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2000) 2016; ATAZANAVIR SULFATE was indexed under OLIGOPEPTIDES and PYRIDINES 2000-2015 D017320 HIV Protease Inhibitors D03.383.725.068 D12.644.456.157 M0445555 atazanavir sulfát[Atazanavir Sulfate] 4MT4VIE29P An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS. 229975-97-7 QZU4H47A3S M0445555 M0369941 M0445555 M0460141 M0445555 M0460138 M0445555 M0449395 M0445555 M0460139 M0445555 M0460142 M0445555 M0450734 M0445555 M0460140 T000879992 Atazanavir Sulfate 2015 05 19 FDA SRS (2015) INN (1999) USAN (2002) T000879992 Sulfate, Atazanavir cze0063199 atazanavir sulfát 2015 08 19 cze Thesaurus M0369941 BMS 232632 0 M0445555 M0369941 T424721 BMS 232632 2000 09 22 NLM (2000) T424721 232632, BMS T424723 BMS-232632 2000 09 22 NLM (2000) T424722 BMS232632 2000 09 22 NLM (2000) M0460141 CGP 73547 0 M0445555 M0460141 T424724 CGP 73547 2000 09 22 NLM (2000) T424724 73547, CGP T424725 CGP-73547 2000 09 22 NLM (2000) T424725 CGP73547 M0460138 CGP 75355 0 M0445555 M0460138 T469185 CGP 75355 2001 11 07 NLM (2001) T469185 75355, CGP T469187 CGP75355 2001 11 07 NLM (2001) T469186 CGP-75355 2001 11 07 NLM (2001) M0449395 Reyataz[Reyataz] 0 M0445555 M0449395 T540739 Reyataz 2003 05 14 NLM (2003) cze0063206 Reyataz 2015 08 19 cze Thesaurus M0460139 CGP 75176 0 M0445555 M0460139 T469191 CGP 75176 2001 11 07 NLM (2001) T469191 75176, CGP T469193 CGP75176 2001 11 07 NLM (2001) T469192 CGP-75176 2001 11 07 NLM (2001) M0460142 BMS-232632-05 0 M0445555 M0460142 T532404 BMS-232632-05 2003 02 10 NLM (2003) T532404 BMS 232632 05 T532404 BMS23263205 M0450734 Atazanavir QZU4H47A3S 198904-31-3 (atazanavir) M0445555 M0450734 T000879991 Atazanavir 2015 05 19 FDA SRS (2013) INN (19XX) NLM (2004) T544125 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester 2003 06 23 NLM (2003) M0460140 CGP 75136 0 M0445555 M0460140 T469188 CGP 75136 2001 11 07 NLM (2001) T469188 75136, CGP T469190 CGP75136 2001 11 07 NLM (2001) T469189 CGP-75136 2001 11 07 NLM (2001) D000069447 tiotropium bromid[Tiotropium Bromide] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1993) 2016; TIOTROPIUM BROMIDE was indexed under SCOPOLAMINE DERIVATIVES 1993-2015 D001993 Bronchodilator Agents D010276 Parasympatholytics D018680 Cholinergic Antagonists D02.145.074.722.822.887 D03.132.889.601.887 D03.605.869.822.887 D04.075.080.875.099.722.822.887 M0458357 tiotropium bromid[Tiotropium Bromide] XX112XZP0J A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 0EB439235F 136310-93-5 (tiotropium bromide) 186691-13-4 (tiotropium) M0458357 M0213717 M0458357 M0363710 M0458357 M0213714 T000880002 Tiotropium Bromide 2015 05 20 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1993) USAN (19XX) T000880002 Bromide, Tiotropium T243718 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide NLM (1993) cze0063887 tiotropium bromid 2015 10 15 cze Thesaurus cze0063890 tiotropium-bromid 2015 10 15 cze Thesaurus M0213717 tiotropium[Tiotropium] 0EB439235F M0458357 M0213717 T000880001 Tiotropium 2015 05 20 FDA SRS (2013) NLM (1993) cze0063891 tiotropium 2015 10 15 cze Thesaurus M0363710 Spiriva[Spiriva] 0 M0458357 M0363710 T416167 Spiriva 2000 06 07 NLM (2000) cze0063889 Spiriva 2015 10 15 cze Thesaurus M0213714 BA 679 BR 0 M0458357 M0213714 T243719 BA 679 BR NLM (1993) T243719 679 BR, BA T243719 BR, BA 679 T243720 BA-679 BR NLM (1993) T243720 BA679 BR D000069448 denosumab[Denosumab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2004) 2016; DENOSUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2015; and under ANTIBODIES, MONOCLONAL 2004-2012 D050071 Bone Density Conservation Agents D12.776.124.486.485.114.224.060.782 D12.776.124.790.651.114.224.060.782 D12.776.377.715.548.114.224.200.782 M0493770 denosumab[Denosumab] 4EQZ6YO2HI A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS. 615258-40-7 (denosumab) M0493770 M0555596 M0493770 M0554986 M0493770 M0478464 T000880008 Denosumab 2015 05 20 FDA SRS (2013) INN (19XX) NLM (2006) USAN (19XX) cze0063396 denosumab 2015 09 04 cze Thesaurus M0555596 Prolia[Prolia] 0 M0493770 M0555596 T788425 Prolia 2011 04 04 NLM (2012) cze0063398 Prolia 2015 09 04 cze Thesaurus M0554986 Xgeva[Xgeva] 0 M0493770 M0554986 T786069 Xgeva 2011 02 23 NLM (2011) cze0063399 Xgeva 2015 09 04 cze Thesaurus M0478464 AMG 162 0 M0493770 M0478464 T625826 AMG 162 2004 12 23 NLM (2004) T625826 162, AMG D000069449 cinakalcet[Cinacalcet Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2003) 2016; CINACALCET HYDROCHLORIDE was indexed under NAPHTHALENES 2003-2015 D057966 Calcimimetic Agents D02.455.426.559.847.638.183 D04.615.638.183 M0452505 cinakalcet[Cinacalcet Hydrochloride] 1K860WSG25 A naphthalene derivative and CALCIMIMETIC AGENT that increases the sensitivity of PARATHYROID GLAND calcium-sensing receptors to serum calcium. This action reduces parathyroid hormone secretion and decreases serum calcium in the treatment of PARATHYROID DISEASES. UAZ6V7728S M0452505 M0464798 M0452505 M0462190 M0452505 M0452507 T000880011 Cinacalcet Hydrochloride 2015 05 20 FDA SRS (2013) USAN (2002) T000880011 Hydrochloride, Cinacalcet T000880013 Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride 2015 05 20 NLM (2003) cze0063139 cinakalcet 2015 08 17 cze Thesaurus cze0063138 cinacalcet HCl 2015 08 17 cze Thesaurus cze0063137 cinacalceti hydrochloridum 2015 08 17 cze Thesaurus M0464798 Cinacalcet UAZ6V7728S 1K860WSG25 364782-34-3 (cinacalcet) M0452505 M0464798 T000880010 Cinacalcet 2015 05 20 INN (19XX) NLM (2004) USAN (19XX) M0462190 Mimpara[Sensipar] 0 M0452505 M0462190 T576492 Sensipar 2004 03 11 NLM (2004) cze0063140 Mimpara 2015 08 17 cze Thesaurus M0452507 AMG 073 0 M0452505 M0452507 T547827 AMG 073 2003 08 07 NLM (2003) T547827 073, AMG T608708 KRN 1493 2004 09 09 NLM (2004) T608708 1493, KRN T547826 AMG073 2003 08 07 NLM (2003) D000069450 liraglutid[Liraglutide] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; LIRAGLUTIDE was indexed under GLUCAGON-LIKE PEPTIDE 1 2005-2015; and under GLUCAGON 2001-2005 D007004 Hypoglycemic Agents D054795 Incretins D06.472.317.469.500.500.500 M0405743 liraglutid[Liraglutide] 839I73S42A An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN. 204656-20-2 M0405743 M0554462 M0405743 M000600990 M0405743 M0472586 T000880019 Liraglutide 2015 05 20 FDA SRS (2013) NLM (2004) USAN (19XX) cze0063920 liraglutid 2015 10 15 cze Thesaurus M0554462 Victoza[Victoza] 0 M0405743 M0554462 T000880021 Victoza 2015 05 20 NLM (2010) cze0063922 Victoza 2015 10 15 cze Thesaurus M000600990 Saxenda 0 M0405743 M000600990 T000872810 Saxenda 2014 12 30 NLM (2015) M0472586 NN 2211 0 M0405743 M0472586 T471184 NN 2211 2001 11 27 NLM (2001) T471184 2211, NN T471186 NN2211 2001 11 27 NLM (2001) T471185 NN-2211 2001 11 27 NLM (2001) D000069451 dlouhodobé vedlejší účinky[Long Term Adverse Effects] 2015 07 01 2015 06 25 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 C23.550.543 M000605744 dlouhodobé vedlejší účinky[Long Term Adverse Effects] Persistent detrimental effects from treatment for a condition. Included are effects from surgery such as POSTOPERATIVE COMPLICATIONS, and from DRUG THERAPY, such as CHEMICALLY INDUCED DISORDERS, or other THERAPEUTICS. Failure to attain a desired outcome from treatment for the condition is not considered an adverse effect. T000880050 Long Term Adverse Effects 2015 05 20 NLM (2016) T000881685 Adverse Effects, Long Term 2015 06 11 NLM (2016) cze0063991 dlouhodobé vedlejší účinky 2015 10 15 cze Thesaurus D000069452 PAMP struktury[Pathogen-Associated Molecular Pattern Molecules] 2015 07 01 2015 06 25 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D23.585 M000605751 PAMP struktury[Pathogen-Associated Molecular Pattern Molecules] 0 Pathogens' molecules with specific sequence patterns that are recognized by PATTERN RECOGNITION RECEPTORS. They include microbial DNA, double-stranded RNA, surface glycoproteins, lipopolysaccharides, peptidoglycans, and lipoteichoic acid. M000605751 M000605752 T000882529 Pathogen-Associated Molecular Pattern Molecules 2015 06 25 NLM (2016) T000882529 Pathogen Associated Molecular Pattern Molecules T000882530 Molecules, Pathogen-Associated Molecular Pattern 2015 06 25 NLM (2016) T000882530 Molecules, Pathogen Associated Molecular Pattern T000880064 PAMPs 2015 05 20 NLM (2016) cze0064521 PAMP struktury 2015 11 16 cze Thesaurus cze0064524 molekulární struktury asociované s patogeny 2015 11 16 cze Thesaurus cze0064523 molekulární vzory asociované s patogeny 2015 11 16 cze Thesaurus cze0064522 vzory PAMP 2015 11 16 cze Thesaurus M000605752 Pathogen-Associated Molecular Patterns 0 Sequences in molecules of pathogens that are recognized by PATTERN RECOGNITION RECEPTORS. M000605751 M000605752 T000882531 Pathogen-Associated Molecular Patterns 2015 06 25 NLM (2016) T000882531 Molecular Patterns, Pathogen-Associated T000882531 Pathogen Associated Molecular Patterns T000882531 Patterns, Pathogen-Associated Molecular D000069453 ultrazvukové vlny[Ultrasonic Waves] 2015 07 09 2015 07 07 2016 01 01 Q000009 adverse effects AE 2016; for ULTRASOUND RADIATION use SOUND 2012-2015 2016; for ULTRASOUND RADIATION see SOUND 2012-2015 Sound (1969-2015) Ultrasonic Therapy (1969-2015) Ultrasonics (1966-2015) Ultrasonography (1963-2015) D000069453 Ultrasonic Waves Q000628 therapy D014464 Ultrasonic Therapy D014465 Ultrasonics G01.750.770.776.891 M0557305 ultrazvukové vlny[Ultrasonic Waves] Oscillating sound wave with a frequency higher than the upper limit of the human hearing range. M0557305 M000605515 M0557305 M000605514 T000880173 Ultrasonic Waves 2015 05 21 NLM (2016) T000880173 Ultrasonic Wave T000880173 Wave, Ultrasonic T000880173 Waves, Ultrasonic T000880176 Ultrasonic Vibration 2015 05 21 NLM (2016) T000880176 Ultrasonic Vibrations T000880176 Vibration, Ultrasonic T000880176 Vibrations, Ultrasonic T789928 Ultrasound Radiation 2011 04 29 NLM (2012) T789928 Radiation, Ultrasound T000880175 Ultrasound Waves 2015 05 21 NLM (2016) T000880175 Ultrasound Wave T000880175 Wave, Ultrasound T000880175 Waves, Ultrasound cze0062590 ultrazvukové vlny 2015 06 24 cze Thesaurus cze0062591 ultrazvukové vibrace 2015 06 24 cze Thesaurus cze0062595 ultrazvukové vlnění 2015 06 24 cze Thesaurus cze0062594 vyzařování ultrazvuku 2015 06 24 cze Thesaurus M000605515 pulzní ultrazvuk[Pulsed Ultrasound] M0557305 M000605515 T000879618 Pulsed Ultrasound 2015 05 12 NLM (2016) T000879618 Pulsed Ultrasounds T000879618 Ultrasound, Pulsed T000879618 Ultrasounds, Pulsed cze0062592 pulzní ultrazvuk 2015 06 24 cze Thesaurus M000605514 LIPUS[Low Intensity Pulsed Ultrasound] M0557305 M000605514 T000879615 Low Intensity Pulsed Ultrasound 2015 05 12 NLM (2016) T000880151 LIPUS 2015 05 21 NLM (2016) T000880153 Low-Intensity Pulsed Ultrasound (LIPUS) 2015 05 21 NLM (2016) T000880153 Low Intensity Pulsed Ultrasound (LIPUS) T000880153 Low-Intensity Pulsed Ultrasounds (LIPUS) T000880153 Pulsed Ultrasound, Low-Intensity (LIPUS) T000880153 Pulsed Ultrasounds, Low-Intensity (LIPUS) T000880153 Ultrasound, Low-Intensity Pulsed (LIPUS) T000880153 Ultrasounds, Low-Intensity Pulsed (LIPUS) T000879617 Low Intensity Pulsed Ultrasound Radiation 2015 05 12 NLM (2016) cze0062593 LIPUS 2015 06 24 cze Thesaurus cze0062596 pulzní ultrazvuk s nízkou intenzitou 2015 06 24 cze Thesaurus D000069454 darunavir[Darunavir] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2004) 2016; DARUNAVIR was indexed under SULFONAMIDES 2004-2015 D017320 HIV Protease Inhibitors D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303 M0461844 darunavir[Darunavir] (3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester YO603Y8113 An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS. 206361-99-1 (darunavir) 33O78XF0BW M0461844 M0499324 M0461844 M0499322 M0461844 M0501231 M0461844 M0480520 T000880179 Darunavir 2015 05 21 FDA SRS (2013) INN (19XX) NLM (2006) USAN (19XX) cze0063410 darunavir 2015 09 04 cze Thesaurus M0499324 Prezista[Prezista] 0 M0461844 M0499324 T676802 Prezista 2006 06 26 NLM (2006) cze0063413 Prezista 2015 09 04 cze Thesaurus M0499322 UIC-94017 0 M0461844 M0499322 T575560 UIC-94017 2004 03 04 NLM (2004) T575560 UIC 94017 T575559 UIC94017 2004 03 04 NLM (2004) M0501231 darunavir ethanolát[Darunavir Ethanolate] 33O78XF0BW M0461844 M0501231 T000880180 Darunavir Ethanolate 2015 05 21 BAN (19XX) INN (19XX) NLM (2006) T000880180 Ethanolate, Darunavir cze0063414 darunavir ethanolát 2015 09 04 cze Thesaurus cze0063415 darunaviri ethanolas 2015 09 04 cze Thesaurus M0480520 TMC 114 0 M0461844 M0480520 T630180 TMC 114 2005 02 09 NLM (2005) T630180 114, TMC T630182 TMC114 2005 02 09 NLM (2005) T630181 TMC-114 2005 02 09 NLM (2005) D000069455 palivizumab[Palivizumab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (1998) 2016; PALIVIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 1998-2015 D000998 Antiviral Agents D12.776.124.486.485.114.224.060.860 D12.776.124.790.651.114.224.060.860 D12.776.377.715.548.114.224.200.860 M0288015 palivizumab[Palivizumab] DQ448MW7KS A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients. 188039-54-5 M0288015 M0358707 M0288015 M0288016 T000880189 Palivizumab 2015 05 21 FDA SRS (2015) INN (19XX) NLM (1998) USAN (19XX) cze0063931 palivizumab 2015 10 15 cze Thesaurus M0358707 Synagis[Synagis] 0 M0288015 M0358707 T409298 Synagis 2000 03 14 AU CA DE ES FR NL UK US cze0063932 Synagis 2015 10 15 cze Thesaurus M0288016 MEDI 493 0 M0288015 M0288016 T318021 MEDI 493 NLM (1998) T318021 493, MEDI T000881266 Monoclonal Antibody MEDI-493 2015 06 03 NLM (2016) T000881266 Antibody MEDI-493, Monoclonal T000881266 MEDI-493, Monoclonal Antibody T000881266 Monoclonal Antibody MEDI 493 T318018 MEDI-493 NLM (1998) T318018 MEDI493 D000069456 tichá mutace[Silent Mutation] 2015 07 01 2015 06 25 2016 01 01 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE 2016 2016 Mutation (1982-2015) G05.365.590.803 M000605818 tichá mutace[Silent Mutation] A change to a DNA SEQUENCE that doesn't change the AMINO ACID SEQUENCE of the protein made. T000880192 Silent Mutation 2015 05 21 NLM (2016) T000880190 Synonymous Mutations 2015 05 21 NLM (2016) T000880190 Mutation, Synonymous T000880190 Mutations, Synonymous T000880190 Synonymous Mutation T000880236 Synonymous Codon Substitutions 2015 05 21 NLM (2016) T000880236 Codon Substitution, Synonymous T000880236 Codon Substitutions, Synonymous T000880236 Substitution, Synonymous Codon T000880236 Substitutions, Synonymous Codon T000880236 Synonymous Codon Substitution T000880193 Silent Mutations 2015 05 21 NLM (2016) T000880188 Mutations, Silent 2015 05 21 NLM (2016) T000880188 Mutation, Silent cze0063926 tichá mutace 2015 10 15 cze Thesaurus cze0063927 synonymní mutace 2015 10 15 cze Thesaurus D000069457 populační předpověď[Population Forecast] 2015 07 07 2015 07 06 2016 01 01 Q000379 methods MT 2016; use FORECASTING 1981-2015; for POPULATION GROWTH ESTIMATE use POPULATION GROWTH 1980-2015 2016; see FORECASTING 1981-2015; for POPULATION GROWTH ESTIMATE see POPULATION GROWTH 1980-2015 Forecasting (1977-2015) D011158 Population Growth I01.320.500 N01.224.667 M0008738 populační předpověď[Population Forecast] Estimates of projected population. M0008738 M0017325 T016843 Population Forecast 1986 12 31 NLM (1981) T016843 Forecasts, Population T016843 Population Forecasts T016844 Population Projection 1986 12 31 NLM (1981) T016844 Population Projections T016844 Projection, Population cze0050555 populační předpověď 2012 10 23 cze Thesaurus M0017325 populace - odhad růstu[Population Growth Estimation] M0008738 M0017325 T032869 Population Growth Estimation 1978 12 26 UNK (19XX) T032869 Estimation, Population Growth T032869 Estimations, Population Growth T032869 Growth Estimation, Population T032869 Growth Estimations, Population T032869 Population Growth Estimations cze0037697 populace - odhad růstu 2009 03 09 cze Thesaurus D000069458 ranolazin[Ranolazine] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1988) 2016; RANOLAZINE was indexed under ACETANILIDES and PIPERAZINES 1988-2015 D002317 Cardiovascular Agents D026941 Sodium Channel Blockers D02.065.199.092.850 D03.383.606.841 M0156295 ranolazin[Ranolazine] A6IEZ5M406 An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS. 110445-25-5 95635-55-5 F71253DJUN M0156295 M000605820 M0156295 M0446732 M0156295 M0156292 M0156295 M0156291 T000880197 Ranolazine 2015 05 21 FDA SRS (2015) NLM (1988) USAN (1988) T186295 N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide NLM (1988) T000880198 Renolazine 2015 05 21 NLM (1988) cze0064019 ranolazin 2015 10 15 cze Thesaurus M000605820 ranolazin hydrochlorid[Ranolazine Hydrochloride] F71253DJUN M0156295 M000605820 T000880201 Ranolazine Hydrochloride 2015 05 21 FDA SRS (2015) NLM (2016) USAN (19XX) T000880201 Hydrochloride, Ranolazine T000880203 Ranolazine Dihydrochloride 2015 05 21 NLM (2016) T000880203 Dihydrochloride, Ranolazine T000880202 Ranolazine HCl 2015 05 21 NLM (2016) T000880202 HCl, Ranolazine cze0064021 ranolazin hydrochlorid 2015 10 15 cze Thesaurus M0446732 Ranexa[Ranexa] 0 M0156295 M0446732 T535040 Ranexa 2003 03 11 NLM (2003) cze0064020 Ranexa 2015 10 15 cze Thesaurus M0156292 RS 43285-193 0 M0156295 M0156292 T186297 RS 43285-193 NLM (1988) T186297 RS 43285 193 T186297 RS 43285193 M0156291 RS 43285 0 M0156295 M0156291 T186296 RS 43285 NLM (1988) T186296 43285, RS T186298 RS-43285 NLM (1988) T186298 RS43285 D000069459 bylinné čaje[Teas, Herbal] 2015 07 01 2015 06 25 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use BEVERAGES 1986-2015 2016; see BEVERAGES 1986-2015 D20.215.784.937 G07.203.100.950 J02.200.950 M0002447 bylinné čaje[Teas, Herbal] 0 Beverages prepared from an infusion of plant tissues. T004720 Teas, Herbal 1990 01 10 NLM (1991) T004719 Herbal Teas 1985 04 30 UNK (19XX) T004719 Herbal Tea T004719 Tea, Herbal T000882519 Tisanes 2015 06 25 NLM (2016) T000882519 Tisane cze0041400 bylinné čaje 2010 08 19 cze Thesaurus cze0041401 bylinkové čaje 2010 08 19 cze Thesaurus D000069460 léčivé čaje[Teas, Medicinal] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use BEVERAGES 1986-2015 2016; see BEVERAGES 1986-2015 G07.203.100.975 J02.200.975 M0002448 léčivé čaje[Teas, Medicinal] Beverages used in TRADITIONAL MEDICINE that are prepared from the infusion of plant tissue (HERBAL TEA), and/or animal tissue or other organisms such as FUNGI. T004721 Teas, Medicinal 1985 04 30 UNK (19XX) T000880204 Medicinal Teas 2015 05 21 NLM (2016) T000880204 Medicinal Tea T000880204 Tea, Medicinal cze0041402 léčivé čaje 2010 08 19 cze Thesaurus D000069461 bendamustin hydrochlorid[Bendamustine Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1972) 2016; BENDAMUSTINE HYDROCHLORIDE was indexed under NITROGEN MUSTARD COMPOUNDS 1982-2015 and under BENZIMIDAZOLES 1972-1982 D018906 Antineoplastic Agents, Alkylating D02.241.081.114.625 D02.455.526.728.650.103 D03.438.103.123 M0307744 bendamustin hydrochlorid[Bendamustine Hydrochloride] 981Y8SX18M A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA. 16506-27-7 (bendamustine) 3543-75-7 9266D9P3PQ M0307744 M0042082 M0307744 M0042083 M0307744 M0042079 M0307744 M0477169 M0307744 M0521655 M0307744 M0042080 T000880212 Bendamustine Hydrochloride 2015 05 21 FDA SRS (2015) INN (19XX) NLM (1972) USAN (19XX) T000880212 Hydrochloride, Bendamustine cze0063142 bendamustin hydrochlorid 2015 08 17 cze Thesaurus M0042082 bendamustin[Bendamustine] 9266D9P3PQ M0307744 M0042082 T000880210 Bendamustine 2015 05 21 FDA SRS (2013) INN (19XX) NLM (1972) T000880211 Bendamustin 2015 05 21 NLM (1972) cze0063143 bendamustin 2015 08 17 cze Thesaurus M0042083 Cytostasan 0 M0307744 M0042083 T072086 Cytostasan NLM (1972) M0042079 IMET 3393 0 M0307744 M0042079 T072082 IMET 3393 NLM (1972) M0477169 Lynetoril[Ribomustin] 0 M0307744 M0477169 T622336 Ribomustin 2004 12 07 DE cze0063146 Lynetoril 2015 08 17 cze Thesaurus cze0063147 Infubend 2015 08 17 cze Thesaurus M0521655 Treanda 0 M0307744 M0521655 T720235 Treanda 2008 05 22 NLM (2008) M0042080 Zimet 3393 0 M0307744 M0042080 T072083 Zimet 3393 NLM (1972) D000069462 dimethyl fumarát[Dimethyl Fumarate] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1988) 2016; DIMETHYL FUMARATE was indexed under FUMARATES 1988-2015 D003879 Dermatologic Agents D007166 Immunosuppressive Agents D011838 Radiation-Sensitizing Agents D02.241.081.337.302.500 M0157348 dimethyl fumarát[Dimethyl Fumarate] FO2303MNI2 A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS. 624-49-7 (dimethyl fumarate) M0157348 M0493208 M0157348 M0582547 M0157348 M0493210 M0157348 M0157347 M0157348 M0493209 T000880221 Dimethyl Fumarate 2015 05 21 NLM (1988) USAN (19XX) T000880221 Fumarate, Dimethyl T839392 2-butenedioic acid, (2E)-, dimethyl ester 2013 03 29 NLM (2013) T000880222 Dimethylfumarate 2015 05 21 NLM (2004) cze0063608 dimethyl fumarát 2015 09 24 cze Thesaurus M0493208 BG 00012 0 M0157348 M0493208 T662863 BG 00012 2005 12 21 NLM (2005) T662863 00012, BG T662865 BG00012 2005 12 21 NLM (2005) T662864 BG-00012 2005 12 21 NLM (2005) M0582547 Tecfidera[Tecfidera] 0 M0157348 M0582547 T839390 Tecfidera 2013 03 29 NLM (2013) cze0063609 Tecfidera 2015 09 24 cze Thesaurus M0493210 FAG 201 0 M0157348 M0493210 T662869 FAG 201 2005 12 21 NLM (2005) T662869 201, FAG T662871 FAG201 2005 12 21 NLM (2005) T662870 FAG-201 2005 12 21 NLM (2005) M0157347 Fumaderm 0 M0157348 M0157347 T187352 Fumaderm NLM (1988) M0493209 BG 12 compound 0 M0157348 M0493209 T662866 BG 12 compound 2005 12 21 NLM (2005) T662866 12 compound, BG T662866 compound, BG 12 T662868 BG12 compound 2005 12 21 NLM (2005) T662868 compound, BG12 T662867 BG-12 compound 2005 12 21 NLM (2005) D000069463 olivový olej[Olive Oil] 2015 07 10 2015 07 09 2016 01 01 Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 2016; OLIVE OIL was indexed under PLANT OILS 1986-2015, and under OILS 1984-1986 Plant Oils (1986-2015) D10.212.302.380.580 D10.212.507.650 D10.627.700.728 G07.203.300.375.400.500 J02.500.375.400.500 M000605827 olivový olej[Olive Oil] 0 Oil extracted from fruit of the OLIVE TREE (genus Olea). T000881593 Olive Oil 2015 06 10 NLM (2016) T000880228 Olive Oils 2015 05 21 NLM (2016) T000880228 Oil, Olive T000880228 Oils, Olive cze0063925 olivový olej 2015 10 15 cze Thesaurus D000069464 solifenacin sukcinát[Solifenacin Succinate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; SOLIFENACIN SUCCINATE was indexed under QUINUCLIDINES and TETRAHYDROISOQUINOLINES 2003-2015; and under ISOQUINOLINES 2001-2003 D018727 Muscarinic Antagonists D064804 Urological Agents D03.438.531.820.594 D03.605.687.900 M0554458 solifenacin sukcinát[Solifenacin Succinate] KKA5DLD701 A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE. 242478-38-2 A8910SQJ1U M0554458 M0407673 M0554458 M0554595 M0554458 M0407671 T000880226 Solifenacin Succinate 2015 05 21 FDA SRS (2013) NLM (2010) USAN (2001) T000880226 Succinate, Solifenacin T000880227 Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate 2015 05 21 NLM (2001) cze0063857 solifenacin sukcinát 2015 10 14 cze Thesaurus cze0063860 solifenacin-sukcinát 2015 10 14 cze Thesaurus M0407673 YM905 0 M0554458 M0407673 T473707 YM905 2001 12 13 NLM (2001) T473708 YM 905 2001 12 13 NLM (2001) T473708 905, YM M0554595 Vesicare[Vesicare] 0 M0554458 M0554595 T000880230 Vesicare 2015 05 21 NLM (2010) cze0063858 Vesicare 2015 10 14 cze Thesaurus M0407671 solifenacin[Solifenacin] A8910SQJ1U M0554458 M0407671 T000880225 Solifenacin 2015 05 21 FDA SRS (2013) INN (19XX) NLM (2004) T844493 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))- 2013 05 21 NLM (2014) cze0063861 solifenacin 2015 10 14 cze Thesaurus D000069465 febuxostat[Febuxostat] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; FEBUXOSTAT was indexed under THIAZOLES 1994-2015 D006074 Gout Suppressants D02.886.675.274 D03.383.129.708.274 M0224789 febuxostat[Febuxostat] 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl- 101V0R1N2E A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT. 144060-53-7 M0224789 M0473600 M0224789 M0544237 M0224789 M0224787 T000880232 Febuxostat 2015 05 21 FDA SRS (2015) INN (19XX) USAN (2002) cze0063733 febuxostat 2015 10 07 cze Thesaurus cze0063738 febuxostát 2015 10 07 cze Thesaurus M0473600 TEI 6720 0 M0224789 M0473600 T612240 TEI 6720 2004 10 06 NLM (2004) T612240 6720, TEI T612241 TEI-6720 2004 10 06 NLM (2004) T612241 TEI6720 M0544237 Adenuric[Uloric] 0 M0224789 M0544237 T766934 Uloric 2010 03 10 NLM (2011) cze0063737 Adenuric 2015 10 07 cze Thesaurus M0224787 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid 0 M0224789 M0224787 T254792 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid NLM (1994) D000069466 červené maso[Red Meat] 2015 07 01 2015 06 25 2016 01 01 Q000469 parasitology PS Q000382 microbiology MI Q000633 toxicity TO Q000506 poisoning PO Q000009 adverse effects AE Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Meat (1975-2015) G07.203.300.600.813 J02.500.600.813 M000605830 červené maso[Red Meat] Meat such as beef, pork, or lamb which contains more MYOGLOBIN than POULTRY or SEAFOOD. M000605830 M000605832 M000605830 M000605831 T000880233 Red Meat 2015 05 21 NLM (2016) T000880233 Meat, Red T000880233 Meats, Red T000880233 Red Meats cze0062779 červené maso 2015 07 13 cze Thesaurus cze0062776 tmavé maso 2015 07 13 cze Thesaurus M000605832 vepřové maso[Pork] M000605830 M000605832 T000880235 Pork 2015 05 21 NLM (2016) cze0062778 vepřové maso 2015 07 13 cze Thesaurus M000605831 hovězí maso[Beef] M000605830 M000605831 T000880234 Beef 2015 05 21 NLM (2016) cze0062777 hovězí maso 2015 07 13 cze Thesaurus D000069467 fekální transplantace[Fecal Microbiota Transplantation] 2015 07 01 2015 06 25 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 E02.095.231 M000605834 fekální transplantace[Fecal Microbiota Transplantation] Transfer of GASTROINTESTINAL MICROBIOTA from one individual to another by infusion of donor FECES to the upper or lower GASTROINTESTINAL TRACT of the recipient. T000880237 Fecal Microbiota Transplantation 2015 05 21 NLM (2016) T000880237 Fecal Microbiota Transplantations T000880237 Microbiota Transplantation, Fecal T000880237 Microbiota Transplantations, Fecal T000880237 Transplantation, Fecal Microbiota T000880237 Transplantations, Fecal Microbiota T000880240 Intestinal Microbiota Transfer 2015 05 21 NLM (2016) T000880240 Intestinal Microbiota Transfers T000880240 Microbiota Transfer, Intestinal T000880240 Microbiota Transfers, Intestinal T000880240 Transfer, Intestinal Microbiota T000880240 Transfers, Intestinal Microbiota T000880239 Fecal Transplantation 2015 05 21 NLM (2016) T000880239 Fecal Transplantations T000880239 Transplantation, Fecal T000880239 Transplantations, Fecal T000882532 Fecal Transplant 2015 06 25 NLM (2016) T000882532 Fecal Transplants T000882532 Transplant, Fecal T000882532 Transplants, Fecal T000880238 Donor Feces Infusion 2015 05 21 NLM (2016) T000880238 Donor Feces Infusions T000880238 Feces Infusion, Donor T000880238 Feces Infusions, Donor T000880238 Infusion, Donor Feces T000880238 Infusions, Donor Feces cze0062661 fekální transplantace 2015 06 26 cze Thesaurus cze0062663 fekální bakterioterapie 2015 06 26 cze Thesaurus cze0062662 fekální mikrobiální transplantace 2015 06 26 cze Thesaurus cze0062664 přenos fekální mikrobioty 2015 06 26 cze Thesaurus D000069468 desvenlafaxin sukcinát[Desvenlafaxine Succinate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; DESVENLAFAXINE SUCCINATE was indexed under CYCLOHEXANOLS 1994-2015 D000068760 Serotonin and Noradrenaline Reuptake Inhibitors D000928 Antidepressive Agents D02.033.415.510.500.303 D02.455.426.392.368.367.318.500 D02.455.426.559.389.657.265 D10.289.510.500.303 M0521993 desvenlafaxin sukcinát[Desvenlafaxine Succinate] ZB22ENF0XR A cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. 386750-22-7 (desvenlafaxine succinate) NG99554ANW M0521993 M0230084 M0521993 M0506532 M0521993 M0230088 T000880285 Desvenlafaxine Succinate 2015 05 22 FDA SRS (2015) NLM (2006) USAN (2006) T000880285 Succinate, Desvenlafaxine T000880287 O-desmethylvenlafaxine Succinate Monohydrate 2015 05 22 NLM (2016) T000880287 Monohydrate, O-desmethylvenlafaxine Succinate T000880287 O desmethylvenlafaxine Succinate Monohydrate T000880287 Succinate Monohydrate, O-desmethylvenlafaxine T723458 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate 2008 08 01 NLM (2008) T000880286 O-desmethylvenlafaxine Succinate 2015 05 22 NLM (2016) T000880286 O desmethylvenlafaxine Succinate T000880286 Succinate, O-desmethylvenlafaxine cze0063603 desvenlafaxin sukcinát 2015 09 24 cze Thesaurus M0230084 WY 45,233 0 M0521993 M0230084 T260089 WY 45,233 NLM (1994) T260089 45,233, WY T260091 WY-45,233 NLM (1994) T260091 WY45,233 T260092 WY-45233 NLM (1994) T260092 WY45233 T260090 WY 45233 NLM (1994) T260090 45233, WY M0506532 Pristiq 0 M0521993 M0506532 T691244 Pristiq 2007 02 08 NLM (2007) M0230088 desvenlafaxin[Desvenlafaxine] NG99554ANW M0521993 M0230088 T000880284 Desvenlafaxine 2015 05 22 FDA SRS (2013) INN (19XX) NLM (2013) T260093 O-desmethylvenlafaxine FDA SRS (2013) NLM (1994) T260093 O desmethylvenlafaxine T260088 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol NLM (1994) cze0063605 desvenlafaxin 2015 09 24 cze Thesaurus D000069469 péče o dospělé pacienty[Medical-Surgical Nursing] 2015 07 06 2015 06 30 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST 2016 2016 D009871 Operating Room Nursing H02.478.676.403 N02.421.533.475 M000605853 péče o dospělé pacienty[Medical-Surgical Nursing] The area of nursing concerned with the needs and care of adult medical and surgical patients. T000880297 Medical-Surgical Nursing 2015 05 22 NLM (2016) T000880299 Nursing, Medical-Surgical 2015 05 22 NLM (2016) T000880292 Medical Surgical Nursing 2015 05 22 NLM (2016) T000880294 Nursing, Medical Surgical 2015 05 22 NLM (2016) cze0064144 péče o dospělé pacienty 2015 10 22 cze Thesaurus D000069470 venlafaxin hydrochlorid[Venlafaxine Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1986) 2016; VENLAFAXINE HYDROCHLORIDE was indexed under CYCLOHEXANOLS 1986-2015 D000068760 Serotonin and Noradrenaline Reuptake Inhibitors D018687 Antidepressive Agents, Second-Generation D02.033.415.510.500.901 D02.092.471.683.948 D02.455.426.392.368.367.318.750 D10.289.510.500.901 M0136959 venlafaxin hydrochlorid[Venlafaxine Hydrochloride] 7D7RX5A8MO A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. 99300-78-4 (venlafaxine hydrochloride) GRZ5RCB1QG M0136959 M0136961 M0136959 M0499209 M0136959 M0136960 M0136959 M0136964 M0136959 M0476515 T000880298 Venlafaxine Hydrochloride 2015 05 22 BAN (19XX) FDA SRS (2015) INN (19XX) NLM (1986) USAN (19XX) T000880298 Hydrochloride, Venlafaxine T570647 Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride 2004 01 29 NLM (2004) T166964 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl NLM (1986) cze0063593 venlafaxin hydrochlorid 2015 09 24 cze Thesaurus M0136961 Wy 45030 0 M0136959 M0136961 T166966 Wy 45030 NLM (1986) T166968 Wy-45030 NLM (1986) T166968 Wy45030 T166967 Wy-45,030 NLM (1986) T166967 Wy 45,030 T166967 Wy45,030 M0499209 Velaxin[Sila-Venlafaxine] 0 M0136959 M0499209 T000880295 Sila-Venlafaxine 2015 05 22 NLM (2006) T000880295 Sila Venlafaxine cze0063597 Velaxin 2015 09 24 cze Thesaurus M0136960 Efectin[Effexor] 0 M0136959 M0136960 T166965 Effexor CA FR US T620473 Trevilor 2004 11 29 DE T620474 Vandral 2004 11 29 ES T620471 Efexor 2004 11 29 AU MX NL UK cze0063596 Efectin 2015 09 24 cze Thesaurus M0136964 venlafaxin[Venlafaxine] GRZ5RCB1QG M0136959 M0136964 T000880296 Venlafaxine 2015 05 22 FDA SRS (2013) INN (19XX) USAN (1989) cze0063594 venlafaxin 2015 09 24 cze Thesaurus M0476515 Argofan[Dobupal] 0 M0136959 M0476515 T620475 Dobupal 2004 11 29 ES cze0063598 Argofan 2015 09 24 cze Thesaurus D000069471 neurochirurgové[Neurosurgeons] 2015 07 01 2015 06 30 2016 01 01 Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000193 education ED Q000523 psychology PX Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI 2016 2016 M01.526.485.810.910.750 N02.360.810.910.750 M000605855 neurochirurgové[Neurosurgeons] Qualified medical professionals who specialize in surgical treatment of diseases of the BRAIN and other parts of the NERVOUS SYSTEM. T000880300 Neurosurgeons 2015 05 22 NLM (2016) T000880300 Neurosurgeon T000882767 Neurological Surgeons 2015 06 30 NLM (2016) T000882767 Neurological Surgeon T000882767 Surgeon, Neurological T000882767 Surgeons, Neurological cze0063924 neurochirurgové 2015 10 15 cze Thesaurus D000069472 kolesevelam[Colesevelam Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1997) 2016; COLESEVELAM HYDROCHLORIDE was indexed under ALLYLAMINE 1997-2015 D000924 Anticholesteremic Agents D02.092.050.500 D02.455.326.271.122.100.500 M0278678 kolesevelam[Colesevelam Hydrochloride] P4SG24WI5Q An allylamine derivative that binds BILE ACIDS in the intestine and is used as an ANTICHOLESTEREMIC AGENT in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS. 182815-43-6 (colesevelam) 182815-44-7 (colesevelam hydrochloride) 1XU104G55N M0278678 M0420411 M0278678 M0420412 M0278678 M0278679 M0278678 M0388731 T000880303 Colesevelam Hydrochloride 2015 05 22 FDA SRS (2015) NLM (1997) USAN (19XX) T000880303 Hydrochloride, Colesevelam T000880304 Colesevelam HCl 2015 05 22 NLM (2016) T000880304 HCl, Colesevelam cze0063550 kolesevelam 2015 09 17 cze Thesaurus cze0063418 colesevelam hydrochlorid 2015 09 04 cze Thesaurus M0420411 Cholestagel[CholestaGel] 0 M0278678 M0420411 T403877 CholestaGel 1999 12 28 NLM (1999) cze0063551 Cholestagel 2015 09 17 cze Thesaurus M0420412 Welchol 0 M0278678 M0420412 T489723 Welchol 2002 04 16 NLM (2002) M0278679 Colesevelam 1XU104G55N M0278678 M0278679 T000880302 Colesevelam 2015 05 22 INN (19XX) NLM (1999) M0388731 GT 31104 0 M0278678 M0388731 T403874 GT 31104 1999 12 28 NLM (1999) T403874 31104, GT T403875 GT-31104 1999 12 28 NLM (1999) T308684 GT31-104 NLM (1997) T308684 GT31 104 T308684 GT31104 D000069473 hypofrakcionace při ozařování[Dose Hypofractionation] 2015 07 06 2015 06 26 2016 01 01 Q000592 standards ST 2016 2016 D011827 Radiation E02.815.639.200.500 E02.815.639.600 M000605876 hypofrakcionace při ozařování[Dose Hypofractionation] A treatment schedule in which the total dose of radiation is divided into large doses. T000880307 Dose Hypofractionation 2015 05 22 NLM (2016) T000880307 Hypofractionation, Dose T000880308 Radiotherapy Minibeams 2015 05 22 NLM (2016) T000880308 Minibeam, Radiotherapy T000880308 Minibeams, Radiotherapy T000880308 Radiotherapy Minibeam T000882558 Hypofractionated Dose 2015 06 26 NLM (2016) T000882558 Dose, Hypofractionated T000882558 Doses, Hypofractionated T000882558 Hypofractionated Doses cze0063612 hypofrakcionace při ozařování 2015 09 24 cze Thesaurus D000069474 sofosbuvir[Sofosbuvir] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2010) 2016; SOFOSBUVIR was indexed under URIDINE MONOPHOSPHATE 2010-2015 D000998 Antiviral Agents D03.383.742.686.850.877.500 D13.695.740.850.877.500 D13.695.827.919.877.500 M0551450 sofosbuvir[Sofosbuvir] WJ6CA3ZU8B A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C. M0551450 M0551451 M0551450 M0580442 M0551450 M000599042 T000880311 Sofosbuvir 2015 05 22 FDA SRS (2015) INN (19XX) NLM (2013) USAN (19XX) T780291 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester 2010 11 07 NLM (2010) cze0063772 sofosbuvir 2015 10 07 cze Thesaurus M0551451 PSI 7977 0 M0551450 M0551451 T780292 PSI 7977 2010 11 07 NLM (2010) T780292 7977, PSI T780294 PSI7977 2010 11 07 NLM (2010) T780293 PSI-7977 2010 11 07 NLM (2010) M0580442 GS-7977 0 M0551450 M0580442 T835904 GS-7977 2013 01 17 NLM (2013) T835904 GS 7977 T835904 GS7977 M000599042 Sovaldi[Sovaldi] 0 M0551450 M000599042 T000868768 Sovaldi 2014 10 16 NLM (2014) cze0063773 Sovaldi 2015 10 07 cze Thesaurus cze0063774 Harvoni 2015 10 07 cze Thesaurus D000069475 reiradiace[Re-Irradiation] 2015 07 01 2015 06 26 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Radiotherapy (1965-2015) E02.815.791 E02.887.500 M000605878 reiradiace[Re-Irradiation] Treatment in which a repeat course of RADIOTHERAPY is administered. T000882573 Re-Irradiation 2015 06 26 NLM (2016) T000880310 Reirradiation 2015 05 22 NLM (2016) T000882572 Re Irradiation 2015 06 26 NLM (2016) cze0064153 reiradiace 2015 10 22 cze Thesaurus D000069476 linagliptin[Linagliptin] 2015 07 06 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; LINAGLIPTIN was indexed under PURINES and QUINAZOLINES 2011-2015 D000068900 Sitagliptin Phosphate D007004 Hypoglycemic Agents D054795 Incretins D054873 Dipeptidyl-Peptidase IV Inhibitors D03.438.759.562 D03.438.786.563 M0554626 linagliptin[Linagliptin] 3X29ZEJ4R2 A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS. 668270-12-0 M0554626 M0554625 M0554626 M0569299 T764527 Linagliptin 2010 01 21 FDA SRS (2013) NLM (2010) USAN (19XX) T000882419 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)- 2015 06 24 NLM (2016) T000882417 (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione 2015 06 24 NLM (2016) cze0063866 linagliptin 2015 10 14 cze Thesaurus M0554625 BI 1356 0 M0554626 M0554625 T717180 BI 1356 2008 04 01 NLM (2008) T717180 1356, BI T717182 BI1356 2008 04 01 NLM (2008) T717181 BI-1356 2008 04 01 NLM (2008) M0569299 Tradjenta 0 M0554626 M0569299 T000881334 Tradjenta 2015 06 04 NLM (2016) T000880313 Trajenta 2015 05 22 NLM (2012) D000069478 lisdexamfetamin dimesylát[Lisdexamfetamine Dimesylate] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2006) 2016; LISDEXAMFETAMINE DIMESYLATE was indexed under DEXTROAMPHETAMINE 2006-2015 D000697 Central Nervous System Stimulants D018765 Dopamine Uptake Inhibitors D02.092.471.683.152.110.200.500 M0502623 lisdexamfetamin dimesylát[Lisdexamfetamine Dimesylate] SJT761GEGS A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. H645GUL8KJ M0502623 M0506857 M0502623 M0592770 M0502623 M0583181 M0502623 M0502624 T000880326 Lisdexamfetamine Dimesylate 2015 05 22 NLM (2006) USAN (19XX) T000880326 Dimesylate, Lisdexamfetamine T000880327 Lis-dexamfetamine Dimesylate 2015 05 22 NLM (2006) T000880327 Dimesylate, Lis-dexamfetamine T000880327 Lis dexamfetamine Dimesylate cze0063951 lisdexamfetamin dimesylát 2015 10 15 cze Thesaurus M0506857 Vyvanse 0 M0502623 M0506857 T691899 Vyvanse 2007 02 20 NLM (2007) M0592770 Elvanse 0 M0502623 M0592770 T000880324 Elvanse 2015 05 22 NLM (2014) M0583181 Lisdexamfetamine H645GUL8KJ M0502623 M0583181 T000880325 Lisdexamfetamine 2015 05 22 FDA SRS (2013) INN (19XX) NLM (2013) M0502624 NRP104 0 M0502623 M0502624 T683230 NRP104 2006 10 10 NLM (2006) T683231 NRP-104 2006 10 10 NLM (2006) T683231 NRP 104 D000069479 kombinace léků buprenorfin a naloxon[Buprenorphine, Naloxone Drug Combination] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2006) 2016; BUPRENORPHINE, NALOXONE DRUG COMBINATION was indexed under BUPRENORPHINE and NALOXONE 2006-2015 D000701 Analgesics, Opioid D009292 Narcotic Antagonists D03.132.577.249.150.500 D03.132.577.249.706.275 D03.549.686.150.500 D03.549.686.750.275 D03.605.497.150.500 D03.605.497.750.275 D04.615.723.795.150.500 D04.615.723.795.706.275 D26.310.352 M0498625 kombinace léků buprenorfin a naloxon[Buprenorphine, Naloxone Drug Combination] 0 A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIATE SUBSTITUTION THERAPY. M0498625 M0498624 T000881238 Buprenorphine, Naloxone Drug Combination 2015 06 03 NLM (2016) T000880332 Buprenorphine-Naloxone Drug Combination 2015 05 22 NLM (2016) T000880332 Combination, Buprenorphine-Naloxone Drug T000880332 Drug Combination, Buprenorphine-Naloxone T000880335 Buprenorphine-Naloxone 2015 05 22 NLM (2016) T000880336 Buprenorphine Naloxone 2015 05 22 NLM (2016) T000880336 Naloxone, Buprenorphine T000880331 Buprenorphine-Naloxone Combination 2015 05 22 NLM (2016) T000880331 Buprenorphine Naloxone Combination T000880331 Combination, Buprenorphine-Naloxone T000880334 Buprenorphine Naloxone Drug Combination 2015 05 22 NLM (2016) cze0063383 kombinace léků buprenorfin a naloxon 2015 09 04 cze Thesaurus M0498624 Suboxone[Suboxone] 0 M0498625 M0498624 T000880337 Suboxone 2015 05 22 NLM (2006) cze0063382 Suboxone 2015 09 04 cze Thesaurus D000069480 kombinace léků emtricitabin a tenofovir[Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION was indexed under DEOXYCYTIDINE and ORGANOPHOSPHORUS COMPOUNDS 2005-2015 D018894 Reverse Transcriptase Inhibitors D019380 Anti-HIV Agents D02.705.429.906.750 D03.383.742.680.245.500.600.750 D03.438.759.138.881.750 D13.570.230.329.525.500 D13.570.685.245.500.600.500 D26.310.423 M000605888 kombinace léků emtricitabin a tenofovir[Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 0 A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS. M000605888 M0475179 T000881260 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 2015 06 03 NLM (2016) T000880339 Emtricitabine-Tenofovir Disoproxil Fumarate Drug Combination 2015 05 22 NLM (2016) T000880340 Emtricitabine Tenofovir Disoproxil Fumarate Drug Combination 2015 05 22 NLM (2016) cze0063811 kombinace léků emtricitabin a tenofovir 2015 10 08 cze Thesaurus cze0063812 kombinace léků emtricitabin a tenofovir disoproxil fumarát 2015 10 08 cze Thesaurus M0475179 Truvada[Truvada] 0 M000605888 M0475179 T617249 Truvada 2004 11 03 NLM (2004) cze0063813 Truvada 2015 10 08 cze Thesaurus D000069497 původ života[Origin of Life] 2015 07 07 2015 07 06 2016 01 01 2016; use ORGANELLE BIOGENESIS 1979-2015 QH 325 2016; see BIOGENESIS 1979-2015 Organelle Biogenesis (1978-2015) G16.595 I01.076.368.584.542 M000605986 původ života[Origin of Life] The process by which life began. T004845 Origin of Life 1978 03 02 UNK (19XX) T004845 Life Origin T004845 Life Origins T000880459 Genesis of Life 2015 05 26 NLM (2016) T000880459 Life Geneses T000880459 Life Genesis cze0063929 původ života 2015 10 15 cze Thesaurus D000069499 kombinace léků ezetimib a simvastatin[Ezetimibe, Simvastatin Drug Combination] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2004) 2016; ETIMIBE SIMVASTATIN DRUG COMBINATION was indexed under AZETIDINES and SIMVASTATIN 2004-2015 D000924 Anticholesteremic Agents D02.455.426.559.847.638.400.900.500 D03.383.082.301.550.500 D04.615.638.400.900.500 D26.310.431 M0474124 kombinace léků ezetimib a simvastatin[Ezetimibe, Simvastatin Drug Combination] 0 A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS. M0474124 M0491906 M0474124 M0517288 T000880464 Ezetimibe, Simvastatin Drug Combination 2015 05 26 NLM (2016) T000880466 Ezetimibe-Simvastatin Combination 2015 05 26 NLM (2016) T000880466 Combination, Ezetimibe-Simvastatin T000880466 Ezetimibe Simvastatin Combination T000880465 Ezetimibe Simvastatin Drug Combination 2015 05 26 NLM (2016) T000880463 Ezetimibe-Simvastatin Drug Combination 2015 05 26 NLM (2016) T000880463 Combination, Ezetimibe-Simvastatin Drug T000880463 Drug Combination, Ezetimibe-Simvastatin cze0063884 kombinace léků ezetimib a simvastatin 2015 10 15 cze Thesaurus M0491906 Vytorin 0 M0474124 M0491906 T613658 Vytorin 2004 10 16 NLM (2004) M0517288 Inegy[Inegy] 0 M0474124 M0517288 T712442 Inegy 2008 01 08 NLM (2008) cze0063885 Inegy 2015 10 15 cze Thesaurus D000069501 abirateron[Abiraterone Acetate] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1994) 2016; ABIRATERONE ACETATE was indexed under ANDROSTENES 1994-2015 D000970 Antineoplastic Agents D065088 Steroid Synthesis Inhibitors D065607 Cytochrome P-450 Enzyme Inhibitors D04.808.054.079.065 M0562608 abirateron[Abiraterone Acetate] EM5OCB9YJ6 An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. 154229-18-2 M0562608 M0237234 M0562608 M0579770 M0562608 M0237237 T000880469 Abiraterone Acetate 2015 05 26 FDA SRS (2015) NLM (2011) USAN (19XX) cze0063387 abirateron 2015 09 04 cze Thesaurus cze0063388 abirateron acetát 2015 09 04 cze Thesaurus M0237234 17-(3-pyridyl)-5,16-androstadien-3beta-acetate 154229-18-2 M0562608 M0237234 T267239 17-(3-pyridyl)-5,16-androstadien-3beta-acetate NLM (1994) M0579770 Zytiga[Zytiga] 0 M0562608 M0579770 T834678 Zytiga 2012 12 20 NLM (2014) US cze0063391 Zytiga 2015 09 04 cze Thesaurus M0237237 CB 7630 0 M0562608 M0237237 T267242 CB 7630 NLM (1994) T267240 CB-7630 NLM (1994) T267241 CB7630 NLM (1994) D000069502 kombinace léků budesonid a formoterol[Budesonide, Formoterol Fumarate Drug Combination] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2002) 2016; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION was indexed under ETHANOLAMINES and ADRENAL CORTEX HORMONES 2002-2015 D018927 Anti-Asthmatic Agents D02.033.100.291.425.250 D02.092.063.291.425.250 D04.808.745.745.654.105.500 D26.310.348 M000605997 kombinace léků budesonid a formoterol[Budesonide, Formoterol Fumarate Drug Combination] 0 A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. M000605997 M0421258 T000881233 Budesonide, Formoterol Fumarate Drug Combination 2015 06 03 NLM (2016) T000880472 Budesonide Formoterol Drug Combination 2015 05 26 NLM (2016) T000880475 Budesonide Formoterol Fumarate Drug Combination 2015 05 26 NLM (2016) T000880471 Budesonide-Formoterol Drug Combination 2015 05 26 NLM (2016) T000880471 Combination, Budesonide-Formoterol Drug T000880471 Drug Combination, Budesonide-Formoterol T000880474 Budesonide-Formoterol Fumarate Drug Combination 2015 05 26 NLM (2016) cze0063384 kombinace léků budesonid a formoterol 2015 09 04 cze Thesaurus cze0063385 kombinace léků budesonid a formoterol fumarát 2015 09 04 cze Thesaurus M0421258 Symbicort[Symbicort] 0 M000605997 M0421258 T000880473 Symbicort 2015 05 26 NLM (2002) cze0063386 Symbicort 2015 09 04 cze Thesaurus D000069503 vilazodon[Vilazodone Hydrochloride] 2015 07 09 2015 07 07 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2004) 2016; VILAZODONE HYDROCHLORIDE was indexed under INDOLES; PIPERAZINES; and BENZOFURANS 2004-2015 D000928 Antidepressive Agents D017367 Serotonin Uptake Inhibitors D058825 Serotonin 5-HT1 Receptor Agonists D03.383.606.980 D03.438.127.818 D03.438.473.957 M0560395 vilazodon[Vilazodone Hydrochloride] U8HTX2GK8J A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT. 163521-08-2 (vilazodone hydrochloride) S239O2OOV3 M0560395 M0560396 M0560395 M0276604 M0560395 M0477866 T000880479 Vilazodone Hydrochloride 2015 05 26 FDA SRS (2015) NLM (2011) USAN (19XX) T000880479 Hydrochloride, Vilazodone T795756 2-benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) 2011 08 23 NLM (2011) T000880480 Vilazodone HCl 2015 05 26 NLM (2016) T000880480 HCl, Vilazodone cze0063519 vilazodon 2015 09 14 cze Thesaurus M0560396 Viibryd 0 M0560395 M0560396 T795757 Viibryd 2011 08 23 NLM (2011) M0276604 EMD 68843 0 M0560395 M0276604 T306609 EMD 68843 NLM (1997) T306609 68843, EMD T306608 EMB-68843 NLM (1997) T306608 EMB 68843 T306608 EMB68843 M0477866 Vilazodone S239O2OOV3 M0560395 M0477866 T000880478 Vilazodone 2015 05 26 FDA SRS (2013) INN (19XX) NLM (2004) USAN (19XX) T306607 5-(4-(4-(5-cyano-3-indolyl)butyl)-1-piperazinyl)benzofuran-2-carboxamide NLM (1997) D000069516 mezinárodní právo[International Law] 2015 07 01 2015 06 30 2016 01 01 Q000193 education ED Q000941 ethics ES Q000266 history HI 2016 2016 D038622 Internationality I01.880.604.583.466 N03.706.535.533 M000606016 mezinárodní právo[International Law] The body of law that governs the legal relations between or among sovereign states or nations. T000880500 International Law 2015 05 27 NLM (2016) T000880500 International Laws T000880500 Law, International T000880500 Laws, International T000880515 Law of Nations 2015 05 27 NLM (2016) T000880514 Public International Law 2015 05 27 NLM (2016) T000880514 International Law, Public cze0063753 mezinárodní právo 2015 10 07 cze Thesaurus D000069520 blogy[Blogs] 2015 07 01 2015 08 13 2016 01 01 This heading is used as a Publication Type. INDEXER: Do not use 2016 Blogging (2010-2015) V01.175.125 V02.170.250 V02.530.150.250 M000606045 blogy[Blogs] A website that contains conversational personal reflections, comments and sometimes links to other sites; typically run by an individual or small group. T000880544 Blogs 2015 05 27 NLM (2016) T000880662 Weblogs 2015 05 28 NLM (2016) T000880661 Web Blogs 2015 05 28 NLM (2016) cze0062726 blogy 2015 07 02 cze Thesaurus cze0062831 internetové blogy 2015 07 27 cze Thesaurus cze0062727 weblog 2015 07 02 cze Thesaurus D000069537 denní pečovatelská centra pro dospělé[Adult Day Care Centers] 2015 07 06 2015 06 30 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD 2016 2016 Day Care, Medical (1981-2015) D064407 Senior Centers N02.421.143.065 M000606058 denní pečovatelská centra pro dospělé[Adult Day Care Centers] Non-residential facilities that are designed to provide care and companionship for seniors who need assistance or supervision during the day. T000880557 Adult Day Care Centers 2015 05 27 NLM (2016) T000881577 Day Care Center, Adult 2015 06 10 NLM (2016) T000881578 Day Care Centers, Adult 2015 06 10 NLM (2016) T000881576 Adult Day Care Center 2015 06 10 NLM (2016) cze0064051 denní pečovatelská centra pro dospělé 2015 10 16 cze Thesaurus cze0064053 centra denních služeb pro dospělé 2015 10 16 cze Thesaurus cze0064052 denní centra pro dospělé s pečovatelskou službou 2015 10 16 cze Thesaurus D000069544 infekční encefalitida[Infectious Encephalitis] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH coordinate IM with specific organism /infection term (IM); note ENCEPHALITIS, VIRAL is available 2016; use ENCEPHALITIS 1964-2015 2016; see ENCEPHALITIS 1964-2015 Encephalitis (1964-2015) C10.228.140.430.520 C10.228.228.399 M0334838 infekční encefalitida[Infectious Encephalitis] Brain inflammation caused by an infectious agent.. M0334838 M000606078 T367445 Infectious Encephalitis 1999 11 05 INFECT ENCEPH NLM (2000) T367446 Encephalitis, Infectious 1999 11 05 NLM (2000) cze0033030 infekční encefalitida 2007 02 27 cze Thesaurus M000606078 Encephalitis Infection M0334838 M000606078 T000880605 Encephalitis Infection 2015 05 27 NLM (2016) T000880605 Encephalitis Infections T000880605 Infection, Encephalitis T000880605 Infections, Encephalitis D000069545 kombinace léků elvitegravir, cobicistat, emtricitabin a tenofovir[Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2012) 2016; ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE was indexed under CARBAMATES; DEOXYCITIDINE; THIAZOLES; QUINOLONES and ORGANOPHOSPHONATES 2012-2015 D019380 Anti-HIV Agents D02.241.081.251.203.500 D02.705.429.906.250 D02.886.675.182.500 D03.383.129.708.189.500 D03.383.742.680.245.500.600.250 D03.438.759.138.881.250 D13.570.230.329.525.250 D13.570.685.245.500.600.250 D26.310.391 M000606070 kombinace léků elvitegravir, cobicistat, emtricitabin a tenofovir[Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination] 0 A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS. M000606070 M0577312 M000606070 M000606071 T000880574 Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 2015 05 27 NLM (2016) T000880576 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate 2015 05 27 NLM (2016) T000880575 Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate Drug Combination 2015 05 27 NLM (2016) T000880573 Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Disoproxil Fumarate Drug Combination 2015 05 27 NLM (2016) T000880573 Elvitegravir Cobicistat Emtricitabine Tenofovir Disoproxil Fumarate Drug Combination cze0063807 kombinace léků elvitegravir, cobicistat, emtricitabin a tenofovir 2015 10 08 cze Thesaurus cze0063808 kombinace léků elvitegravir, cobicistat, emtricitabin a tenofovir disoproxil fumarát 2015 10 08 cze Thesaurus M0577312 Stribild[Stribild] 0 M000606070 M0577312 T000880577 Stribild 2015 05 27 NLM (2013) cze0063809 Stribild 2015 10 08 cze Thesaurus M000606071 Quad[Quad Pill] 0 M000606070 M000606071 T000880579 Quad Pill 2015 05 27 NLM (2016) T000880579 Pill, Quad T000880580 Quad 2015 05 27 NLM (2013) cze0063810 Quad 2015 10 08 cze Thesaurus D000069547 kobicistat[Cobicistat] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; COBICISTAT was indexed under CARBAMATES and THIAZOLES 2011-2015 D019380 Anti-HIV Agents D065692 Cytochrome P-450 CYP3A Inhibitors D02.241.081.251.203 D02.886.675.182 D03.383.129.708.189 M0558562 kobicistat[Cobicistat] LW2E03M5PG A carbamate and thiazole derivative that functions as a CYTOCHROME P450 CYP3A INHIBITOR to enhance the concentration of ANTI-HIV AGENTS, with which it is used in combination, for the treatment of HIV INFECTIONS. M0558562 M000606069 M0558562 M0558563 T000880567 Cobicistat 2015 05 27 FDA SRS (2015) INN (19XX) NLM (2011) USAN (19XX) cze0063357 kobicistat 2015 08 31 cze Thesaurus M000606069 Tybost 0 M0558562 M000606069 T000880572 Tybost 2015 05 27 NLM (2016) M0558563 GS 9350 0 M0558562 M0558563 T792578 GS 9350 2011 06 26 NLM (2011) T792578 9350, GS T792580 GS9350 2011 06 26 NLM (2011) T792579 GS-9350 2011 06 26 NLM (2011) D000069549 ustekinumab[Ustekinumab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2005) 2016; USTEKINUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2005-2011 D003879 Dermatologic Agents D12.776.124.486.485.114.224.060.937 D12.776.124.790.651.114.224.060.937 D12.776.377.715.548.114.224.200.937 M0490173 ustekinumab[Ustekinumab] FU77B4U5Z0 A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies. M0490173 M000606473 M0490173 M0585167 T000880599 Ustekinumab 2015 05 27 FDA SRS (2013) INN (19XX) NLM (2008) USAN (19XX) cze0063354 ustekinumab 2015 08 31 cze Thesaurus M000606473 Stelara[Stelara] 0 M0490173 M000606473 T000881340 Stelara 2015 06 04 NLM (2016) cze0063356 Stelara 2015 08 31 cze Thesaurus M0585167 CNTO 1275 0 M0490173 M0585167 T654418 CNTO 1275 2005 10 05 NLM (2005) T654418 1275, CNTO T654419 CNTO-1275 2005 10 05 NLM (2005) T654419 CNTO1275 D000069550 strojové učení[Machine Learning] 2015 07 10 2015 07 10 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016; use ARTIFICIAL INTELLIGENCE 1997-2015 2016; see ARTIFICIAL INTELLIGENCE 1997-2015 G17.035.250.500 L01.224.050.375.530 M000606076 strojové učení[Machine Learning] A type of ARTIFICIAL INTELLIGENCE that enable COMPUTERS to independently initiate and execute LEARNING when exposed to new data. Strojové učení je podoblastí umělé inteligence, zabývající se algoritmy a technikami, které umožňují počítačovému systému 'učit se'. Učením v daném kontextu rozumíme takovou změnu vnitřního stavu systému, která zefektivní schopnost přizpůsobení se změnám okolního prostředí. (cit. cs.Wikipedia.org) T000880600 Machine Learning 2015 05 27 NLM (2016) T000880600 Learning, Machine cze0064070 strojové učení 2015 10 20 cze Thesaurus cze0064408 učící se systémy 2015 11 11 cze Thesaurus D000069551 environmentální psychologie[Environmental Psychology] 2015 07 01 2015 07 01 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST use for the discipline (education, history, etc) only 2016 2016 D004463 Ecology D019550 Environmental Medicine F04.096.628.033 M000606079 environmentální psychologie[Environmental Psychology] The field that studies interactions between individuals and the built and natural environment. It includes investigating behaviors that inhibit or foster sustainable, climate-healthy, and nature-enhancing choices. T000880606 Environmental Psychology 2015 05 27 NLM (2016) T000880606 Psychology, Environmental cze0063746 environmentální psychologie 2015 10 07 cze Thesaurus cze0063748 ekologická psychologie 2015 10 07 cze Thesaurus cze0063749 ekopsychologie 2015 10 07 cze Thesaurus cze0063747 psychologie životního prostředí 2015 10 07 cze Thesaurus D000069552 rivaroxaban[Rivaroxaban] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2005) 2016; RIVAROXABAN was indexed under MORPHOLINES and THIOPHENES 2005-2015 D065427 Factor Xa Inhibitors D02.886.778.727 D03.383.533.640.713 D03.383.903.727 M0501463 rivaroxaban[Rivaroxaban] 9NDF7JZ4M3 A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. M0501463 M0558836 M0501463 M0488536 T000880608 Rivaroxaban 2015 05 27 FDA SRS (2015) INN (19XX) NLM (2006) USAN (19XX) T649750 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide 2005 08 29 NLM (2005) cze0063962 rivaroxaban 2015 10 15 cze Thesaurus M0558836 Xarelto[Xarelto] 0 M0501463 M0558836 T793064 Xarelto 2011 07 05 NLM (2011) cze0063964 Xarelto 2015 10 15 cze Thesaurus M0488536 BAY 59-7939 0 M0501463 M0488536 T649749 BAY 59-7939 2005 08 29 NLM (2005) T649749 BAY 59 7939 T649749 BAY 597939 D000069553 strojové učení s učitelem[Supervised Machine Learning] 2015 07 06 2015 06 29 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D000069558 Unsupervised Machine Learning G17.035.250.500.500 L01.224.050.375.530.500 M000606081 strojové učení s učitelem[Supervised Machine Learning] A MACHINE LEARNING paradigm used to make predictions about future instances based on a given set of labeled paired input-output training (sample) data. Učení s učitelem je metoda strojového učení pro učení funkce z trénovacích dat. Trénovací data sestávají ze dvojic vstupních objektů (typicky vektorů příznaků) a požadovaného výstupu. (cit. cs.Wikipedia.org) M000606081 M000606086 M000606081 M000606084 M000606081 M000606085 M000606081 M000606082 M000606081 M000606083 T000880609 Supervised Machine Learning 2015 05 27 NLM (2016) T000880609 Learning, Supervised Machine T000880609 Machine Learning, Supervised cze0064410 strojové učení s učitelem 2015 11 12 cze Thesaurus M000606086 Semi-supervised Learning M000606081 M000606086 T000880614 Semi-supervised Learning 2015 05 27 NLM (2016) T000880614 Learning, Semi-supervised T000880614 Semi supervised Learning M000606084 Inductive Machine Learning M000606081 M000606084 T000880612 Inductive Machine Learning 2015 05 27 NLM (2016) T000880612 Learning, Inductive Machine T000880612 Machine Learning, Inductive M000606085 Active Machine Learning M000606081 M000606085 T000880613 Active Machine Learning 2015 05 27 NLM (2016) T000880613 Learning, Active Machine T000880613 Machine Learning, Active M000606082 Machine Learning with a Teacher M000606081 M000606082 T000880610 Machine Learning with a Teacher 2015 05 27 NLM (2016) M000606083 Learning from Labeled Data M000606081 M000606083 T000880611 Learning from Labeled Data 2015 05 27 NLM (2016) D000069555 intratympanická injekce[Injection, Intratympanic] 2015 07 01 2015 06 26 2016 01 01 Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Injections (1968-2015) E02.319.267.530.655 M000606090 intratympanická injekce[Injection, Intratympanic] The administration of liquid substances into the TYMPANIC CAVITY with a hypodermic syringe. T000880688 Injection, Intratympanic 2015 05 28 NLM (2016) T000880619 Intratympanic Injection 2015 05 27 NLM (2016) T000880619 Injections, Intratympanic T000880619 Intratympanic Injections T000880671 Transtympanic Administration 2015 05 28 NLM (2016) T000880671 Administration, Transtympanic T000880671 Administrations, Transtympanic T000880671 Transtympanic Administrations cze0064139 intratympanická injekce 2015 10 22 cze Thesaurus D000069557 travoprost[Travoprost] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; TRAVOPROST was indexed under CLOPROSTENOL 2001-2015 D000959 Antihypertensive Agents D10.251.355.255.550.775.500.175.500 D23.469.050.175.725.775.500.175.500 D23.469.700.670.175.500 M0403483 travoprost[Travoprost] WJ68R08KX9 A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 157283-68-6 M0403483 M0512618 M0403483 M0476868 M0403483 M0403484 M0403483 M0403486 T000880623 Travoprost 2015 05 27 FDA SRS (2015) INN (19XX) NLM (2001) USAN (19XX) cze0063616 travoprost 2015 09 24 cze Thesaurus M0512618 Travatan Z 0 M0403483 M0512618 T704220 Travatan Z 2007 08 17 NLM (2007) T704220 Z, Travatan M0476868 Travatan[Travatan] 0 M0403483 M0476868 T621553 Travatan 2004 12 03 CA DE FR MX UK US cze0063619 Travatan 2015 09 24 cze Thesaurus M0403484 (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester 0 M0403483 M0403484 T468213 (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester 2001 10 29 NLM (2001) M0403486 AL-6221 0 M0403483 M0403486 T468217 AL-6221 2001 10 29 NLM (2001) T468217 AL 6221 T468218 AL6221 2001 10 29 NLM (2001) D000069558 strojové učení bez učitele[Unsupervised Machine Learning] 2015 07 06 2015 06 29 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000592 standards ST Q000600 supply & distribution SD 2016 2016 D000069553 Supervised Machine Learning G17.035.250.500.750 L01.224.050.375.530.750 M000606094 strojové učení bez učitele[Unsupervised Machine Learning] A MACHINE LEARNING paradigm used to make predictions about future instances based on a given set of unlabeled paired input-output training (sample) data. T000880624 Unsupervised Machine Learning 2015 05 27 NLM (2016) T000880624 Learning, Unsupervised Machine T000880624 Machine Learning, Unsupervised cze0064411 strojové učení bez učitele 2015 11 12 cze Thesaurus D000069559 loteprednol etabonát[Loteprednol Etabonate] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1990) 2016; LOTEPREDNOL ETABONATE was indexed under ANDROSTADIENES 1990-2015 D018926 Anti-Allergic Agents D04.808.054.079.129.284 M0174971 loteprednol etabonát[Loteprednol Etabonate] YEH1EZ96K6 An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions. 82034-46-6 M0174971 M0399624 M0174971 M0424549 M0174971 M0399625 T000880627 Loteprednol Etabonate 2015 05 27 FDA SRS (2015) NLM (1990) USAN (19XX) T000880627 Etabonate, Loteprednol T204974 CEHOAC NLM (1990) T000880628 Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate 2015 05 27 NLM (1990) T000880628 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, Chloromethyl T000880628 Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate cze0064085 loteprednol etabonát 2015 10 21 cze Thesaurus M0399624 Lotemax 0 M0174971 M0399624 T463273 Lotemax 2001 09 26 NLM (2001) M0424549 Loteprednol 0 M0174971 M0424549 T000880626 Loteprednol 2015 05 27 FDA SRS (2013) INN (19XX) NLM (2002) M0399625 Alrex 0 M0174971 M0399625 T463274 Alrex 2001 09 26 NLM (2001) D000069576 rovnost ve zdraví[Health Equity] 2015 07 01 2015 06 29 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000656 utilization UT Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000458 organization & administration OG Q000592 standards ST 2016 2016 N04.590.374.350.500 N05.300.430.383 M000606118 rovnost ve zdraví[Health Equity] Opportunity to attain full health potential and no one is disadvantaged from achieving this potential because of their social position or other socially determined circumstance. T000880665 Health Equity 2015 05 28 NLM (2016) T000880665 Equity, Health cze0064044 rovnost ve zdraví 2015 10 16 cze Thesaurus D000069577 morcelace[Morcellation] 2015 07 01 2015 06 29 2016 01 01 Q000534 rehabilitation RH Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000401 mortality MO Q000009 adverse effects AE Q000744 contraindications CT Q000656 utilization UT Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000191 economics EC Q000193 education ED Q000295 instrumentation IS Q000379 methods MT Q000451 nursing NU Q000592 standards ST 2016 2016 Minimally Invasive Surgical Procedures (2000-2015) E04.502.648 M000606125 morcelace[Morcellation] Use of a non-cautery–dependent mechanical device that simultaneously cuts and aspirates polyp and/or myoma tissue. T000880675 Morcellation 2015 05 28 NLM (2016) cze0063936 morcelace 2015 10 15 cze Thesaurus cze0063937 rozmělnění 2015 10 15 cze Thesaurus D000069578 nemoci přenášené vodou[Waterborne Diseases] 2015 07 01 2015 06 29 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000201 enzymology EN Q000209 etiology ET Q000635 transmission TM Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH 2016 2016 C01.539.221.750 M000606133 nemoci přenášené vodou[Waterborne Diseases] Illnesses due to micro-organisms and chemicals in drinking water, those caused by organisms having part of their lifecycle in water or those with water-related vectors, and others spread by aerosols containing pathogens. M000606133 M000606132 T000880685 Waterborne Diseases 2015 05 28 NLM (2016) T000880685 Disease, Waterborne T000880685 Diseases, Waterborne T000880685 Waterborne Disease cze0062719 nemoci přenášené vodou 2015 07 02 cze Thesaurus cze0062720 nemoci pocházející z vody 2015 07 02 cze Thesaurus cze0062721 nemoci šířené vodou 2015 07 02 cze Thesaurus M000606132 Water-related Diseases M000606133 M000606132 T000880683 Water-related Diseases 2015 05 28 NLM (2016) T000880683 Disease, Water-related T000880683 Diseases, Water-related T000880683 Water related Diseases T000880683 Water-related Disease D000069579 ranibizumab[Ranibizumab] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000493 pharmacokinetics PK 2016 (2005) 2016; RANIBIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2011-2015; and under ANTIBODIES, MONOCLONAL 2005-2011 D007155 Immunologic Factors D020533 Angiogenesis Inhibitors D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868 M0481787 ranibizumab[Ranibizumab] ZL1R02VT79 A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION. 347396-82-1 M0481787 M0499546 T000880687 Ranibizumab 2015 05 28 FDA SRS (2015) INN (19XX) NLM (2005) USAN (19XX) T000880689 RhuFab V2 2015 05 28 NLM (2005) T000880689 V2, RhuFab cze0064010 ranibizumab 2015 10 15 cze Thesaurus M0499546 Lucentis[Lucentis] 0 M0481787 M0499546 T677225 Lucentis 2006 07 03 NLM (2006) cze0064011 Lucentis 2015 10 15 cze Thesaurus D000069580 bimatoprost[Bimatoprost] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2001) 2016; BIMATOPROST was indexed under AMIDES and CLOPROSTENOL 2001-2015 D000959 Antihypertensive Agents D02.065.141 D10.251.355.255.550.775.500.175.250 D23.469.050.175.725.775.500.175.250 D23.469.700.670.175.250 M0395184 bimatoprost[Bimatoprost] 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))- QXS94885MZ A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 155206-00-1 M0395184 M000606137 M0395184 M0395183 M0395184 M0379711 T000880692 Bimatoprost 2015 05 28 FDA SRS (2015) INN (19XX) NLM (2001) USAN (19XX) cze0063115 bimatoprost 2015 08 17 cze Thesaurus M000606137 Bimican[Latisse] 0 M0395184 M000606137 T000880694 Latisse 2015 05 28 NLM (2012) cze0063117 Bimican 2015 08 17 cze Thesaurus cze0063120 Bimatoprost 2015 08 17 cze Thesaurus M0395183 Lumigan[Lumigan] 0 M0395184 M0395183 T456832 Lumigan 2001 08 10 CA DE FR MX UK US cze0063116 Lumigan 2015 08 17 cze Thesaurus M0379711 AGN 192024 0 M0395184 M0379711 T437570 AGN 192024 2001 03 01 NLM (2001) T437570 192024, AGN D000069581 vystavení násilí[Exposure to Violence] 2015 07 01 2015 06 29 2016 01 01 Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history HI Q000145 classification CL Q000191 economics EC Q000208 ethnology EH 2016 2016 I01.880.735.900.869 M000606136 vystavení násilí[Exposure to Violence] Experience of and exposure to VIOLENCE. T000881665 Exposure to Violence 2015 06 11 NLM (2016) T000881665 Violence, Exposure to T000880691 Violence Exposure 2015 05 28 NLM (2016) cze0063901 vystavení násilí 2015 10 15 cze Thesaurus cze0063903 ohrožení násilím 2015 10 15 cze Thesaurus D000069582 eszopiklon[Eszopiclone] 2015 07 06 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2007) 2016; ESZOPICLONE was indexed under PIPERAZINES and AZABICYCLO COMPOUNDS 2007-2015 D006993 Hypnotics and Sedatives D03.383.606.398 D03.383.679.600 D03.383.725.322 M0463158 eszopiklon[Eszopiclone] (+)-(5S)-6(chloropyridine-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)-pyrazin-5-yl-4-methyl-piperazine-1-carboxylate UZX80K71OE A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA. 138729-47-2 M0463158 M0489635 M0463158 M0504261 T000880697 Eszopiclone 2015 05 28 FDA SRS (2015) INN (19XX) NLM (2004) USAN (19XX) cze0063621 eszopiklon 2015 09 24 cze Thesaurus M0489635 Lunesta 0 M0463158 M0489635 T638990 Lunesta 2005 05 01 NLM (2005) M0504261 Estorra 0 M0463158 M0504261 T686770 Estorra 2006 11 28 NLM (2006) D000069583 pregabalin[Pregabalin] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000819 agonists AG Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000737 chemistry CH Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000145 classification CL Q000191 economics EC Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (1993) 2016; PREGABALIN was indexed under GAMMA-AMINOBUTYRIC ACID 1993-2015 D000700 Analgesics D000927 Anticonvulsants D002121 Calcium Channel Blockers D014151 Anti-Anxiety Agents D02.241.081.114.500.350.500 D12.125.190.350.450 M0214473 pregabalin[Pregabalin] 55JG375S6M A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA. 148553-50-8 M0214473 M0486135 M0214473 M0259583 T000880706 Pregabalin 2015 05 28 FDA SRS (2013) INN (19XX) NLM (1993) USAN (19XX) T848182 (S)-3-(aminomethyl)-5-methylhexanoic acid 2013 08 20 NLM (2014) T244478 3-isobutyl GABA NLM (1993) T244478 3 isobutyl GABA T244478 GABA, 3-isobutyl T289586 3-(aminomethyl)-5-methylhexanoic acid NLM (1996) T244475 (R-)-3-isobutyl GABA NLM (1993) T244476 (S+)-3-isobutyl GABA NLM (1993) cze0063759 pregabalin 2015 10 07 cze Thesaurus M0486135 Lyrica[Lyrica] 0 M0214473 M0486135 T643869 Lyrica 2005 06 21 NLM (2005) US cze0063760 Lyrica 2015 10 07 cze Thesaurus M0259583 Pragiola[CI 1008] 0 M0214473 M0259583 T289588 CI 1008 NLM (1996) T289588 1008, CI T289587 CI-1008 NLM (1996) T289587 CI1008 cze0063761 Pragiola 2015 10 07 cze Thesaurus cze0063763 Pregabalin 2015 10 07 cze Thesaurus cze0063762 Preglenic 2015 10 07 cze Thesaurus D000069584 jednostranný karcinom prsu[Unilateral Breast Neoplasms] 2015 07 09 2015 07 08 2016 01 01 Q000469 parasitology PS Q000276 immunology IM Q000382 microbiology MI Q000175 diagnosis DI Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000201 enzymology EN Q000209 etiology ET Q000401 mortality MO Q000453 epidemiology EP Q000517 prevention & control PC Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000151 congenital CN Q000178 diet therapy DH Q000188 drug therapy DT Q000628 therapy TH Q000648 ultrastructure UL Q000737 chemistry CH Q000523 psychology PX Q000652 urine UR Q000821 virology VI Q000736 ultrasonography US Q000662 veterinary VE Q000266 history HI Q000098 blood supply BS Q000145 classification CL Q000150 complications CO Q000191 economics EC Q000196 embryology EM Q000235 genetics GE Q000378 metabolism ME Q000451 nursing NU Q000473 pathology PA Q000532 radiotherapy RT Q000601 surgery SU Q000208 ethnology EH human only; coordinate IM with histological type of neoplasm (IM) 2016 2016 Breast Neoplasms (1977-2015) C04.588.180.682 C17.800.090.500.682 M000606652 jednostranný karcinom prsu[Unilateral Breast Neoplasms] Tumors or cancer found specifically in one human BREAST, but not in both. M000606652 M000607323 M000606652 M000606142 T000881620 Unilateral Breast Neoplasms 2015 06 11 NLM (2016) T000881620 Breast Neoplasm, Unilateral T000881620 Breast Neoplasms, Unilateral T000881621 Unilateral Breast Cancer 2015 06 11 NLM (2016) T000881621 Breast Cancer, Unilateral T000881621 Breast Cancers, Unilateral T000881621 Unilateral Breast Cancers cze0063599 jednostranný karcinom prsu 2015 09 24 cze Thesaurus cze0063600 unilaterální nádor prsu 2015 09 24 cze Thesaurus M000607323 nádor pravého prsu[Right-Sided Breast Neoplasms] Tumors or cancer found specifically in the human right BREAST. M000606652 M000607323 T000882762 Right-Sided Breast Neoplasms 2015 06 30 NLM (2016) T000882762 Breast Neoplasm, Right-Sided T000882762 Breast Neoplasms, Right-Sided T000882762 Right Sided Breast Neoplasms T000882762 Right-Sided Breast Neoplasm T000882765 Right-Sided Breast Cancer 2015 06 30 NLM (2016) T000882765 Breast Cancer, Right-Sided T000882765 Breast Cancers, Right-Sided T000882765 Right-Sided Breast Cancers T000882766 Right Sided Breast Cancer 2015 06 30 NLM (2016) T000882764 Right Sided Breast Neoplasm 2015 06 30 NLM (2016) cze0063602 nádor pravého prsu 2015 09 24 cze Thesaurus M000606142 nádor levého prsu[Left-Sided Breast Neoplasms] Tumors or cancer found specifically in the human left BREAST. M000606652 M000606142 T000880701 Left-Sided Breast Neoplasms 2015 05 28 NLM (2016) T000880701 Breast Neoplasm, Left-Sided T000880701 Breast Neoplasms, Left-Sided T000880701 Left-Sided Breast Neoplasm T000882763 Left Sided Breast Neoplasm 2015 06 30 NLM (2016) T000880704 Left-Sided Breast Cancer 2015 05 28 NLM (2016) T000880704 Breast Cancer, Left-Sided T000880704 Breast Cancers, Left-Sided T000880704 Left-Sided Breast Cancers T000880702 Left Sided Breast Neoplasms 2015 05 28 NLM (2016) T000880703 Left Sided Breast Cancer 2015 05 28 NLM (2016) cze0063601 nádor levého prsu 2015 09 24 cze Thesaurus D000069585 filgrastim[Filgrastim] 2015 07 01 2015 06 26 2016 01 01 Q000031 analogs & derivatives AA Q000276 immunology IM Q000493 pharmacokinetics PK Q000096 biosynthesis BI Q000627 therapeutic use TU Q000557 secretion SE Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000592 standards ST Q000600 supply & distribution SD 2016 (2011) 2016; FILGRASTIM was indexed under GRANULOCYTE COLONY-STIMULATING FACTOR 2011-2015 D006401 Hematologic Agents D12.644.276.374.410.240.350.500 D12.776.395.240.200.500 D12.776.467.374.410.240.350.500 D23.529.374.410.240.350.500 M0028831 filgrastim[Filgrastim] PVI5M0M1GW A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, and to prepare blood progenitor cells for collection and use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 121181-53-1 M0028831 M0373311 M0028831 M0546684 T057740 Filgrastim 1999 01 01 BAN (19XX) FDA SRS (2012) INN (19XX) NLM (1997) USAN (1990) T057742 G-CSF Recombinant, Human Methionyl 1996 04 05 NLM (1997) T057742 G CSF Recombinant, Human Methionyl T057741 Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor 1996 04 05 NLM (1997) T057741 Recombinant Methionyl Human Granulocyte Colony Stimulating Factor T000880712 R-metHuG-CSF 2015 05 28 NLM (2016) T000880712 R metHuG CSF cze0063741 filgrastim 2015 10 07 cze Thesaurus M0373311 Neupogen[Neupogen] 0 M0028831 M0373311 T057739 Neupogen 1996 01 31 NLM (1997) cze0063744 Neupogen 2015 10 07 cze Thesaurus cze0063743 Tevagrastim 2015 10 07 cze Thesaurus M0546684 Zarzio[Topneuter] 0 M0028831 M0546684 T000880718 Topneuter 2015 05 28 NLM (2010) cze0063742 Zarzio 2015 10 07 cze Thesaurus cze0063745 Nivestim 2015 10 07 cze Thesaurus D000069586 dospělí traumatizovaní v dětství[Adult Survivors of Child Adverse Events] 2015 07 01 2015 06 30 2016 01 01 Q000145 classification CL Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN 2016 2016 M01.860.300 M000606149 dospělí traumatizovaní v dětství[Adult Survivors of Child Adverse Events] Persons who experienced traumatic events during childhood. T000880716 Adult Survivors of Child Adverse Events 2015 05 28 NLM (2016) T000882768 Adult Survivors of Childhood Trauma 2015 06 30 NLM (2016) cze0063367 dospělí traumatizovaní v dětství 2015 09 03 cze Thesaurus cze0063368 dospělí překonávající nepříznivé události v dětství 2015 09 03 cze Thesaurus D000069590 ligamentum arcuatum pubis[Round Ligaments] 2015 07 09 2015 07 07 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU 2016 2016; ROUND LIGAMENT now ROUND LIGAMENT OF UTERUS, was a heading 1991-2015 Ligaments (1966-2015) A02.513.901 M0019283 ligamentum arcuatum pubis[Round Ligaments] Cord-like fibrous tissue structure that connects two articular extremities of bones, ligaments and /or cartilages. M0019283 M000606077 T000880707 Round Ligaments 2015 05 28 NLM (2016) T000880707 Ligament, Round T000880707 Ligaments, Round T036892 Round Ligament 1999 01 01 NLM (1975) T000880604 Ligamentum Teres 2015 05 27 NLM (2016) T000880604 Ligamentum Tere cze0014058 ligamentum arcuatum pubis 2006 03 22 M000606077 Round Ligament of Elbow Cord shaped ligament found spanning between the ULNAR and RADIUS bones near the ELBOW JOINT. M0019283 M000606077 T000880601 Round Ligament of Elbow 2015 05 27 NLM (2016) T000880601 Elbow Round Ligament T000880601 Elbow Round Ligaments T000880603 Chorda Obliqua 2015 05 27 NLM (2016) T000880603 Chorda Obliquas T000880602 Oblique Cord 2015 05 27 NLM (2016) T000880602 Oblique Cords D000069592 oblý vaz jaterní[Round Ligament of Liver] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU Ligaments (1963-2015) A02.513.901.750 A03.620.575 M000606073 oblý vaz jaterní[Round Ligament of Liver] A cord-like remnant structure formed from the closed left fetal UMBILICAL VEIN. It is located along the lower edge of the falciform ligament. Vaz, který je obliterovanou pupečníkovou žilou (v. umbilicalis) vedoucí od pupku k játrům (k přednímu okraji lig. falciforme hepatis) a pokračující až do adventicie v. cava inferior. Má význam pro fixaci jater (např. při pádu z výšky může dojít k roztržení dolní duté žíly a okamžitému vykrvácení). Na spodní ploše jater vytváří jeho průběh zářez (fissura lig. teretis), který z levé strany ohraničuje lobus quadratus. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) T000880583 Round Ligament of Liver 2015 05 27 NLM (2016) T000880583 Liver Round Ligament T000880583 Liver Round Ligaments T000880739 Hepatic Round Ligament 2015 05 28 NLM (2016) T000880739 Hepatic Round Ligaments T000880739 Ligament, Hepatic Round T000880739 Ligaments, Hepatic Round T000880739 Round Ligament, Hepatic T000880739 Round Ligaments, Hepatic T000880584 Ligamentum Teres Hepatis 2015 05 27 NLM (2016) T000880584 Ligamentum Teres Hepati cze0064032 oblý vaz jaterní 2015 10 15 cze Thesaurus cze0064031 ligamentum teres hepatis 2015 10 15 cze Thesaurus D000069593 ligamentum capitis femoris[Round Ligament of Femur] 2015 07 07 2015 07 06 2016 01 01 Q000469 parasitology PS Q000002 abnormalities AB Q000276 immunology IM Q000382 microbiology MI Q000502 physiology PH Q000503 physiopathology PP Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000201 enzymology EN Q000294 innervation IR Q000166 cytology CY Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000637 transplantation TR Q000821 virology VI Q000736 ultrasonography US Q000528 radiation effects RE Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000293 injuries IN Q000378 metabolism ME Q000473 pathology PA Q000601 surgery SU Femur (1963-2015) Ligaments (1963-2015) A02.513.514.800 A02.513.901.500 A02.835.583.411.500 A02.835.583.512.950 M000606074 ligamentum capitis femoris[Round Ligament of Femur] Ligament that connects the fovea of the FEMUR HEAD and the ACETABULUM notch in the HIP JOINT. Intraartikulární vaz kyčelního kloubu. Jde z incisura acetabuli na hlavici femuru. Nemá mechanickou funkci, prochází jím funkčně nevýznamná drobná arterie. (cit. Velký lékařský slovník online, 2015 http://lekarske.slovniky.cz/ ) T000880585 Round Ligament of Femur 2015 05 27 NLM (2016) T000880585 Femur Round Ligament T000880585 Femur Round Ligaments T000880587 Ligamentum Capitis Femoris 2015 05 27 NLM (2016) T000880587 Ligamentum Capitis Femori T000880586 Ligamentum Teres Femoris 2015 05 27 NLM (2016) T000880586 Ligamentum Teres Femori cze0062601 ligamentum capitis femoris 2015 06 24 cze Thesaurus cze0064033 intraartikulární vaz kyčelního kloubu 2015 10 15 cze Thesaurus cze0062602 ligamentum teres femoris 2015 06 24 cze Thesaurus D000069594 abatacept[Abatacept] 2015 07 01 2015 06 26 2016 01 01 Q000276 immunology IM Q000096 biosynthesis BI Q000502 physiology PH Q000627 therapeutic use TU Q000633 toxicity TO Q000506 poisoning PO Q000008 administration & dosage AD Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000744 contraindications CT Q000648 ultrastructure UL Q000737 chemistry CH Q000187 drug effects DE Q000652 urine UR Q000528 radiation effects RE Q000266 history HI Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD 2016 (2002) 2016; ABATACEPT was indexed under IMMUNOCONJUGATES 2002-2015 D007166 Immunosuppressive Agents D018501 Antirheumatic Agents D12.776.124.486.485.114.580.225 D12.776.124.790.651.114.580.225 D12.776.377.715.548.114.580.225 M0442852 abatacept[Abatacept] 7D0YB67S97 A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS. Abatacept je molekula CTLA4 fúzovaná s částí Fc imunoglobulinu IgG1. Blokuje kostimulační signál mezi antigen prezentující buňkou a T-lymfocytem a zabraňuje aktivaci, proliferaci, diferenciaci a přežívání T-lymfocytů, čímž tlumí zánětlivý pochod u onemocnění, ve kterých T-lymfocyty hrají důležitou úlohu, jako je např. revmatoidní artritida. 332348-12-6 M0442852 M0498618 M0442852 M0498619 M0442852 M0498621 M0442852 M0568539 M0442852 M0497994 M0442852 M0498617 M0442852 M0498620 T000880727 Abatacept 2015 05 28 FDA SRS (2015) INN (19XX) USAN (2004) cze0063111 abatacept 2015 08 17 cze Thesaurus M0498618 Belatacept 0 M0442852 M0498618 T000880723 Belatacept 2015 05 28 NLM (2006) M0498619 BMS224818 0 M0442852 M0498619 T675373 BMS224818 2006 06 07 NLM (2006) T675374 BMS-224818 2006 06 07 NLM (2006) T675374 BMS 224818 M0498621 LEA29Y 0 M0442852 M0498621 T675380 LEA29Y 2006 06 07 NLM (2006) M0568539 Nulojix 0 M0442852 M0568539 T000880728 Nulojix 2015 05 28 NLM (2012) M0497994 Orencia[Orencia] 0 M0442852 M0497994 T670174 Orencia 2006 03 30 NLM (2006) cze0063114 Orencia 2015 08 17 cze Thesaurus M0498617 BMS 188667 0 M0442852 M0498617 T675370 BMS 188667 2006 06 07 NLM (2006) T675370 188667, BMS T675371 BMS-188667 2006 06 07 NLM (2006) T675371 BMS188667 M0498620 CTLA-4-Ig 0 M0442852 M0498620 T675375 CTLA-4-Ig 2006 06 07 NLM (2006) T000880726 CTLA4-Ig Immunoconjugate 2015 05 28 NLM (2006) T000880726 CTLA4 Ig Immunoconjugate T000880726 Immunoconjugate, CTLA4-Ig T675377 CTLA4-Ig 2006 06 07 NLM (2006) T675376 CTLA4-Fc 2006 06 07 NLM (2006) T000880725 Cytotoxic T Lymphocyte-associated Antigen 4-immunoglobulin 2015 05 28 NLM (2006) T000880725 Cytotoxic T Lymphocyte associated Antigen 4 immunoglobulin D000069597 presenteismus[Presenteeism] 2015 07 01 2015 06 29 2016 01 01 Q000364 manpower MA Q000331 legislation & jurisprudence LJ Q000941 ethics ES Q000706 statistics & numerical data SN Q000639 trends TD Q000266 history